ࡱ>    c {bjbjZZ D$8b\8b\&|  ~~~~~8D{}}}zzzzzzz$<}dzQ~}}}}}z~~<{UrUrUr}j<~~zUr}zUrUrttT;ɪ[ tzR{0{t,Ve VttV~tUr}}}zzIq }}}{}}}}V}}}}}}}}} > D: Published in  HYPERLINK "http://www.thyroidmanager.org/" http://www.thyroidmanager.org/ 2018 Chapter12-GRAVES'DISEASE:COMPLICATIONS Luigi Bartalena, MD, Professor of Endocrinology, University of Insubria, Ospedale di Circolo, Viale Borri, 57, 21100 Varese, Italy  HYPERLINK "mailto:luigi.bartalena@uninsubria.it" luigi.bartalena@uninsubria.it Revised February 2018 ABSTRACT Thyroid storm is an acute and life-threatening worsening of hyperthyroidism, characterized by an exacerbation of symptoms and signs of hyperthyroidism, with high fever, dehydration, marked tachycardia or tachyarrhytmias, heart failure, hepatomegaly, respiratory distress, abdominal pain, delirium, possibly seizures. It may occur in patients submitted to thyroidectomy or radioactive iodine treatment while hyperthyroid, or as a consequence of infections in unteated hyperthyroid patients. Treatment consists of antithyroid drug treatmnt, rest, sedation, fluid and electrolyte replacement, cardio-supportive therapy, oxygen therapy, antibiotics, cooling. Mortality is about 10%. Graves orbitopathy (GO) is the main extrathyroidal manifestation of Graves disease, found in about 25% of patients at diagnosis, often mild and self-remitting. Removal of risk factors (refrain from smoking, correction of thyroid dysfunction, oral steroid prophylaxis after radioactive iodine therapy, antioxidant therapy with seleniomethionine) are fundamental to prevent progression of mild GO to more severe forms. In moderate-to-severe and active GO, intravenous glucocorticoids are the first-line treatment, second line treatments include cyclosporine, orbital radiotherapy, rituximab (controversial). Novel biologicals, such as teprotumumab and tocilizumab are under investigation. Rehabilitative surgery (orbital decompression, squint surgery, eyelid surgery) is often required. Thyroid dermopathy (pretibial myxedema) is a rare complication of Graves disease, usually observed in patients who also have severe GO. Topical glucocorticoids are usually effective. Thyroid acropachy (clubbing of fingers and toes, with swelling of hands and feet) is an extremely rare conditions, for which no treatment is available. Hypertyroidism may be complicated by severe cardiovascular manifestations, such as tachyarrhythmias (most commonly atrial fibrillation), congestive heart failure, angina, particularly in the elderly or in patients with preexisting heart abnormalities. Prompt restoration of euthyroidism is, therefore, warranted, as well as specific treatments for the heart. THYROID STORM Thyroid (or thyrotoxic) storm is an acute, life-threatening syndrome due to an exacerbation of thyrotoxicosis. It is now an infrequent condition, because of earlier diagnosis and treatment of thyrotoxicosis, better pre- and postoperative medical management. However, acute exacerbation of thyrotoxicosis caused by intercurrent illness, especially infections, may still occur. Thyroid storm in the past most frequently occurred after surgery, but now it is usually a complication of untreated or partially treated thyrotoxicosis, rather than a postoperative complication. Clinical pattern Classic features of thyroid storm are indicative of a sudden and severe exacerbation of thyrotoxicosis, with fever, marked tachycardia, tremor, nausea and vomiting, diarrhea, dehydration, restlessness, extreme agitation, delirium or coma. Fever is typical and may be higher than 105.8 F (41 C). Patients may present with a true psychosis or a marked deterioration of previously abnormal behavior. Sometimes thyroid storm takes a strikingly different form, called apathetic storm, with extreme weakness, emotional apathy, confusion, absent or low fever Signs and symptoms of multiple organ failure may be present. Delirium is one example. Congestive heart failure may also occur, with peripheral edema, congestive hepatomegaly, and respiratory distress. Marked sinus tachycardia or tachyarrhythmias, such as atrial fibrillation, are common. Liver damage and jaundice may derive from congestive heart failure or a direct action of thyroid hormone on the liver coupled with malnutrition (Chapter 10). Fever and vomiting may produce dehydration and prerenal azotemia. Abdominal pain may be a prominent feature. The clinical picture may be masked by a secondary infection such as pneumonia, a viral infection, or infection of the upper respiratory tract. Death may be caused by cardiac arrhythmia, congestive heart failure, hyperthermia, or other unidentified factors. Storm is typically associated with Graves' disease, but it may occur in patients with toxic nodular goiter (1, 2). At present, although still life-threatening, death from thyroid storm is rarer if it is promptly recognized and aggressively treated in an intensive care unit. In recent nationwide studies from Japan mortality rate was >10% (3, 4). Incidence In Nelson and Becker's series reported in 1969 (5), there were 21 cases of thyroid storm among 2,329 admissions due to thyrotoxicosis (about 1%). Other series, which included all cases with fever of 38.3 C or more in the postoperative period, reported an incidence of thyroid storm as high as 10% of patients operated on (6). Few patients are now seen with the classic pattern of thyroid storm, but patients are occasionally encountered with marked accentuation of symptoms of thyrotoxicosis in conjunction with infection. The incidence of thyroid storm currently may currently be as low as 0.2 cases/100,000 population (3). Cause Thyroid storm classically began a few hours after thyroidectomy performed on a patient prepared for surgery by potassium iodide alone. Many such patients were not euthyroid and would not be considered appropriately prepared for surgery by current standards. Exacerbation of thyrotoxicosis is still seen in patients sent too soon to surgery, but it is unusual in the antithyroid drug-controlled patient. Thyroid storm occasionally occurs in patients operated on for some other illness while severely thyrotoxic. Severe exacerbation of thyrotoxicosis is rarely seen following 131-I therapy for hyperthyroidism; some of these may be defined as thyroid storm (7). Thyroid storm appears most commonly following infection (1), which seems to induce an escape from control of thyrotoxicosis. Pneumonia, upper respiratory tract infection, enteric infections, or any other infection can cause this condition. The decreased incidence of thyroid storm can be largely attributed to improved diagnosis and therapy. In most cases, thyrotoxicosis is recognized early and treated by measures of predictable therapeutic value. Patients are routinely made euthyroid before thyroidectomy or 131-I therapy (8). Using thionamides preoperatively, thyroid glands have only minimal amounts of stored hormones, thus minimizing thyroid hormone release due to manipulation. Diagnosis Diagnosis of thyroid storm is made on clinical grounds and involves the usual diagnostic measures for thyrotoxicosis. Semi-quantitative scales and related scores evaluating the presence and severity of clinical manifestations may be of some help in confirming the diagnosis (1, 3, 9). There are no peculiar laboratory abnormalities. Free T4 and, if possible, free T3 should be measured. Serum total T3 may be not particularly elevated or even normal, due to reduced T4 to T3 conversion as observed in nonthyroidal illness (1). Electrolytes, blood urea nitrogen (BUN), blood glucose, liver function tests, and plasma cortisol should be monitored. Therapy Thyroid storm is an endocrine emergency that has to be treated in an intensive care unit (Table 12-1). Table 1. Treatment of Thyroid Storm Supportive Measures 1. Rest 2. Mild sedation, or anticonvulsant therapy if convulsions occur 3. Fluid and electrolyte replacement 4. Nutritional support and vitamins as needed 5. Oxygen therapy 6. Nonspecific therapy as indicated 7. Antibiotics 8. Cardio-supportive 9. Cooling Specific therapy 1. Propranolol (20 to 200 mg orally every 6 hours, or 1 to 3 mg intravenously every 4 to 6 hours) 2. Antithyroid drugs (150 to 250 mg PTU or 15 to 25 mg methimazole, every 6 hours) 3. Potassium iodide (one hour after first dose of antithyroid drugs): 4. 100 mg KI every 12 hours 5. Dexamethasone (2 mg every 6 hours) Possibly useful therapy 1. Ipodate (Oragrafin) or other iodinated contrast agents, if available 2. Plasmapheresis or exchange 3. Oral T4 and T3 binding resins 4. Dialysis  If drugs cannot be given orally (e.g., in the unconscious patient), they can be administered by naso-gastric tube or enemas (1). In some European countries intravenous preparations have been used (10). If the thyrotoxic patient is untreated, an antithyroid drug should be given. PTU, 150-250 mg every 6 hours should be given, if possible, rather than methimazole, since PTU also prevents peripheral conversion of T4 to T3, thus more rapidly reduces circulating T3 levels. Methimazole (15-25 mg every 6 hours) can be given orally, or if necessary, the pure compound can be made up in a 10 mg/ml solution for parenteral administration. Methimazole is also absorbed when given rectally in a suppository. An hour after a thionamide has been given, iodide should be administered. A dosage of 100 mg twice daily is more than sufficient. Unless congestive heart failure contraindicates it, propranolol or other beta-blocking agents should be given at once, orally or parenterally in large doses, depending on the patient's clinical status. Permanent correction of thyrotoxicosis by either 131-I or immediate thyroidectomy should be postponed until euthyroidism is restored. Other supporting measures should fully be exploited, including sedation, oxygen, treatment for tachycardia or congestive heart failure, rehydration, multivitamins, occasionally supportive transfusions, and cooling the patient to lower body temperature down. Antibiotics may be given on the presumption of infection while results of culture are awaited. The adrenal gland may be limited in its ability to increase steroid production during thyrotoxicosis. If there is any suspicion of hypoadrenalism, hydrocortisone (100-200 mg/day) or its equivalent should be given. The dose can rapidly be reduced when the acute process subsides. Pharmacological doses of glucocorticoids (2 mg dexamethasone every 6 h) acutely depress serum T3 levels by reducing T4 to T3 conversion. This effect of glucocorticoids is beneficial in thyroid storm and supports their routine use in this clinical setting. Propranolol controls tachycardia, restlessness, and other symptoms. Usually rehydration, repletion of electrolytes, treatment of concomitant disease, such as infection, and specific agents (antithyroid drugs, iodine, propranolol, and corticosteroids) produce a marked improvement within 24 hours. A variety of additional approaches have been reported, but indications for their use are not well defined. For example, oral gallbladder contrast agents such as ipodate and iopanoic acid in doses of 1-2 g, which inhibit peripheral T4 to T3 conversion, might have value. Unfortunately, these agents are no longer available. Peritoneal dialysis can remove circulating thyroid hormone, and plasmapheresis can do likewise, but at the expense of serum protein loss. Orally administered ion-exchange resin (20-30g/day as Colestipol-HCl) can trap hormone in the intestine and prevent recirculation. These treatments are rarely needed. Antithyroid treatment should be continued until euthyroidism is achieved, when a final decision regarding antithyroid drugs, surgery, or 131-I therapy can be made. GRAVES ORBITOPATHY Graves orbitopathy (GO) is the main and most frequent extrathyroidal manifestation of Graves disease, although it may less frequently occur in patients with Hashimotos thyroiditis or apparently without thyroid abnormalities (so-called Euthyroid Graves disease) (11-15). Epidemiology  Fig. 1: Prevalence of GO in a series of 346 patients with newly diagnosed Graves hyperthyroidism. Moderate-to-severe GO includes one case of sight-threatening dysthyroid optic neuropathy (DON). Derived from Tanda ML et al. (17). Data on the incidence of GO are limited (11, 14). In a population-based setting in USA, an adjusted rate of 16 cases per 100.000 per year in women and 2.9 cases per 100.000 in men was reported (16). In a recent study of a large cohort of newly diagnosed Graves patients, about 75% had no ocular involvement at diagnosis, only 6% had moderate-to-severe GO, and 0.3% showed sight-threatening GO due to dysthyroid optic neuropathy (DON) (17) (Figure 1). In a Danish population, moderate-to-severe GO showed an incidence of 16.1/million per year (women: 26.7; men: 5.4) (18). Ocular involvement is in most cases bilateral, although often asymmetrical, but it may be unilateral in up to 15% of cases (12, 14). As recently reviewed by the European Group on Graves Orbitopathy (EUGOGO), the overall prevalence of GO in Europe is about 10/10,000 patients, but the prevalence of its variants (hypothyroid GO, GO associated with dermopathy, GO associated with acropachy, asymmetrical or unilateral GO) is much lower, and recently euthyroid GO has been listed as a rare disease in Europe (19). The onset of GO apparently has a bimodal peak in the fifth and seventh decades of life, but eye disease may occur at any age (20). It is more frequent in women, but men tend to have a more severe disease (21-23), as suggested by a decrease in the female/male ratio from 9.3 in mild GO, to 3.2 in moderately severe GO, and 1.4 in severe GO (20). There is a close temporal relationship between the onset of GO and the onset of hyperthyroidism. In approximately 85% of cases GO and hyperthyroidism occur within 18 months of each other (20), although GO may both precede (about 20% of cases) or follow (about 40% of cases) the onset of hyperthyroidism (20). The natural history of GO is poorly understood. However, in a longitudinal cohort study, spontaneous amelioration was observed in two thirds of cases, while ocular involvement did not change with time in 20% and progressed in 14% (22). The observation that mild GO rarely progresses and often spontaneously remits was recently confirmed by a large prospective study of patients with recent onset Graves hyperthyroidism (17) and summarized in a review of published studies (24). It is worth noting that GO seems to be less frequent than in the past. A review of the first 100 consecutive patients seen at the same joint thyroid-eye unit in 1960 and 1990 revealed a decrease in the proportion of Graves patients with clinical relevant GO from 57% to 32% (23); likewise, a reduction in the proportion of severe forms of GO compared to milder forms was observed (18), likely reflecting an earlier diagnosis and treatment of both hyperthyroidism and orbitopathy. It should be noted that a multicenter study carried out by the European Group on Graves Orbitopathy (EUGOGO) reported that 40% of GO patients had mild disease, 33% had moderate GO, and 28% had severe eye disease (25). It should be noted that these figures were clearly influenced by the fact that EUGOGO centers are all referral centers where it is likely to see more complicated cases of GO. Accordingly, a recent single-center study confirmed that most patients newly diagnosed with Graves disease have mild GO (26), although whether these forms are chronic remitting or a transient disease (27) or whether GO ever disappears completely (28) is unsettled. In summary, based on recent studies and reviews of the available literature, it can be concluded that GO is a rare disease, particularly in its severe expressions (19). An important epidemiologic feature of GO is its relation with cigarette smoking (29,30). The prevalence of smokers among Graves women with orbitopathy is much higher than that in Graves women apparently without GO or in normal controls (Figure 2) (31). Smoking is a predictor of Graves hyperthyroidism, with a hazard ratio of 1.93 in current smokers, 1.27 in ex-smokers, and 2.65 in heavy smokers (32). In a case-control study, the odds ratio of cigarette smoking for Graves hyperthyroidism without GO was 1.7, but raised to 7.7 for Graves disease with GO (33). Whether passive smoking may have the same impact as active smoking is unsettled; however, in a recent European survey of GO in childhood, the highest prevalence of Graves children with GO was found in countries where the prevalence of smokers among teenagers was also highest: since >50% of children were <10 years of age, it is likely that passive smoking rather than active smoking influenced GO occurrence (34). Mechanisms whereby smoking may affect the development and course of GO are unclear. In addition to direct irritative effects and modulation of immune reactions in the orbit (35), smoking was associated with an increase in the orbital connective tissue volume as assessed by MRI (36), and with an increased adipogenesis and hyaluronic acid production in in vitro cultured orbital fibroblasts (37). Whatever the mechanism(s) involved, cigarette smoking is strong (probably the strongest) predictor of GO occurrence in patients with Graves hyperthyroidism (38).  INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure1.png" \* MERGEFORMAT  Figure 2. Prevalence of smokers among women with Graves disease with (GO) or without (GD) associated orbitopathy. NTG: Non-toxic goiter; C: controls. Derived from Bartalena et al (31). Pathogenesis Clinical manifestations of GO reflect remodeling of the orbital space related to the enhanced orbital volume, due to an increase in retroocular fibroadipose tissue and swelling of extraocular muscles (39-41). Orbital tissues, including muscles, are infiltrated by inflammatory cells, including lymphocytes, mast cells, and macrophages. Proliferation of orbital fibroblasts and adipocytes, both in the retroocular space and in the perimysial space, is also associated with an increased production of glycosaminoglycans, which are the ultimate responsible for edematous changes both in the connective tissue and the muscles, owing to their hydrophilic nature. The relative contribution of the increase in fibroadipose tissue volume and extraocular muscle swelling is not always the same, and a predominance of either component may be observed in different patients with similar clinical features (42). Furthermore, the increase in orbital fat might be a rather late phenomenon (43). Because the orbit is a rigid, bony structure anteriorly limited by the orbital septum, the increased orbital volume deriving from cell proliferation, inflammatory infiltration and edema, results into enhanced intraorbital pressure, forward displacement of the globe (proptosis or exophthalmos), extraocular muscle dysfunction causing diplopia and/or strabismus, soft tissue changes with periorbital edema, conjunctival hyperemia and chemosis. If proptosis, which can be considered a form of spontaneous decompression, is severe, subluxation of the eye may occur. Proptosis is responsible for corneal exposure which may be particularly dangerous at night for the incomplete eyelid closure (lagophthalmos), and may result into sight-threatening corneal ulceration. The enlarged muscle volume may cause optic nerve compression (dysthyroid optic neuropathy), especially if the orbital septum is tight and proptosis is minimal. Optic nerve compression is particularly evident at the orbital apex and may be responsible for sight loss. Orbital inflammation and related anatomical changes may cause venous and lymphatic congestion that contribute to periorbital edema and chemosis. With time inflammation subsides and muscle fatty degeneration and fibrosis may contribute to further extraocular muscle restriction and strabismus, which, at this stage, can only be corrected by surgery. GO is an autoimmune inflammatory disorder related to the thyroid and triggered by the migration of autoreactive T-helper cells into the orbit, which is infiltrated by CD4+ T cells and, to a lesser extent, CD8+ T cells, B cells, fibrocytes, mast cells, and macrophages (40, 41). Orbital fibroblasts are the main target and key effector cells in the disease (44). After recognition of one or more antigens (shared with the thyroid) on fibroblast surface, facilitated by HLA class II antigen expression on antigen-presenting cells (B cells, macrophages), CD4+ T cells secrete cytokines which activate CD8+ T cells, autoantibody-synthesizing B cells (45) and stimulate orbital fibroblasts (46). Fibroblasts proliferate, may differentiate into myofibroblasts and adipocytes, accumulate and secrete hyaluronic acid (HA), synthesize and secrete chemoattractants (interleukin-16, RANTES, CXCL10) and a number of cytokines (interleukin-1, interleukin-6, interferon-g, tumor necrosis factor-a, interleukin-8, interleukin-10, platelet-derived growth factor, transforming growth factor-b), which concur to auto-maintain the inflammatory process (47). HA is hydrophilic and thereby attracts water and causes edema of the extraocular muscles and orbital tissue (40). Orbital fibroblasts can be differentiated based on the expression or lack of expression of a cell surface glycoprotein (thymocyte antigen-1, thy-1). Thy-1+ fibroblasts are mostly represented in extraocular muscles and produce HA, thereby contributing to extraocular muscle edema and enlargement, whereas thy-1- fibroblasts are mainly present in connective tissue and may differentiate into adipocytes, thereby contributing to fibroadipose tissue expansion (40). The TSH receptor (TSH-R), the ultimate cause of hyperthyroidism due to Graves disease, is likely the shared antigen responsible for GO. TSH-R expression has been shown in the orbital tissue of GO patients, both at the mRNA and protein levels (48, 49); however, TSH-R is also expressed in several other tissues not involved in Graves disease and orbitopathy (50), and, although at lower levels, in normal orbital fibroadipose tissue samples and cultures (51). On the other hand, BALB/c mice injected with spleen cells primed either with a TSH-R fusion protein or with TSH-R cDNA developed thyroiditis with blocking-type TRAb, but also showed orbital pathological changes (lymphocytic and mast cell infiltration, edema, presence of glycosaminoglycans) similar to those seen in human GO (52). This model could not be reproduced in other laboratories. More recently a novel preclinical female mouse model of GO was established (53). In this model, some of the mice immunized by human TSH A-subunit by TSH receptor plasmid in vivo electroporation showed large infiltrates surrounding the optic nerve, increased adipogenesis, orbital muscle hypertrophy, exophtahlmos, and chemosis (53, 54). The role of the TSH-R seems to be supported also by other animal models (55-57). Another putative antigen involved in the pathogenesis of GO is the IGF-1 receptor. As recently reviewed (58), increased IGF-1 receptor levels have been reported in orbital fibroblasts as well as in B and T lymphocytes from Graves patients, and immunoglobulins displacing IGF-1 from its binding to the IGF-1 receptor have also been found in these patients (59). Colocalization of TSH receptor and IGF-1 receptor has been shown both in orbital fibroblasts and thyrocytes, suggesting that the two receptors might form a functional complex (60). Stimulation of the TSHR by the monoclonal TSHR-stimulating antibody, M22, could be inhibited by an IGF-1R-blocking monoclonal antibody in orbital fibroblasts (61). Involvement of the IGF-1R is not specific for Graves disease, since it is implicated in other autoimmune diseases, such as rheumatoid arthritis (62). Thus, although involvement of the IGF-1R in the pathogenesis of GO seems likely (63), it is tempting to speculate, for the time being, that autoimmunity to the TSH receptor be the initiating mechanism, while subsequent increased expression of the IGF-1R might be fundamental to maintain ongoing reactions in the orbit (64). Interestingly, two recent reports found that, at variance with TRAb, only a minority of patients with GO have circulating antibodies to the IGF-1R (65, 66). This may be related to the low sensitivity and specificity of tests used to detect such antibodies (62). Alternatively, it may be conceived that IGF-1 (and/or IGF-1R antibodies) locally produced in the orbit be relevant for the pathogenesis of GO (67). Other autoantigens, including several eye muscle antigens, acetylcholine receptor, thyroperoxidase, thyroglobulin, alpha-fodrin, have been proposed as putative shared antigens, but their true role is, to say the least, uncertain (68). The role of genetic factors in the pathogenesis of GO is not very well defined, and no striking differences have been observed between Graves patients with or without associated GO (69-73). An association between GO and Major Histocompatibility Complex (MHC), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or intercellular adhesion molecule 1 gene polymorphisms has been looked for, but results are not unequivocal (74-76). GO likely stems from a complex interplay between endogenous factors and exogenous (environmental) risk factors (13, 77). The latter are probably more important and include cigarette smoking, thyroid dysfunction, and, in a subset of patients, radioiodine therapy for Graves hyperthyroidism (13, 77). The relationship between cigarette smoking and GO has been discussed above (see paragraph on Epidemiology). Both hyperthyroidism (78, 79) and hypothyroidism (80) seem to influence negatively the course of the orbitopathy. TRAb are independent risk factors for GO and can help to predict severity and outcome of eye disease (81). Radioiodine therapy for Graves hyperthyroidism is associated with GO progression in about 15% of cases, although this effect may be transient (82-86). This effect is more frequently observed in patients who already have GO prior to radioiodine therapy, smoke, have high TRAb levels, or whose post-radioiodine hypothyroidism is not promptly corrected by L-thyroxine replacement therapy (13, 77). Radioiodine-associated progression of GO can be prevented by a short course of prednisone (87). Lower doses of oral prednisone (0.2 mg/Kg bw) for 6 weeks are as effective in preventing RAI-associated progression of GO as higher doses used in the past (88). Neither thyroidectomy (typically partial) nor antithyroid drugs influence the course of the orbitopathy (89-91). The above observations have important practical implications in terms of GO prevention (Table 2), because GO patients should be urged to refrain from smoking, their thyroid dysfunction (both hyper- and hypothyroidism) should be promptly corrected, and, in the case of radioiodine therapy, a short course of oral prednisone should be administered (92). Table 2. Risk factors for the occurrence/progression of Graves orbitopathy and preventive measures Risk factor  Preventive measure  Cigarette smoking  Refrain from smoking  Hyperthyroidism  Restore euthyroidism by antithyroid drugs and/or obtain a permanent control by thyroid ablation (thyroidectomy, radioiodine, both)  Hypothyroidism  Restore euthyroidism by L-thyroxine replacement therapy  Radioiodine therapy for hyperthyroidism  Give oral prednisone concomitantly with radioiodine administration. Avoid leaving the patient with untreated post-radioiodine hypothyroidism  High TSH-receptor antibody levels  Control hyperthyroidism as soon as possible Oxidative stressGive a 6-month selenium course in mild GO Clinical Features Signs & Symptoms. Clinical features of GO include soft tissue changes, exophthalmos, extraocular muscle dysfunction, corneal abnormalities, and optic nerve involvement (Figures 3-6). The NOSPECS classification (Table 3) is a useful memory aid of GO abnormalities (93). Recommendations for GO assessment in clinical practice have recently been reviewed by EUGOGO (94) and other groups (VISA classification) (95). Soft tissue changes include eyelid edema and periorbital swelling, eyelid erythema, conjunctival hyperemia and chemosis, inflammation of the caruncle or plica: their assessment and grading can be done with the aid of a color atlas (96), which can be downloaded from EUGOGO website (www.eugogo.eu). Proptosis, i.e., protrusion of the eye (exophthalmos), is usually measured by Hertel exophthalmometer; normal values are usually less than 20 mm, but vary with race, age, gender, degree of myopia, and should be established in each center or institution. Extraocular muscle dysfunction is responsible for diplopia (double vision), which can be subjectively defined as intermittent (i.e., present only when fatigued or when first waking), inconstant (i.e., present only at extremes of gaze), or constant (i.e., present also in reading positions and primary gaze); objective assessment of extraocular muscle functioning can be done by several methods, including measurement of duction in degrees (94). Palpebral aperture may be increased due to several factors, including upper and/or lower lid retraction, and proptosis. Lid retraction and proptosis are responsible for corneal exposure, which may lead to corneal epithelium damage (punctate keratopathy), corneal ulceration and perforation. The incomplete eye closure at night (lagophthalmos) and the absence of Bells phenomenon (no upward eye rotation on attempted eye closure) are risk factors for corneal damage (92, 94). Intraocular pressure is often increased, particularly in upward gaze, but this abnormality rarely progresses to true glaucoma. Dysthyroid optic neuropathy, due to optic nerve compression at the orbit apex by swollen extraocular muscles, or, less frequently, to optic nerve stretching in cases of marked proptosis or eye subluxation, is a sight-threatening expression of GO. It can be diagnosed by fundoscopy showing disc swelling, reduced visual acuity, abnormal color vision test, contrast sensitivity, perimetry, visual-evoked potentials, and pupillary responses (95).  INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure2.jpg" \* MERGEFORMAT  Figure 3. Female patient with moderately severe GO. Note periorbital swelling, injection of conjunctival vessels, proptosis, marked lid retraction, and proptosis.  INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure3.jpg" \* MERGEFORMAT  Figure 4. Male patient with moderately severe GO. Note marked periorbital swelling, conjunctival hyperemia, esotropia (strabismus) in the left eye.  INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure4.jpg" \* MERGEFORMAT  Figure 5. Male patient with moderately severe GO. Note the superior eyelid edema, mild conjunctival vessel injection, marked proptosis, and marked upper lid retraction.  INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure5.jpg" \* MERGEFORMAT  Figure 6. Female patient with severe GO. Note marked periorbital swelling, palpebral hyperemia, conjunctival hyperemia, proptosis (particularly in the left eye), caruncle edema. Eye motility was markedly reduced, lagophthalmos was present, there were two corneal ulcers in the left eye, and corneal punctate staining in the right eye, reduced visual acuity in the left eye (5/10). CT scan showed enlargement of extraocular muscles (particularly medial rectus and inferior rectus) in both eyes, but no relevant compression of the optic nerve at the orbit apex. Table 3. NOSPECS classification of eye changes of Graves disease Class  Grade  Symptoms and Signs  0   No symptoms or signs  1   Only signs (upper lid retraction, without lid lag or proptosis)  2   Soft tissue involvement with symptoms (excess lacrimation, sandy sensation, retrobulbar discomfort, and photophobia, but not diplopia);objective signs as follows:   0  absent   a  minimal (edema of conjunctivae and lids, conjunctival injection, and fullness of lids, often with orbital fat extrusion, palpable lacrimal glands, or swollen extraocular muscles beneath lower lids)   b  Moderate (above plus chemosis, lagophthalmos lid fullness)   c  marked  3   Proptosis associated with classes 2 to 6 only (specify if inequality of 3 mm or more between eyes, or if progression of 3 mm or more under observation)   0  absent (20 mm or less)   a  minimal (21-23 mm)   b  moderate (24-27 mm)   c  marked (28 mm or more)  4   Extraocular muscle involvement (usually with diplopia)   0  absent   a  minimal (limitation of motion, evident at extremes of gaze in one or more directions)   b  moderate (evident restriction of motion without fixation of position)   c  marked (fixation of position of a globe or globes)  5   Corneal involvement (primarily due to lagophthalmos)   0  absent   a  minimal (stippling of cornea)   b  moderate (ulceration)   c  marked (clouding, necrosis, perforation)  6   Sight loss (due to optic nerve involvement)   0  absent   a  minimal (disc pallor or choking, or visual field defect, vision 20/20 to 20/60)   b  moderate (disc pallor or choking, or visual field defect, vision 20/70 to 20/200)   c  marked (blindness, i.e., failure to perceive light; vision less than 20/200)  From Werner (93).  Symptoms of GO (Table 4) include, in addition to changes in ocular appearance related to periorbital swelling and proptosis, excess lacrimation, photophobia, grittiness, pain in or behind the eyes, either spontaneous or with eye movements, diplopia of different severity with or without strabismus, blurred vision, which may clear with blinking (due to excessive lacrimation) or covering one eye (reflecting extraocular muscle impairment), or may persist (probably reflecting optic neuropathy, particularly if associated with gray areas in the field of vision). In addition to reduced visual acuity, optic nerve involvement can be heralded by decreased color perception. Diplopia may be absent if extraocular muscle involvement is symmetrical in both eyes. Table 4. Symptoms associated with Graves orbitopathy 1. Changes in eye appearance, particularly eyelid or periorbital swelling, eye bulging 2. Excessive lacrimation, often more pronounced on waking 3. Incomplete closure of eyes at night (lagophthalmos), as reported by the partner 4. Photophobia, need to protect eyes with dark lenses 5. Increased eye sensitivity to irritative factors other than light (e.g., wind, smoke, pollution) 6. Ocular discomfort, described as grittiness, foreign body or sandy sensation, often defined as allergy 7. Ocular pain, either related or unrelated to eye movements 8. Neck ache, with abnormal head posture (torcicullum) 9. Diplopia a. Intermittent: present only when tired or on waking b. Inconstant: present only at extremes of gaze c. Constant: present also in primary and reading positions 10. Blurred vision a. Disappearing with blinking b. Not disappearing with blinking 11. Reduced color perception  Clinical manifestations of GO have a profound negative impact on quality of life and daily activities of affected individuals (98). By the use of general health-related quality of life (HRQL) questionnaires, such as the SF-36 or its shorter forms, it was shown that GO is associated with significant changes in several functions, including physical functioning, role functioning, social functioning, mental health, general health perception, and bodily pain (99). Interestingly, these changes in HRQL parameters were similar to those found in patients with inflammatory bowel disorders, and even more marked than those observed in patients with diabetes mellitus, heart failure or emphysema (99). Since HRQL questionnaires are broad and may not address items specific for a given disease, a GO-specific quality of life (GO-QoL) questionnaire was developed and validated in clinical studies (99, 100-102). This questionnaire (dowloadable from EUGOGO website at www.eugogo.eu) is composed of 16 questions, 8 concerning the consequences of diplopia and deceased visual acuity on visual functioning, and 8 regarding the consequences of changes in physical appearance on social functioning. The Go-QoL is a useful tool for self-assessment of treatment outcomes for GO (103). Activity & Severity. Definition of GO severity is somehow arbitrary and may reflect different views (11, 23). According to the most recent EUGOGO definition (92), mild GO is characterized by one or more of the following features: minor lid retraction (<2 mm), mild soft tissue involvement, exophthalmos <3 mm above normal for race and gender, transient or no diplopia, and corneal exposure; the above features usually have a minor impact on daily life to justify immmuno-suppression or surgical treatment; moderate-to-severe GO have any one or more of the following: lid retraction >2 mm, moderate or severe soft tissue involvement, exophthalmos >3 mm above normal for race and gender, inconstant or constant diplopia; Patients in this category have an impact on daily life as to justify immunosuppression (if GO is active) or surgical intervention (if GO is inactive); sight-threatening GO is due to dysthyroid optic neuropathy (DON) or corneal breakdown, and warrants immediate intervention (Table 5) (92). Assessment of severity is particularly relevant to decide on whether a given patient should be treated by aggressive treatments (either medical or surgical) or simply by local or general supportive measures (see below).The other important feature of GO is its activity. Although, as stated above, GO natural history is not completely understood, it is commonly accepted that GO undergoes an initial phase of activity, characterized by progressive exacerbation of ocular manifestations until a plateau phase is reached; GO then tends to remit spontaneously, but remission is invariably partial. In the inactive phase (burnt-out GO), only residual ocular manifestations are present (e.g., proptosis, strabismus due to muscle fibrotic changes), but inflammation has subsided and it is unlikely that it may flare up. It is unknown how long this process takes to be completed, but it is widely believed that it takes between 6 months and two years. Recognition of the different phases of the disease is important, because active disease, basically characterized by the presence of inflammation, can respond to immunosuppressive treatments, which are largely ineffective when GO is burnt-out. Different indicators have been proposed to assess GO activity, including short duration of treatment (<18 months), positivity of octreoscan, decreased extraocular muscle reflectivity at orbital ultrasound, prolonged T2 relaxation time at MRI, increased urinary glycosaminoglycan levels, but they lack sufficient specificity and accuracy. A useful tool to assess GO activity is represented by the Clinical Activity Score (CAS), which can be calculated very easily and is recommended by EUGOGO in the assessment of GO in routine clinical practice, in specialist multidisciplinary clinics, and for clinical trials (92). In its original formulation (104) it included 10 items, which were subsequently reduced to 7 when revised by an ad hoc Committee of the four sister thyroid societies (105). (Table 6). If one point is given to each item when present, CAS, which basically reflect eye inflammation, may range from 0 (absent activity) to 7 (maximal activity); GO is generally defined active if CAS is >3. Table 5. Assessment of severity of Graves orbitopathy Degree of Ocular involvementFeaturesMild GOMinor lid retraction (<2 mm), mild soft tissue involvement, exophthalmos <3 mm above normal for race and gender, transient or no diplopia, corneal exposure responsive to lubricantsModerate-to-severe GOLid retraction >2 mm, moderate-to-severe soft tissue involvement, exophthalmos >3 mm above normal for race and gender, inconstant or constant diplopia Sight-threatening GOPresence of dysthyroid optic neuropathy and/or corneal breakdownDerived from Bartalena & EUGOGO (92) Table 6. Clinical Activity Score (CAS). 1. Spontaneous retrobulbar pain 2. Pain on eye movements 3. Eyelid erythema 4. Conjunctival injection 5. Chemosis 6. Swelling of the caruncle 7. Eyelid edema or fullness  One point is given to each item, if present. CAS is the sum of single scores, ranging from 0 (no activity) to 7 (maximal activity). Active GO: CAS>3  From Mourits et al (104), modified from an ad hoc Committee of the four Thyroid sister Societies (105).  Diagnosis Diagnosis of GO is usually easy on clinical grounds and by careful ophthalmological examination. Although not necessary in most Graves patients, CT scan or MRI of the orbit confirm diagnosis by showing enlarged extraocular muscles (without involvement of the tendon) and/or increased orbital fibroadipose tissue (106). Modest extraocular muscle enlargement and increased fibroadipose tissue volume are often found in Graves patients without clinical manifestations of ocular involvement. Orbital imaging is very useful to detect signs of optic nerve compression, which support the diagnosis of optic neuropathy. Imaging is required in asymmetrical or, particularly, unilateral forms of GO, to rule out that proptosis, periorbital swelling, inflammation, or diplopia be due to disorders other than GO (12, 106). The latter include primary or metastatic orbital tumors, vascular abnormalities (e.g., carotid-cavernous sinus fistula, carotid aneurysm, cavernous sinus thrombosis, subarachnoid hemorrhage, subdural hematoma), granulomatous disorders, IgG4-related ophthalmic disease (107). Occasionally, angiograms or venograms may be required for diagnosis. Octreoscan may be useful to identify patients with active GO (106), but its role in clinical practice is limited, also in view of its high cost. Management Management of GO is based on a multidisciplinary approach which involves endocrinologists, ophthalmologists, orbit surgeons, radiologists and radiotherapists. In a survey of GO management based on a questionnaire distributed among members of the European Thyroid Association, European Society of Ophthalmic Plastic and Reconstructive Surgery, and European Association of Nuclear Medicine, 96% of responders stated that a multidisciplinary setting for GO management is valuable, although 21% of patients were in the end not treated in a multidisciplinary setting (108). The therapeutic approach to a GO patient should be based on both severity and activity of the disease, the former being the feature to assess first. Mild GO. Most patients have mild GO, which does not require particularly aggressive treatments and often is self-limiting (92, 110, 111). If GO activity is modest, simple local measured can be suggested to obtain symptomatic relief until GO is burnt-out (Table 7). Photophobia can be mitigated by sunglasses; grittiness due to corneal exposure can be controlled by artificial tears and topical lubricants, particularly indicated in the presence of lagophthalmos; the latter may require taping the eyelids shut at night; eyelid retraction can be controlled (with a variable degree of success) by b-blocking drops (useful for the increased intraocular pressure) or by botulinum toxin injections (112); elevation of the bed may be helpful to reduce periorbital swelling due to congestion; mild diplopia often is controlled by prisms (if they are tolerated). Reassurance is an important issue, and the patient must be informed that his/her eye disease is unlikely to progress to more severe forms, usually stabilizes, and often ameliorates spontaneously. Control of thyroid dysfunction is fundamental, because progression often is associated with hyper- or hypothyroidism (12, 92); refrain from smoking is also essential, because it is associated with a decreased chance of developing proptosis and diplopia (113), and decreases the likelihood to develop severe GO (29). Patients who do not succeed to quit smoking by themselves, should be helped by professional stop-smoking clinics, organizations, groups, where they can receive counseling, behavioral therapies, pharmacological treatments. In a subset of patients with mild GO, the impact of GO on the quality of life is so pronounced as to justify the risk of immunosuppression (or surgery) as for moderate-to-severe GO (92). A recent randomized controlled trial performed by EUGOGO in a large cohort of patients with mild GO showed that selenium supplementation for 6 months has beneficial effects on mild GO compared with placebo and can often prevent its progression to more severe forms (114). Thus, selenium, for its anti-inflammatory and immunomodulatory actions, should be considered both as a therapeutic tool for mild GO and a preventive measure (115). Whether selenium is also useful as an adjuvant therapy in patients with moderate-to-severe GO is presently unsettled. Table 7. Management of mild Graves orbitopathy Sign and/or symptom and/or associated problem  Therapeutic measure  Photophobia  Sunglasses  Foreign body or sandy sensation  Artificial tears and ointments  Eyelid retraction  alpha-blocking eye drops. Botulinum toxin injections  Increased intraocular pressure  alpha-blocking eye drops  Lagophthalmos  Nocturnal eye taping  Thyroid dysfunction (hyper/hypo)  Restoration of euthyroidism, as appropriate  Smoking  Refrain from smoking  Anxiety about possible further progression  Reassurance on the natural history of mild GO Management of clinical picture and prevention of progressionSelenium supplementation Moderate-to-severe GO. Management of moderate-to-severe GO depends not only on severity, but also on activity of the orbitopathy (Table 8). Medical treatment is likely to be beneficial in patients with active GO, with florid signs and symptoms of inflammation, recent-onset extraocular muscle dysfunction, recent progression of the ocular abnormalities as a whole. On the contrary, in long-standing GO, with chronic proptosis and residual, stable diplopia and/or strabismus, but no no evidence of inflammation, medical treatment has little chances to produce favorable effects, and the surgical, rehabilitative approach is preferable (92). Dysthyroid optic neuropathy, the most severe expression of the orbitopathy, is a clinical, sight-threatening emergency, which requires immediate treatment. If there is no response to medical treatment (high-dose intravenous glucocorticoids), orbital decompression is warranted (92).  INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure6.png" \* MERGEFORMAT  Table 8. Management of moderate-to-severe Graves orbitopathy TreatmentValidityGlucocorticoidsEstablishedOrbital RadiotherapyEstablishedOrbital DecompressionEstablishedRehabilitative Surgery (squint surgery, eyelid surgery)EstablishedSomatostatin analogsNon-validated (octreotide, lanreotide)Intravenous immunoglobulinsNon-validatedCyclosporineLimited applicationsAntioxidantsSelenium (validated only for mild GO)RituximabTwo conflicting and small randomized clinical trialsEtanerceptLimited data (non-validated in randomized clinical trials)MycophenolateTwo randomized clinical trials with positive resultsTeprotumumabOne randomized clinical trial with positive resultsThyroid ablation by 131-I and/or surgeryControversial Glucocorticoids are the mainstay in the medical treatment of GO (12, 92, 116, 117). They have been used for decades because of their anti-inflammatory effects, but also because they exert immunosuppressive actions useful to control the course of the orbitopathy (12, 92, 116, 117). The latter include interference with the function of T and B lymphocytes, decreased recruitment of neutrophils and macrophages, down-regulation of adhesion molecules, inhibition of cytokine secretion, inhibition of glycosaminoglycan secretion. Locally (subconjunctivally or retrobulbarly) given glucocorticoids are less effective than systemically given glucocorticoids ) (11, 92), although favorable responses in terms of improvement of diplopia and reduction in extraocular muscle dysfunction have been reported with in a recent randomized clinical trial of periocular injections of triamcinolone acetate (118) . Glucocorticoids have for a long time been given mostly orally. This route of administration has several drawbacks: high doses are required every day (e.g., prednisone 60-100 mg daily as a starting dose, or equivalent doses of other steroids) (11), treatment lasts for several months (at least 5-6 months), recurrences are frequent upon drug tapering or withdrawal, side effects (particularly Cushings syndrome) are frequent (12, 92, 116, 117). In the last 20 years the intravenous route has become the most commonly used (101) and currently represents the first-line treatment for moderate-to-severe and active GO (92). Intravenous glucocorticoids are more effective, with a rate of favorable responses reported until few years ago of about 80-90% versus 60-65% with oral glucocorticoids (117, 119), and better tolerated than oral glucocorticoids (120). As a proof of principle, in a placebo-controlled, randomized trial, intravenous methylprednisolone (four cycles at a dose of 500 mg for 3 consecutive days at 4-week intervals) effected inflammatory changes and extraocular muscle dysfunction in 5 of 6 patients (83%) compared to only one of 11 placebo-treated patients (121) Glucocorticoids are most effective on soft tissue, inflammatory changes, recent-onset extraocular muscle dysfunction, and dysthyroid optic neuropathy, whereas proptosis and long-lasting eye muscle impairment are less responsive (11, 117). However, it should be noted that severe liver damage, heralded by a marked rise in serum concentrations of hepatic enzymes, was noted in 7 of about 800 treated patients (approximately 0.8%), three of whom died (122). The causes of this hepatotoxicity are unclear, but might include direct liver toxicity of glucocorticoids, precipitation of virus-induced hepatitis, sudden reactivation of the immune system upon drug withdrawal leading to autoimmune hepatitis. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for GO (123). The cumulative dose of glucocorticoids might also be important, since no cases of liver damage were reported in a recent randomized clinical trial in which lower, but equally highly effective, doses of glucocorticoids were employed (124). In this trial, the cumulative dose of methylprednisolone was 4.5 grams, subdivided in 12 weekly 2-hour infusions (500 mg for the first 6 infusions, 250 mg for the remaining 6 infusions) (124). A questionnaire-based surgery carried out among members of the European Thyroid Association showed a wide heterogeneity in the regimens of intravenous glucocorticoid therapy for moderate-to severe and active GO (125). A recent mullticenter, randomized clinical trial of a large cohort of patients with moderate-to-severe and active GO showed that a cumulative dose of about 7.5 g of methylprednisolone was associated with more favorable treatment outcomes than lower doses (about 5 g or 2.25 g), but also caused adverse events more frequently (126). Thus, the cumulative dose should somehow be tailored to the severity and activity of GO, reserving the highest dose to patients with most severe expressions of the disease. In any case, the current recommendation is that the cumulative dose of glucocorticoids per course should not exceed 8 grams (92). Response to intravenous glucocorticoids may occur early in the course of the intravenous course, but also later; accordingly, the lack of response after the first 5-6 infusions is not an indication to stop the treatment (127). Adverse events of high-dose glucocorticoid treatment remain a relevant issue (128). Accordingly, patients should be treated in specialized centers under strict medical surveillance (92). Intravenous glucocorticoid treatment of Graves ophthalmopathy is not associated with secondary adrenocortical insufficiency. (129, 130),presumably because it is given for a limited period and intermittently. Orbital radiotherapy is the other non-surgical mainstay in the management of GO (131). The rationale for its use and the indications are quite similar to those of glucocorticoids; in addition, irradiation exploits the radiosensitivity of T lymphocytes which infiltrate the orbit (131). Irradiation is currently carried out by linear accelerators, using a cumulative dose of 20 Gray fractionated in 10 daily 2-Gray doses over a 2-week period (131), although other regimens (and lower doses) might be equally effective (132). Favorable responses have been reported in about 60% of treated patients (131). Recent years have witnessed a lively debate on the true effectiveness of orbital radiotherapy (133, 134). However, the results of several randomized studies confirmed, with one exception, its efficacy (132, 135-138). In addition, orbital radiotherapy is a safe procedure devoid of relevant short-term and long-term side effects or complications (139, 140). Preexisting retinopathy associated with diabetes mellitus or hypertension represents a contraindication to its use (92). As for glucocorticoids, orbital radiotherapy is mostly effective on soft tissue inflammatory changes and recent-onset extraocular muscle dysfunction (131). Orbital radiotherapy can be used either alone or in combination with glucocorticoids. The association exploits the prompter effect of glucocorticoids and the more sustained action of irradiation; in two randomized prospective studies, combined therapy (using oral glucocorticoids) proved to be more effective than either treatment alone (141, 142). Whether the combination of intravenous glucocorticoids and orbital radiotherapy is more effective than intravenous glucocorticoids alone is presently unsettled. For this reason the recent guidelines for the management of moderate-to-severe and active suggest the combination of orbital radiotherapy and oral glucocorticoids as a second-line treatment in the case of a partial or absent response to intravenous glucocorticoids (92). Cyclosporine, used in GO for its immunosuppressive properties, has been reported in only two randomized and controlled studies (143, 144) . Cyclosporine has a lower efficacy than glucocorticoids as a single-agent therapy, although a combination of both drugs might be more effective than either treatment alone (143, 144). Thus, the use of cyclosporine might be maintained in patients who are relatively resistant to glucocorticoids in whom persistent GO activity warrants continuing medical intervention (145). Side effects of cyclosporine are not negligible and should be carefully considered. As for orbital radiotherapy, no studies have compared the combination of cyclosporine and intravenous glucocorticoids. Therefore, the association of oral glucocorticoids and cyclosporine is considered an alternative option when the response to intravenous glucocorticoids is poor (92). Rituximab is a CD20+ B-cell depleting monoclonal antibody originally used for B-cell non-Hodgkin lymphoma, but then utilized for autoimmune B-cell (and T-cell) driven autoimmune disorders. This drug has been used for GO in small and uncontrolled preliminary studies (reviewed in refs. 146 and 147). The rationale for using rituximab is sound, based on our understanding of pathogenesis of GO. The available data suggest that rituximab may have favorable effects on moderate-to-severe and active GO, with relatively low adverse event rate (146, 147). Two small, single-center, randomized clinical trials have recently been published. They produced conflicting results, because the first one (148) showed no difference in the effect of rituximab compared to placebo (148), whereas the second one (149) showed that rituximab was as effective as intravenous glucocorticoids in inactivating GO and was not associated with a flare-up of the disease, not infrequently seen after withdrawal of glucocorticoids. The reason for this conflicting results remains elusive and larger multicenter studies are warranted to clarify this issue (150), nevertheless rituximab may be considered as a possible second-line treatment in the case of a partial or absent response to intravenous glucocorticoids (92). Rituximab is contraindicated in patients with overt or impending dysthyroid optic neuropathy (92). Two recent randomized clinical trials have evaluated the effect of mycophenolate, an immunosuppressant agent inhibiting both T cells and B cells, widely used for the prevention of organ transplant rejection, but also for autoimmune disorders. The first, single-center study showed that mycophenolate mofetil was more effective than intravenous glucocorticoids on moderate-to-severe and active GO, but the experimental design had several limitations (151). The second, large, multicenter study carried out by EUGOGO demonstrated that the combination of mycophenolate sodium and intravenous glucocorticoids was more effective than intravenous glucocorticoids alone (152). The safety profile at the dose used (720 mg/day for 6 months) appears to be good (153). Therefore mycophenolate sodium may represent a useful tool for the management of GO. Teprotumumab is a monoclonal antibody inhibiting the IGF-1 receptor. Because the latter seems to be involved in the pathogenesis of GO (154), teprotumumab might play a role in the management of the disease. A recent placebo-controlled randomized clinical trial showed that teprotumumab is more effective than placebo in reducing the CAS (155). The most striking effect was marked reduction in the exophthalmos (155), a feature of GO which is very poorly modified by whatever medical treatment. This study is not devoid of limitations and further studies are warranted before it can be included among the tools for the management of active and moderate-to-severe GO (156). Orbital decompression is a milestone in the management of GO. It is aimed at increasing the space available for the increased orbital content by removing part of the bony walls of the orbit and/or the orbital fibroadipose tissue (157). It is indicated in patients who have impending sight loss due to optic neuropathy and do not respond promptly to intravenous glucocorticoids (157). Other important indications for decompressive surgery are represented by corneal damage due to eyeball exposure in patients with marked proptosis, or by recurrent subluxation of the globe, which may stretch the optic nerve and cause sight loss (157). In recent years, thanks to the improved surgical techniques and the diminished surgical risk, the indications for orbital decompression have expanded, including also correction of residual cosmetic problems (157, 158). Several techniques of orbital decompression are available, aimed at removing part of one, two, three or four orbital walls (floor, roof, lateral wall, medial wall) as well as part of the retroorbital fibroadipose tissue. The different surgical options should be discussed with the patient, as well possible complications of the procedure, particularly the de novo occurrence or worsening of diplopia, particularly frequent after extensive removal of the orbital floor (157, 159). Removal of fibroadipose tissue can be done together with or without bone removal, but removal of fat alone is associated with a lower reduction of proptosis (159). Rehabilitative surgery includes surgery for strabismus or eyelid retraction. Extraocular muscle surgery is aimed at correcting residual diplopia after medical and/or surgical treatment of GO. Timing of surgery is crucial, because it should not be performed when GO is active, but when it has been inactive for 6 months (160, 161). The goal of eye muscle surgery is to align the eyes, avoiding abnormal head posture and restoring single binocular vision in primary and reading positions; multiple operations may be required to achieve this goal. Eyelid surgery may rarely be an emergency procedures in patients with exposure keratitis and corneal ulcerations, but it usually is carried out to correct eyelid malposition after medical treatment or orbital decompression. Eyelid surgery usually constitutes the last step of rehabilitation (161). Thyroid ablation. The question of whether in a patient with GO, Graves hyperthyroidism should be treated by non-ablative (i.e., thionamides) or ablative (i.e., radioiodine therapy, thyroidectomy, both) therapy is unanswered (162, 163). Supporters of thyroid ablation justify this approach by mentioning the pathogenic link between thyroid and orbit: removal of thyroid-orbit shared antigen(s) and autoreactive T lymphocytes might be beneficial to the eye (162); supporters of non-ablative thyroid treatment suggest that control of thyrotoxicosis by antithyroid drugs may be associated with a reduction of autoimmune phenomena which might be reflected by an amelioration of ocular conditions; furthermore, once triggered, GO might proceed independently of thyroid treatment (163). Two retrospective studies showed that total thyroid ablation (thyroidectomy followed by radioiodine therapy, as in thyroid cancer) was associated with an improvement of clinical GO (164, 165). A recent randomized, controlled clinical trial demonstrated that, as compared to total thyroidectomy alone, total thyroid ablation is followed by a better outcome of GO in patients given intravenous glucocorticoids (166). A follow-up study of this cohort recently showed that in the long run total thyroid ablation was no better than total thyroidectomy alone, although it was associated with a prompter achievement of the best possible result obtainable by medical treatment and with an earlier possibility to submit the patient to rehabilitative surgery (147). Other cohort studies emphasized the opportunity to postpone definitive treatment of hyperthyroidism until GO is cured (168, 169). Thus, the optimal thyroid treatment in patients with GO still is a dilemma (170-172). THYROID DERMOPATHY AND ACROPACHY Thyroid dermopathy (also called pretibial myxedema or localized myxedema) is an uncommon extrathyroidal manifestations of Graves disease (less frequently of chronic autoimmune thyroiditis) (13, 173). It almost always occurs in Graves patients who also have GO. In a review of 178 consecutive patients with thyroid dermopathy, only 4 patients had no evidence of eye disease (174). However, in a community-based epidemiologic study, only 4% of GO patients also had thyroid dermopathy, although the latter was more frequent in patients with severe GO (175). It is more common in older than in younger patients, with a large preponderance in women (176). Skin lesions are edematous and thickened plaques, typically localized in the pretibial area; however they can be less frequently found in other skin areas, such as feet, toes, upper extremities, shoulders, upper back, nose. Prevalent localization in the pretibial area is related to mechanical and dependent position. The occurrence of lesions in less common sites is often preceded (triggered?) by local trauma (177, 178). There can be three clinical types: nodular, diffuse, and elephantias-like.(179, 180) (Figures 7-9).   INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure7.jpg" \* MERGEFORMAT  Fig. 7: Thyroid dermopathy. Courtesy of Dr. Vahab Fatourechi, Mayo Clinic   INCLUDEPICTURE "../../../../AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/LiveComm/08e3a1e44c685c00/120712-0049/AppData/Local/Microsoft/Windows/INetCache/AppData/Local/Microsoft/Windows/INetCache/Local%20Settings/Temporary%20Internet%20Files/Content.IE5/4O4GCSE9/figures/figure8.jpg" \* MERGEFORMAT  Fig. 8: thyroid dermopathy. Courtesy of Dr. Vahab Fatourechi, Mayo Clinic  Fig. 9: Thyroid dermopathy. Courtesy of Dr. Vahab Fatourechi, Mayo Clinic Histopathologically, skin lesions are characterized by the accumulation of activated fibroblasts (and, to a lesser extent, mast cells), with a markedly increased production of glycosaminoglycans in the dermis and subcutaneous tissues (181). Whereas in normal skin approximately 5% of the acid mucopolysaccharides are hyaluronic acid, in pretibial myxedema this amount increases to 90%. Glycosaminoglycans are responsible for fluid retention, subsequent compression and occlusion of lymphatic vessels, and lymphedema (182). Thus, as in GO, fibroblasts seem to play a central role in the pathogenesis of localized myxedema. This notion is further supported by the finding of limited variability of T cell receptor V gene usage in pretibial myxedema, pointing to a primary immune response of antigen-specific T lymphocytes (183). Furthermore, as is the case with acropachy, lymphocytes do recognize local fibroblasts. IgG from patients with pretibial myxedema was shown to stimulate proteoglycan synthesis by human skin fibroblasts (182). As for GO, TSH-R has been implicated in the pathogenesis of localized myxedema. TSH-R is expressed in peripheral skin fibroblasts from patients with localized myxedema, both at the mRNA and protein level (13). However, TSHR is expressed also in skin from normal subjects (183, 184). Likewise, TSH-R immunoreactivity was detected in cultured fibroblasts from pretibial myxedema, although the specificity of this finding remains to be established. As mentioned above, IgG from Graves patients with localized myxedema was reported to stimulate glycosaminoglycan production in cultured skin fibroblasts (183), but this data is not unequivocal, because IgG from normal subjects were equally effective in other studies (185). To summarize, although pathogenic mechanisms remain to be fully elucidated, localized myxedema appear to result from autoimmune reactions leading to fibroblast proliferation and increased glycocosaminoglycan secretion. From a clinical standpoint, localized myxedema presents as light-colored (sometimes yellowish brown) skin lesions, frequently with an orange peel texture (Figures 7-9). Skin lesions may be characterized by hyperpigmentation and hyperkeratosis. They usually represent only a cosmetic problem and are asymptomatic, but sometimes they may be associated with itching and pain, or may be functionally important, e.g., they may cause problems to wear shoes, especially the elephantiasic form of localized myxedema. Localized myxedema may remain stable, but frequently improves with time, partially or completely (13). Many cases of mild localized myxedema do not require any treatment, but in moderately severe lesions or when there is cosmetic concern, topical glucocorticoids applied with occlusive plastic dressing produce beneficial effects in a relevant proportion of patients (13). If necessary, treatment is repeated until clinical remission occurs (13). When localized mxedema is severe and extensive, steroid pulse therapy, or decongestive physiotherapy, a combination of manual lymphatic drainage, bandaging, exercise, and scrupulous skin care, may be tried (13). No substantial effect was reported by long-term octreotide treatment in three patients with localized myxedema (186). Two studies on the use of intravenous IgG in a small number of patients have reported discrepant effects (reviewed in 13). Thus, measures such as compression bandaging and topical glucocorticoids still are the most cost effective treatments for localized myxedema. Acropachy is a very uncommon extrathyroidal expression of Graves disease, usually associated with severe GO (13) and localized myxedema (13), thus reflecting severity of the autoimmune process. It seems more common in women than in men (13). It is characterized by clubbing of fingers (Fig. 10) and toes, with concomitant soft-tissue swelling of hands and feet. These abnormalities are usually painless and may be asymmetric (13). As for GO, there seems to be a strong relation with cigarette smoking. X-ray of affected sites shows soft-tissue swelling and subperiosteal bone formation. There is currently no treatment that can solve the esthetic and (less frequent) functional abnormality of thyroid acropachy, which occasionally may remit spontaneously in the long-term.  Fig. 10: Thyroid acropachy. Courtesy of Dr. Vahab Fatourechi, Mayo Clinic CLINICAL ABNORMALITIES OF THE HEART The biochemical actions of thyroid hormone on the heart are described in Chapter 10. Hyperthyroidism is usually associated with relevant cardiovascular symptoms and changes in cardiovascular hemodynamics (186, 187).Thyrotoxicosis increases the demands on the heart both by chronotropic and inotropic alterations. Cardiac output is markedly increased owing to increased stroke volume and rapid heart rate (186, 187). It is possible that the metabolic efficiency of heart muscle is decreased (186, 187). Irritability of the heart is increased. Investigation with stress echocardiography shows in hyperthyroidism impaired chronotropic, contractile, and vasodilatatory cardiovascular reserves, that are reversible upon conversion to euthyroidism (188). In a recent, large, matched case-control study, cardiovascular symptoms and signs, including palpitations, chest pain, dyspnea, cough, orthopnea, displaced apex, cardiac murmur, chest wheeze/crepitus were much more frequent in hyperthyroid patients than in controls, and some of them persisted despite effective restoration of euthyroidism by antithyroid drug treatment (182). This common finding of cardiovascular alterations in hyperthyroid patients may result from thyroid hormone excess itself, by hyperthyroidism-related worsening of preexisting cardiovascular disorders, or by the occurrence of novel cardiovascular abnormalities (186, 187). The importance of cardiovascular abnormalities is underscored by the observation that mortality of hyperthyroid patients is increased, mainly due to cardiovascular events (189, 190). Similar conclusions were reached also in a community-based study of elderly people (191), in which, however, definition of hyperthyroidism was based on the finding of low/suppressed serum TSH, which may not necessarily reflect thyroid hormone excess, but rather be the result of non-thyroidal illness syndrome. Mitral valve prolapse was found more commonly in hyperthyroid patients (43%) than in controls (18%) (190). This increased incidence might be due to increased adrenergic tone, autoimmunity, or the augmented cardiac output associated with thyrotoxicosis. Most patients with thyrotoxicosis are adults. Many, especially those with toxic nodular goiter, are in the 50- to 70-years age group, which has a relatively high incidence of organic heart disease anyway (192). Thus, it is not surprising that cardiac abnormalities are prominent among the symptoms of thyrotoxicosis. Frequent premature beats and paroxysmal tachycardia sometimes appear in thyrotoxic patients and may be disturbing to the patient. Atrial fibrillation occurs in thyrotoxicosis with or without preexisting heart disease, but it is more frequent in older patients (193), probably reflecting an increase in the prevalence of underlying cardiac abnormalities of ischemic or different origin (194). It may be paroxysmal or persistent during the thyrotoxic period. Attempts to correct this arrhythmia to normal in patients with persistent atrial fibrillation are usually unsuccessful while they are hyperthyroid. Once euthyroidism has been restored, atrial fibrillation may revert spontaneously or may be converted pharmacologically or by electroconversion. About two-thirds of patients undergo spontaneous reversion to sinus rhythm after receiving therapy for thyrotoxicosis, usually within 4 months; later on, spontaneous conversion is unlikely (195). It is wise to always evaluate thyroid function in clinically euthyroid patients with atrial arrhythmias with or without heart disease, because in about 20% of patients TSH tests and/or FT4 point to an overactive thyroid and in 50% of these patients normal sinus rhythm resumes after treatment with antithyroid drugs (195). It is widely accepted that subclinical hyperthyroidism is associated, in individuals aged 60 years or more with a 3-to-5-fold increased risk of developing atrial fibrillation (195). Congestive heart failure is a frequent complication in thyrotoxic patients with pre-existing organic heart disease, particularly if old (196-198). In the elderly hyperthyroid patient, cardiac symptoms may so dominate the clinical picture that diagnosis of thyrotoxicosis may be overlooked. Careful attention should be given to this possibility in all patients with congestive heart failure, especially if goiter is detected (196). Congestive heart failure may occur in patients who have no detectable preexisting organic heart disease (199). Overt hyperthyroidism may cause ventricular dilatation and persistent tachycardia, which may lead to heart failure and fatal events (200). It is often difficult to establish whether an underlying heart disease is present in a hyperthyroid patient who also has a disorder of rhythm, a cardiac murmur, or congestive heart failure, because all these conditions may be ascribed to thyrotoxicosis per se. It is frequently gratifying to observe normalization of cardiac findings once euthyroidism has been restored. In hyperthyroidism, owing to the increased metabolic demand, angina can be worsened if pre-existing, or induced de novo (186, 201, 202). Evidence of myocardial lactate production when the heart is paced at an accelerated rate (203), and normal coronary arteries are found at angiography after episodes of angina or infarction (203), have suggested that changes in thyrotoxicosis are due to an imbalance between O2 demand and supply rather than to arterial obstruction. This possibility is corroborated by the finding that coronary artery spasm of an otherwise normal vessel may occur during thyrotoxicosis (202). Cardiac abnormalities found in Graves' disease often are entirely reversible, except that longstanding atrial fibrillation due to hyperthyroidism is not always convertible after euthyroidism is restored. It has become evident that even in the mildest forms of thyrotoxicosis subtle cardiac abnormalities may be present. Thus, in patients with so-called "subclinical" thyrotoxicosis, i.e. suppressed TSH and normal serum free T4 and T3 concentrations, due to multinodular, autonomous goiter or TSH-suppressive T4 treatment, mean basal 24-h heart rate is increased, there is an augmented risk of atrial premature beats and atrial fibrillation, and left ventricular function and wall thickness are increased (204).There is controversy whether TSH suppressive T4 treatment leads to functional cardiac abnormalities (204, 205). Treatment of heart failure in the presence of thyrotoxicosis does not differ from its treatment in euthyroid patients, but it may be more difficult. Rest, salt restriction, diuretic therapy, digitalization and administration of afterload-reducers, like angiotensin converting enzyme (ACE) inhibitors, betablockers, aldosterone antagonists and other specific measures, are in order (186, 196). Larger than normal doses of digoxin are required, but there is probably no change in the toxic-to-therapeutic dose ratio. Atrial fibrillation may be controlled by digoxin, propranolol, or both. Electroconversion is usually successful only after thyrotoxicosis has been resolved for a few months (206). Hyperthyroidism should be controlled as expeditiously as possible. Congestive heart failure is a contraindication to operation. Most patients with thyrotoxicosis and clinically relevant heart disease are now treated with RAI. This treatment may be preceded by a 3-to-6-month course of antithyroid drug therapy to deplete their glands of stored thyroid hormone, a program that lessens any chance of an exacerbation of the heart disease caused by a radioiodine-induced release of thyroid hormone from the gland. Administration of 131I followed by antithyroid drugs, and potassium iodide or ipodate, that also inhibit T4 to T3 conversion, may be used in severely ill patients in whom a prompt response is needed. This method is described in Chapter 11. Propranolol has been used successfully in the control of tachycardia, and also in patients with congestive heart failure if tachycardia appeared to be adding substantially to the problem. In these instances, possible depression of myocardial contractility by the drug was outweighed by the benefit derived from controlling the rate. In such circumstances, one must proceed with caution and often digoxin should be added. References Klubo-Gwiezdzinska J, Wartoksky L 2012 Thyroid emergencies. Med Clin North Am 96: 385-403. Carroll R, Matfin G 2010 Endocrine and metabolic emergencies: thyroid storm. Ther Adv Endocrinol Metab 1: 139-145. Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T et al. 2012 Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 22: 661-679 Akamizu T 2018 Thyroid storm: a Japanese perspective. Thyroid 28: 32-40 Nelson NC, Becker WF 1969 Thyroid crisis: diagnosis and treatment. Ann Surg 170:263-273. Kobayashi C, Sasaki H, Kosuge K, Miyakita Y, Hayakawa M, Suzuki A, Abe E, Suzuki K, Aizawa Y.2005 Severe starvation hypoglycemia and congestive heart failure induced by thyroid crisis, with accidentally induced severe liver dysfunction and disseminated intravascular coagulation. Intern Med. 44:234-239. McDermott MT, Kidd GS, Dodson LE, Hofeldt FD 1983 Radioiodine-induced thyroid storm. Am J Med 75:353-359. Bartalena L 2013 Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9: 724-734. Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Teramukai S, Akamizu T 2016 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (First edition). Endocrine J 63: 1025-1024. Thomas DJ, Hardy J, Sarwar R, Banner NR, Mumani S, Lemon K, Hillson RM 2006 Thyroid storm treated with intravenous methimazole in patients with gastrointestinal dysfunction. Br J Hosp Med. 67: 492-493. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves ophthalmopathy: reality and perspectives. Endocr Rev 21: 168-199. Bartalena, Tanda ML 2009 Clinical Practice: Graves ophthalmopathy. N Engl J Med 360: 994.1001. Bartalena L, Fatourechi V 2014 Extrathyroidal manifestations of Graves disease: a 2014 update. J Endocrinol Invest 37: 691-700. Smith TJ, Hegedus L 2016 Graves disease. N Engl J Med 375: 1552.1575. Bartalena L, Chiovato L, Vitti P 2016 Management of hyperthyroidism due to Graves disease: frequently asked questions and answers (if any). J Endocrinol Invest 39: 1105-1114. Bartley GB 1994 The epidemiological characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92: 477-588. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L 2013. Prevalence and natural history of Graves orbitopathy in a large series of patients with newly diagnosed Graves hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98: 1443-1449. Laurberg P, Berman DC, Bulow Pedersen I, Andersen S, Carl A 2012 Incidence and clinical presentation of moderate to severe Graves orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97: 2325-2332. Perros P, Hegedus L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L et al. 2017 Graves orbitopathy as a are disease in Europe: a European Group on Graves Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12: 72. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A 1989 Studies on the occurrence of ophthalmopathy in Graves disease. Acta Endocrinol (Copenh) 120: 473-478. Perros P, Crombie AL, Matthews JNS, Kendall-Taylor P 1993 Age and gender influence the severity of thyroid associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38: 367-372. Perros P, Crombie AL, Kendall-Taylor P 1995 Natural history of thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 42: 45-50. Kendall-Taylor P, Perros P 1998 Clinical presentation of thyroid associated orbitopathy. Thyroid 8: 427-428. Piantanida E, Tanda ML, Lai A, sassi L, Bartalena L 2013 Prevalence and natural history of Graves orbitopathy in the XXI century. J Endocrinol Invest 36: 444-449. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A 2003 Multi-center study on the characteristics and treatment strategies of patients with Graves orbitopathy: the first European Group on Graves Orbitopathy experience. Eur J Endocrinol 148: 491-495. Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi F, Zerbini F et al. 2016 The phenotype of newly diagnosed Graves disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 39: 1445-1451 Anagnostis P, Boboridis K, Adamidou F, Kita M 2017 Natural course of mild Graves orbitopathy: is it a chronic remitting or a transient disease? J Endocrinol Invest 40: 257-261. Sabini E, Leo M, Mazzi B, Rocchi R, Latrofa F, Nardi M et al. 2017 Does Graves orbitopathy ever disappear? Answers to an old question. Eur Thyroid J 6: 263-270. Bartalena L, Bogazzi F, Tanda ML, Manetti L, DellUnto E, Martino E 1995 Cigarette smoking and the thyroid. Eur J Endocrinol 133: 507.512. Wiersinga WM 2013 Smoking and thyroid. Clin Endocrinol (Oxf) 79: 145-151. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A, Pinchera A 1989 More on smoking habits and Graves ophthalmopathy. J Endocrinol Invest 12: 733-737. Holm IA, Manson JAE, Michels KB, Alexander EK, Willett WC, Utiger RD 2005 Smoking and other lifestyle factors and the risk of Graves hyperthyroidism. Arch Intern Med 165: 1606-1611. Prummel MF, Wiersinga WM 1993 Smoking and risk of Graves disease. JAMA 269: 479-482. Krassas GE, Segni M, Wiersinga WM 2005 Childhood Graves ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153: 515-521. Bartalena L, Marcocci C, Pinchera A 2002 Graves ophthalmopathy: a preventable disease? Eur J Endocrinol 146: 457-461. Szucs-Farkas Z, Todt J, Kollar J, Galuska L, Barman KD, Boda J, Leovey A, Varga J, Ujhelyi B, Szabo J, Berta A, Nagy EV 2005 Volume changes in intra- and extraorbital compartments in patients with Graves ophthalmopathy: effect of smoking. Thyroid 15: 146-151. Cawood TJ, Moriarty P, OFarrelly C, OShea D 2007 Smoking and thyroid-associated ophthalmopathy: a novel explanation of the bilogical link. J Clin Endocrinol Metab 92: 59-64. Khong JJ, Finch S, De Silva C, Rylander S, Cgarig JE, Selva D, Ebeling PR 2016 Risk facrors for Graves orbitopathy: the Australian Thyroid-Associated Research (ATOR) study. J Clin Endocrinol Metab 101: 2711-2720. Smith TJ 2010 Pathogenesis of Graves orbitopathy: a 2010 update. J Endocrinol Invest 33: 414-421. Bahn RS 2015 Current insights into the pathogenesis of Graves ophthalmopathy. Horm Metab Res 43: 773-776. Salvi M, Berchner-Pfannschmidt U, Ludgate M 2017 Pathogenesis. In (Wiersinga WM, Kahaly GJ (Eds.) Graves orbitopathy A multidisciplinary approach: questions and answers. Karger, Basel, pp. 41-60 Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves disease and ophthalmopathy. Endocr Rev 24: 802-835. Potgieser PW, Wiersinga WM, Regensburg NI, Wiersinga WM 2015 Some studies on the natural history of Graves orbitopathy: increase in orbital fat is a rather late phenomenon. Eur J Endocrinol 173: 149-153. Wang Y, Smith TJ 2014 Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 55: 1735-1748. Ajjan AR, Weetman AP 2004 New understanding of the role of cytokines in the pathogenesis of Graves ophthalmopathy. J Endocrinol Invest 27: 237-245. Feldon SE, Park DJJ, OLoughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP 2005 Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves ophthalmopathy. Invest Ophthalmol Vis Sci 46: 3913-3921. Khong JJ, McNab AA, Ebeling PR, Craig JR, Silva D 2016 Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalomol 100: 142-150. Bahn RS 2004 TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves ophthalmopathy. J Endocrinol Invest 27: 216-220. Agretti P, De Marco G, De Servi M, Marcocci C, Vitti P, Pinchera A, Tonacchera M 2005 Evidence for protein and mRNA expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. Eur J Endocrinol 152: 777-784. Agretti P, Chiovato L, De Marco G, Marcocci C, Mazzi B, Sellari-Franceschini S, Vitti P, Pinchera A, Tonacchera M 2002 Real-time PCR provides evidence for thyrotropin receptor mRNA expression in orbital as well as in extraorbital tissues. Eur J Endocrinol 147: 733-739. Garrity JA, Bahn RS 2006 Pathogenesis of Graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142: 147-153. Ludgate M, Baker G 2004 Inducing Graves ophthalmopathy. J Endocrinol Invest 27: 211-215. Moshkelgosha S, So P-W, Deasy N, Diaz-Cano S, Banga JP 2013 Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 154: 3008-3015. Banga JP, Moshkelgosha S, Berchner-Pfannschmidt U, Eckstein A 2015 Modeling Graces orbitopathy in experimental Graves disease. Horm Metab Res 47: 797-803. Nagayama Y, Nakahara M, Abiru N 2015 Animal models of Graves disease and Graves orbitopathy. Current Opin Endocrinol Diabetes Care 22: 381-386. Tu Y, Wang Y, Ding L, Zhang Y, Wu W 2016 Development of a novel thyroid function fluctuated animal model for thyroid-associated ophthalmopathy. PLoS One 11: e0148595 Ungerer M, Fassbender J, Li Z, Munch G, Holthoff H-p 2017 Review of mouse models of Graves disease and orbitopathy Novel treatment by induction of tolerance. Clin Rev Allerg Immunol 52: 182-193. Smith TJ, Huetwell FGL, Hegedus L, Douglas RS 2012 Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves orbitopathy. Best Pract Res Clin Endocrinol Metab 26: 291-302. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P 1993 Autoantibodies to IGF-1 binding sites in the thyroid-associated phthalmopathy. Autoimmunity 16: 251-257 Tsui S, Naik V, Hoan N, Hwang CJ, Afifiyan NF, Hikim Sinha A, Gianoukakis AG, Douglas RS, Smith TJ 2008 Evidence for an association between thyroid-stimulating hormone and insulin like growth factor 1 receptors: a tale of two antigens implicated in Graves disease. J Immunol 181: 4397-4405. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS 2012 A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab 97: 1681-1687 Pritchard J, Tsui S, Horst N, Cruikshank WW, Smith TJ 2004 Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol 173: 3564-3569. Smith TJ 2013 Is IGF-I receptor a target for autoantibody generation in Graves disease? J Clin Endocrinol Metab 98: 515-518. Wiersinga WM 2011 Autoimmunity in Graves ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96: 2386-2394. Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Kohrle J, Eckstein A, Schomburg L 2013 Autoantibodies to the IGF1 receptor in Graves orbitopathy. J Clin Endocrinol Metab 98: 752-760. Varewijck AJ, Boelen A, Lamberts SJ, Fliers E, Jofland LJ, Wiersinga WM, Janssen JAMJL 2013 Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves ophthalmopathy. J Clin Endocrinol Metab 98: 769-776. Song D, Wang R, Zhong Y, Li W, Li H, Dong F 2012 Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 250: 433-440. Bartalena L 2005 Graves ophthalmopathy: search for shared autoantigen(s) continues. J Endocrinol Invest 28: 396-397. Vaidya B, Kendall-Taylor P, Pearce SHS 2002 The genetics of autoimmune thyroid disease. J Clin Endocrinol Metab 87: 5385-5397. Brand OJ, Gough SCL 2010 Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol 322: 135-143. Brix TH, Hegedus L 2012 Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf) 76: 457-464. Tomer Y 2014 Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol 9: 147-156. Marin M, Latrofa F, Menconi F, Chiovato L, Vitti P 2015 Role of genetic and non-genetic factors in the etiology of Graves disease. J Endocrinol Invest 38: 283-294. Tomer Y 2010 Genetic susceptibility to autoimmune thyroid disease: past, present, future. Thyroid 20: 715-725. Yin X, Latif R, Bahn RS, Davies TF 2012 Genetic profiling in Graves disease: further evidence for lack of a distinct genetic contribution to Graves orbitopathy. Thyroid 22: 730-735. Juriecka-Lubieniecka B, Ploski R, Kula D et al 2014 Association between polymorphisms in the TSHR gene and Graves orbitopathy 2014 PLoS One 9: e102653 Bartalena L 2012 Prevention of Graves ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26: 371-379. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. 1989 Amelioration of eye changes of Graves ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121: 185-189. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. 1990 Effect of abnormal thyroid function on the severity of Graves ophthalmopathy. Arch Intern Med 150: 1098-1101. Karlsson AF, Westermark K, Dahlberg PA, Jansson R, Enksson P 1989 Ophthalmopathy and thyroid stimulation. Lancet 2: 691. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H, Taube A & the Thyroid Study Group. 1992 Occurrence of ophthalmopathy after treatment for Graves hyperthyroidism. N Engl J Med 326: 1733-1738. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, DellUnto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves ophthalmopathy. N Engl J Med 338: 73-78. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hdner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G 2009 Thyroid-associated ophthalmopathy after treatment for Graves hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94: 3000-3007. Acharya SH, Avernell A, Philip S, Burr J, Bevan JS, Abraham P 2008 Radioiodine therapy (RAI) for Graves disease (GD) and the effect on the ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 69: 943-950. Li HX, Xiang N, Hu WK, Jiao XL 2016 Relation between therapy options for Graves disease and the course of Graves ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest 38: 1225-1233. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A 1989 Use of corticosteroids to prevent progression of Graves ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321: 1349-1352. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95: 1333-1337. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curr N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marin M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158: 273-285. Bartalena L, Baldeschi L, Dickinson J, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curr N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marin M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European Group on Graves Orbitopathy (EUGOGO) on management of Graves Orbitopathy. Thyroid 18: 333-346. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L 1999 The course of Graves ophthalmopathy is not influenced by near-total thyroidectomy. Clin Endocrinol (Oxf) 51: 503-508. Bartalena L, Baldeschi L, Boboridis K et al 2016 The 2016 European Thyroid Association/European Group on Graves Orbitopathy guidelines for the management of Graves orbitopathy. Eur Thyroid J 5: 9-26. Werner SC 1977 Modification of the classification of the eye changes of Graves disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab 44: 203-206. The European Group on Graves Orbitopathy (EUGOGO): Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marin M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G 2006 Clinical assessment of patients with Graves orbitopathy: the European Group on Graves Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387-389. Dolman PJ 2012 Evaluating Graves orbitopathy. Best Pract Res Clin Endocrinol Metab 26: 229-248. Dickinson AJ, Perros P 2001 Controversies in the clinical evaluation of thyroid-associated orbitopathy: use of a detailed protocl with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55: 283-303. McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ. Hullo AI, Kahaly G, Krassas G, Marcocci C, Marin M, Mourits MP, Nardi M, Neoh C, Orgiazzi J, Perros P, Pinchera A, Pitz S, Plummer MF, Sartini MS, Wiersinga WM 2007 Clinical features of of dysthyroid optic neuropathy: a European Group on Graves Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91: 455-458. Wiersinga WM 2017 Quality of life. In Wiersinga WM, Kahaly GJ (eds), Graves orbitopathy. A multidisciplinary approach Questions and answers, Karger, Basel, 3rd ed., 260-274. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM 1997 Quality of life in patients with Graves ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 7: 885-889. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM 1998 Development of a disease-sepcific quality of life questionnaire for patients with Graves ophthalmopathy. Br J Ophthalmol 82: 773-779. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT 2005 Psychosocial morbidity of Graves orbitopathy. Clin Endocrinol (Oxf) 63: 395-402. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, Prummel MF, Wiersinga WM 2001 Interpretation and validity of changes in scores in the GO-QOL after different treatments. Clin Endocrinol (Oxf) 54: 391-398. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, Prummel MF, Wiersinga WM 2001 Interpretation and validity of changes in scores in the GO-QOL after different treatments. Clin Endocrinol (Oxf) 54: 391-398. Mourits M, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves ophthalmopathy: a novel approach. Br J Ophthalmol 73: 639-644. Pinchera A, Wiersinga WM, Glinoer D, Kendall-Taylor P, Koornneef L, Marcocci C, Schleusener H, Romaldini J, Niepominiscze F, Solomon D, Garrity J, Gorman CA 1992 Classification of eye changes of Graves disease. Thyroid 2: 235-236. Pitz S, Muller-Forell W 2017 Orbital imaging. In Wiersinga WM, Kahaly GJ (eds), Graves orbitopathy. A multidisciplinary approach Questions and answers, Karger, Basel, 3rd ed., 61-73. Bartalena L, Chiovato L 2014 Graves-like orbitopathy: do not forget IgG4-related disease. J Endocrinol Invest 37: 1233-1235. The European Group of Graves Orbitopathy: Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marin M, Mourits MP, Nardi M, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Wiersinga WM 2006 A questionnaire survey on the management of Graves orbitopathy in Europe. Eur J Endocrinol 155: 207-211. Bartalena L, Marcocci C, Pinchera A. 1997 Treating severe Graves ophthalmopathy. Baillieres Clin Endocrinol Metab 11: 521-536 Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L 2013 Prevalence and natural hostory of Graves orbitopathy in a large series of patients with newly diagnosed Graves hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98: 1443-1449. Bartalena L, Masiello E, Magri F et al. 2016 The phenotype of newly diagnosed Graves disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest 39: 1445-1451. Boboridis K, Anagnostis P 2017 Local treatment modalities. In Wiersinga WM, Kahaly GJ (eds), Graves orbitopathy. A multidisciplinary approach Questions and answers, Karger, Basel, 3rd ed., 202-206. Pfeilschifter J, Ziegler R 1996 Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45: 477-481. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W and the European Group on Graves Orbitopathy 2011 Selenium and the course of mild Graves orbitopathy. N Engl J Med 364: 1920-1931. Marcocci C, Bartalena L 2013 Role of oxidative stress and selenium in Graves hyperthyroidism and orbitopathy. J Endocrinol Invest 36 (suppl. to no. 10): 15-20. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marin M, Pinchera A 2005 An update on medical management of Graves ophthalmopathy. J Endocrinol Invest 28: 469-478. Zang S, Ponto KA, Kahaly GJ 2011 Intravenous glucocorticoids for Graves orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96: 320-332. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, Bonelli L, Niepomniszcze H 2004 Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 88: 1380-1386. Bartalena L 2005 Glucocorticoids for Graves ophthalmopathy: how and when. J Clin Endocrinol Metab 90: 5497-5499 Marcocci C, Bartalena L, Tanda ML, Manetti L, DellUnto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A 2001 Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562-3567. van Geest RJ, Sasim IV, Koppeschaar HPF, Mourits MP 2008 Methylprednisolone pulse therapy for patients with moderately severe Graves orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 158: 229-237. Marin M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C 2004 Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves ophthalmopathy. Thyroid 14: 403-406. Sabini E, Sisti E, Coco B, Leo M, Ionni I, Menconi F et al 2016 Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves orbitopathy. J Endocrinol Invest 39: 1323-1327. Kahaly GJ, Pitz S, Hommel G, Dittmar M 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves orbitopathy. J Clin Endocrinol Metab 90: 5234-5240. Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J, Bartalena L and the European Group on Graves Orbitopathy 2012 Fatal and non-fatal adverse events of glucocorticoid therapy for Graves orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 166: 247-253. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curr N, Boschi A, Bernard M, von Arx G and the European Group on Graves Orbitopathy 2012 Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves orbitopathy. J Clin Endocrinol Metab 97: 4454-4463 Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marin M et al 2017 Does early response to intravenous glucocorticoids predict the final out come in patients with moderate-to-severe and active Graves orbitopathy? J Endocrinol Invest 40: 547-553. Zang S, Ponto KA, Kahaly GJ 2011 Dose of intravenous steroids and therapy outcome in Graves orbitopathy. J Endocrinol Invest 34: 876-880. Jespersen S, Nygaard B, Ostergaard Kristensen L 2015 Methyprednisolone pulse treatment of Graves ophthalmopathy is not associated with secondary adrenocortical insufficiency. Eur Thyroid J 4: 222-225. Giotaki Z, Fountas A, Tsirouki T, Bargiota A, Tigas S, Tsatsoulis A 2015 Adrenal reserve following treatment of Graves orbitopathy with intravenous glucocorticoids. Thyroid 25: 462-463. Tanda ML, Bartalena L 2012 Efficacy and safety of orbital radiotherapy for Graves orbitopathy. J Clin Endocrinol Metab 97: 3857-3865. Kahaly GJ, Rosler H-P, Pitz S, Hommel G 2000 Low- versus high-dose radiotherapy for Graves ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 85: 102-108. Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A 2003 Orbital radiotherapy for Graves ophthalmopathy: useful or useless? Safe or dangerous. J Endocrinol Invest 26: 5-16. Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, Holck DE, Woog JJ 2008 Orbital radiation for Graves ophthalmopathy. Ophthalmology 115: 398-409. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM 1993 Randomised, double-blind trial of prednisone versus radiotherapy in Graves ophthalmopathy. Lancet 342: 949-954. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HPF, Tick L, Terwee CB 2000 Radiotherapy for Graves orbitopathy: randomised, placebo-controlled study. Lancet 355: 1505-1509. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstrahl EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB 2001 A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves ophthalmopathy. Ophthalmology 108: 1523-1534. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM 2004 A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves ophthalmopathy. J Clin Endocrinol Metab 89: 15-20. Marcocci C, Bartalena L, Rocchi R, Marin M, Menconi F, Morabito E, Mazzi B, Mazzeo S, Sartini MS, Nardi M, Cartei F, Cionini L, Pinchbera A 2003 Long-term safety of orbital radiotherapy for Graves ophthalmopathy. J Clin Endocrinol Metab 88: 3561-3566. Wakelkamp IMMJ, Tan H, Saeed P, Sckingemann RO, Verbraak FD, Blank LECM, Prummel MF, Wiersinga WM 2004 Orbital irradiation for Graves ophthalmopathy. Is it safe? A long-term follow-up study. Ophthalmology 111: 1557-1562. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, Cavallacci G, Baschieri L, Pinchera A 1983 Orbital cobalt irradiation combined with systemic corticosteroids for Graves ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56: 1139-1144. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A 1991 Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study. J Endocrinol Invest 14: 853-860. Kahaly G, Schrenzemeir, Krause U, Schweikert B, Meuer S, Muller W 1986 Ciclosporin and prednisone v. Prednisone in treatment of Graves ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16: 415-422. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga AM 1989 Prednisone and cyclosporine in the treatment of severe Graves ophthalmopathy. N Engl J Med 321: 1353-1359. Bartalena L 2010 What to do for moderate-to-severe Graves orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf) 73: 149-152. Salvi M, Vannucchi G, Beck-Peccoz P 2013 Potential utility of rituximab for Graves orbitopathy. J Clin Endocrinol Metab 98: 4291-4299. Minakaran N, Ezra DG 2013 Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013 May 31;5:CD009226. doi: 10.1002/14651858. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS 2015 Randomized controlled trial of rituximab in patients with Graves orbitopathy. J Clin Endocrinol Metab 100: 432-441. Salvi M, Vannucchi G, Curr N, Campi I, Covelli D, Dazzi D et al. 2015 Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100: 422-431. Wiersinga WM 2017 Advances in treatment of active, moderate-to-severe Graves ophthalmopathy. Lancet Diabetes Endocrinol 5: 134-142. Ye X, Bo X, Hu X, Cui H, Lu B, Shao J, Wang J 2017 Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves orbitopathy. Clin Endocrinol (Oxf) 86: 247-255. Kahaly GJ, Riedl M, Konig J, Pits S, Ponto K, Diana T et al 2018 Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves orbitopathy (MINGO): a randomized, observer-masked, multicentre trial. Lancet Diabetes Endocrinol, in press. Riedl M, Kuhn A, Kramer I, Kolbe E, Kahaly GJ 2016 Prospective, systematically recorded mycophenolate safety data in Graves orbitopathy. J Endocrinol Invest 39: 687-694. Smith TJ, Huetwell FGL, Hegedus L, Douglas RS 2012 Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves orbitopathy. Best Pract Res Clin Endocrinol Metab 26: 291-302. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA et al 2017 Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376: 1748-1761. Piantanida E, Bartalena L 2017 Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves orbitopathy? J Endocrinol Invest 40: 885-887. Baldeschi L 2017 Orbital decompression. In Wiersinga WM, Kahaly GJ (eds), Graves orbitopathy. A multidisciplinary approach Questions and answers, Karger, Basel, 3rd ed., 211-229. Mourits MP, Bijl H. Altea MA, Baldeschi L, Boboridis K, Curr N, Dickinson AJ, Eckstein A, Freidel M, Guastella C, Kahaly GJ, Kalmann R, Krassas GE, Lane CM, Lareida J, Marcocci C, Marin M, Nardi M, Mohr Ch, Neoh C, Pinchera A, Orgiazzi J, Pitz S, Saeed P, Salvi M, Sellari-Franceschini S, Stahl M, von Arx G, Wiersinga WM 2009 Outcome of orbital decompression for disfiguring proptosis in patients with Graves orbitopathy using various surgical procedures. Br J Ophthalmol 93: 1518-1523. Garrity JA, Fatourechi V, Bartley GB, Bergstrahl EJ, DeSanto LW, Gorman CA 1994 Graves ophthalmopathy. Results of transantral orbital decompression in 428 patients with severe Graves ophthalmopathy. Am J Ophthalmol 116: 533-547. Nardi M, Eckstein A 2017 Eye muscle surgery. In Wiersinga WM, Kahaly GJ (eds), Graves orbitopathy. A multidisciplinary approach Questions and answers, Karger, Basel, 3rd ed., 230-246. Clarke L, Eckstein A 2017 Eyelid surgery. In Wiersinga WM, Kahaly GJ (eds), Graves orbitopathy. A multidisciplinary approach Questions and answers, Karger, Basel, 3rd ed., 247-259. Marcocci C, Bartalena L, Pinchera A 1998 Ablative or non-ablative therapy for Graves hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 21: 468-471. Weetman AP, Harrison BJ 1998 Ablative or non-ablative therapy for Graves hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 21: 472-475. DeGroot LJ, Benjasuratwong Y 1996 Evaluation of thyroid ablative therapy for ophthalmopathy of Graves disease. Orbit 15: 187-196. Moleti M, Mattina F, Salomone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F 2003 Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves ophthalmopathy. Thyroid 13: 653-658. Menconi F, Marin M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C 2007 Effects of total thyroid ablation vs near-total thyroidectomy alone on mild to moderate Graves orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92: 1653-1658. Leo M, Marcocci C, Pinchera A, nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marin M 2012 Outcome of Graves orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97: E44-E48. Elbers L, Mourits M, Wiersinga W 2011 Outcome of very long-term treatment with antithyroid drugs in Graves hyperthyroidism associated with Graves orbitopathy. Thyroid 21: 279-283. Laurberg P, Berman BC, Andersen S, Bulow Pedersen I 2011 Sustained control of Graves hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves orbitopathy. Thyroid 21: 951-956. Bartalena L 2011 The dilemma of how to manage Graves hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96: 592-599. Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F 2015 Effects of treatment modalities for Graves hyperthyroidism on Graves orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest 38: 481-487. Moleti M, Sturniolo G, Vermiglio F 2016 Safety of total thyroid ablation in patients with Graves orbitopathy. J Endocrinol Invest 39: 1199-1201. Fatourechi V 2012 Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab 26: 553-565. Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Powell CC, Ahmed DD, Garrity JA 2003 Graves dermopathy and acropachy are markers of severe Graves ophthalmopathy. Thyroid 13: 1141-1144. Bartley GB, Fatourechi V, Kadrmas EF, Ilstrup DM, Garrity JA, Gorman CA 1996 Clinical features of Graves ophthalmopathy in an incidence cohort. Am J Ophthalmol 121: 284-290. Schwartz KM, Fatourechi V, Ahmed DDF, Pond GR 2002 Dermopathy of Graves disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 87:438-446. Tong DW, Ho KK 1998 Pretibial myxedema presenting as a scar infiltrate. Australas J Dermatol 39:255-257. Misner CS, Ramsay EW, Houck He, Kauffman CL 1998 Gravesdisease presenting as a localized myxedema in a thigh donor graft site. J Am Ac Dermatol 39:864-869,1998. Cohen JB, Balzer B, Wapnir I, McDougall IR 2004 Elephantiasic pretibial myxedema. Thyroid 14: 237-238. Fatourechi V 2005 Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6: 295-309. Shishiba Y, Imai Y, Odajima R, Ozawa Y, Shimizu T 1992 Immunoglobulin G of patients with circumscribed pretibial myxedema of Graves' disease stimulates proteoglycan synthesis in human skin fibroblasts in culture. Acta Endocrinol(Copenh) 127:44-51. Hanke CW, Bergfeld WF, Guirguis MN, Lewis LJ 1983 Hyaluronic acid synthesis in fibroblasts of pretibial myxedema. Cleve Clin Q 50:129-133. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS 1993 Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves ophthalmopathy and pretibial dermopathy. Thyroid 3: 297-300. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM 2000 Elephantiasic pretibial myxedema: insight into a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves disease. Thyroid 10: 685-692. Metcalfe RA, Davies R, Weetman AP 1993 Analysis of fibroblast-stimulating activity in IgG from patients with Graves dermopathy. Thyroid 3: 207-212. Kahaly GJ, Dillmann WH 2005 Thyroid hormone action in the heart. Endocr Rev 26: 704-728. Danzi S, Klein I 2012 Thyroid hormone and the cardiovascular system. Med Clin N Am 96: 257-268. Kahaly GJ, Wagner S, Nieswandt J, Mohr-Kahaly S, Rayan TJ 1999 Stress echocardiography in hyperthyroidism. J Clin Endocrinol Metab 84:2308-2313. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P 1998 Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338: 712-718. Osman F, Gammage MD, Franklyn JA 2002 Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid 12: 483-488. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358: 861-865. Kahaly GJ, Nieswandt J, Mohr-Kahaly S 1998 Cardiac risk of hyperthyroidism in the elderly. Thyroid 8:1165-1169. Agner T, Almdal T, Thorsteinsson B, Agner E 1984 A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull 31: 157-159. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K 1982 Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72:903-906. Sawin LT, Geller A, Wolf PhA, Belanger A, Baker E 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New Engl J Med 331:1249-1253. Biondi B 2012 Heart failure and thyroid dysfunction. Eur J Endocrinol 167: 609-618. Siu CW, Yeung CY, Lau CP, Kung AW, TSE HF 2007 Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 93: 483-487. Yue W-S, Chong B-H, Zhang X-H, Liao S-Y, Jim A-Y, Jim M-H, Kung AWC, Tse H-F, Siu C-W 2011 Hyperthyroidism-induced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure. Clin Endocrinol (Oxf) 74: 636-643. Boccalandro C, Boccalandro F, Orlander P, Wei CF 2003 Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of the literature. Endocr Pract 9:140-6. Soh MC, Croxson M 2008 Fatala thyrotoxic cardiomyopathy in a young man. Br Med J 337: a531. Featherstone HJ, Stewart DK 1983 Angina in thyrotoxicosis: thyroid related coronary artery spasm. Arch Intern Med 143: 554-558. Moliterno D, Debold CR, Robertson RM 1992 Coronary vasospasm relation to the hyperthyroid state. Am J Med Sci 304: 38-42 Resenkov L, Falicov R 1977 Thyrotoxicosis and lactate producing angina pectoris with normal coronary arteries. Br Heart J 39:1051-1055 Biondi B, Fazio S, Carella C, Amato G, Littadini A, Lupoli G, Saca L, Bellastella A, Lombardi G. 1993 Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77:334-338.  :;YZ[`abcdkmny^C5hc3^h[ 5CJOJQJ\^JaJmHnHsHu5hc3^hc5CJOJQJ\^JaJmHnHsHu5hc3^h5CJOJQJ\^JaJmHnHsHu/h75CJOJQJ\^JaJmHnHsHu1h7h75CJOJQJ\^JaJmHnHu h7CJhr#9h7CJjh70JCJUhch70JCJh7jh7Uhch7CJbcdj k 1  GXy*$7$8$H$^gd[ $*$1$^gd[ *$7$8$H$^gd[ $*$1$gd[ dgdTF$d*$1$gdTFgd[ $*$1$gd[ $a$gd7n  ɶhS>S)S)(hc3^h[ CJOJQJ^JaJmHsH(hc3^h-@CJOJQJ^JaJmHsH(hc3^h'GCJOJQJ^JaJmHsH,hc3^h0JCJOJQJ^JaJmHsH$hc3^h0JOJQJ^JmHsH$hc3^h'G0JOJQJ^JmHsH hc3^h'GOJQJ^JmHsH$hc3^h'G0JOJQJ^JmHsH5hc3^h'G5CJOJQJ\^JaJmHnHsHu5hc3^h[ 5CJOJQJ\^JaJmHnHsHu  J K h i j k s Y Z   楐nUD1D1D1D$hTFhTFCJNHOJQJ^JaJ hTFhTFCJOJQJ^JaJ1hTFh[ 5CJOJQJ\^JaJmHnHu hc3^hCJOJQJ^JaJ hc3^h'GCJOJQJ^JaJ(h7h[ CJOJQJ^JaJmHsH(hc3^hcCJOJQJ^JaJmHsH,hc3^htt0JCJOJQJ^JaJmHsH(hc3^httCJOJQJ^JaJmHsH1jhc3^httCJOJQJU^JaJmHsH A B ~  VWst GXV{ܹvvev hc3^hYuVCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu1hc3^h[ 5CJOJQJ\^JaJmHnHu hc3^h[ hTFCJOJQJ^JaJhW3CJOJQJ^JaJ hTFhTFCJOJQJ^JaJ$hTFhTFCJNHOJQJ^JaJ ?ABCQSTUEX\      S U ͼ޼ޒͫͫށށޒͫp hc3^h1CJOJQJ^JaJ hc3^h\LCJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu hc3^heCJOJQJ^JaJ hc3^h=YPCJOJQJ^JaJ hc3^hYuVCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h(3CJOJQJ^JaJ)""\%d%%%%&ddd$*$7$8$H$If]d^dgd[ $ &Xd*$7$8$H$^gd[ $d7$8$H$^gd[ y*$7$8$H$^gd[ $*$1$^gd[ d*$7$8$H$^gd[ U V W )"+","-"""K#####$$X$$%%\%d%v%w%x%%%%%%&&ͼ͒́ṕ́́͒́́́͒\&hc3^h'G6CJOJQJ]^JaJ hc3^hRCJOJQJ^JaJ hc3^h%!XCJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu hc3^heCJOJQJ^JaJ hc3^h%?CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hYuVCJOJQJ^JaJ hc3^h4CJOJQJ^JaJ&&&Z&&&&&& ''','.'''0(M(t( &Xddd<$*$7$8$H$If]d^dgd[ ddd$*$7$8$H$If]d^dgd[ " &Xdd$*$7$8$H$If]d^`gd[ &&)&Y&''','-'3't(u(((((((()+)-)ʹʹ͠ʹ͇nXG hc3^h{w%CJOJQJ^JaJ+hc3^hcCJOJQJ^JaJmHnHu1hc3^hH5CJOJQJ\^JaJmHnHu1hc3^hYuV5CJOJQJ\^JaJmHnHu&hc3^h'G6CJOJQJ]^JaJ1hc3^h^|.5CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu1hc3^h'G5CJOJQJ\^JaJmHnHut(u(((()()))*)X1kd$$If add<$*$7$8$H$If]d^dgd[ &Xddd<$*$7$8$H$If]d^dgd[ ddd$*$7$8$H$If]d^dgd[ " &Xdd$*$7$8$H$If]d^`gd[ *)+)/w14t556667[>XEoSd*$7$8$H$`Sgd[ y*$7$8$H$`gd[ y*$7$8$H$^gd[ gd[ $*$1$^gd[ *$7$8$H$^gd[ $*$1$gd[ d*$7$8$H$^gd[ *$7$8$H$^gd[ *$7$8$H$gd[ -)4))))+++,,,--c//[1u1I3X3]3h3i3314O4t55555666r666666Kppp hc3^hOCJOJQJ^JaJ hc3^h41CJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu hc3^hXCJOJQJ^JaJ hc3^hYuVCJOJQJ^JaJ hc3^h)CJOJQJ^JaJ hc3^h{w%CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ&66677777777P8R8T8U8W889D9F9G9ñÎ}l}}[}J9J[J hc3^hwLCJOJQJ^JaJ hc3^hwCJOJQJ^JaJ hc3^h=BCJOJQJ^JaJ hc3^hhCJOJQJ^JaJ hc3^hYuVCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ#hc3^h=B5CJOJQJ^JaJ#hc3^h?5CJOJQJ^JaJ#hc3^h5CJOJQJ^JaJ hc3^hCJOJQJ^JaJ1jPhc3^hCJOJQJU^JaJmHsHG9L9O9R9S9999G:I:O:P:Q:;;;I<K<M<N<<<<<=!=#=$=%=ͼ͚͉x͚g͚g͚xV hc3^h8CJOJQJ^JaJ hc3^hVlCJOJQJ^JaJ hc3^huCJOJQJ^JaJ hc3^hb_CJOJQJ^JaJ hc3^hqzCJOJQJ^JaJ hc3^h=BCJOJQJ^JaJ hc3^h,dCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h4CJOJQJ^JaJ hc3^h@`CJOJQJ^JaJ%=&=====T>V>X>Y>@?B?D?E?F?G?W??@@5@7@9@LANAPAQAAAAAB2B3B5BiBBBBͼͼޫމxxxxޫޫggggޫ hc3^h8CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h CJOJQJ^JaJ hc3^hVlCJOJQJ^JaJ hc3^hqzCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h4CJOJQJ^JaJ&BBBC(CCsDuDvD}DDD E ESEUEWEEEEENFOFPFRFTFUFFFFFGGGG(I*I,I-IIIͼ﫼މxމމމg hc3^h:CJOJQJ^JaJ hc3^h4CJOJQJ^JaJ hc3^h9CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h-:uCJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h CJOJQJ^JaJ hc3^h#CJOJQJ^JaJ(IIIDJFJHJIJJJJJJ^K_K`KaKLLLLLLiMͼͧoV=V1hc3^h45CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu)jhc3^hQCJOJQJU^JaJh7CJOJQJ^JaJ)jhc3^hcCJOJQJU^JaJ)jhc3^h CJOJQJU^JaJ hc3^h=UCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h CJOJQJ^JaJ hc3^h:CJOJQJ^JaJXE_KLpM}MVj^ijslsnsfd<$*$7$8$H$If]d`gd[ $d7$8$H$^`gd[ *$7$8$H$`gd[ `gd[ Sy*$7$8$H$`Sgd[ $*$1$gd[ d*$7$8$H$^gd[ $7$8$H$^gd[ Sd*$7$8$H$`Sgd[ iMkMmMnMpM|M}MMMDNFNKNLNO1OPPPPQAQKQQQV洛yhyhWhyhyFy hc3^h[ CJOJQJ^JaJ hc3^h`\CJOJQJ^JaJ hc3^h CJOJQJ^JaJ hc3^h =CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ1hc3^h-5CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu1hc3^h:5CJOJQJ\^JaJmHnHu1hc3^h 5CJOJQJ\^JaJmHnHuVWW9WCW{W|WWWWXXXXX:Y=Y>Y?YHYIYaYdYeYfYYYZZ[[*[,[[[[[\\"\%\&\'\\\\\V]W]$^%^[^\^c^ﺩﺩﺩﺩ hc3^h-CJOJQJ^JaJ hc3^hvCJOJQJ^JaJ hc3^hA CJOJQJ^JaJ hc3^h4CJOJQJ^JaJ hc3^h6JCJOJQJ^JaJ$hc3^hvCJNHOJQJ^JaJ hc3^hvCJOJQJ^JaJ5c^h^j^^\_^_d_e_____0`2`4`5`{a}aaaaa b bbccͼxggVg hc3^hdCJOJQJ^JaJ hc3^h 'CJOJQJ^JaJ hc3^h%ACJOJQJ^JaJ hc3^h>FCJOJQJ^JaJ hc3^hI CJOJQJ^JaJ hc3^h5CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h6JCJOJQJ^JaJ hc3^hvCJOJQJ^JaJ hc3^h4CJOJQJ^JaJc cc]c^cccdddddye{e}eeeefffͼxgVE4Eg hc3^h"/CJOJQJ^JaJ hc3^h18CJOJQJ^JaJ hc3^hQpCJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^h$GCJOJQJ^JaJ hc3^hUHCJOJQJ^JaJ hc3^hHCJOJQJ^JaJ hc3^h!CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h@6CJOJQJ^JaJ hc3^h 'CJOJQJ^JaJ hc3^hs~CJOJQJ^JaJf#ffffff g gggggghhhhhhiiiiiiiiijIj|j~jͼޫ͚͉ͫxgVgVV hc3^hcCJOJQJ^JaJ hc3^hUHCJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^hPCJOJQJ^JaJ hc3^hdCJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^hwiCJOJQJ^JaJ hc3^hZCJOJQJ^JaJ hc3^hQpCJOJQJ^JaJ hc3^h18CJOJQJ^JaJ ~jjj8k:k?k@kkk)l-l0l1lllllTmVm\m]mmmmmmmmnnnnn6oͼ͚ͫͼxͼxͼgͼgͼV hc3^hzCJOJQJ^JaJ hc3^h4CJOJQJ^JaJ hc3^hRqCJOJQJ^JaJ hc3^hR4^CJOJQJ^JaJ hc3^h3QCJOJQJ^JaJ hc3^h?& CJOJQJ^JaJ hc3^hnCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h5CJOJQJ^JaJ hc3^h^9CJOJQJ^JaJ!6o8oo)p+p1p2ppppppp0q2q4qKq_qqqqqqqrrrrrsssssK͚)xgg hc3^hiECJOJQJ^JaJ hc3^h|CJOJQJ^JaJ hc3^haCJOJQJ^JaJ hc3^hKCJOJQJ^JaJ hc3^h?_CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h^PCJOJQJ^JaJ hc3^hzCJOJQJ^JaJ hc3^hnCJOJQJ^JaJ#s s sascsnszs~ssssssssss]tbtqtutttttuu,u/uPu]ujukuluouyyyyyyyyhyWyhyy hc3^h<9eCJOJQJ^JaJ hc3^h,yCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ+hc3^hcCJOJQJ^JaJmHnHu&hc3^hc5CJOJQJ\^JaJ1hc3^h,y5CJOJQJ\^JaJmHnHu1hc3^h#45CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu"nszs|s~ssssssssr]dd$*$7$8$H$If]dgd[ @kdD$$If40H ad<$*$7$8$H$If]d`gd[ dd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ ssssssss]t_txxd<$*$7$8$H$If]d`gd[ ?kd$$If0H add<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ _t`tbtqtstutttxxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kd$$If0H attttttluxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kd7$$If0H alumuouuuuuuxxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kd$$If0H aouuuuuuuuvvv#vZvfvvvvvwwwííٔo^M@BLRkda$$IfFp         add$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ dd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ BDEFHtvwxySRkd?b$$IfFp         add$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ $7$8$H$If`gd[ dd<$7$8$H$If]d`gd[ y{}LRkdb$$IfFp         add$*$7$8$H$If]dgd[ dd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ d<$*$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ dd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ d<$*$7$8$H$If]d`gd[ $7$8$H$If`gd[ iOdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ d<$*$7$8$H$If]d`gd[ $7$8$H$If`gd[ Rkdb$$IfFp         aDFGHIK~llSd<$*$7$8$H$If]d`gd[ $7$8$H$If`gd[ Rkd/c$$IfFp         add<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ KMOQLRkdc$$IfFp         add$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ dd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ =wʔlQQQ &Xdd$*$7$8$H$If]dgd[ $ &Xd*$7$8$H$`gd[ $d7$8$H$`gd[ *$7$8$H$`gd[ *$7$8$H$`gd[ ,kdc$$If add<$7$8$H$If]d`gd[ =gl579: "#cʹ͛ͅtcRAtcRAtcRAt hc3^h54CJOJQJ^JaJ hc3^h{'CJOJQJ^JaJ hc3^hZfCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ+hc3^hcCJOJQJ^JaJmHnHu1hc3^h&|F5CJOJQJ\^JaJmHnHu1hc3^h'G5CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu1hc3^h)85CJOJQJ\^JaJmHnHuʔeЕ DP&Ifijdd$7$8$H$If]d`gd[ d<$*$7$8$H$If]d`gd[  Vdd$*$7$8$H$If]d`gd[  &Xdd$*$7$8$H$If]dgd[ jklb6?|e$d$7$8$H$If`gd[ $d$7$8$H$Ifgd[ $d7$8$H$`gd[ d*$7$8$H$`gd[ *$7$8$H$`gd[ *$7$8$H$`gd[ ,kd-d$$If ack79Z\_`buŜǜ͜Μ 9:]sͼޚͼކޚޚtcctc hc3^h`gzCJOJQJ^JaJ#hc3^h`gz5CJOJQJ^JaJ&hc3^hc56CJOJQJ^JaJ hc3^h54CJOJQJ^JaJ hc3^hjCJOJQJ^JaJ hc3^h{'CJOJQJ^JaJ hc3^hZfCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h[ CJOJQJ^JaJ#ɟ۟CKLOQRSTY[]^{} ݨܹuduSuSuu hc3^hP*CJOJQJ^JaJ hc3^h.=VCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hPusCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hbCJOJQJ^JaJ hc3^h-CCJOJQJ^JaJ#hc3^h`gz5CJOJQJ^JaJ hc3^h`gzCJOJQJ^JaJ#hc3^h`gz>*CJOJQJ^JaJݨި*?@%êÑx_F_x_x_F_1hc3^h,$5CJOJQJ\^JaJmHnHu1hc3^hPus5CJOJQJ\^JaJmHnHu1hc3^h,$5CJOJQJ\^JaJmHnHu1hc3^hPus5CJOJQJ\^JaJmHnHu1hc3^hb5CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu hc3^hcCJOJQJ^JaJ#hc3^hc>*CJOJQJ^JaJ?@HjWWW$d$7$8$H$Ifgd[ $d$7$8$H$If`gd[ }kd}d$$IfF0 Z.M; t0644 layt,$llll$d$7$8$H$Ifgd[ kd e$$IfFh0 Z.M; t0644 layt,$%&efl(*+,-̚̚jR<+hc3^hcCJOJQJ^JaJmHnHu.hc3^hPusCJOJQJ\^JaJmHnHu.hc3^hP*CJOJQJ\^JaJmHnHu.hc3^hPdCJOJQJ\^JaJmHnHu1hc3^h,$5CJOJQJ\^JaJmHnHu1hc3^h,$5CJOJQJ\^JaJmHnHu1hc3^hPus5CJOJQJ\^JaJmHnHu4hc3^hPus5>*CJOJQJ\^JaJmHnHu Ūll$d$7$8$H$Ifgd[ kde$$IfF0 Z.M; t0644 layt,$,-UWl]lC$ &Xd*$7$8$H$`gd[ *$7$8$H$`gd[ $d7$8$H$`gd[ kd,f$$IfF0 Z.M; t0644 layt,$-34Wwɫʫ PRUV9枍{jYjjYjjHj hc3^huBCJOJQJ^JaJ hc3^hP*CJOJQJ^JaJ hc3^hPdCJOJQJ^JaJ#hc3^hc>*CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ+hc3^hcCJOJQJ^JaJmHnHu1hc3^h'G5CJOJQJ\^JaJmHnHu1hc3^hb5CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHuWwɫrdd$*$7$8$H$If]dgd[ ,kdf$$If add$7$8$H$If]d`gd[ d<$*$7$8$H$If]d`gd[  &Xdd$*$7$8$H$If]dgd[ _P*$7$8$H$`gd[ ,kd]g$$If add$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ,kd g$$If add<$7$8$H$If]d`gd[ .9ǿ')+wdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ $d7$8$H$`gd[ d*$7$8$H$`gd[ y*$7$8$H$`gd[ $*$1$gd[ 9;BC/Vٱ۱ޱ߱.9jlop ¸Ƹʹ͒~͒m\K hc3^hcCJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^h~!CJOJQJ^JaJ&hc3^hc56CJOJQJ^JaJ hc3^hbCJOJQJ^JaJ hc3^hy CJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu hc3^hcCJOJQJ^JaJ hc3^huBCJOJQJ^JaJ hc3^hPdCJOJQJ^JaJƸ̸θʹ<>DEĻƻɻʻսTjKNOPƿǿͼͼͼͼxg hc3^heCJOJQJ^JaJ hc3^h0ICJOJQJ^JaJ hc3^h/ICJOJQJ^JaJ hc3^h8CJOJQJ^JaJ hc3^hj;CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hPdCJOJQJ^JaJ hc3^h~!CJOJQJ^JaJ$ǿ̿ο'+?BDPT_d8=KOdiABCD棒|+hc3^h/ICJOJQJ^JaJmHnHu hc3^hcCJOJQJ^JaJ+hc3^hcCJOJQJ^JaJmHnHu&hc3^hc5CJOJQJ\^JaJ1hc3^h/I5CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu,+?ABDPRT_ar]r]dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ @kdg$$If40H add<$7$8$H$If]d`gd[ dd$*$7$8$H$If]d`gd[ abdxxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kdh$$If0H axxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kdPh$$If0H a8:xxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kdh$$If0H a:;=KMOdfxxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kdh$$If0H afgixxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kd@i$$If0H axxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kdi$$If0H aCxdd<$7$8$H$If]d`gd[ dd$*$7$8$H$If]dgd[ d<$*$7$8$H$If]d`gd[ ?kdi$$If0H aCD7l]L*$7$8$H$`gd[ *$7$8$H$`gd[ ?kdj$$If0H ad<$*$7$8$H$If]dgd[ ?kd0j$$If0H a$%024578۹۹ۓpW>W1hc3^hWN85CJOJQJ\^JaJmHnHu1hc3^hc5CJOJQJ\^JaJmHnHu)jhc3^hQCJOJQJU^JaJh7CJOJQJ^JaJ)jhc3^hcCJOJQJU^JaJ hc3^hCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hWN8CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ&hc3^hc56CJOJQJ^JaJ7F}kdj$$IfF0T$ t0644 layt1Q$d$7$8$H$If`gd[ $d7$8$H$`gd[ $7$8$H$`gd[ n}kdOk$$IfF0T$ t0644 layt1Q$d$7$8$H$Ifgd[ '7BCOh:PRʹʹʹʹʹii1hc3^hE+5CJOJQJ\^JaJmHnHu1hc3^h-h5CJOJQJ\^JaJmHnHu1hc3^hbD5CJOJQJ\^JaJmHnHu1hc3^h5CJOJQJ\^JaJmHnHu1hc3^hWX5CJOJQJ\^JaJmHnHu1hc3^h5CJOJQJ\^JaJmHnHu4@nn$d$7$8$H$Ifgd[ }kdk$$IfF0T$ t0644 layt1Q@Aynn$d$7$8$H$Ifgd[ }kdMl$$IfF0T$ t0644 layt1Qnn$d$7$8$H$Ifgd[ }kdl$$IfF0T$ t0644 layt1Qnn$d$7$8$H$Ifgd[ }kdKm$$IfF0T$ t0644 layt1Qnn$d$7$8$H$Ifgd[ }kdm$$IfF0T$ t0644 layt1QDnn$d$7$8$H$Ifgd[ }kdIn$$IfF0T$ t0644 layt1QDEOnn$d$7$8$H$Ifgd[ }kdn$$IfF0T$ t0644 layt1Qnn$d$7$8$H$Ifgd[ }kdGo$$IfF0T$ t0644 layt1Qnn$d$7$8$H$Ifgd[ }kdo$$IfF0T$ t0644 layt1QQnn$d$7$8$H$Ifgd[ }kdEp$$IfF0T$ t0644 layt1QQR{nn$d$7$8$H$Ifgd[ }kdp$$IfF0T$ t0644 layt1QR{ ! #淥rarrrL)hc3^hcB*CJOJQJ^JaJph hc3^hZfCJOJQJ^JaJ hc3^h9SCJOJQJ^JaJ hc3^hrICJOJQJ^JaJ hc3^hcCJOJQJ^JaJ#hc3^hc5CJOJQJ^JaJ+hc3^hcCJOJQJ^JaJmHnHu1hc3^hWX5CJOJQJ\^JaJmHnHu1hc3^hH5CJOJQJ\^JaJmHnHuN0[gVEEEEd*$7$8$H$`gd[ *$7$8$H$`gd[ $ &Xd*$7$8$H$`gd[ }kdCq$$IfF0T$ t0644 layt1Q#<CI~&<w իtcRcAtRt hc3^h+CJOJQJ^JaJ hc3^hWXCJOJQJ^JaJ hc3^hrICJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h) {CJOJQJ^JaJ)hc3^hrIB*CJOJQJ^JaJph)hc3^h) {B*CJOJQJ^JaJph)hc3^hcB*CJOJQJ^JaJph)hc3^hK@B*CJOJQJ^JaJph)hc3^hTvB*CJOJQJ^JaJph "*+[]`abmygilmCabͼxމgV hc3^hQCJOJQJ^JaJ hc3^hKCJOJQJ^JaJ hc3^hWXCJOJQJ^JaJ hc3^h|CJOJQJ^JaJ hc3^h?_CJOJQJ^JaJ hc3^h0XCJOJQJ^JaJ hc3^hK@CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hXCJOJQJ^JaJ hc3^hp2ZCJOJQJ^JaJ!YZ]_`]iͫ͚͚xgxgxgxggV hc3^hlCJOJQJ^JaJ hc3^hp2ZCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h[ CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h\KQCJOJQJ^JaJ hc3^hdCJOJQJ^JaJ hc3^hQCJOJQJ^JaJ hc3^hXCJOJQJ^JaJ hc3^h|CJOJQJ^JaJ v{|Mdfhij RTVWXnK͉͉ͫ޼xgxxgxxgxxgx hc3^h NHCJOJQJ^JaJ hc3^hp2ZCJOJQJ^JaJ hc3^htpCJOJQJ^JaJ hc3^hvCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hQCJOJQJ^JaJ hc3^h<9eCJOJQJ^JaJ hc3^hKCJOJQJ^JaJ( qsvx{~  !Yw;sux|}~  /0ͼ޼ͼ޼޼ͼͼޫͼ޼﫚 hc3^h[ CJOJQJ^JaJ hc3^h+CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hQCJOJQJ^JaJ hc3^h NHCJOJQJ^JaJ hc3^hp2ZCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ50<fhkopq(*,-.˺˺˩ܩܩtcRtc hc3^h>0CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h*ZCJOJQJ^JaJ#hc3^hJi5CJOJQJ^JaJ#hc3^hJi6CJOJQJ^JaJ hc3^hJiCJOJQJ^JaJ hc3^hQCJOJQJ^JaJ hc3^hbtCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ#hc3^hc5CJOJQJ^JaJ 8Xnn S`[ͼͼͼͼKwff hc3^hGSCJOJQJ^JaJ#hc3^h?5CJOJQJ^JaJ hc3^h?CJOJQJ^JaJ hc3^hN[CJOJQJ^JaJ hc3^h[ CJOJQJ^JaJ hc3^h+5CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h*ZCJOJQJ^JaJ hc3^h>0CJOJQJ^JaJ#[gxtvyzostuEGܺܺܘܘ܆uddudduud hc3^hbtCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ#hc3^hc5CJOJQJ^JaJ hc3^h8tdCJOJQJ^JaJ hc3^h-hCJOJQJ^JaJ hc3^h>0CJOJQJ^JaJ hc3^h[ CJOJQJ^JaJ hc3^h-vCJOJQJ^JaJ#hc3^h-v5CJOJQJ^JaJ"[! V    D  ]^Sd*$7$8$H$`Sgd[ S*$7$8$H$`Sgd[ $S7$8$H$`Sgd[ S*$7$8$H$`Sgd[ $*$1$gd[ d*$7$8$H$`gd[ GJNOP%'*./0f!1]_ &(*+,ͼͼͫͼͼuͼͼ͉ͼ&hc3^hc56CJOJQJ^JaJ hc3^hFCJOJQJ^JaJ hc3^heCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hbtCJOJQJ^JaJ hc3^h-hCJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ. ! ͼͫͼx_1hc3^h75CJOJQJ\^JaJmHnHu hc3^hiQCJOJQJ^JaJ hc3^h!CJOJQJ^JaJ hc3^h8QCJOJQJ^JaJ hc3^h4fKCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hbtCJOJQJ^JaJ hc3^hFCJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ .PRcdOa°°|kZI||8ZI8 hc3^hH CJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hM9CJOJQJ^JaJ hc3^h}zCJOJQJ^JaJ hc3^h7CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ#hc3^hM95CJOJQJ^JaJ#hc3^hc5CJOJQJ^JaJ#hc3^h75CJOJQJ^JaJ#hc3^h3D5CJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu->@BCDEFGHCEGHLMNvKKͼޚͼމp1jqhc3^h9CJOJQJU^JaJmHsH hc3^h`CJOJQJ^JaJ hc3^h[ CJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hM9CJOJQJ^JaJ hc3^hH CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hcKCJOJQJ^JaJ#    + K U V W X Y  궝dF0+h75CJOJQJ\^JaJmHnHu:jhc3^hc5CJOJQJU\^JaJmHnHu>johc3^h`5CJOJQJU\^JaJmHnHsHu1hc3^h`5CJOJQJ\^JaJmHnHu1hc3^hcK5CJOJQJ\^JaJmHnHu hc3^hcCJOJQJ^JaJ)jhc3^hQCJOJQJU^JaJh7CJOJQJ^JaJ)jhc3^hcCJOJQJU^JaJ      D - / 1 2 3 GIKLMwyī~m\K:\m\K:\m\ hc3^ht5CJOJQJ^JaJ hc3^hM9CJOJQJ^JaJ hc3^hH CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ4jhc3^h`5CJOJQJU^JaJmHsH#hc3^h`5CJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu:jhc3^hc5CJOJQJU\^JaJmHnHu:jhc3^hQ5CJOJQJU\^JaJmHnHuy{|}HJLMNVu   ^`bcghiY[]^giklͼͼͼK﫼މxމxމxx hc3^h3xsCJOJQJ^JaJ hc3^hWCJOJQJ^JaJ hc3^hL=&CJOJQJ^JaJ hc3^hyCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hH CJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^h}zCJOJQJ^JaJ/7=wxz  wy{|(2|޼ޫ͚ͼͼ͚͚́1jhc3^h9CJOJQJU^JaJmHsH hc3^h[ CJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hL=&CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h3xsCJOJQJ^JaJ hc3^hWCJOJQJ^JaJ.]^MOQRVWX kmoptuvg i k l m !!ȯ|k|k|k|k|k|k|kZ hc3^h# CJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu hc3^h`CJOJQJ^JaJ#hc3^h`5CJOJQJ^JaJ(hc3^h`CJOJQJ^JaJmHsH ^$,0K3699'<==2>>d??@5AAB3C & F*$7$8$H$gd[ S*$7$8$H$`Sgd[ Sd*$7$8$H$`Sgd[ S*$7$8$H$`Sgd[ $*$1$gd[ !!!"""""""#####$$$$$$H%J%M%N%Z%[%&&&&&"($(&('(((((((޼ޚޫ͉xxgx hc3^hSCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h)CJOJQJ^JaJ hc3^hCCJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h# CJOJQJ^JaJ hc3^huCJOJQJ^JaJ(((***** ,,,,,1,P,,,,,,Q-S-V-Y-Z-[-q.u.v.w.......m/p/r/]1_1a1b1f1g1k1l1m11ͼͼޫ:ޫމxxx hc3^h[CJOJQJ^JaJ hc3^h0ICJOJQJ^JaJ hc3^h!CJOJQJ^JaJ hc3^hP2CJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hsCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hSCJOJQJ^JaJ/11111+2-2/20212C3E3G3H3I3 44 6 66666u6v6w6y6z6~66678K͚xg͉VV hc3^hCJOJQJ^JaJ hc3^h+CJOJQJ^JaJ hc3^h9<`CJOJQJ^JaJ hc3^h'ZGCJOJQJ^JaJ hc3^h{ CJOJQJ^JaJ hc3^h0ICJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^h[CJOJQJ^JaJ hc3^hSCJOJQJ^JaJ 88888 81939596979====$>%>'>(>1>2>>>>ͼͫͼppppp_N hc3^h(3CJOJQJ^JaJ hc3^h=YPCJOJQJ^JaJ hc3^h-@CJOJQJ^JaJ1hc3^hc5CJOJQJ\^JaJmHnHu hc3^hmCJOJQJ^JaJ hc3^h'ZGCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^ht5CJOJQJ^JaJ hc3^hmCJOJQJ^JaJ>c?d????@@4A5AAB3CCC}D~DDEIFͼxxcRA hc3^hpHCJOJQJ^JaJ hc3^hOCJOJQJ^JaJ(h7h :XCJOJQJ^JaJmHsH hc3^hwCJOJQJ^JaJ hc3^hRCJOJQJ^JaJ hc3^h%?CJOJQJ^JaJ hc3^h4CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^heCJOJQJ^JaJ hc3^h=YPCJOJQJ^JaJ hc3^hgCJOJQJ^JaJ3CC~DD_EEVFG]H[ICJOJQJ^JaJ hc3^huCJOJQJ^JaJ hc3^hQ!CJOJQJ^JaJ hc3^h,dCJOJQJ^JaJ(hc3^h,dCJOJQJ^JaJmHsH hc3^he+CJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h=BCJOJQJ^JaJ hc3^h8CJOJQJ^JaJbMcMO2O3OP^QQQR RiRjR"S#SSS/T0TTT9U:U>V?VVW︣ɒp______N hc3^h=UCJOJQJ^JaJ hc3^h:CJOJQJ^JaJ hc3^h9CJOJQJ^JaJ hc3^h'CJOJQJ^JaJ hc3^h%kCJOJQJ^JaJ(hc3^h-:uCJOJQJ^JaJmHsH hc3^h-:uCJOJQJ^JaJ(hc3^hcCJOJQJ^JaJmHsH hc3^hcCJOJQJ^JaJ hc3^h#CJOJQJ^JaJ?VVW(XXYYYZF[[\]"^,_:``+aTbbc)ddeWf{gthij & Fd*$7$8$H$gd[ WW(XXXXYYYY!ZZZF[[[\]`b︧tctRA0 hc3^h>FCJOJQJ^JaJ hc3^hI CJOJQJ^JaJ hc3^hW@CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h(iCJOJQJ^JaJ hc3^h,FCJOJQJ^JaJ hc3^hQhCJOJQJ^JaJ hc3^hcCJOJQJ^JaJ hc3^h =CJOJQJ^JaJ(h7hCJOJQJ^JaJmHsH hc3^he+CJOJQJ^JaJ hc3^hCJOJQJ^JaJbccdeWfthmnoooppp$q%qqqqurvrtͼͫxxxgVgEgE hc3^hRqCJOJQJ^JaJ hc3^hMlCJOJQJ^JaJ hc3^hR4^CJOJQJ^JaJ hc3^h)6CJOJQJ^JaJ hc3^h(CJOJQJ^JaJ hc3^h?& CJOJQJ^JaJ hc3^h"/CJOJQJ^JaJ hc3^h|nCJOJQJ^JaJ hc3^hHCJOJQJ^JaJ hc3^hI CJOJQJ^JaJ hc3^h.CJOJQJ^JaJjjklmnnoopp%qqvrrsnttvvwIyzz{|~X & Fd*$7$8$H$gd[ tz@zzzK>AGNdEFKxgxgxgxVE4 hc3^h99 CJOJQJ^JaJ hc3^h.=VCJOJQJ^JaJ hc3^h{'CJOJQJ^JaJ hc3^h2cCJOJQJ^JaJ hc3^h&|FCJOJQJ^JaJ hc3^h tCJOJQJ^JaJ hc3^h]8CJOJQJ^JaJ hc3^hRqCJOJQJ^JaJ hc3^hKCJOJQJ^JaJ hc3^h LsCJOJQJ^JaJ hc3^h^PCJOJQJ^JaJ hc3^hzCJOJQJ^JaJXKJ&P6dF;2p[$הa & Fd*$7$8$H$gd[ :;12[$̘<=޼ޫxgVgE4E hc3^hQCJOJQJ^JaJ hc3^hXCJOJQJ^JaJ hc3^h) {CJOJQJ^JaJ hc3^h9SCJOJQJ^JaJ hc3^h0ICJOJQJ^JaJ hc3^hj;CJOJQJ^JaJ hc3^h~!CJOJQJ^JaJ hc3^h\CJOJQJ^JaJ hc3^hwCJOJQJ^JaJ hc3^h.=VCJOJQJ^JaJ hc3^h1CJOJQJ^JaJ hc3^huBCJOJQJ^JaJ̘=̛J`fvg Ƨªí̯ & Fd*$7$8$H$gd[ `efv9=|>޼veTC2 hc3^hCJOJQJ^JaJ hc3^h+5CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h2.CJOJQJ^JaJ$hc3^hn{0JCJOJQJ^JaJ hc3^hn{CJOJQJ^JaJ hc3^hJiCJOJQJ^JaJ hc3^h+CJOJQJ^JaJ hc3^h NHCJOJQJ^JaJ hc3^hvCJOJQJ^JaJ hc3^hNCJOJQJ^JaJ hc3^hKCJOJQJ^JaJ9|?YʷcJFɿ:+ & Fd*$7$8$H$gd[ >?ʷF:*+ 3ͼͫxgVgE4 hc3^h}zCJOJQJ^JaJ hc3^hM9CJOJQJ^JaJ hc3^hbO!CJOJQJ^JaJ hc3^hiQCJOJQJ^JaJ hc3^h4fKCJOJQJ^JaJ hc3^hw=CJOJQJ^JaJ hc3^hFCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h8tdCJOJQJ^JaJ hc3^h-hCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h?CJOJQJ^JaJ+$-8 X3!2~Ema & Fd*$7$8$H$gd[ 3~EqͼxgVTVC;7;7;7h<jh<U h6=hcCJOJQJ^JaJU hc3^h'ZGCJOJQJ^JaJ hc3^h[CJOJQJ^JaJ hc3^h9CJOJQJ^JaJ hc3^h!CJOJQJ^JaJ hc3^hsCJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^h.CJOJQJ^JaJ hc3^hCJOJQJ^JaJ hc3^hbO!CJOJQJ^JaJ hc3^h3xsCJOJQJ^JaJaql  78ef h d7$8$H$gdh*d*$7$8$H$^gd[  & Fd*$7$8$H$gd[ 199. Shapiro LE, Sievart R, Ong L, Ocamo E, Chance R, Lee M, Nanna M, Ferrick K, Surks M 1997 Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 82:2592-2595. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, Hardman SM 2000 Is there a place for late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 12:327-333.     Chapter 12. Graves' Disease: Complications Chapter 12. Graves' Disease: Complications  478:defgjkmnopstvwxyz{еԵԵ h6=hcCJOJQJ^JaJ4jhc6CJOJQJU]^JaJmHnHuh9hcmHnHu+hc6CJOJQJ]^JaJmHnHuh<jh<Ufjkopstxyz{d*$7$8$H$^gd[  h d7$8$H$ h d27$8$H$ B 00P1F:p6=/ =!"#$% DpN$$If!vh#v:V 5/ 4aDd q&'  s >^AOggetto 1#"X'L'PK!Y1[Content_Types].xmlN0H+j)G@JP^ꐜtMT: >OW ؛JE9ʑ&YdA3Ė\h[2 -;oIVFݠ{놲PN8Qa2gh^A6UO}XW 6♄.`1atW9a^sSY( @&9WqPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!2drs/e2oDoc.xmln6E֯e#4N([E $-;}(KQ-zrD3GO' Sba"y)vK#PS.[z/L{Wr{,{s(zqޘz1l*?Ț ,WA{'tLR嵒ZNoe̟E!|m*4"۶O<:e;Ak$<$cy  6YG9Y$T@&e 2j59PG+B;*&L[qj`Q 9%09XB{GǛT9g[!dDnsmY̺XS8w#H9c9}.4iWhQV#?Ϯlny:֩0FI;i!` < 7UGV|f"ha3A6;뫼/9o;ik93 J=,9.-ߡBK7C+\yrVlڊoS+JsyыH'`G{(-VI=#mJ^AdS.9 [$ <3[uJ2G<%4f3.z(eg%f`7ܸQmGGq'[eGBq|žO$W>z>~8í#W@H RqP@ %8@Yڳ5ɯ4JudÑJ{"-yrSs%8)a ?ʬ9pswLzۚ3 1jm"E?1Oi?L w<=2|C1q˼t4v ^&/#v'wPK!rgQ drs/charts/_rels/chart1.xml.relsj0 ``t0ƈZa Fw$f,o?0Xa#u5q̞V6 0Yr>Mގ\Lr&PB gd7+S~aQRG KZ0H9R<34ͽʿ Lqp &o8zOd?#GOz%MhRa|G}/=M̉z6X ?VkTߩG_PK!F"drs/_rels/e2oDoc.xml.rels 0nz&ЫXIFooЋqvov1ONGgYqh{كYRC׫La,Ų!F@3rYPtOC2F(2 6MW0}P*Qy(L5, c5vRGrwr^K'n8gk~ G]QvRw D6S;|FNa$SzZ8)XYȺoPK!'J'T drs/charts/chart1.xmlVMs0wp%Pd $ z5h"KI&>C6VV\\ <'QOEF<&^(MxF+P󧋴.ԏ%I! \8\h][-. D, r$yku۲AB| @A(_ߗs_9Ma,Ҫ]шZR,.#ߢ`I>w73gSRi1hL¬DmĄȑјq=JsRT%ͬR$dP4iVș]?f&bΨhi\5-cq#3RD~:oad!ZFI 0%V?%mgq(7+h6ٍ O<[[^qxkG&C˺m] w9,Ģao g#t/.{s{ 0QY l+ҲESj^\zz_&tW1*`W;բ׆N#ap alk=+tkKmsEMRxav(:ݞ]"C}mb5 Iqة4TP~GjuǑSKr4}M̡3jDdJ?)+a*̯ Q }gS"7S.7X$4 F ~h#՘y O Kؐ͹Zz փuz $vHE M li JpKdږǻf@?N%n⛁:}'UvZNq7B|oQE 9acI ՌCy7§f PK!-!c!?drs/embeddings/Foglio_di_lavoro_di_Microsoft_Office_Excel1.xlsxY[:DKDC ;ncP))o{={Yk]Z뷔d@ 8D\<+1['c'}uw;cG]67k+i,,a(QSs`5Pa|dD"ڒvR H^x(R("2AHyOC&JL@(Dc["yq 6r3//TFlk6ad)>&.G,/=)X!ɺ@ĝ♶K,y޻6_|<„o`CMZJo4gBofNMGjG-oϳq<  ka⤂ 2. 7b>9"QM6L?B?`ڋLk3zu& ܹ5 pwUipPB%u-4 #;ۏ;EN}?"c^y zm#_//]ONBm.Y WusGd@vEp'@) Y@*Ss.wd/BӀSWkj C%<]^8b|Pp32D2҇g˿p)غ{#3p\LЊ@}2ǰ{ 2fuNy† .; e]4 ..)]v`Cw=O:AN@qb@[[O>4&%CXX6ceTTi^i8+M9sAƍ'8&7){dHt/iO!ԍ4$WBQt4S/ɸ6V/TWrޥcl({@" RZv_#9YDbQipdTqy;5v-j`UBlQs] , 7&*\iF[_)'3 vZu<FiN7}.dmwX;1a6ԾBO 瀬ɯ3tx?NXj5C]F ?\@f]<@c ԜmL8z#m!{UkMLd-n4-;2mt.$WK^Y_IWy~erg_t> j0ԜS? ƎR&HcJ t3ڵs4+T咑]x!L2|A|fSnz"6߁p1?Hxߩ8QvP.c+EׂQ|")YvlGO柿L_{>lf)#ݔ f͌<~><ՊƁ%~uf3+1txdALH3Ϣ!.ƕI7}7H hu87w\R-TjdDjӑ\r ;xApE*VF7xօպ('|ߟϝ7><_玓{N'Nj'{{S_&GpŦ  ?*dflmwlI%IzһH9Lj6&kI88yL4r' Lv~T weOefŋ0\ܛ?cE[]̒>GJWwDJN^v1Q=V?Hs&&SuK {{Vk~lO#C  l;L!2[e4ѥ^wII;̥tl~7jΟ UApz܈1|D7KG -b8UԎǩ&$R6㌷qXv$ _+&ho-WHDj؎Oc@|Yj}m:# 47蛗4HD!Tb5gڳS0/@Ƈ|l~*)gf3Wn #㚈,M4$4>=d (P5#iRTbXMD'㹡KÓ1[g9$}>I?"" <}s!~4Qs^zB4,A G`l݈fPq$3|*v9t6U )wGMf!TŷcK 6yF8ƹX3f)m7H8f./EӈS޼SB.ON^j2Z9J+cX)gWk\Xk%LK~}vH}&| d0MSBCä}卪HX6x/S.+ bwnj78JT,No =G MP8+6Z%[xWM֍ K OASCl929gv F©AA}.K&0z {jY */?cB ?j9e#=a" "7 idyy<< D}z6A{7@Z~=>d'ۉt<%E(jepDA+pI!Ymq͙7rĎ5~n ̱Ɛ&>FnI%߇m9Be,ͫm)XD",YrMelz;zpϴ& B<ӫY.Y_s-tl+)I>&sM'o}-h `|\%MiyķOY[lz=50\%+c0Rs#}TEΡaۦq /3syXզU?A<(͉CZ[ kUŕ7vZBubʦyr[_A2BjfQC"/(Y/0 2R4x1tk)/0P!BM^Sv)]fdݲy10.X I'WmF"xBvfdx]dZrRNyo&JjJ})U&Gn501VVɣ;aʍ-HЈj 8)WedDz8I*ϊE/m3WlO^En}ܛU})f[@$Jwk0!-w(/p$Gmn|;,G'w+㟉Nn85&ĊT٘UNBveH6'햒)muރ?ӟ;J\_Ȇr {[c<3A˔Yy] IEm+9)ɑPcӆ Jb$ҞKWMNn[u\di[yOrޠ^ 91Wv9~r2LE^ FH\oDiItn{#,tlhW˜GM';Mb^^0YVZ]d-5xlN_Jc!4Tt9YXnB;NF~CqB[b+T볙kϱ޴b#e =Q(e+|d.[bq55 p>v7 z񔕀6&hvd#^))^K/X-oGbΣ#gwOޓhcU <ȅ .11D{N㫳?t=&>qs XYYԇUy|R]{o>n˂2pf<7fh>z7i##<\D.8.Qg%.WKXw2ZRf@g!VdDmN࣒1lt|k;cIQ3l~;v4̆e18oP95P] %"L{4 nۑ,C=IEBJJMc/C%(ؑ͑^H]cܓz"p3m<.zh?M|3^ܭ'+ ݚ*!_]js{ݩv*} EI ȝSZTk"Ykcx{UeL(f@?k)' la9LGaE%Cd ,\44H .)&׍". sc&!1rD%m.4[%F ppA 6oK>r>쒚 k:6)lip袎ɝeQ6Y(ࣽ$w*nph/*ĸdΛ87Fa8Dlc#Yj$!P3f4pAȲSKt WT|X㑱43V6g'{w2On^Ϝ4_34VhQ(5.†RHFv솶4*AmAH_zXe`d+a+vIyeH{r]MY1>7ԕO堈`8Tj UjRJIٙqrّS0 x9\4NX_4C ;`QR 2l>nS^99Գ=BE44vLF"{[F(w&LԌgQOUO_`r 2Um|+۲F9aKh9VA_n9P:nN+l-X4eA)c6b!_*0ᣜ ha<Aqmwvv1c[-V8Ю0Dϵ5iZzR뙢p?\$Xel_gJmR޳n1eg)_NjWvj1lS5/4)ؑZhMkSsL`W即qᨑ`OT#䥜F@zg#%4}b E0\9l+qYx18DT-u0Xd%ߙHk\/J2kԒd.=֔8hHbʳbk9h#Eː56舩4:\$QĈ( RgJR7zur}=4.yfʪ%F=\; 1oHި.p-;f؃y#wx[qe h/@B?w},wo]K 4 WA3]zsÿ4Ci_?#9kҠx ejTx;~K}W!s_~6Kmkb%l羆_@14-9Wqj(o?Ome9(tٓ?GPK-!Y1[Content_Types].xmlPK-!8! b_rels/.relsPK-!2adrs/e2oDoc.xmlPK-!rgQ drs/charts/_rels/chart1.xml.relsPK-!F"drs/_rels/e2oDoc.xml.relsPK-!drs/downrev.xmlPK-!'J'T  drs/charts/chart1.xmlPK-!-!c!?> drs/embeddings/Foglio_di_lavoro_di_Microsoft_Office_Excel1.xlsxPK8$b@3 z{\nT@3 z{PNG  IHDR%nsRGBgAMA a cHRMz&u0`:pQ< pHYs&?IDATx^E/I "9Μ|;̧wzgN(&9"*N1|&kB0G@T0 קS띝ݝ}fw󩧪Z,p{[{y晀R @ @y?p}]]wokkkkkkkkkkkkk5p?.{P@]x>L0׀k૯2?ׯ߀" 'pȑ#  @ @a=ڜr)7l*  @ 0Ϝz7"M- @  !@ @a Mm @  !@ @a Mm @  !@ @a Mm @  !@ @a Mm @ ThѢFA_u\ckTe@ @hϞ=L09}fРAQJt[guaf&Ms@ @(@ŋ͋_,bEm2{l-!@^uvy晑P6mژ>!̋!@ @/~gs饗F=Gu+/6o}>Hܹ!^{盭*\`Mybo7=z>r-ͅ^wgu]7z]v~ E^J @ ?/7_c5~{FOu7^4zj/'馛򟭽fԨQQƍ3p@Y.]̰au.\М|gZ2l?~< @ @ *^P믛-Zџ3gNN| 6/(6Z;Pl 4-\yN"q  @ /gK,:th~w% @;FQSN?x(S@CkfmfLR>tA>64v,\  @@ՈZO)ZOY?xӲe˨GO>?{nQ޶mh,P9\&*}ի&&oZPh;eh6@ @@FO͟W_FAzO;4'0`@^PԩSkBs|Q.лwos뭷֚OuY1:tҾ̩ @DjDW_}(0/\Oios*Mwi_|LMLO?=饗6<0`֬Y!"] @ L @c5_)g#<2?ߚkivqh|"۠2"AZ L>(P{オL+h? @ l_~1ӧOzr|v{߉߿*KS@WٳgP& fL4wq9klZ@<_-7xc$A @"P"@]'5yVpK)=_z&i̸qjS:~_Mw衇3f8N x`~u'|2 $8A @~\]tQBo>kV+u]^K/4?O ok7b[Dǩ7x#է  ` @ T0g_iӦ:)S;/+#`Ȑ!~cƌ1ӟAz56jV't8@ :g={4#G׫L -pǭZѰ"@@ @ Tpz+P>0Z.Pi@rk@m;7-Z>?&L0/z_s߉ 'N4?|ɑ@q?},I Bl!(S @ &P"w,rfV2Yy啍tnhx pcɻ]Y,L$(,첦m۶|ZU@4>P/YuUM^L֭c;hP"@(@ @r T@{f.׫f?cK/df͚US_ǏSfkM:^{ժSB(!6uA @L/z5_pD%.7vmK.ӫʪ8efF zhA  4q @ PyB<ɷ y@ @ TGđ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @J T#đ @ < Y4"@H@ @2 TjJi@ @H#ܐE#M] @*"@eL*@ @ $D=E&G @ @JT믿y晅 sMkCO3y嗱*c0bgs @)@Aĉѣͣ>j b(h駟">}y7B>|xom̙Soy]wez!oI&w)"?w s)^ڴl2ڵ3kt}  @JEh{Gl`tb:t`Xb өS'˚;|fѢE53ϘeYt=:sεlV0n-3{Snݺw|GADgΜi?YlŰ*e q緿5j!@ 2K?tPk)8o̘1cjV}CA]Vȑ#k^#pSOA Mi u`.bs??+Fz:ӱcws=橧27|j۶mk:$wD4+P⌆A @Z T0k,OG;c,XJ\pF!_?.φ ffϞ}oqJ_a Yg}7|AD{j6tS3`ӧ#q  @JEm "zg̘QT( r&< {ajZ+}W_ r \Lp'0@ ME_,<%]' /q?\8p!Dh'xք%UTNe+cb"\F U@ @ՊZ @sL|>Wpa 5&XAua/V"8Ah_~FǏ7GqDԤyx1ئ]2"@~@ VX<0˧ g_3kK8餓c^&,y4@hU!D_|{。fQ"@z}˙A 'P"RKDxNRv@|S>[|k pc*b^~aqছn%hBAMHvKHϞ}YDOrDO`3P,"@@ @J@K3?._)8/4_F#FDn,c=h8mq@ 3TLR;vфrۊe]fy䑠Os z=P @:@뮻n>34SN-@ޥQnN^zo0qDsGPV0h6yd3foG ;"@z}˙A Tvӟs9+"PϺVXaoD_uU}gK-Q|{ZFP!6VG۴KFH@ @ФyJnC4ҤIQi& tf͊3fb>}E?F)4IFm}֣G͞=ۜzgZzp-bCG۴KFH@ @ŋ ]f۷{̐!C l'|-w嗛{h^z)(/-ػwo,X 5$@A~˖-͡lcW6O=T8ߎEG۴KFH@ @ŋ^ߺuh?E]1?~9ML۶m#+K[cX2 $lVM6QKs.8䓣̃P"?҈ئ]2"@~@ *^PzDž#Z@7dZutAQܿ樣2Zqkin&7%"?܈ئ]2"@~@ *^и*JLjScF HЫf7n\K}'Fe4@ qDl. mP? @@h/y۴KFH@ "@hCm%# @M 4qO!xlJFȀh @@PAq [2MdD=@ @ &>DO`mئ]2"@~@ BT"'fdD 8&@ %%۴KFH@ "@hCm%# @M 4qO!xlJFȀh @@PAq [2MdD=@ @ &>DO`mئ]2"@~@ BT"'fdD 8&@ %%۴KFH@ "@hCm%# @M 4qO!xlJFȀh @@PAq [2MdD=@ @ &>DO`mئ]2"@~@ BT"'fdD 8&@ %%۴KFH@ "@hCm%# @M 4qO!xlJFȀh @@PAq [2MdD=@ @ &>DO`mئ]2"@~@ BT"'fdD 8&@ %%۴KFH@ "@hCm%# @M 4qO!xlJFȀh @@PAq [2MdD=@ @ &>DO`mئ]2"@~@ BT"'fdD 8&@ %%۴KFH@ "@hCm%# @M 4qO!xlJFȀh @@PAq [2MdD=@ @ $-]l:Yl:SN9Ç>ߪkMdD=@ @ +(_֖,WZ_kgYZTDd],xiئ]2"@~@ 菴6u&Ynm]  $jDdy"㙥 @ @"V #\dƾlm5S`\, Y"$,%o@ Z`~\oCsZ?kslmB! Y"$,%o@ Z@\U=}mm )3@0}ם2'?i @ 4rD m0iֶr"spHՈ$,%o@ Κ+W}e3&ܔ{eklɺ YxfdD,y@  POU.wjZ">C {gJFȒ7h  @@{Y;{YӒ;ZӜnWmߕ3'?i @ 4ƈ5ۿXڪ>DX[ǚ I&?Y* Kޠ- @!+t H}]fֺ ߕ m%# @M\` ?KK>^Gz׬a-'?Ld],O2RɈYm @A\`k@MxL=">z +Cᾈɺ YxfdD,y@  P ෶ o˽ pޛ`!ɺ YxfdD,y@  P 'z$`klɺ YxfdD,y@  Ppl {aɺ YxfdD,y@  P ?˜ ^~W=a?Z{DDǘMdD=@ @ "hYmeMc焀sb}U1@ I&?Y* Kޠ- @!"xMxmVW_ɺ YxfdD,y@  P5ZJ >ɺ YxfdD,y@  PP/nhC=: ,0ӧO7s-E̬Y>n…q/$wFHfͲ۴KFH@ @cEm`㬝nosBP믛Gy 0\pꫯ6̜{[n]ve#a޼y5S;cVZ:n 7~6DMdD=@ @ +hiY@ηg|PORK-M6m۶u\o74;wq۷7IXxkd;f:Nǻ6`{'"?Ԉئ]2"@~@ Zw;kSs8zLZ>֖ĀӦM3g}vr!7O?B]6^.ӡCh]w5:>0Ç7}+@3g.(/zfȑqO=y督$̘1#OaF6C &P{ZXŬm>E9sDAC=dLݣ5oq6ts !6DMdD=@ @ #(r">3 2dHk|5M~"VбguVhA GoFpC :ud}Q#0"?i @ 4rExKִ_'k4֖T&@]p"z5dm7pC~2/L>FQ?9_ve}F)oW_}e:꨼Paח_~9Z֐-y3JY @E\@&گF[;[`dEw}n>:?jEPPK*oWVˣIO?踥^ 4GPT@`ܸqu0%O yY) + @+m p˰CSL1'xb-QOy|sN-@wQpM7.DEѣGGsͪ)ACؒ'<ӬO@ P67,ua b@P@5n%ȧ:Vj@Le|͵հd&ܹsԩS6e?B]7ͪDu7"@3 @(N\@KjMP|P{1Z>e7ZFpD ۴iW@|hٲeߵ^k94ǀ{/~Gӱc(E (½ޛd#P"@3 @HFhm[ &m-{A&pw 6 5k50xh?Mk?ɓ'?>?@ ( mݶVlg.]bcuMdD=@ @ PSQ%:y"`׏UW]ը_=umO=T4P8g;c]wn(q=z0oאc)"?̈ئ]2"@~@ "bݿY;&t+Z[Z 0rH&DK.i8 ?D5[LiK|6DٳgG5|+ m^uV[86hxgZV'fDl. mP? @@h۬p=u5m kZ;>EoQЭJF^uU /̛f?̨Q" 5$Cq%\Mw饗Eݻ~h@k֭[G뮋kBW_=z׎"?ʈئ]2"@~@ }ٚV r/SxMϞ=K^3/̑GizUe]6p7xa1!$*GBAA6C &P r?}YkO!I t{ } ֭ڵkQjn_̈́ Xc өS(3@̭jn ?#s޽{GΝ;?Q怆F6C &P@~Gk?YZk_#9`X9@] n?m4^>A:uj-4&ԫfobAznjcFqƙc KkJEȂh @@HZokYS5/k_Dkw_"@HXY wMdD=@ @ +oyMxֹ~ez&DpD۴KFH@ @9"bmMNh_Z- MODdu-"?ئ]2"@~@ [^cv7hLkZ @i..Rsy۴KFH@ @"9!߭#cvɈi{!@B(WP<͚ڼ:ĀM$Xt# YW#$3^"?i @ 4ƈNq1˦[{6 KqF6C &X@} kKZ<l=:HՈ$,%o@ "49"@EH'"?Y* Kޠ- @!'Q*4_|?֫Dk_L @HֽD3K%#d @ Dm> _jMKRߕ3'?i @ 4DSl>ۚ?kZpCkss5ڟr"g"m%# @M{;kZ0ZZe  YW#$˓Lpd],xiئ]2"@~@ Jv4 0//fe<{`Dl. mP? @@hZoekk[ڏ9!{zi.G&@FH'xfdD,y@  P㗴\mvk>"@EH'"?Y* Kޠ- @!+hjm)>!h "? 6C &PPKfk=Ɯ2"?i @ 4ƈ ױwkgYKsS,ɺ YMdD=@ @ 4F Ț[cDl. mP? @@h.ks"T:œ %\>00ڍ݊1"?i @ 4rEl@u.W6emd/X[`k=cDl. mP? @@h-m06ִR 6zY{gֶAVDMdD=@ @ #־6ڲ~Ŝ0޾j@iocMK ؘ0YW#$3^"?i @ 4rD 5/r~)q_Y$oglMC "G"m%# @M@AVpi~m6`k[[ 49pk_Dl. mP? @@hJ ׶~:7UshyZPu5"@[[ @&@FH'xfdD,y@  P6CNi_?^6{֦ܾZB! Y"$,%o@ ~mi%%mlvi >p 樣e׿_:^ȑ#'l>`{:{n+I|HوIҬY"?i @ 4>ssuיW_=|anѣr}JZpĈ55k6lS=zٳg'"?Ԉئ]2"@~@ BPP}tɴh"fرE>cM6Ѿo7뭷Ywu#~g~ߛ{/jpk?׻wo[lFٳgߢEfDl. mP? @@hl00WJ3tݴo>f-̋+R" .r;z˼5*zoܹyQʿvڙ.L6-|ĉC>[|alD_Dl. mP? @@huZo/kZ5'(|ocm kZU I6k9̌3̹[]R^zlfx#@e˨m!6DMdD=@ @ %A֦[$KeKkfEpe?l',W\5ᆱqڱnEwѼ%ԝJMdD=@ @ %\/-`-'dE(vg-h?-)8g3sL% 7t~зoZ}O>>@+`Szm%# @M.`ľ ?Yl!ks￞{OeW϶)&$9)"@֭}2po ?p3lذx!O_few M'tRO]wUTPHѯJ^ $4+%"d @ DM x_rIKձYZ"79̷~C" ^zisM7y&\xy@AFr<~x _/BQC=TN["DAUn4 @ $ o 1Y4i!e8SV֭[^4hP~d࣏>{{EꫯIdK"@LR""@Vss'|G̢ES`F5 "d  @ $RE/i8YV+ܗOsΩ:{W6SLJ@83όoٲYk_"sfeݘX1J;4N"@%z6C 4@"z;x~>Es=Hi~p .lRK-e>ek.]Oʪ;#4\!4̨R@Tn@ (WlM<֖oH!HRЬZoܸqfc-yꩧ̄ ̤IckOѣGSFK-X̙3 2ĬQ-Z0_~9sfXA_38go}pꩧ3f47ePvF( WEPQ @ hv6fߟX{AִԠL׿{Zϵ}_jsOgx9ÌӧYmofرys57xڵk:cowh?hiP"?҈ئ]2"@~@ 4\?LbT$3|b}O3kS@߾}M֭*D(O&\{ḱvhB"?ڈئ]2"@~@ d0kMg=I9! o`ĉQOc5n@ovee{?7iӦ?>pnvGh*G6C &PͬiykZcìi#PtCHՈD3K%#d @  Zjmykk[e6u}Dd݋,OD?[1F6C &P1779[ݾ߽^{ w+"?ƈئ]2"@~@ zu5"@sCHՈD3K%#d @ ƊZ%`kO[2g +ۿb4ֆ{gJFȒ7h  @@4kW 1k[{V]1MdD=@ @ +,iƂOZ>' ޗHp%""cm%# @M\`sO6;ӿ}ڋ"sb +/ ۴KFH@ @9"&w4hr"``L׵"cvɈi{!@B(GlYllk{M!`>DMdD=@ @ +m}Mxr"ҹLu{m\&k|h$jDdyKC6C &P} kXckZo k[$3@޳k.K@C jlɺ YxfdD,y@  P-}ڻ9`}cMu/"@<RɈYm @A\@?nMgYr0MdD=@ @ 4FP@+fMq1`Yk}<{`Dl. mP? @@hwӬ]kQ6ֶX{ɺ YMdD=@ @ 4E/o3Dd],OD գ gZpV>ZКVذXpd],xiئ]2"@~@ $ldmwkNuGkp5Mw3Ykmok#ֆgJFȒ7h  @@u]m>ڷ־U[is)\+c2MdD=@ @ %,ewr| ދ݊1"?i @ 4DM䧴A6t݊1"?i @ 4&d^z4tʩ1'@FHg4Dl. mP? @@h.X,o{ɺ YxfdD,y@  r:A&۴KFH@ @cEV_._-pnE۴KFH@ @cDgsKjY@-X FVDMdD=@ @ +,a3}TR O 8{l3e3}/櫯2cǎ51cFI͙3nj7Ό3|fܹ%NI!cvɈi{!@B(WXF9vo{ľwbH@u]gvuW;>}uW^fm[laj+;?o-zY#!m%# @M sNxվcְ l]D7|Ӝ|ɦW^ ]v5NQ3Æ 2$L0?̺[:38L:5?F6C &P  K}/%l_=ڵ3[+R__7뭷^/oo?sGC9Ĭ2z.\h~aruܚke8ԩS2 Bl(#cvɈi{!@B(Ghaͬ}.5 oGΝ '`?7(L6͜wy뗟@W\LCFF?賎;oHPЦ$6mژ=|7A|3"?i @ 4rD]fm!Vld&zG.Ea=\ #F0=zȗs}E?3a={4~i!uf8Ć2"?i @ 4rEY{\kZOױs 0|3i$߿A0Z2-Z0]t1&o*cɗsmE=]viٲed 1}o[t3tPOΝc=*{cuMdD=@ @ +־vUi@"/PaVZi%⪇7&6~xsq\pA1GqD>_fecƌ1e_is.c3cǎ5ZP^k624/Ӱ.qݺuV3gN"Ìm%# @M\`c*%o@A_g-4{ηO:fM75mY~} /Y{}Zjv)zU7h#y뮨_/rqlMcHh!#m%# @M\@l_[x뭷J%nj$ķhu"HvL#F%"?܈ئ]2"@~@ ٠^֖jz>o[PPe_i~EѣG3<3p衇F7~a7oѲ|'p?wG|Wh!G6C &PP,o{>Wh,Dϝ;VCi `]mAhK~$"@=D @&@K֪D+*dQHnF6C &PcmlZCDl. mP? @@hXk?YRh!gg""cm%# @M\`,CVDMdD=@ @ +h~֮vrkZgmm߭#cvɈi{!@B(Whk.ֺ[Z`ݬ}=0YW#$3^"?i @ 4rEb7okmVDMdD=@ @ 0kִ`Ld],O2RɈYm @AFY{2'>ѣ m%# @M\`qɯnMKson_vos"3+~]/"?i @ 4rE#sc5ٗ S&Tv."?i @ 4rEMm$4ֿ!eƚ1'@FHg4Dl. mP? @@h+hBkP _i)ɺ YxfdD,y@  Pݭ֣T?"@EH'"?Y* Kޠ- @!+4ۗ9"@EH'"?Y* Kޠ- @! D۴KFH@ @C"rkk[X嘎YZ&VDMdD=@ @ '}b?ibhDnE۴KFH@ @}"6xZCK6=݊1"?i @ 4DV6x?ڽ˽ognʙ3݊1"?i @ 4׿VUc㶬Uakc"dcDl. mP? @@h {?vc4֎[1F6C &X &+ =kZZ˺TSN9Ç>ߪkMdD=@ @ +(3}YƾjRz7Dd],xiئ]2"@~@ Jوε6˜ 1Zk[[%mɺ YxfdD,y@  Аtim™&,kCHֽD3K%#d @ Dld)cjoִ*@6Dd݋,ODY~MϞ=͒K.iw^VYeH(Əo.Ν;;FK-}ͧ~@۴KFHԟD$(f DATZx衇b-֠5;n8sGGA[liveBmH#cvɈi{ 얁]2@JYJoժU>s1guVdzۼΝk 븝w~F 7`bmFk"?ʈئ]2"@$ $A1e d7 @h"טYf0}ȦNO?{W+{ Lnς\0#cvɈi{ 얁]2@J 7@ :,rQߣG3q5X#Cp(A)u4fDP+D8U^5\H D/g@ 9',gOnO?T/r!>2r-ZTRM )?۴KFHԟD$(f DAT^hѢEk.^xZ1@~}K{^OszPmNgPFnrv ЬEGy[66mDKvaW^1 ,|#ओNݻ2ڷoo{o3mڴ%~ҥyg|o0"?i? IPn - Pܝwޙ[n|&W\# gϞF=Ml}~ "?̈ئ]2"@$ $A1e d7 @h"ٳͷ~kf͚Uwu)?ͤI^|EFAVn;w۷otM:Bl(#cvɈi{ 얁]2@Jيq45\c~iꫯ#G^z'p-8ydsGA~VGa[oenGǮAG۴KFHԟD$(f DATVlvԩرcڹs-~"6onZn :tm׮]$t- ̙@۴KFHԟD$(f DATV>}2dH~~|@M~M 7_Yꫯnn3qĠ"?܈ئ]2"@$ $A1e d7 @h"z=d*p~ag*R|3u% m%#O"@["@v}C#p#4ࠃ*`#S!"*۴KFHԟD$(f DGO!t5g*a2,S÷dHcoD4{\ئ]2"@$ $A1e d7<"@޽ԩS+3G`…f5@Ȝgo"@9"s$"?i? IPn -+@ЫW/_W{gəsII B( SwB#nnئ]2"@$ $A1e d7<񪔽yNOl'"@eV9?i? IPn -+"@y*eo+SZϭMdD=@I@Hbv@ȮohYyU){\)BLO!7nn^1"wT"@)V"|N"@83SəqEY a8@Y3|۴KFHԟD$(f DG<^7ɕ⩚DLj5"?Grs6'A - e@(Wsrx 2=@?i? IPn -+"@y*eo+S)D-5+F @9*ROՉ@Hgf 993(! ( Wvw&ocvɈi{ 얁]в ǫR9R&ڸCǭB2AL@n6CNo\~Eh-Zdƌc?xӮ];bհ6̌5hP"?MdD=@I@Hbv@ȮohYyU){\)NDFM=O^hժiӦiٲe^ dMf 4‘%ͭDP"@:&"P"@u9"@uz+"@~9sKL۶m6/ywc=fvq_\pFQm%#O"@["@v}C#PJٛJMQߣGK/(Ϗ>kѢY{͇~ؤJ=TRͭ|fr"@xvGDos:;D6ɕW2&T@2~mGo >;"@㸕r7R(U>7Z]"@u_tvm+ӯeo߾6ӦMQ—_~iөS'裏 LG{ۑGYF US8c@%(&뮕t ?Yr%kܫ,J#P(L:NRkF{Ke"@_5dW__C殻2/ ￿qsT$,V{ V >Z"O>7Ge9QKdܟ*%5q\<*8j\ǚ_k^Uϓ7|ڵk x\'P$tIEKAy(Ay$(ݸ"_m$0e?;ݧnq 68޽ܹ3V pCS>6i$3qDs?/_|avײzGU=K.Sr ߡC;{(?1څWUJ>oNܷʊ.KMT߽u4urܣ*ToJG_wuܧ<ܧ ݣ%YmZ+xgI2[exkzͧ~ZF[{WD2 0c sy%*̞=L2h\?Xy8R2<|ϔ}o7|3 ^Ə뷇Sߟ5LG\k|GMM-qR3Sz(Is3z;wn2'L`4i2:vׄ7-UȜ)S> ƍ3;X8)er, E?SRER ~F+M()d&;찃Qa|;12?x{cu߄)h*i.ZA-5ic E ,&' w4U(oJo~}ޮ];3f̘ -DJ &@h<@ &@h">j([FAfT1}|vyh  eB)8M7aʇJyƉuYuQ׿527ZYﯹW_5-jdMP/@Ϝ! Ί=!t =_7ᄏԩS+lLjCEz I9I@":v'eʆB@񥖎gNPl䱂{~Eh_,Pү!7M@8lذUR |'ecg@ $D h ':@c%tV^xsϙW^yŨ_~Iҋ>|yGK?=!&_̜93pT@a;@ NM|%Sp*y?(2!$B`Μ9QL5B)@Bԉ3iҤT:s:ܡP @ @p @ @̈́"@3q4 @ @@ @ 4ќ& @ @k @ L 4Gs @ D@ @@3!LiB @ @ @̈́"@3q4 @ @@ @ 4ќ& @ @k @ L 4Gs @ D@ @@3!LiB @ @ @̈́"@3q4 @ @@ @ 4ќ& @ @k @ L 4Gs ={_̦ۨ 9UH`…f̙Fl@@^rfB`ڴiヒ͚5L4Fl@uPP!C{|_NvΜ94GmFm-ZT7?f̘1%[X1yTN?StO UA ꪫAd.7ߤ @[Ô)S-LXϙ-@H2^ysy~s=<fƌ͟??zH袋gm|`Νkt+v#0w\믿޼;>@O:s=QO8yO̟nl@X9͙gم^h~|^Wk_:Ί_|E>~/f7wqMI,b}%?4)>ꨣZnmz1%b>裦SO5׿";Ssk&NX/>\wusΉD ziڼ[~ {P[S HкۣkAz[6O7|scu5Vj?>.w ͅz(g[߅K. 6x]رc5\w7гᳰ!d 9|!X?kyk0pe-ZDۧ~vtuz~m}Y(tҥ2~D7W_}@ SDn׷IdMj}M0!w>DN ~zYnݢR{% |ѱK-TЗʬ^UVYQ6m2 $f};+ˆ[uP~ߣ;F{eZ>۷qFmF>s?9-h{MաL"=<駟6_u&}'4O=?~|к,9ysǚVX{>Z=_RojLd $w QL=D*M>\|ŦC/or ^^ ]wݨW﷿Ys5^>=4|Fnӏ?^zE 뭷^TC;*zfPZ2]vu+w[<8'I| W7w`.7  lA[n(xӽHuYǬ{f饗6}׺,"kw]m|lJ&:hĀ-2rb4@C۪{x6]e-Q[Pڿ2,=%oj&w⦛nћ/{~3TFv"aYu*C+r;kFuCz݃K,[chòN:EMhhz08z(Vi>ɓ'Zԫ^HiUzPVջIQ*O7W=x~9GL2,;_A~],Jsvoq=wx&*pֽB)1r2tz ur|ͣ qELWwߍ%j*䪌HT-[DRen)`~U6}Om{1h 7][;N WW*zdZ:C;][{c~H(') uQƂkN)[)eR{K9$'6SIؐ#?FpNk{u;ûTnQ@[6N0 ^&}@',CA$=^rDMܧYK^*gLK gϞуLTRx==Hè=ʯ^qᘊhZ+Uk@Lu.U$jfm?Ήeu͉Y7OףPl ]P4"  - "܃TIt\to(@7+Rki«aŜ_գG5Pnfҵ)lNXuUt}0+b$jBPa굔P ԛy뭷BM^R=xĕW])VRՃ'R7'4~X_7[@C Toj&СCK}*@\#Ja@p{7HtI1/@txwJIֱ(K/,hKJYV:;IP׾LJj QlT=ޫAOT2p]g5$ѫ~L= <8*s(軥z4oV bg+nqpRW8RJӟd:w/O"⫺Vs<:J[sWգ{mX⮲=j[ou$kFD]%&T@!G~06ev*CKϳY׫ E?DO |*hzfuv|S4,V^ =p%\2=ſW|_ߦk'ީL6DS/15  RY5~UsNqԏns15R9E3It3r_&.(Jw׷IAOUPnNz]OAn>}DK*) .6@n}[UL<~[ݫkzS] qTn(K}S8&ԽU=Jm]Rk8U'wBk'T s׆~U ,6@z-ݰA^iMS<`覔f7@f=3ϊeh<7LAs  !*xB%1 >SzNڣg=>N[;E{WF㬞wzkᤀ=i =ŮPQYN:9Cx6)hv7kFƥ/qj=-mb]Zph(DD,hԑ$͟"D+{~K$V4$Hud ]R|}]Ѹ|Ұ/ޝV5Q)yKmK!K!ä'M*צ@tꥊK7eqKJ=Ԛ=kpZJaaJ`A=*E̥éP+ջM?Hg"h:'h89=XQM={zz)/&(W>DZ |JP6ݗ|*O`D>i5qWZ҃=M7-O[shC˿))xm(!K"^MV;@A `Hᆴýګh&҇U=}U$ C %V1:vwGx^,@bg2jگՀ>,P{G~t)AmRXjͽP=J!׳U4}o,V3λD ¨V @*, 빫M=^P_\z Tg=^WƔqtޥmcezvtV>S6\D Kz.0 CBzJn"EϏ~.A"ڠ]c: E=}CXI,e][tWM"O uֹ;3=q]Ž7lGuWu4,-L87_] uXֆy@NЏҼdKt7 HFgq%Q7*J*TTi=hVlqq^juwN7QI} zPonT2\H;>nJ)`p"{#`]*C 0G}+^vE='] }P&jƃzHC:'N)'(ocV" T)U0G۔q#_{¬j]GN WinS*u1nS[LSz[b{M̕g" GTz@eRǙ8/@/_C=u_Xuֳ˄==YMK;^Ql 2na)v+9i^ eomzf,]w=u_uԸE]9V׬QK⛘KؑhA]J 1ܦ:uW  $=(խ܏uS3TorB9!Liz8UϊhVPp^MX[ W\yT8|ɥjVPp?~S/RCtOR~O:/'% PߦBv)pמxi_ ԣsD~:ΨS..Tt>W7  8kwI\ڼĺfpjآI$vh}U2p4t/X,@=ܮbx:0&^g9%Mb+_כ t-V~,סV^ AOӼ~QV}$Q?lK, .;C e}5qzhY=n{[$$->@]z-EPրwq5uѽ\0Ve88@=Mny@=6(4'j"`&(ܵIwE FBg qz"(`w"iI︞EtM; P') .?C0  u}O!?nw'6O9?/EPNePXX(}M@YŠzH&QVk/eqbt;l 喫VօkS@xB>gDu:Q`p ‹m(D/_u.PW9~ $p35]s5~@6/aC[I7FL&@#q|(܏nFlK7mݰ4~P3::@܆2 E2~&u\7]Zvl4&T릧dBf9jnᚻ|@h Ew8c=>c\y睗_هd&8l(=b~aܸTnŖ}s%֥j?ۜj=D HUub%7z.PP[a&ĨbLVT&V oe)ps4;xچO U07:C S= ݚHnJWLt"Ld/B#&ᰰ~=(˯9Bρ.{@Y Z]/RXlKj|Y=UR5ͭ]_}\C@ЩuЧ؉ $Ebsh8BazzМjRݒf ;[׌;"{VMI]iJ).s@ %UJ I.@m<.TF|Ne 9 u=H};^~ULk>>1`1.EFpNM( )M\!@-Ϋ.ѤG\P_iQ8I\=Fo?u!ӭҠ1d |&ݐ F(JׯLϭaTrDRREnN*ច_ Qlu$vNpOq&>Ӣ&ĭ$2rJr?D$iRH>@?&؉E WqV*fuJ銫zzW?fj u3RȜ0.C2SyJr"~t4vjqs8 P@Pg&}@AƖWIRpzVCO=L"խ3L5:N! F]iYĆx0{[w\J}XqAڨ&6}TTd6UW>@&u{pDJW _VNzS͔ =a q=M}o5 gS,4.'Usņ'BV/E<ܳLS}_82v.WLJڠ >^|qC4G%%.'I/tn%MsӲgh׉%KW|Sf%:W=:@Z*1.DRm@܃j=Ńqh5si|MX7I0P(G?kT)ZiXR̫ g|+A?$z.6+K7Q-D P 5+8֤kfij,a=Ks~@M[nnCSР?.=diYRz5U*7i}M=t [xԃP׻Z잨szWج/ =yNi6xگ龣/O\$wZ.}O[=zp.螥,~}mMUuԔZj,W+~?R=픠{Vx^w(SA%qSDӴPx8/CTҵ32!}IDx^|Doe b 5 iR@\P9ܽ]Ϟ:6+}Uu^/Q!>^PA/ ѱ&5^w(Y]9?Le]|$5lMoڧ5Mr ^ pc#]CNWeF)KuSIqiACGCiA:NS< w؃/WFc?sgB13L67.=~i}{ ڧt+dG)Y ~}>hCe7^׭wBK dD@])p T߳G߹wb-^﹎k3tuK(q Ÿt*J+W] ݫt|wm7}Sy}UuXw)ߛt\]\3t}v>EGC|T-1{鞏K9!I~$Mʂ @ d"@C @ @I@H&eA @2L Ρi @ $ $I @ @&a4@ @@IY @ @Ȱsh @ @ IIҤ,@ @@ d94  @ $D$iR @ @ 2@ @H"@4)  @ avM @ $I I@ @0D ;A @$$Mʂ @ d"@C @ @I@H&eA @2L Ρi @ $ $I @ @&0r i @ "[oSN9Bo}W^1s`55555555555555jb^x]w/e <^o_.%4P IENDB`^$Dd Z D  3 A"b#()yBvʹ#*n#()yBvʹPNG  IHDRdP|gAMA7 pHYs&?PLTE     >>>(((444:::222777<<<===888,,, '''555%%%"""---+++!!!000///;;;###???...111$$$999333666)))***&&&GGGRRR[[[FFFKKKUUU^^^OOODDDAAAYYYVVVQQQCCCEEESSS@@@JJJNNN]]]IIIBBBWWWTTT___PPPHHH\\\ZZZLLLMMMXXXyyy}}}{{{ssstttzzzmmmxxxqqqiiikkkpppjjjrrrccc~~~ooonnnfffuuulllggg```eeewwwdddvvv|||bbbaaahhhzIDATxw\7&A D[ܫ*Vm?m]ujjk*ukժ\(.7AH4@}|% ||.# a !Q7G cF;刘#AhAJNw *Sӂh 1c=Y|ZD̍6̯_ծeSq ~W+"k[;"Z)lmbI"fF a[WK %9Z{?01p-sxyd<)YT,k(s"ox٫kDu<V}TD|HOy1'KɲTU?8ݒ>Tr]Z7"K#jp1'gHAD߰7o++l"N·X9QpOȚ*}ǁ\哖a >DT (\'I|R',][7/LE$J@Z#6؉&n\,c !r޽Sc"%̵_&z%ouM}{5ޗ.N 'grw孛OuNAD"{EsHyse`-?qo%kۓ(ak9r,#{CMC95լ <há*ݫ` |ΊS =ċ&,[HdLف?{PT-YSn}jz}g ͣ׮9Pb-æMTZL4 " ׆ןjrHsD}& q>hB-Dn4[x/ O߸)ڜA0A4A3g@$L'1tZv>Dv~) ȕlVk"^ #~pڊn?D"; f#i׶Y~7b ȍv}'z(ډ@$L@=)8i9sD:yY~, hU8pHA%!ǂwm"aLݷ姛ӌ )`Fj H| o$ LเGA!=k邺8"'ɶH(BVJ* ȉ@g1ÁZT]h?  -H%N}cC Hxe3"k;E3 &y_f H@ݕá- $ȇGъ8B, ܮyy'"G BNeYXOwR˃M"G k8JCyS@H ؋*tOP@H eǵD؃Ie)[. $bo\Jai'nd"GIiF.$h&/&j P.ٻr&/&Dq J+%K }=@J)FM{b6nJMm@J|0 %P9i ȑ0hnC#1.צi8{Qz(䝿Ktw H@T+)ʆtMc|G WN 8ŇyLWUL @M@s{'e,pIzПBKITnKO&Ɗ ndrfB= 4LC'Xwׯ[ҪP5A@/vSVWE' =dm\||J3@̉ddx&O  <]?/ab  r$x)E3 &ϓԅDG"7+^ņ+V8 )0tc3@Fk@C  r#PDQY 2%99Ϸq ȒpREl69s@9@HJ}zgw~l{9Xz?$TDV*ΫP/@HFw @9!_ȑ8VɼF G[]E $O~B6m l<}* 7 #/m"תKAH`=Y:Wk r$pݨ4 < O͉@@to}f/ 'sۚc $2,a&L s%hիO 7qJ #h8xðDeN  K_"$NA9IĕV^ I#UvRi."r0'I/~$T-Y[.@H"ۻGT9e [77r!uOdGdsJ似Hֳ^Zg,|bB޻uD5u$gO}r7ojU0k ' %R%7B]^67S{ÁHN@aއ$ @@bgVq#PP`5+f F&ox;9|Bs&r.@\Y>J+λ\r[)]0 R']|A6.**Q]舋 'pɋZv<"@@Wןji7@@֓Yyȑ_Cŷ6.oR" koZXM}e P| ȾߪW4.`ꄫ-꥽ '`\@@@@A#ݖ96*}AH p0-m@dM`_]բ7Ĝ#3 ~\fU}nȑ7 7#E0Ț:!hLQ"yݐ r$Phi^>($وݗsmIwt 0Cs5[+W8g(ѵ ; O՛e?u  `vR}\.7BI46/ڐE}k&#IJ;#Q0g_ed3I1(@[ưfP$$ |Md{/^D@̍r<Ncu[!V3"`)OϏ6mV/~?k,ryalCy@@BiԢϼ࣠*1v 0@[9n iS-jX?Ŏ*|b @Sݭ}#PZB9dH}(k[Ҏ@@_VSH*aU^,~=LdϷ7_{@N1M3[Tt;j1{ dH5(HP,"s\,'JRaM6Ks"Щm+jCUL7ZjN!ɁHOyZ?`,z7~4 `VZOa͕3 +™3 aOSQ  a4ůf@@ԇ CK#A㟞 r$p!z Fȑ:r㒚V G76vAHPsWQ5 G+vo/@@V]0F_dI@Hψ$5)h[ d;ШB  q!@@zx/ @@S ElHZqlu6?тȑZ[t G~wফ S. S^`5xPt  G#BVeg]O!%Tސ :XK !9ƒvpɏ4g.ws#>Z  GG=TAHr8FcX3&r%F۪ȑQޛ4*E0A$N uU*OeAH@sl}#ۍ[L(UB R']_*A$NӍ 'u p8 c1_Yt暘s r$p=|@@@Txȑ@Z! r$`l@M NhMm6b .  jOѷ( t$RRȑz{w(+WGgd@̍)f줋j8e_y" @4 }H)6S@̍@~ ^:ՓT >@~07ҮZ7WkR  `ьD.|Y' z-@W˗w ~D6!$*{칗'P䗪I%33DX7CD7JqsBKyWٸ9G%G@͗?zӎ2y jV2&/M n\P{%n4и9!ZQu\Lf5Qu ?dG3/yɏm$ˇ|B<<)=e SD^/DĻ7{yUMgDgL^mUdl9'zC슛@"WUcczEK#.z=Wd_kIs{d ;,qMN/ch!G@̞K^ۅ7 uȑco~4F$L઩ױ̒-Z(u3Lwqdב^u>ݞzCmROb48rhC߸xb^E]BL+%  Pt\ݡ&;ޝ/ = )3YIЖ} k\|Q> }E>ͮevD:X{셥ytOݿ:t7ĖTh/~ىjTpl 5 ~_P`ದZR(c/hk_iRu׭+}dzxwN5]*W?$VUmy*4}A,J%5fDhNۺ>1*M`q,!* -@u-PA\JWjuW^[UEj)⠁yu;΋V7[|;Kgi X}|}{xU&Cڅ i 5ѿu.#sF kA8·K߮U$뾾C߬@Q?BUp竸&D+k7}}}}:L[Hgo??gutМ*6'wU7űcx\{%n{&{'X̛ߩ ;9MѕG [[^t{Yv- ¿Ś4!`QD>i|`xP^!wf*jhn5bS厌 iO4iՉo?J+/ ڃl5w1gb.@or#ߥN/4kՉoanP(XiOjo)T>12"U2 `diaд'e8KNްުD Ix}$KBT[~ż穩qnTZnWruKAZ`s]|UR9%ro)g:ɘDӲL@K`GV$nR&.Q EѣPOU9VKSƉhvo{sB1Dkd]_-1 $ #n5V̷x(&\ݼ$9>h\>9&G ,sCV@"8cc2?ȿ'7}ӅM@PQ5?+z^i,U,2SlFO@<#9NU]G%*$eeL@7gFs?pOM i@?WOO)M F./O`]: nm{uXLk1w-7QyPiS"^):F@ʩ_zd8B,௔]Z;nS,yXNNjfWR\~63 &dl{TDOx.[Jw/[#YZ,#JiN^97:" SXWMzA| )韱*}oU٥ c9Wb=9wo6eݦ-?}8vncq%g%1ǚ?هԡ~~wy~pDRojd=(gSρS:Y\iw)W:~8< YJ$aϻm"zTXtSoftwarexsLOJUMLO JML/Ԯ MIENDB`Q$$If!vh#v:V 45/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aDd D  3 A"RQ onԴz\h-F% onԴz\hJFIFC    $ &%# #"(-90(*6+"#2D26;=@@@&0FKE>J9?@=C  =)#)==================================================A":!1AQ"a2q#BR3br4CSs!!1AQ"2a ?;A-0K,%xb]l l"!9G3Hbۋ2F@VфFZ@F *I NLzb5`\ziNLD#J6K'or$i4RbXP~Lb@E $~ 4ȠZMI*{Tŧ()(C}[/>#;jdTݨܣ@} nE*T7dLSM ԁHxƤYc{F*hw7؃A Tf;m0 '/{,I v5@"rъ/RA8Z\W3g*mVWCODbzAFOxYJ5e;".EʏUu*~$ !hCяN=0.$Wgѿwe<'ѽDW0LJlY RA &mrՀPZF,H7 -•3VnIaͱjc +Mh"DLURT Wqf[İ$ljm4AAws $ 1AdI߶s-6xY$ŕ-;F@Ȁ("\Dc5+^91V/^kDwcVJ٣u-T Sj1b.OQwRr@JFV+D:L7#W'fSj]y&K27C MQ 61CL,=L[0!(" Y]eZy;%ɏI,80HjPǸE:I $F&0[PVi"] jOj2X_2aJ#d;M#97*OiɲG\I1xĞd="dv'yD0g{yzN0j jSCGv1.`~ r*DRm)0 `s.BϷWT@bZR5C;GiXk N0iL1oǮ2G+.~#T-qQG*g-9-6mci 55a_jc.µ%h, Bl`LU f6}U7ꈨ&0 0@Qc$]O!Eՙ3-w<8*(m`[PT1dnḾ{ DrLڥ#tWTk$M06) k`pQ$]dA )k;D$fzEOɆbLrW k er`]}\2k5V"5U|0h-\e6"zwS7P6L&- ^e^ :r39ҼtĉhYnLEb'Md3$8VBT mLuP0?TBZ [k0##m/.q,cZo2CǃWH2^6?2;q.REP"WW3FۘoCs;YAmG8QEja lvv ;ZԌv`sXivHI6`Xɀo@\ HCɎ+cZvLU@]ȸ4I?X2Rp]#haH``c1Pk* [Oi@9>!owhLiMK$&y;ѸjDSb@5xmhKV v ٨u"MQ j5ݠVbm"ZDv`%Ojm6䍾ewXg(yi aiQQ@ S^ P CM01p8+Q`'Zh Z M0I`M3n}MZwDGH${S 5bQ4P;Aa|XEH G[0vrE,05? Y d6['~$" v PcYs ,+ B)TvdMD@[";eQv2wR7:SDn{A,QuRXAlY {{N<Ų5&Q0y @̋CJw`Aۃ Z1 j)P665(e8LAIsVIf&jG F&M;TFbX'C/VQShC >$Ā 1ޠIse<&@q'Sh 7ff<%=.ӧ,6fNkM`:Nl O}`diů) r4/MnaSA8>εaF5 #Ĭۈ`ZQ7QH H#鬩>$aȷAr,%* f ]s ۘ4 7Zi hKmdLPSRtZ ;%vh@0:I6t n5R-sq,AT9(ݤK_Z%m hc6H t۶@LW缐F%dMW~DҚw]isLˮͤU(b8%EwjA_')0 YVU IJ5rĜ5 z*;ilyGNkw1&9rȫ, IHߣ HzU W40& ilTlf'+Rnf2>fI<8LFҴWuW?$wo3!!(bf*KaM"ɎDV]㱢<p͜LWcqđ!-V(p`<>hBoBv"i cFiUmS b!C1Ŧc>lw!ztH.9^|.B˳6;D%t" Q&9=gīQRM}p][$a N#VF7F+{Ïfs ͺh4We]>Bw*w"; c)4%xwGs-A0QjE -T74z;׉F-\2pi[c̥J˜4sH^95 |MјyxFCZ;|ʘ0G( lbXG+#@er|Lx(7=MM.seH2aHT!ȶjŎfo$+ -f\r!CyPDI2h-cM7Pi[Q&imMT1_܉@;M'n*,Z19']<\*l(kotm;#& a+!%XO0Nmjwx4@EF"3I-3@$Q1)\ E%z NT,o#snj-hY}Po@ҍ4jlXʘ[bLo<\Õ?!I*Br4x')F Ԡly>P{;]{y${bj4W͋2E~ 8T݉# Ap xA*j1s> m$ڞؕ;ENf3.(C $ ב6NKMBGO+ Edٲz{<:8F]r Kݖ$]b4vH "}WJMM*Ѽ$ViYxWr1ɜyg2de$KI)kԪT"@j7D~#S%U|Mdm(lIp =&ƻ ;q0BK  ]2g Ġb`R(yV0Lbm*Vd!a~!f'm.*4{mb]˥hcRQr1#jc$s4UQ0FQ{(##Fڠ`ydq WpBw$ibF(z~f}ݘTSػ &ve|+B z--Vq :XU_V|AAͫ\Y'jLim,YA6%R NhވM3SBI#mPV5FČ{/acqxЂGyE)S֚h¥@ UR 9M*OqBDw:`Ùc!In7EoA (+ ?5MK&(( bMUbGa$ i|Q'$#G:JYh5TlE<;xv4"j X}t&g~J] \BӮJmMdZ5ww [c.!jmU`#a@ @;&6'ҰE$}ޑFڮ6b|lrk27mqy36HL: b(sE4r; @eΫbLs-0]܍F#3M|lpp70dc0szXWC"XͯLV:A1O ~|]:f-v|) CK^ uxUZ'R L9Y<GY /r }S>B/x|nVWNXuԌH&Y7m9i9/S(;XLuCpoPW'q|9B$C\X7Jw-^scJ0NF Ndi+/ ٜ/ء[dZ'[Ѷv8367(NyIZ;6z݄9u?#^ ( P#"^:Ebf:l. Wque7Wڢ 5iYrbb^v\ɤo9gIǧшY1\z<ܟ?R1ōm8WՎ.&scXc;DdvlT ]aL鎼P7NS9XÔRazX.`6q<>ɥx}kgTuuwASO31Wɨ`lǻ̏/vaqFLޅ B@̙3Kbns^sTn'v;䓿yD 3&Lw宍Lqd>F~r\j}ܢ3Q yև{ߧcQ27X> ܲY3Bqg^L?@./K8|bצUGoٸ^d ,~D3cp[41)xL@B,5/VSR;qVR5Zfmު5I}x)ӕpA<~4Z2Ŭ{ ; $EI 76C0F`U?)exBIkQu5kdPsJ>⵾q3(:ضȮGn!2F߿ݎq<Ǫ8.GE J(tOP{ke=$&a!@<ݫ] "Wv)fFx7YTyWIinCԹ:bK~rPglN@+xVLtc jW@ʮc;#7df2\{ށlc[W0-T'x<-=BRz.T Zq5NTVv /XSc`P̘rEYU*RHa؃\ #zP"s9ʌ t \<]ԦE>Zj~Vr,>Vlwމ:~O'I/G: G,Oj| l+">k(#m## Y&+R.|XgdrlNn6,q & |} }'Y\Z!u}is߃p땛P yfN U#qqƹK4 ^kHztjD#Ncm#ff+s dBI!nt$XOtFOI}AƤȲ1?h<,rtD A<ī>_fdžak'&R\3!lQ(m؍NWYGNN̻ ׽"reJTIbt|2{gQ IǓ>t?vPmݱ.FU6lڲN}[j?¾lccSdLN^ Qc¯7.l1 VQzkF@9Ki.)!jqQNސF'$t| ?05+k:20Rܨ?iv5uf 1Nߘ8~"'،HW"<6zpkie}DLK@*OCW%$9%I51sty:g$( F3G%y"zγWEyt*EiQa$*]if뉪<-6ۉPWq.-̏1 $ ~fF1ZvEIe.t}(t2MpKD47vcőfIB &bAe,"k1#dP1";$=Psl/ B-y1bM@.dB5ȅj:\)IN5EG':RXqu^ꪗmnrА|UAꁰ0 >grNlCj3ؕ[jv?Hԕ.(FCJ; ^'w!qGj F`bϠl܉zٔYF*U0^=y 7Q&zb>ښqz|=B*uyΫnʓ }\uatv9GK,YKV<> 2HMx_+=.o&h+`]I XY;%P+OQ3*4g2cNvŖ WDCL;Yr29(c^e@8xBF4YTPbJp&kt+ĚncGhȗ`Vw76}P" v$%16eMvNT Qf`oq8߮㫅a핣7&;Zc!Ao8;#bvb9Me$jP6R ?X&2UR }JXE-{V9hP'g[*5:,zV`q1㥄Q#q$xvWM7Fɝc`TZ1:"DɥJ*+M0Ly[Fk`q G P'&!1<ͳu4P8{-guqVԫ{=S V\m_YfC,Xмx^ZR2)xH6LOuqjD&0Np.b=YEBk7-^7C$ɓzksSngP{1H-='2:dnj *+b1E 0(wãiD6P4(?fo& 3! TYHb{X%ѡ3=C`;n55Lh} k[0B_4aڤb}GR j_`ЄU/ҮE3C؀6\TI?hf >fĆ"ӭe#؋8bP 9fFA?>5y> @<J盝 *h_++imŏ["l OPEqagp `3S0~fAC'L""NuTQoz}9@4%JvcT2桰Fn@ydnj0Vzd>&I.~ d>تZf%хJQ)18WJXa[a`sq] [^ <#35uHOnEc9rqmr~JY[cYңP@ZLe3]dQ&m˕@d<)Z H5+t4HIὣi71TXJ`o; z ~tI maczJ@,`ߙPWiS_<<ƮC\nv }HiA챿bl8C:HcbeЩؑ00NW qhukϫy-_wPA(oRr_#ȣZ=\@)Ts8=gAd{O?3*iRSIZ^ȹUOw?}_hTl~~&=hq;UkYw P2!d?rd 4S9I;CW7Po?QV(m$3h8x A ;MaskcdV9l"!V1+U7ӀTfgjH Af/Ÿkq.}D5V(mcmr|Mf'䊿goaٮcY@]; 1Ri+]L+O  42 *qݍ~$J1{edk0j"h1 `jbVTVajIEG*dW@E*=6Xx]nF'spaRf?>'9ud4x Q#3cg崬4c5b8hΛfWMGcË@1T"n%fōo8e+hҗ )ĵ`FP` z+%X [kRB{WˆBaN>DqfMipdb5 1y^V@ @}N;uҔ1]CbǗR r*ńdG*x=RRseV:R ,` "Yo2l9Qfcz$BY>lt*`8&OҫH1IZWNVe H"}C~ Xˌ`Mx/t'r Aq9f =c(J]1}Jz]Aei~Ѵs+QJt=ǽ4K)& ]"1rb9դ By٘`H$kf'Uy9k5 g2*dD14"*FNmsfEbhMñ ɨ)65Tˮ9C Bf5nBS(N,BN'E"wT`jOL jXQZ>.H2%1th pXa0"wnL@ԋlѸs;To5˦T+Ni ݤajSmn'J[8j'{J*x~a 8vq"?k;M3PQA@ yGagN5:pRə=T{Fc\M: I[ `pD6Wx8fGaq+^MX=4)ޥ2(QI ܝyAoIT7!H\I5 C_."\qv?5K| ˿(f{03QJqM5nyH9Lx3^WI_pƪP?Hq1B( #a1 }v7ĞYN|2L(pYZBɖcZJ|GJ0SݷB?:x<ʼndnT%EBQZMdm A"PlQUDK-# .~#?Yn> zĵxzMIRٵpb(C8 o?2[M.2[j'ɏ*M{KH5:J.́[HWyӥT xke3@?Nk˾;JluT@ޡ&\jEA 4n7=&2P,Ԫwf)[&kEqY-;00q& 66̸Pf;Ip 9PȄ p"f{1c2lcZllꕬ:^m.DnE{CZQOW`;LkyMޠ,B/>UcgPFDy&AR0-h"ԻJ*GkE1wsy , 048MO˨d΁(I(X!>1u&Z, "&(vE o9UH'c:y4<ɩud+K SH1epOpi }CdPQsz.D(ɹr0eO[TmW-X$N%8Pi#TTPI}41 ]@Hmb3QZb0ވP$"s Rh鉐6ʸ"Ⱦ.q"ly@PG5.Ltx꺤^s/*3\Kϻyjps rEJꂝHlw3I3@Z1Ô&R{x~FM]GQpS_ⲩ[mjB u^.ͨ7ƪ,3=8>wMO3blY.ÅtwҦC༄xf .fYSǣYqK [ ݶ}L])cFs !( OZl!DmpqյLSO6 y5Ǔbk"{@Gk o[߼`#Em^"79v;U\5S~fFITvF3%7QqEED%^7(H5v؜>n䝦.TrcuȰ p&PQbI`MǸfWjҶfYd;BȺLY@K69u0c`Xw=߉M( $@U5jFC&p"ke`YVnmIMc޵X=hSlLQpw! l!݄]dӾԌ*B_A8ϩ:$?Ǚ&L8g$^ VL'y.Lܱo&RzOkds7Xejת/yx`KَMjqgGv VDYETWպN/&l6V_jFqb#7QNTWNhgȧb?Jz츑.r^c-EH֮M^.x,S>Q}SKrs#-l)3h6OcXؕ^%o"d5%uCmiN&P[kM5ш@B#[0f De!+yO-\OCpkϷyȓP$yS(2v&ܪ~iZ61QE\7!* lLӷ̐2|}]bkIh̒uA@F'sSտNcD~1Mf@ D*M @;qM֚<ɭUOh (.@k^ձF>2&q kY=6e6\chxr.QӶ,>'KF# `׭|c 㘣D͉?8VO dRk՟wo7r2] AAX~~1S}|N}G.,\J2d16\~PXɳws_LCOB{~&/Fv\8 +p{ r=X Vď]Cc*I[uV:R:MLޛn_rڱu,IE .@9eai V(,QY\UnIra2tPHfb0L׼5*kUIy&Ac"(ņ}xAh WaGp!(=#kKeZa.`]#hjH`<aď@:Ͳ i6,ښI2d;esR*|_j:7$HuEs3uJYMNLbi?X_8>!9Q@9 f~bz7.1ɉnܦǦv_^3;d>3Gc2{vNUS8Wm꺰 gJθKfqUHlv3=P68` 7Fj991G~&&]U䉸\;n\С4Sc,Tא:qtnQP *đZ P2`c2dj!}$ɚKRC*Q}Z#Q˗8fm_maQ1ԅ .u4.+}pLi NӺijj|IfC+USI~):%}m sgزkMX'_?T/=u=V7BU~\RMbĎ,5y>%]7A A}7鄏S6OC?#c}'6`H[`SȨz="dsR؉0rON/9i~<ɔ" c(!,+;2iȴISiF3VcR@ BP9ex> @sEF;k Xz}q&|EJ1[s1J[S#J;.aPHb!(s$xa['m?ҟom|mImHܳTErZrԬ6,ONa"[1C{˜[߬s"06NEg6dx&oj9)U 㤙onǮr$,oXA2Ն)r|@RhcS;'>lմ xv7sT|K.a+V?szz`,w]J;?7RC9$8Nz!,3HF)n}7鉏ZnVۙu}{;'GG ʺg?>6'or|swXMfg=g_s(lhy^$9OOQꌈ,ӓD:_Huimw]O<+bF͗_Loqb aY -,u"v3qU1gDR5:r͵OSef,H/SM8;0rÉr|~?bEϜBcgyqoֹygւ7bUItMxtOtWX9?Abȩ[ŝenWN\g)3Mu03QҦ 2yO6c)a о OK8TDOht2^-Efgè͈){(qd݌z}3]ƙi#{7=!ȃc,a fl3k0ZOhC b@Jn]({>,Fq@62w^Jw)2~{o5ob-oq˨5' [CMTmVNF]OZfo7۰5ym3VV*vdNl"5ɛIbw|Evk}FPMԾc5%BR vWɄ^VB Y$1cGj(҇4zV{07(s\Іm\Fl(n{Hޘrh$gbhxK(؞S>=>kG}=NB#q֑\w ɱ?`Bj)`m̐9wMj('HsflRSN?z̺q}̾<7  MfcҾ-k3<'u5?@@HC}?^C,]9(\7 / eޞ?'׻F}_J=])O9~^!q$/_9X6l渗!H0 mY{ R_3C&gf|q7A8͖QyV@/R *\ϕvxJɍhкn2㸇)ǏIqQ+Org;^ 9VSg&#?i-ccOR[!}h૜RLKPm9qcÐcij躥 dˎ-\cn 9@ ;{ׂhЀ4[%V[;Lq<}^*jIz$hPMƧ[cK#SJTiޣ]z|\2$vn$Yla3 tǘ"52-,V>j) 30bs]#NGx# bT6 x5 CWZu"0*y$Vz[L):@mr-^j:wʞ-,K!P֍trm zok]6Z>;6:x:Xˈr "yWOv1y?~ˁO<Ռx3_W[Ή\ט85<\U,mR}tRDN~axuaK(TVT"s'uWIuő  Q={,23%n\:pr95Q]?LS9-'³gZI*C-vuMH~^.:Z~VȚq aQGC)a6=I]ШK]K 9:&!tOM'P:Lg`Ƹ1[gc29_'Զ}J }V^8R 49c%WQa֝cF%,z|"?'Ldv1`\zQ'LBl= vvȨv2MՊz LdU6H]{ j*x>L.?,ưh2e>]ܩI]"j$It:\_̛2 96O۽b|y% :XˁĨYw@*F2:NX@("5w13G$izoPXC:sV%Qe%p B|Bw]GXbdloAk{. HBJ5q gۗcrv` b%NWD.e8.Eti`+V*#.1P.MPHVμn^n^.>0&3}O8_sqQǕ^QlcR%aax"ץ?I59qKUa|MtB:Aܙ<= 8EI_p5_8ljI۵\JԀl. T0` db(ňڧ.rz 62"r/n8_H en.\??՞۴u鰪aFU 6q8D*cc&<2Hj+Ŏ~D6PAI!DP#F!oĪi@H;%j'")S^5E8 y 3&̒vN62Xwc~Ӱ޶* .<^I؆G[F$Q3]8hBtreHٜ1-iVa"1K~!&)͂Lr)+$\_89Iň0䍧c)NgO[5tw 'yGA*ԧt@澤>Ѱ1j=&Lkӄ]&5unAOy5-FV2;zKM9:"pdRN>ƨʀioJSuJ)w59\9xcCzg4sK acpYĴ{&{||g)~1҉wu6\`5:A&* 7I4r<\EUstA{i}Uv~4TCbUr0?jTWoS(..U&uCx.T2fdBn8בF+׊)cQ x&7c{% 'cS 7-Sg ( aLO=?f)I)'SP#:6BLET.exkD]6Jo:ε'єLc$7-iNLDA*Ĭ}2A;|)Ƅwbx=KNڈ /aXӿ=bkf6AA{&6`Y, 1tת0lR0IVtzFQ-Hr zгcrI"sr%tqY&_B yQ_kojF#k(Ct~DhٮnskќwuBsW2bW~<>bUMcR CA G8ΒCȋɃA463|ΟѠJIG^%\&̊J~ĂF\z͉2G|DV:R6-Y3v!;;{Md(ԜJoHSFUxa,ŌɥcΧ D48`v `QyTZVi>].G^6$i(89xYFM?Q320lNj@;BLC?kN^ J[Ia/\l5#:t kZ׳u}ftG]I2 K,Ǽ73^r ęl[GKV)f q_?F+WGЮ$P({ M;PWXalyEZRoiLH6|dgLsfH'r~'q0l G!q/ѳ:ՔKzeoT33@_ ZNR/f3 ]'8؎gDpv 3L=1[6݄hRg&caH)GR'$U\ddw2cyQ\Du@,(3/|BĆίrR¨|L~; m7l n=|BF,U&͍H)KH-&H]M" ୶H 4N᪔co T1s(]UcHHclOZmNE.QQbXŒ7IN"* 7C #"Y/./SVi8*A7 ץjgH.Cc2;7;4U@z YCoM5y.LIҨZ3ހaBHlGRic$@P6NXS~oP8Py*t8iM4x8k-lA㱨~fB|v ϩT%mAp (B*?N S -)Qhjǽ[4I[VtG&:cl{m:wDqlE۟93K2J(,1M.o+ebɝscve`yQqVt5"2GX$Hܙ[Gǩ~&ت\`VX-J6:mk *dyhf G;8~$Y2%FqrF@ ͮS,IɓC vFo @Ukr{7V\{Lzc (ؾ2U]-GjȐaH\"\I5s $`Uf-ToO-lm~N+ Us3cQF'>Dn;ch3롇Ke]GHV$y> p1}@˓F"Qje#BAYe\ά'+9<Uu0pG eUo.'ѡIbrmn7I @"@5Q"#1fBmЕ5,1zX_Ch_[IaCE/oa g vߴr6 4%hP Jlssj ƎZMETݦq8bTՉ8/8 f;Jc;7x8ܑ; M g O~sc a<|Y1@90F$ LL=x5;ޥ ''ēJX1cra@f`m'R{㑽`xd F+'z!v% EGӸH,Ime.,"MJh#oz8]"g(LvkFbڛj!iSw{\)VHvAS:l8$9;x?׽4v< jTJ("3"e^edՋ#X^@b;욵SS?w@W^$nV͎yiJE!ȗPÓVnk57(ԙ (9DE98?nFg0UǍtwLb>Ȣ^ ekw-ZKٛYusDl8gn vm-ybYjNF9d-f1N ϾY76e9ĝ\ CfuE&E[1ިt(c]AU\լ_yP* ݤZ:ˠ{wu,92<:O2j$9R}bn1JӺV>k~#e7}֖Lj\`Y;X~a[ N'O@d!{I5d+$5@(>z"K< 7SZmdjYхnZY_11_\e {2q)Ƕ5 nh@?#UIk`J5S@䟐$tc|A̓T`(tv̒]PLқaY bרq[@TmfdLQ~=y 3ZX-i]`Obw${BeDEi2&bZA{{ d=56õ 0wx͎lv3ZH< V@"*ϸnVIu!Q5*YZb/-8Ԏ܉lHl$颲gA24bb*VXv$ZZ0j "_P+~(dԤ @W""XbemU-lL Zno=av,̙-u7h-R$d-ڠt(Y"Kb-Pomm1:sڦŇVljI[UBÏJ~0$ eO[Tdd)_n{Ns7eYOL[҈wWP=(~gC+\L$w+=jLf4 H[<&Ժq<jcYVSYMլe\f?(6UGاOb{͛ _`ڴ;p87+{3bJ7v7Cx{nc.5#榑 5j!1M971v$c^#Gv52f[`/ 0J;B)7BDwXQ7.E_9D+{M)`HQi Luhi R>ib)\B*1h̹ݰ̡H:KtM'D TN;Cy7܋TY@guk\# ܻUq:<`؅6A+;,PC,Z`y] ѣqybOh%wH0Gy2NR@),oiL.D9:ei3v@Pu$n;T% ίP>g#!qʷ]C0i+JgOH4VX{& &*4fṽ2I|1(r#b4wQN93-@5{Ò dʌ6K #R'9IwTS 5/[0ZNC d\0y3 iF[2F}qI6$`lŘ_xh5^JIIG9l`!/2A\MrR(qQY2ܐ~$P3U^,o+ ۙcɨ1z"!&ljcMMQs/vb<`}gؔuZ\VF*JOnbl=![RJ@C9kaB > 7`܂MT7e/C_riKmGU](6SLnG (Kن@ЀT*"$b"UAͪ/lyLʝ3H$h҂W0r\# W+ wuérk[̀ґm{;@zAe,S '*GLlss KcSl X ƣ (n' 'iRR[`;cT?Y4OFp ?je[>%r6Ǽ5MAU2hÍG&$=*4lb2j8{wBAbL}f:[y1N m9Ʋ#d$c|CIAKK0 t\nT{wLD¦=]5;cf* GUoZUy ؍c\[g&=jҕc#XÌ~gKΒy_.U@3Tא WN+PьT^O *Mh̆@@F_T(1W0jqh9$PGH5N6lCQj\ 3 & ́P6 !i fbNkɄc0+=fЙBs* 6[ͨfj &Ư"AG`;Wnъti`HIM&'f$UܤSv7.aY}s{C@Y!^ѶK6$=i'`&{<<ȚwFڢ.0ԍƑ )Xt6 L@LC!|@)]<~s@yEZmUmսƄq0n,Mv;@'OhI԰`J>f XkP}*LVl[EQ !T0Lԫ2n#Fu9u*PPW&@K9bl$Γ>{q+&!ٷ !P* RoV\Y3%@v]{{ьp12o|˪D;\xºuYB!UA!v릥rOn;:2hl/ mx314{GcZj3`݈V"@AhJ[~iObPc6DbRW$4FxѕdpvƻUo@kl(BJ>:f f _Ŧ#!._ h660 o˕AQ61.*(5sI2v@Kόiϻ{|NR '>=W7M`7@tt:|7h)pޝA6 @~:3Yq>mEO6#\^@4ț!4c1r!FQbO^ncP69U55zӲj˕wf#EU>;8H Gr.-R4RUqAn q&xb%P$j;vZhl3SiB `n%^Ɂڷ@b,ѯ\eݶ5!pU''cGc!)CyCjK={@-ŚMM$kg7FQ*349+ud5mfcAӋ1s\ӑs'z{B$^噧:&Ոp`w;-lD\6HV&@NYCI7ENP9J `w6fZ}964kiޞKY52*GYu^&v:S혭E@VPJ$I~e ำTN;扈 }Z f:D[CPM`ǻoy}Z4 0(_Hmuw; ﰁwhj(@޹@tE\S`w10y6cmq"[U\0 j]ev;UM1CcV515"37^΅j mlQ>Vk%EIxN=cI/Ľz.OQI%|YPi90ױ0\np l ͚'QI3f!HXÓ[wb^yPw#x:(sSyM2ӋMQ b36cQt4(mHbm.]GO"CV;WRɠw$AGxVĢ7)aV*S4退 9B>73cIX gr;8dlgY;N[ljE;MkX>5K|Hb4 o&>kIEuHG%&|o1.vVBےdЃh&T$FlΦEԣz̓]H[Z_O1(_ c5lALH8sFc,1=Zu169xRGRVf[=I+ 3U!V#fQK eYT1r7-1!ʯ\WW'3Y6NБ=mM(e]L ws,a68EgL*{nOf7rhwNĺߙS(y;o!0?|wV y5FG܈Jh!H#c17&"""]u'͐Wd[QDFf,sh*m$;TnI&I=1PO=Tjz we#ru d4 m̌.'Kmsp./Q<%(Ųu:cIQ3#jEո3.oyN̴#1브#;@cSڶ7a^( 6>j0P@̓qUYCQk# #!hRprx+Tf>xdxEj6;ͱqGU!l >qP˹kP0ke՟oc\hE6 AQiQȕiɏ"-lcu/j;'ܥvu'B|I [s9ٍxϨP0b~#l[˒w l8=ɛ;SbO&.BAbohP7qs2fӴopF{q(Q jA4WQ3̵2xXuA,)i:_ip 8JKopm̹N0Ne+\7IMKO*|Ⱥ͓'YDi`s$:h Wt3[ePs|0ǥmBHGr8~Va3 Ph2ވ{l%u`vW=p|MrMcNF3Ӂ/* z͆uė(-b+)oM.L `wafvM -#V |E~|ŜSa3Vdc[(s`T1`;MDEq 6EaQt"jg5v ~w8/8;aT-ؖ1Zd 4#! 61ئ֊ b,2aJnxMwbdd@C~ >},Ky)19@Ө TmumJ1w^b٨\ƺH̙ {IsI!GK%egĉRAQNq֣Gѱu,c5(=;'I!U:YTo51ȮbjnylG!eWk VbȎT\f 6+1*ǧTA2ljC.@2oW9XBZ.u_35VI#s5tOi7_3Zΰtܔ' 5bCD+mzfrف.~GAuT 93{}N_PTŸE1f^I|;sCUfM^%''7cT3ԎmO2WfM;dbo#{y)ӂW39w'78X 5yOjCMY%C H|)K/hKmˢY (eH:{~kСV7&#*~fVٛ&xMʈdXVA%'hPFN⁣$Z5p!cp|I+NQE_ Nexע,dh dG܅bP.,#ɍT]7im }bJr{zNMlMNΥ\XT1LM q2/C&2d`y3;GQqF6˜hD><Ά#@$]n K0f+5GiTtMs(n*&"o 1)4P=q=6pk=L_$CF ZsLZGbx|T*=7[~"{j7Y^‚#cE-5SGOiTZGEh6pbm\HI 7c4P-MdpUvNb2(opQ"2xv =ttMĻMV'DAr ?dfU6:/1r]"qѨE cbOuee:`b'-Ewl^PHY#Z7Git R>!P{m T)ӡ7+&ks Sԥhlۑ6(xcSBTjVe+HE Jlnr;Q(Ӹ0`N,d(YcP$P_Lht %&ǓE "'K4OONb\oY bQ|1'iFh~h8aG!a#lӥ5-NnrRnHꁡ^'S'e)#$VaTw4ca7hsq$!3c&L$5 & G8ښקnn?WL_npu]FdP`(c/hgo_ a4(:NYNMfP\UsBLBvaq+`kvo wӅZ(=1a"-NP9UO"WlttFcM^:nfť̑*<k M]pLrh kuz4@ 2wkSbBWōDqaau0XJkB vx؈GMA hŚ#[Bq rܛ5 I5oS~Yb&aj ;Kac#/XP>aL(m$k3w2g7V",ࢁ\siMO `3Ie&K!XNv{;:GHP{i&D&L2gy&L$H@q܋PSoZJ4pףSW1&%{[n@~& NIE@8dK;]{A1օ&0T7-mBJ7Jpn$jۼ I~1gxڌe"wjΙB?y4؃+.}(A;6t$`G Ũ'zw,ˏ` *)7}@ V+ښ>ZCu a;Eo48b9c 4}JtTE7 `'5iorm.kC[ؚp̠õ̺7#{b+OK{$GEwTA5(Ӯ&A 3MauX#hS m`-00l5s|II>#i+GڧhCo X7GG-669b7db8xhqױmX* &NI6ju8U${Gz!p'ݽ*ҁ{gk:|L%`$œ;jKD^5N,`q`x8j+Ghޠ& T 2M8ȅƨS- tMP /HR5T( ('ȇo-_R{;&xC gOzOS6$oPqJcHEL[$fJT$cl5wtBpc*f7yXAT%zI;o7.PdvlHIao`m06zqA[a#Q0/}u7y].Bv"Ԭщ4kU? .4ٶq5 Sŕ$F7-Z E=U4N^$y5BT[.(1 cH2u"Bc4Ŏ_VWH;NXdq56\U6#0[ \%0jw2A$#7fL ?3&MFy){NM&MUiN̙9EX~ƛɒ& Rlj2dɓ$qm$D82d9>ه2UFh̙M&LPG32df/ꇏ?"܏ L76ɒ/ܳI "ƺ_2&I(L$QU&LL?O^>s&F?tk2d`_9fL?O?s&L??wG$N[dɂxYOə2D#w2dy~/4~&L_5ɒA2IoRd!1ݙ2Hiə2B_LP_t&F3K=v2h1A$mɊ?y2@̙[}M")_&$*neDɓQ?~ 3&ME0dɶ92d-y$2d'ٷdDd s D  3 A"Rd$UXN+#-ѓސ7cFc$UXN+#-ѓސ7JFIFC    $ &%# #"(-90(*6+"#2D26;=@@@&0FKE>J9?@=C  =)#)==================================================L"9!1AQ"a2q#BR3brC"!1AQ"2aq ?=?ħv5r7:VpZ[1lKF]D;;N kN64 N!&/q)@Dr{mm'F~d?Y  nxѮ45mFvF&& nH4:L\ \\DL ,NqFnPԚݡ-hk ;"hZ$D(6 хьWߙ^›yoۓ To"I#fDpƬvj*I.jz4Z76zؓGd'(PAq P.2wg:j#H*l&zG첅N3մ!Y \PDJ ?kTX˫v^{@;:UivI*7, 0N59(Bqp?(qT 9XN ]75!W&5_P[ާ>]*~gzͷA49aTڲmkB[Bj87 Aـ(l-cBӤiǬ&ȅvIR.f:cB$DyzIVg\#+u;I-#i>LҌo> 2Ы&7Uy` d-a=IP\F:` }O0oi$b#`>G0qQPfx$"eP}aR; kn6*iMi;dw 1dQ|CAk`сV(% 71=Ɋ7E .71} N1,bhr(;@qfs[E 4xbيF!X$bf!S nɽ gp]'Q lc'pU$IdgN'FDh ϓ~fŽ{ım+u8Lr6 ^ų<5 5vWGfC`ku7mW9s#ŗӸXij^w(&ݙ*P((rcWq@&@xa^H%(5[(O] khl#AMw"jv1}Ѧ>fѐ:5vɋNqDFP|LE6l{!hbv![U'Qb;Xʑ7gj02 xx]0k9 ȢxށDŽ1*E?]TU|F! ޶ڛ.=*vu1 m!GsڝaI1W:'B\Rm+E>qɤaIr%ͨ<@{ZFHj@?`hKk;~ eZ7FljV[_HŇ@|xk $(mTQrMG棕TۼK-T0;7h5NQ0 =iџ{@(KJc;/nMT ,XZ;pcYvQK*pGwh&hXEZq9؁{Z}xn5bVD#x7B43 %'00"Cnyk @.8˨~b64`q2*x.'$1[@0zf*.#xzT$5bK^ K96 QU$BMo2f9v爔!N_ i5w55,gv#`hl7E,Ay .6 {}qZµ"1bhAHr`Wq3okx[87@"iM\ X:c=pDlY;ʼnkڢYP>L.RtkG!P|P1ǔdri8ɑUh[d˥[XlpاLxŽ?;-02C}37e{]ĸ$3-Ҭ5ꂯ\qHR8A4i ^E#ujG=]ny0ym=pXbPvУR,o%OX&wۈyFYԌ2,?z;'SYo<į[a\lBGv.E:qB1g !{L_&r |ٳJOzlc'aŌRfabX܊椗Dg8c6|*1Esrd7rMKl)b@kգo>*k27z<2Lm]3{i\Ռ SS~cՏGv~UK(|@,*Fz6Jo$7R> er EbQ`#N)OxvH21Zc0(6O[𶟈ĨVCgFIT pA5GD.evb]Y\j&NM͑tRc'ΥNW gӂgh-QBDn r $V ӹܡ iPYpߘ.dp3q߽?"S[L]ԗ?Hzvj^ c7?8VoǕ cWo|u]H{Ita'KuߦQZcLKH=FlYB,8cze¥ Mr: v>C>>a KxWM^%q cɌ O'14sĥqfW ˉwUy)scUӌk!2QWk+ ;Ю̶ WNb*r{ aȺ#\lDqF 55 Szxz .IrljcpzSt2OQT=z{bSo*Y7R%>h|{# 5yY8'ʎp6񳫯ardy_Mb Lb*tPcR쪡ȋ xu#Q\(}Ý+\΀ P]92cC:&õoV y'ϝSYӷR:PjwQ2, fV3zTqv>]5\ۦ h 1\VkO4 ]B jh;8=;G6-tL?61iƻ{6#OOvVݖCdFC6 +NUfr Ӆ{h.U*|^V>&zQC)؂7`7q+_'p{gN % j+;ܩo1yaH2j8q p:D{?&뾎CjZGrsO-FLqO?2챩~0zWcUG`Yr higu"8L*:tcsY:?z A\#.-YCǕ}&븒fgǐ.7$3/Mcq9ff{/X&N5+ix13 ղ7u[+8 1|TAb250eM玩 ҝU\'W*Mw`f@E̕scma3Q~cFkhB5.EkDQ4R5Q"̄#BQw p!Z,qZ2T uxr)bt׈B:oxё,}V"Ojśh,E@CJbf @NB dgɗBѹceb*7tL:6+o`}u +9V.2ݪ bPlAl[dn#4 /0gmD5q6n"'@mECNJQ q~N 9d*T3=ש6"+ 3y3"et!PmqZkKm6N U oȓ,fq[V!2-VZ^7$cױnt{\zl'N[[G b͗r62}X 1Z <NLʌ,v.$,ٲ[""ROz -V* *?28ќ#xW! 4e'j c5Pj-3su*-rƮ^:B171b%e*͏fQo/n: EyGa c*oI%:V˨lN PzgjSҳ$ 8TTN\vmcWG7Itd'>KDЀlgl* ~1i =7FK ݅P}06'Hݢ2齸W7NJ,( 1r]Sɐw ݼA3}6X\wl.XzB \j=JMJĥƕ ғA噻Y:a@]LN c`vm0GS7-KXnU(QcJ#/4em˲{H2B;!=/O:ta-B5u- 8-ME 1c\۷_,{vRv45Rlx5S0$|KcK1tő/FE-\J]0Df9/_ g۔Uԃ Deq { d `p|W7]}, |pя 8`63=Jx9ɐ9}" dxLp1I: b1,Aez:Ƭ6a@r-o!V+hL$ou6[Zh[&,xTKUq0%OxΥX6GL R[p>#MšPxy.lNy7!lm"- d<"ƒUM 1\}d@M" )ǘpP&!_BŶP!E%ːW2"2BwSJ9rv7P 5U|%=0"?SG`agCK"?3Nڡ֘Y=ƾc_r7RA!@4$ȁjvu˲(9Hh6+Qj$xֻfTAU 5 YayR]Qr}*;vXp΍=L (&/TX}>Fڸ)YX\>!{?PUo$;ۚtvڄ,4)W4xIl@ɑӲb1cu˗&eUG˓Xik!fV-zeqsxA61"bO]ޤ:e<ޥ'ÐՍF'nǪ/ ˇJƾoWY׿/a0&qqicnßS3Y*c:oegQփȣH=aH(ʡ-<~fΗX:<lsYʢ:p95BDWZvND+` C9&6^j* vIR<eQ3;b HbUrù3r%w03n_[vcS.`EuA#Y-K7OO>'uB)\•/jc=V@ r(}CT{<$m)Nq9>;.-mtgf/Je,6BBXWm9//tҚ@7&E&k}!=mO'sMӷgN Q#Uyƫy-pzs |ja-)v`m2I%e 8+ńdJRĞ?)ԠBn; vD2urr8E (3ssrp7pY+kQc1M& ;кMaБI#tn?wo=H76Bsu8@$!iyhF3OZ XZp"B4'.;`5S=p\KB« 99\h"v@FtD19iZ@${Cgcl$ƟzmN2-61 %y?GG>U>dDة?mcO{'C{ioQ&yyLr8hY8YI#z^UnqzlHHo/oǧ0:Gc U'cZ2N\~|o*c/?-HrW]Q=5{e"b\E){*o3u  0JBU߹KUE0 f6K_z0ɅY <ČcrY2n=g60tBB:m, _%Nof˘>J |YT ŋLY>&]KE6LٽN%U236ZbH=O0d{ml˄Y]C 2>|t)O5J7XPT&DĤ!>{LTI,@ _KӶMʖ=KA=騤(@Lj]!G[!|Ǣrk5܁a ty'Dt$5+Ѫ~b^5Mc^IҠ[P/3_?jHE |s=eŸ A UE1KЧJKĺ\QPc0}o8r¥F 3h&BG ܘ7d(/nx.'ܐyȈ`׍(x["kgB M&]Pk~,`F[aq)X7ܻ{3.uX`7Ժf;xWDKhy7Xro v]J<ú ^坋 /`PXB(\wUuզf٭H,q3~hTVɏPPQ7@J;.F4jHGAR8#Fv.92եyǬT?PVXmŘ2QJƨG*w/k֡6H?&QY4~a>F)KGTo4 81`'  a4u{ibPcoq+⠝%&JvkrgzDl7!h'jЍ`U 4b 3|5A-@ä }keߘ: J7\Q'a;nb\]46Q >j6u.V6w:$ ?ߤԴ5X~07tט@FBaBKy6'@v*"0-oQj4"#(`cFB+8ȕayEex~eu~W) ԘyL "1[֠Pc桜FѦӆB7{žU<>N($u?P H]7z:;1NTU帞.^j3R9o#%nM|oL1cԕ\kJWޟe RϯSG5ğ']v+:\3iE_&xQ']i\f8ک]#cp]ng1vܛ&cQG O!v~6kuQ[;tQWcMN7CVosu8OrGONV7^?L8cNNgɏ d}o'\Y.>Ҷ?08qyZ޴>lcѩYL/ԡPG5?:}`aL"y1*0dǒ^Fm0e jy (-] SJH"1-MEDaZoQ' afy7JO[Vf$D jSu.R1JXl;"=TW*SVتm XX#}ЇNҀ@X9P_~"#n$(iNWjt@TYlؽH,`C~zhQ'ƺ{G.TIJQ^X^Cx 4bZfz5'9ho5"6]X- *+ppc =hs:S]AZ1a|>/O7C/(3+oc<`>D˙?\z y6 It|;`HW󋟵f@uK;W:dOoS)1M]ֽ*~5>׌da'L[ZğO !<2ap겫nvyT=ȰuX57̻~a4*ӽ;~v]~|!Q-,ċ% FAٛQ!!RIv583;FtNBL?PVT V|Pt2m рmDqaqM0ޤ韰yj VL95q2\d"'q}413) 6؟XwKz\z睏& oRkyV8 3!\P\v ]sMcM?TlK&9W ;#DWH\ 9 {|Ƅf1b@eNY`UG䉲ӌHJ<ߥ`NɍKnO1iZ*5v]De$xéu=aW!??6mz@ "SklD@ǘ1f~ Qnl9_T4y. #N]BUNE[\v:gB*bv2Aba]Rkn~)Bؔ=a>:_W1e-u`PKpA UrUHO tV"ԍJ\Qe];6MRI2Q9bS:Ģ\ʩ u *WŏTFՖ9 (w$ h]ՊC3.rN2d;  1_Rp*O0_8{"ruiwU:G'΋*`cc_Se{ȞGG>@q6 dj+-r>b:ǢI󐚯30@~Lrc]`-p uP57*Y/3S:oӃڇ%u$|/f8}z^39q&?U7'ǨoO[ÀN,?D]G_K4=~'N^ P6NzbɋeLf"\_qAb'_H!OW~h>|lCƠ7C&ӟO6Dˌ=ڀ=o\ڑ=jP(A ЎxؙS2_1}WHTM_cWr]A_bg(\bHq4 ?In'#רP$+#r; ׺G$y\o$l[e#C8E_tbs&0O[*hQwr;{ -LQ QtRAg"iDء2gL:ԻF"qj";#yNnFEEл.q3$ܺ}/O0#z{:\{4c&@ i>4^t>EpdWiH[ܷbIf}6&eģa;8j+ZPdn;93ɾT$]>EF%雚/ӛD9=>n?iCr@ ]9s0Dq`|I-t^L۫4%ݹ>Fz2"~8M>: (rd3ff\ y#z0*&=k126DYRSEȽ LZѱZ1q_;lк޿&d\hEy2lߧ2j: >?Lӥ ;Q30P#YN~':+3CQUtFSW]_*iIgzcQ<z^ˊԕ 3'2]_iZ̑+w^$),&^ (ycjMa{! SwObwmd@Ҝ$1$G0lw2+I ~xf:FF+rL"N umhΓRF2ߘJ.X 건.+ٌUhQ uof'Wb cj'A]Y6ni3[uYV- g2&Ԅ;b#^fܨĀI3@=5vGc^ӫb#>=\x-;EeFv19e"::>/ɋ:H1 +SsP0գ q)qΘ^M\wZh[Hm\>?@ .⽘3MtpTGZX7(J"25ԍ@r&VrwIWqY |lt ɓ4LVU҆Z ؒ?߉ku +$HW7.{xOShb=V!h̽_c0$Z7ӗF\ZKDEdm{3Ew!ߛ r -)/OJv?h/y)hÕ EAjoX=}IrqB^/ǏHvE=(9ŀf|SZ6;'%7 C]yIQ#ƽf3td)ޢ1njR69QƄm6 @RHfaCi-D5jZmw04 D);Kr'GTLzm&h \1vcUm+S#ljMV!b2(IIۉ>|I\C/Nh{&GtϬL=1Vlws[qg(fdpLqklhrS<44zB/xNwړbJ/OˌD2@{u}pc/ex,Yq.nM,8XA"I}"Jdb(UgӺO>vWz /Z>[l* lA:a%UJzu,H>?ȀNV<@c%$-o0MۍI52\ϘM|ڹdZR Le*,c l;H x7&-X1:}Ru 1>M+m $0z(w71/c'rI:?'7Ǻ܍< @ 2qD1N-b#+ZXxjB#*sII`"l/UA4qrAcGM"G@]>AbK]D\>g],w5D#1|qRn 0STb@ hEZ| x5"D]}Wd[(Jѹ|ij<^˖Ek9 9OTPF˕~56ǐT_M%{'.wI}7Wzwi[Ul!_3p؎lT"MCqTLmm]JjUb=NHyknn"`o'ɧ5* VLOShb\|Fs?äcL+`y;sDў>anwQ́SYg}'\a 60?uJoRcޔx"$=oqj\$Bbs) i{^2;g]@u5Tnx19rY*,}d+1>d2UcŻRna1Ăt)HĩIUeQ3z|JܶiV+7D7Gy@4Qm\qu'~I3龅A3Z>.㐂*ᨼR1tPl ٱ2|^NYaMJJ]̌ǜ"!ΒhOY6duӧ0U}MAoו| GMьV,D vԄÜ3;{sZVv:/Pz8/ת/tW"F\eFDVMƬvXlQn1Xh !z/_!| يƅ - ;_OiդQi3$ۅ1ӈ٢;H{&}M p 1R]@@vaYC/#W1v,a&Ʈb L MεŘSSq*@/I;/+X-U9qsA 5LZ0BǨǵ#.VKVe'7&ٞh\x-lL1 l/V1wQ#:U"- Ғ>. #E,-+#k#i7 ܣ]VhC@hD2770ոTj"qqjhKzTl{Efǫ+0t!p_2d|HQw)LiulqlKԨFtFI\~Nxdۊ1| (cpwyoɪDs)ā{VikRi;81,v r{rC:V_՘ۈIp&QI\4/^ȁyLEITSM 'sěwSc%9ZjY4W!6,O:ߚރ@ z8"l̢ߴ~<凨jڬG tT89\.J:^jC;> 8eL[+tٱq+n>^ũ1ۑ_f.W\&]q__8ڰ^FzNI]ZHs}[#fDojǧa|2,sB*2zz26?F|LJBkM\ n^5EUf Lv =]%^{*j>aq(@H&&1缧L rƻ*RXW@ZUǨ]|Ů1WaB= @E6+}5tz]1P~nf Ar#Xj ԩ2j\~fיcxƔ:D6@Lp񁶀CGUI6%"Lbn5wȭV!XdxD~4% FQ$6$ R2mO`nF$w"LH*mIB]M`x4X0q/4`B h 3@m|@ T]ҀjO`j? TxUȷ`/%ωSM;F6"5XsI0}on o(Ӎ21Qlj6k^z"؊׸Jj~mX' 1{4x}?UӾL aWOM4:ClK*8eM1 Aψ2+2F .>.n1Wi>*>ǭU}ω6l2E:;bܻh-EU1q1 kMbvelPAuM ->Zi@cpM $ħN7)鱆 N.23;W&k[^,n)Y;X2xwWG6 I&rcb!ʈgF͞#Q;ĆQ듚0F{5&R@3*F24'[Q 5ε;[-)tw@enhqP*HjcdT臁s31E$lG-+cbJ0!KJ}WJF=A{ӣ R=CU(r)I@Yw@ )\p#j*#W1pmw@D!P$ Ӝmua[*@Mwj_wOLl"۴-Us(T$Q>&LgS-%Xx@I<>W XYn<8B(|G (YX["oP&&{vZP-rum5ߐ+hsUp#d}sdtd6CFWIȢ8qĜZ\DU*CosPCo h=ŸK, LE xkc%Z&Pz(Rk+sUw,f$]3\&BbQӄUbI Ԡ}I1s.Ak*ӘS`j"T#&Lu ^6(FÈíwa''O?o PJ?j~% VEfī2QCdCĪoIHFUd=7rx=qLarqkz?NG* ,T0q'iv0  Ni6#c| [xK]CQp>LjEm@߉=#>btVұ)S~vV$TB#a7T/jU@̉ 54-3.-`e8*̣,Ժ(IP1yR;CFq΀ QD i'Tcc%ZPhH5HR7SVwv!mF-vio4 pڀnY)Z_d' &`rԾ&1zsǂ@Q\:F cĵa_> T1Z#bqrnbPċu"ǀ62Ia2:Ƚ -Ü鍐!'QMbNėx^*}@LUo!6G N| o&H<dzVlT4';nB&]c= mo5Vxzq,ho&űJs3 Ӹ F -^bcNvcQ41Vb fͪS`@O1iPG.]ħ6Ƅ! ʄ~Ť>f8TDcC*;MX7K"BR:0nMf+BBꆁw V .5~%QZ. %s *Q [r5w(i9!͗Soy97c{39njnmmgiR.m E'{cu|cψ)dlux F|}_idbf-F!4jۼٿsك7MT 1vnictٳx3!f37Z R/$'?$,AjO0T){G& f2;񞝋`ƒQhv[5;E= Inv;X`S}Weg%ȃ0EKl)jҁ7v6#!/+ ,'4uy %"8YhZ&k'˓zUI6y,Jd2Lv0@+ 2k+Zs Mzcxr+Xn:aG҅:ψP;1S4Ht7Z}" ]\iQpK>ɽ 3p+xMbV-%0ߑFѬH;q6BEAJ9?@=C  =)#)==================================================";!1A"Q2aq#B3Rb$rC45c$!1A2Q"aq ?2IFJzpA]$@I$ !I,u@@K*I(e$DRH{JUB(.HR`XA'R_ 2ģ-2S%Խԝp܃D@cOO;346'Ȟ:u?*B[:X~ٛJtY1y7Íhk0Qʨ=Ɇ=@E>D%!WV)fM3}%#@Z7<3kC3݇nՅLذvpO~ƪT'?) t9 TgHAxԧz5qՓ,tR,A:W "#l4D`3 kOW m$0p`~ [rXq%0MK-/-VrLdQJggFn,eVȰOq8+H2{Ny$P5PéA CqMkhg"k{rk Z ӗ:3uo3&0rfFǑr{[FHr=0Z;rpK&nR12+)]F5b$CL.E?0y1v"מ屯l7IM0 nxN]M!S84/^1( ARPRQ@ ^jޡxRɦTH6K>d_-2v%!(k,EkX5(㸭qQLA5 TԶ4VY>FטY1|w(!B+Rl?H{ dJN" R6âI Y9IoW2۩$0*I$w*T:fXn Y%ܐ$T$IIRėUIԒ@ĒII%~jP%r $5U)I&n1]~&-tZ5`!ήCǐf#+j r,Zqw|ZT_G6x >Z1+7Čg7K53Il͍y562q Ǒ̢6"}>]f;+tJޕiOg-n|CZ0RbƵum ͉݌XDՍl !uf= 1$3c SV4cpyɏIY)'h_d0P*Ck<ɒ?@dl,1O(|I >61yvdnD "LVJ&D2#bS kkpOAJo3b.#fӻ O[v2Tb@%X&C?ze326+pDpȋ7њ?ONXt!@͙=LH4&x%j;`63 Mxfs ,E߳d>#p+fVXRx.';2lQl8A$H j`#xqw%k |x 돈U%Aܒ ;=MFȠbcPDpP4G]2jnԫ$ȆɕU,U\/Qx^P)\}~#1 7,)/oi0vbOkDIƩMKr[r,P0Qu؄8 ĐnHI'$HQI I$I A.PI$$Ğ`I$bB8W BX Q9H#@[ FeE5YB,:U^'>W͛P7b4fa#&MCo" ÐvSTh"oS(`Rg*渹ϣrGMe>&+ @+m xęh'ILbA>u.1!Ccd˓mߩo 1}͈C1\đ=X٧-wKA[Ql &ŕifC=llRua^ ;@fUu!\tcʃoW v6 \Gtt1czzӓ\!1MP1`9CؙB #&51 5~suF\o};T5`HJц͈eO1ZMd9ɏ>&Ssq#6f2Rڅ9.l.fς&,(uc2\#r-VHL^b2nFY6ͷfc66@&nM^(F,5?1,SC9Ԃ>kMxUWK1ln@S /OL$M*0`oDQ,n .F'aL.voj̿ܟi̲V́V+(p`ɰsj ^HP Gu, Ljn,8u%p1t 9}ˮd+ qG0< ̶{^9Z(6fXxw~_00TrX >`+X ^bQ Ř@xAvƸ,w(u(t>E*=Ϣ|2\2+ |\ $*X(KI?!X_dJ0$IUb rUЎMFx Ēi$u3p AЋCJLޚ~Mjv &~DlH,132eN]~kU{tVS`f)ǣ0?~.+T+Q2).Ma W&kb_}2WH1SDdK,DϣBCǍr`aoWCn B(Dj,d$y;_ˍ6?QKa dSpۚ3kej K_M9΄S$83& ;f=a!뮛qv闣&b$%f2Of.P7l>]I\?͉X|ӛ T+N6n*h1piՔ; Gx̚WL29p-/㹔j@dRU2 0,IOMAcȹ?PЮq\ّ A@Qry=sPQuK˔!<3Ntfٍ4UN8h@<ԼNׄ\0*&2 |M1P2c2/- ~:Dʯe$L(\nBE$$XDTI I+̒p/*PIBH;訉%rI$I*%m2@O* )d+RXPͼmi_Q)E0C dș4Fe6I{l$)O39WR_1fgNji3Tk>9V N|I zDvLϑe+̎P"g^307"dƹ`wԔ4XT/'aa3,z7>c,ߦ]BGSf߈g MO3j6P0s T?{6keLD'R[Drp+~9sc[80Vhe\Q>e|nH"fl o7by7Ë6_%IfV_9= Ӷ;1? ,>/LB06lqMN~P55ψd* ű V:}ʫטÏC evӌLՍ[3&<~u\L6k4qQB˧jD[}05ݵ% dǝ=dKOc+dLTHbYK ¯ow~!9ɼePQ YE|AY\N=SX}S(\ N;:5w4 @2aofK(7Gپ s%@\kP_VYdUxfD?LYkMJ3<̘@7 E53abC##Z=݁>ȚW꫉9:`9hӑwɑ4a*̻q%80&}Rz1(>n7 ]-SvGDj遶چ+.4FVvSQm85v(&Wɒ+%Ȓ>`LvchW0H@:nR?xmZ3J qUO $UƄeVN#1d>ݍF*3E⻯A"jX  KMn*ݓܨ-r1IVL,7/u y$Ku !#ByF4u'\ 9'?$%ITII$0ԕ*,%WrjVx+Y&NͮvZ0rsfGQr%-gS L&-ӧEŎ:E]jڼ8Pt}So=QS\LUo3&6o)@sl!=L |jWR\Xaڤ}c}VDm(0 {@_FY\;ry\ *3=;"[k5h )ETsz[ iiML=1gʡ31 JfLsfLޏa;F⦺x갰n\.EP"guU)]OL4קy rJ lbYUՂ'4gϋ`*7ٚ?/%c˰Ƹ]V`1|&+Q6)J]6Ou0hߐטF!g[+SSfNAcߩG)7,=͉ϕ6PqZNQ8vŖèMɩEON- ViqzxƝq* ʲWN ^ gLW"V؜5r$ ծ<{{ǽNyXrzvt<jUigqSħ~n\zܕ[jQ\Ffȸω.mx=1MM K>$^T%GfuPrϴu Olhϙ/e)^$٩A!02{elŪi$FG0wM=؁d X浕[^eܺ1nvDT@I2 ,5(DIp:2'!%K'P$P $$HPT{b|@ GwW3:lϑYE.bǣ)LV=ȌpTjAnczV T6&x2RBJ0ܠtDr8jq49\xZcH!y^ 5؉ 7Uܶ>eT7gKVۧU$1n$G%~'=vE.♞&;qnīGnR#e|zZZO ec+Bԣd1-قHz__P$+ͺ}VD-t]΂CU1S[dl$fqa9 c=2 S쫁J\ڝ38:SZAi`##}5HpZAÑOM;XO{ucNjr*}Oe](է66 T3 F iҾH2k?"c͌e&1a􍹫 1yY㱧O&RY CdFerdɸw9~q٩JJ8ꜞ\lK!>;& A>˄l% g52s# mKc}]Rj+/4YL7$,џZy\l ٌ3F3OR'\&boMal!ؤbd's%\|1馬: ~fMȸ]nP1r1ԺTӃE?f,N&OnǏʼn7f|y)U 3b 3 @l@QLB8'` :Z5f^Qm=Wڢ%͡ j0[~*bAlmSqm9m2wn.D6DEt1aFS."z8TƼA2TАH1.g[g3Bp Ul(ԁB *؆L q,w% Ó̼~#a!VZ?jn(]ܥ<XKȥĩ9DDW]˸Uܜʖ. *IpPX?r$eĐq%ʱFJ.B̲2o3]xYZ GS>LEWY&em"Z#ה0Q}vOzpH>Tq괧Y$j fkqr̬MِꟋ6W.}?OX8[^J"ttH"Ƀf:xu[pkir,DZ][Ń]yԯmE]摧.1_[4{gt_n̚rQHr l Ԍ~ , wbk;I8~J$c:6E''Up6,hX5Џ#9 G v/ϧ .VgKlj/栮P]٩ .;?19q33/rnmNgZwQ\יL^*j`tW0ڡKy:8*~q2N."lS+,8P#&kL29"xH?gg3}2?73cr5?%I3`mkYuXG1I2waT%*(+c_k3.2Is#o k䉩0n:Ã<8NpIWLj[}5ɨ;#hly~n.fښMsN3 g&mVa{HǥM0tf+Ldz*3`ӕ 5Ž-܏c#vP'?SˍHv⤾·sI::ϝNc)PXLHQbey L2&h.*pGY2( HWs:jɳ^$3&F㊨Lϥ]"GU&Vt1:'?Ns™Qc+qbSr te͌%CլˡU-2U,Jsp4\X$L 6a3Tn^"Ƥ6a TQb;҄Cy[/QqVuKwW bnqE5̐7 |I$BDJHT:|I{I$I$GG_;"5MwI0)FBOh#LNl qj=iPH StJiэM8W VŮh#yV<|D0ɛW0܋*FEXjI3cR1Rb9[|JyJfH(P'R۽yu YLH3fèӦ썱ObV y3w46A$HEjh`lӯ2]ӧƘq̷r[;?&o.>-'HgSB?4A\'Yxm?37\lDtǿ]6<)HRgǃ&~rf[}'$pOA-n34M#3-1X0 jUɬiq"BXF*ģZٝGᄤm>-6b902jց]XXE\&\,W=FBUH] Gz:|KXw =Gyn?wTی.aՁ:9r%%8ˏKі1dR1wNΕ0?=.2ʿpʉDoaSi {n9-n30t/\_nET~2R.0Pt3*0ɧLI[R|tqv(ۀS#>}؊#2VLOK2j̺xT ccl9\ٍTyRnNcKU̞+y^J?S !Esܲ@uRYhJ8NՐb,x|d0 p9,TEa=\V\'hՅ`n;f13d[H~O4*Q_3n1QM@|g ʮ2^/><$~f‹' Tɩ+Ej[Y#Np oG)tWShLڧSp`Pİ1?[).]RߍH qC2'Z M: A?x9 Ըۜ5o'`2jŋϊ3 \?pq&Z(ZS&LQA/mb6#}̙S;}cZ٥a/T~'4+A(T_1; (ӥǦd{'N(ŐaPBx 9ql'OȂQ¢Co1yr(Hܚ5XʦJ:0c j~fZU@-(d7o,&+?I+l-x>,χ%#nlLB `A}Cc"fqf牕RAK+BDd}6[ Bkş }ɿ Vh g<9?MBϪPw4Q+bq{HbHw2rԈ[YY/$7.r`Qa"'S(g,x"K}I_#L|O0}PIRq$%JI.DIU$*\m$2B<ʒIbT!%I$ RI %K"u H# "h#<8up e752df>(̽N37SW}|ξ$q1w*<-R:<:z9hJ rj׉i=", TdnboXo2ꌋTsSeℕ[A-[&f>cS _<` E -{u~ }8Oʙg<=Dr`d:?0 ;&dT`Gvܧ k&/b\+T#Tϕix5Y3.`fm_̭rQdWՈ>4`יhUS'YtV)X(?R㋛cr1s>0|aI1qW$7>NwiD4&=m(?zf*',/b G9ͦԧY,~eU{AEЙhq2oŘR>( @XAO fWd'ulyV=`ɉ׍2dƖ}].'af'& h=/J4rM'հK)tx3R_0Dp1s2VDЎ >o3?Ľ݌%5O5@]̙q50O4_ BA&x%Ʌ/0\0> >$XRq^=@(cfEWRFB,ژUEa1*x4"CY `Q2dU"[fԢZF=KT rUK$$BdI'$2I'Us$.$ 7.T$ܹP>PĚԗojfLصX_Orc"s_3Nԗ'!RWr@IRI.IcLTR@T P IRJ/ĒUɈ(WR5/eOu)l?e'(\q3I>'XۋD{ N<4syHus 5P69h,Cs꥛EAByݸ&qn%ܜX$}^)8BAApv v',DKxzcfU$+ #)U35O [3Wb Ir9 œ02fm$|A~&Hŀ`@T9f$g2PiB@BL賩E$X͜?` 6hce\dLzk.-KtՓ݌1Q_HFJLL˩'`#P?OLˇg <?Ʌ-8r?čFXV?cv&%kTQ#==xZLۿqO?JF1ϩ1jqY'MB[LV< B@>Dُ6toԞ\0I"2|;'J8[zOīzXcы.J63yzp8e2EqM6d[Qψ"fm2 ӻ. `ee`z"LOHXn(;/LWe&Tc1oPOl;a~dMLG-&`27 Y)qs@Єi][?{X@# G`ievpUЅJU1Ҙ PMP>$$K'|.ĸDD*PIB@*\ %K rI RHaV$q*4\dW{̖_e% ;VH̥|YTzٞo?K!LjQO5~1mmcoebn^؀z.gbo2cR(f$p&mɒ&bC0b{W&qarת j&B;7*RǸyr!c6u3Zf~bR(ZKm`s\> MJe ! c̚Hj3&Qz (JX@+v[raQ 8@`Eo1mSIAR`:̣ S`#0'#,ҷd͇'4#YIk') z?BM~=*>4.5)@xondTaRZ46/ #Ƕ51}_IL?6`iY?Um,E͓ܹ~T@ =s_UR2ĵW+M"Z<*Nv rO2CɟU(c*2o_ѳ"sy ˈ~Cu~CE+7|JMVFOUǀ{Pψsa_lɋyxũȆ%~GFf_`sY |GY1+VdXsdw1І[LjYtrf#Pn IQ@:j5XF@?6O! b_rT .I!bI(߉|yIW.JI*\"I$|.I8%IW'27M[*I/o0FM2@,\U~,C7N=vQ5 lH뛍*ŵ]O=wc;2o N3X&L8Ŋ+FRLpgl]c''.Us0Ӳr,Yj3BeL6@1u٘N6`G `bԩ rgObV]XQ]D+hEKu TVTXnfr3AiuCi3-k@O+ (b\Tě.OR"\>,`'4 R=̘ ٛGc̣6crܲ?fcr'-UvC&'4a(aH[T $JP(02c@^]@SIqTJ(? ܼ04{\I6>A3._Qb W0Qݝu`ݵGȋly5 X]"%иe1+ڟjty,||аǀ&sVrX=& >8kckbFMd?!6ϓs5|620GD7^~߃*a=Jj1z'=nm1i`3UY~34̼Y&w+9^&q]\rvÛjл lt洜x@2g)®W/\,y7>#rcEx>%=07ivvmHa3yWY;jkX ũ!yZtFW ɯ.ڪ{΂c>6^RUЀ:PD#&<#4O1 7g˒q/bj vSU2qӗkzbh5z X#(Ծ.60~gGMŊ5؃2bǵ1W04%ht¬f3_c [d8_nu9q66f+d\c't|x-]Fc2ǘMʧvd9;QzYdK\9| it8]\ͣLWqN? YM20-C2h͊S6~d@ܪAAF?~G#G㏎IdZim7s0y|c$2عg6P,G27J̴b("B ϒa(a(j[ ncLC*&F&Z "YQ<Ե,U !rBQ*S_2UT$KAFJ$*\K8]X{YK7}C2*cSzIӤVa i9yj|fHM GǍf>)KGDçV<KWc8], ONeAj+nbDNMvA9Z?Q Ԧԯs1 z?s.dž>B-"^5M# JfeBhś7AiK~aV#F6gːJ3>G~n%nKd;Y7a I̠kxrŃ+)Zs1y^+0^y˄&;Z=Euck/K8&N 1Ҹ>S`®j\X+o͹Dֺoƶ!zvhw ǣkZ0@mN C`OSĴY1e_€X?G?xA8N>Q>Aᮢƌ_l^+~cW l\`EeޕāXؘ&rTLͅ+$L$}PaYjDVcqf;W5+" q<[9'K̵_Lb @<9q 2 Ԓ;Bp*I RI$$=I$%;Sw*Zt~Iʹ|/qf,/=yw~JTQaRТǻ^ioe[GD{mw(= t$pf|~ !oT'_>eȣ9)țoZ/OZ9IboL;u`U_;3cfne- >д,׏HZ &,x.0<\ؠ {9o"65cƀ, ]`ف,H;L,ty^ĭw|,27jq=Ǣz91px[F $t\JBJɝiOg$4b_{(ꑲlc#~rQ !Smfk==Ĭ@1LrjckK*FxN_ĭ>vˀslXH!1fXя:^ cgr&NAqߋa+n#@4O1@Bac8cS65&H^bcLWcQL9{&@rw'Yڊ8~. ݊ 3wA5 aȆQq .Bx\5lŠڥ[q&dŐ'#3j _177/uRq&=MF\D'&--`֙FS=FX' V"܇O}cV^:0c;FEzȭ7^UiG 3/q09ŗ6[0ɣǝӟA)l z#w_ <Ƅ6?7$X6!0Mw6SLՏJvy1ܳ_zT EǪ,U]O*9i%>I2zo[?ec+Tm]fǎ1`]%\pw-Ĥ\i6dM!2Z~.3ad(*L6*@ b#/6"У.H[De$@,BTI+"I~%%mIr@UԗpP̺2IDb UG\wq1TYހɿvHJU\{Pv{-c8e]-CtyS&/|zFwA]Kù:>IfGNz0C"ɑO536,8|E3-Gŵ6ɵf9pb|Tkx ,NNt! t;<ر]@Ë>B~d ?(r< gEyP$ƿԌ`ܽ'Ҕm4 >3O2陗vЫ{3VPS+><ΆVr)B@+Oy~}If;j(͋TlCɧmG1]eaϠ 45zÑ&4V5xѥ˹r.;X_\t]0bCG#Oa` }q{gr:VLMG{ <|INw,ۨCL[RB̩+!1raw̨4b;"4*wl42@B@(b i 0hfYR",15]zAB ɼXT1}S?yU2țSnV~L2iݢ 5`YIF!rX(+1ɨV?:ju0qcbo!e -1xh5p ɳt oU3O)esTێ#Hَv PZOg:@J?1`+"̷K"ˉF٦u1*Rr.Sfe ]oJn/&2đԈEqY7pF繋[dqn! ~"[?fKэA03J9yađ{LZY KO|*UI$ AԖ$,d @܇] @؆,u*X;-M05pɡ(K/[lƀr󝎼yc-rx5`{P7Tk[ Rڄ?N6Pw/هQSnwtv躍A,)G 2z׫s 2z逿#!RF 4˕3y 5(X%k1}%~0\*~&6aHr˵G|Nvct[NYǤl],tm&>)ىI',jv<͸Ō h,wc h_pr7EZm>-%?L 5w?gM\q/u F )ŘQ*s їu%b3ZVyֈ;DjrfG PbM'V2$u4L~gҠkrs/ sL 1'g\G"XtafZ[7MLo& ٙuIбq=2ř?Ŕ3Aly(9.L-̸e?K}MB. ;_^Hd?v=.>8ń>=N3>!n#hHɕ&,i0T֤r}KZH81ͮ.u@7Sj!"ܮ^/rbê|~0G"2r:gŀ*[erҝl|Gݹ?$b =Qf+0iRK"ZScȋa}u3Pia=Wq''ʃffʁf D dȀf-IkR3}r(Vȁɩn0^3AMq5uGk$IOġ̺~0R$ B_RA.$#\bWPaBԐ±FcRO2[91.:ǥ9vNN==ubǢWJ-s -UvL[~jًuu0v_F5Aneu3Y%*ŲC( g5ͶFg&HtO=l K; 28<-v,C*jƜR3c̾Xю]J#TUY˙1ًcɭd ŶUPl&4ۗSم@Y[j-.F l_hiMJ0QɌfXt_PoM'sKŧZb"n )ۉRIIױiM2f&YZudGU@ɭΌN3WW]!L^GW:ƼفuvaًQqS:E; U[ :ljr1ܾ/0'&N ?NdM9'ȉOR yCf^dM|z@$:I I%s/D\Ԃ"MrCW(@Hg-uXǦ57ЊMGr>Lo3ci؛.G6 /|\aǘrsR(2ї۽fuV=dsXG(]:8p&. "h. çy5wœ*ڙIb{*QjwT֛vWD̸1iK0,Lʹ714pXGpXԝxkOs6,7P'bSz@\0[* ^Lo_ XS?2@ebt~d~bՅ,3q3EƝ7UR;ħpPx+Q{=~eĽ{Pd̹} Lv3gzm.FF[*uPq}KeNp(?=54d&EP2gœM5aVQ{ 1CQ&^Dd:r6BI>8prV~LdT5QȚ~#`GݎC@<!lƪyQ@ A< H!?'*ăTLq`G=d- s1uBDy\*f,d.sGo^&|ʽq(I=Fc%g>)$z%*NnJ.NLf5? -LߦUBMGї=M]%M~i>Oǻ\Zf>:]Mشu0j](^S/O)V8#No!cHDff&j}7 >' PjJcǥSM?t>|wd=XA0Զ8z P2qw7_tg)-c6%F3R~'zݧҳ-݃^Ҵrnm a:'LuS%`RNùIwVH‿s[a1voӍ&5 BK(m'X{915:cA^,90x4I%2 =z\DS~b|6hŌӆs幝oխ &91(q˄ݰP i .vV"TkK?W(Q U_aLe@s]H>n59FOZcn M xـ&=.8Z_)d9uLx5Z .¶ۨJsL#A4ɓL+SE^kvM6ft"QtL׏:|8<8N_Gۨ; < 1t?xLuV =>N"SFNqn5.nlyKGSB!08++=1,%~#;} ((c_Fm3>c#h 8وi3|f+m@|Kog4"Il~=Eq|ƹ|dj*5h5RnpSx}\On:\V܃1"02$`Ȋl)Wwiz9+"LNH~D*0]K+a> ɔѥ>!+XUUێ?oP&'^9XN}#6B!ط,Ji'LokIŖqB+oTĘa&5;p;(3pXXt5*2`Mhws3ct`äh͏"=r_2DžVSwrUˣlGҹS|&2>֙o0shW6 Q[Yŗ>prbwdLTQLq#S8g/qfw|:_1XGW=."Ӄylvٗjj }_l ecw ߶lp22T%7qlniV$m!}>5$O|jr Js/t= 9{>gO6fzp*] >{k~ XUBNJhNJ/VϨT:pe H5RŞ=)=!4r;=B8P#<8 Ɉ-JaĠe3``1y2$R7z<Ư;fh['kmi_)?sn_ s5Ů_$g#$7~bن$9صy'睚[%wt9s mz8y303ۗgs:zDڗ/6'OiV9qiT0sb p 玒ӄ!aƻ -A!O a|1cϒ1t&Ȫ-@3σScl|$ƭ6Lc)|^cosrxKBY5 Uԋ4Cٻc\dhm)7d6dÀ.G.4uDd뙍J"uI]3i뱱M-mO"u2zY3?F؉ޣ'2a~OmVTϧpI7ӆw)vfOd6mkt+61ϗvR,<λot_ozOdLwdvfG>OZy$M5QvpA3Ic< m@3'3KOpGu/UZXP3il3CMM|Sz.k([ L_];ɎfC\'_P͸ {F֣SL6;bAN}qZVx7\ e<"o۬{{W s@cRFX/w1ٟԢy5aYߐ6@6`4b[@cwnePrm@H%jZ^(Eم Jfe|$(I2@Yh~BKLcL֢i1'3NI#ܼ#|Hye»r$汔HeLWDۦ0o7'9:uW]Ȝ.V8oqp| F'd4?&A1,v,80ٍ@"qDu- h>H5zz[A)JrnQh~Lti{[ōaP qHFYP$gnl5%_"2e;vT݇N/DKe#>JR,ZLcfg7cT*APG"K:}ePɎ1MթW?T﹋pf-ȟ;D˓9GlzgG.:o#ƴ+h0h;q{UR5dӯ̠nP".}C ww7=eV:'IJ1s1W겍ujEL+QmBd(pI>&}>1ON.>Ed j.grţ*-<>_S2RT;U:4h -6?]r)~]zo{qv6宦uzqd>8*o+S(Sv+^5*09uvJxw1j\: I(.P[V1||cCwc,IQLh]l~b1"i>%J$p6f u~`cȕ>{8$6ɥZ&@3wN'W.:?(:Z?dcoSnEjmeq `g~6ڿ7SHE])"įL0ۍvߓ N w7:p1s5+,Vl3Ph+JjڱLYrW\]vM5ZՙCAN3hF-< TV)4crU̥v0eoBH3jrk8 _4vrfGF}Xipj mF.$^U'Z5F߉z!řMjҌ8C1eF,?Oh,yf`QpAJ$b8Mx^^74:L6Q{?o3c(t8Y4ɍKdsǗjmUjLuW[& ؠ&#>TMl5ZTsQpa(vd'XfLc2nJǹPHqc[m=3b8"Fjm`C#cK~ -Wp@}LkɳOt>LъFV;#'QI11 ̘{!qnDA{AU/ӱ54ʽd O2B"YĂBn7#;H%51뎡>z\|J&#LT!lAj0@>d/K2"n<Ɓ@$9Ԏ*PI=N1APn5Ԩ`m_̼~iT1;1Nǯn??N]imfL/3L[0Kn#R><| G MG@0dN'` \NTrmNC$1$eeMʽ<05ɧz&Fb:X˹ &l_2N5j1I,\\Q|'0'Ƶ,uۦ ~~`,=~hɪUN%qSZ]NZK `,\(U34,y{f`mS 19ri`xΝ}¦ B_>D2 .Z~cu'L -Sd^ '&S9?Nf0ǘ̙l_ Zy8W+5lEJ9m̞lJmLfUu6x"Rk3.mg/uft2 jjSы9MrUN_faPuK~$cS^ lC~'C.3.";B\E 3)j Kg%($ob]=Qi ~#PāJlJ.& *24OBZ`k- T 0vv(A_r*zYu͈ᇙ~aXYLH _Mrv^Lr<MmlwcY\x(. iv/zQO|ekLeG1ۃ|9N"KL9,^ZKilz3"^ٸ'%N}cn* cMsNgE}oe)tؼ$L1cR<*//g<Hw9]#En["5[ D*@n&Ű+TNJ'O)Cg&O0rۙ]c2'Ğ(uۥ A?(͐ENOK5*"7zi5GjZ|?VG$d|GŤ2EvjN(ۇHq>N6e̠OHS S&aJh`iܰ%~$c èn@D-]r^a_?0bR% =dEPz4Nl9Q7-O5_2Y K.-I*(#a),řA A4{VMu/rcL#wXNa 9P{Enk@cmljH n DKrhK̰j # )J`d(yem'Ra/ e$FW- |Lԅ7BV Z[n(q0@;V3|FTpXs 0ƨ&.[ĺ穓Tҁk?k )uX$y=f5!>۾&[}/Uf؈&rqj_M\j~'.8͈#7ܤ.qAF~gAob[9S+/*& ꛋ&URW0 33gͻ3rӓQ|Sڼ|ĆaKz;-v8G>d8wLV ;F{ߘRb*ta*f mͶ4l@b^T X]KPqDtdfȑ3Y{6qʸe"]cףcPIs"iHcjD^DrU3b}GҹB2u1lx> or9:i+.́Q!Ҩ<,6gn@Q 9ŗhd@Fhf,nLJ^m"(ٙg0e@+Ҫ.?Hr W~!*>4*Nr`x1mMbFK1 b͑eE@[Dr3|#2JB z0s+ ȶ%r̵&*ɳ%ԡܦ~T7ə\ pIY<$IZ \k\T*,h"{e\7Ԟ!I``3"@ [j)#Yt~?S Fkr ̹:`G;\\c`}:&E&[6qf/)_gox}MzFyd-mR4KlMۇۙ]1@/`;ܚ!8,j{@^{.~`33+iDl E}ߩ{ɻR<{1~L qoգ s1cԎ?ļܫфȫ`9it|, NU91zt]yy2JLe!f.4Mt&"0b؜f͕59r!k3krmQ7͈H761 dqnk&T\kDFؚҽ;>D;ZqA!jK5 nNVU޷F{Ejgq7ܷ\MIA`Z9r|fuF9#lFUYC/gFцGor68P˹1$k7 K{6؏P w, Tj#":bPҋr PIB2]ve A~j5Tq =: <\cFl&ٱ11>XTQ2e׺&ld"|-&9lW38c[7\&Aw  bķfqɫ]ԘHԃM:ӄ;'9"@#$vRS2dd*v+qf|JHD#e`.Oy*0.6 iLc̺̍t-8(#!]$7fաIJ*K ̸L⸸Hܥ;3ZئŷxqL*7G5 ‰1! Ӄ!/R:%2$?!yDan>!ءPSZ,M`jnt#U۠l~f/UJlMXD3܄3mb |LE6c}s qmrZ,obp :h0I7,oj9f1v0n8 lq*L9B7YE@6f9S+(l;nJ`\Xszƛq|8VD*2n> Pp;2j1:S\.2PO3hbTŪsp~wn!y@zj_LXvuaCK^_8$!ՑepYs-aFr8S*q .!mW(v|B: AÛ_)<23z 9-37[FjV|[WH1.i/|=Cy?39mjDс@n17 `x18cADqs8li`r!+3TsbEhF!-.ԘYj+k-ŨᷩK}\\r ;6xS,IW$@`xƦ2h~yTOhϏ޸^SeA($p*2W/~ebÊSȝ,Y1.]lC2cTߐT ׸/1b7]_=0,݋1'- ܦs&fdEfa b100b~ Ca `^{{bS\¤; #!Jy cġ.fFV tnt&ձA^,͆6MӉC-\Y@OP u;k cdэ{6]KSe_\`SHA4umfyVXGŗ&r(uWM?ǯ02ebpD_q㈵>ld5wsC2_bcrFVܫpAiYV8LV9-d< w543{Of mu\e YQ{ŷn(pʢY Gܴ,yJ :)QQʸпPlj*V j;xRӱaR"xM׶c@qPVR=5cB$]Ҧ6؁/m-Άy"׎ w&M$ ߉ P^jjwq-w.Jk7YT0 n}1Pw1n穳Pp DgU{Gj4 Y$Ɯf=ģPrkplHrpd@[0HjJ9',8,"be/Sk%[(sч dWƴ>n3hdʥXdEJQY50E+gSĸUr1|M Dxgr/6NM,^4MyiSn1@ *O ۲BgP~fV5L^=z\kA#5*JZW`Ի`RFcCr&' !Lwe,O5ZR3*M-z7&kmfj2)hN$''.YokH@@]RkZXW&l\JJDcX.n3jJG9I+0,Br- c4ۈ\ua,8vL: ySe/7*,:aG.O7 Ql4$+d=C+WrboWHrFD,%Y}y';&L׶p_'l+4&RhWyqhŋ&5 8q2E.M8Rn4u"(~!4>dsBխʞHz,rn7շ̸ɕ1l6[25:N/K59iClEeI$1iaD-pL6,rQG-y S7An;\{yo2}$K\E*4PR7+&qe`@S 7|*P+&]s-Ѝ8:9ƌyvإfeP\|_`$&UdJpGz0s!#7ƒmy-tLk:na 8(Kt.s5Lԏf\aPR {$ZVX/1DMOUX "ħ!z| @}LR2*'(⹨fđFiIj4$ƥZ/fIa=TN5AT 3̊~./:3grR@yS\. 2eYG?0-uQ!qBb~lJ̤e ^UJCd IG0p{!ã `}K*VNeھ謮@eKS. p< d|r$TcL7GD[YJ2~ c*8=CMuBJ[]X6 w PxyV6`ftƠ!#ĔcRT·TQ̫V=o@)&4{?^L1eʘm?|(n^m_3K"Ե*rBE;*p$3pADӀoh1n6acmF@C*t%_hNHcv2.6=`='rk0o`OB4PU%!uG>KDkH&wuDj@ɑUɉ@ɔ`@#XhZ0&Q pZЍ]-}瞡g1P Pz+=cT 4@ d*Q%jb,U TPIХ 8xʑ9 jUG I2)3!BLb"&lhQ֧wq3(#9e"otSw%n_#L(8T֠RUxĘcLԋٚBJc1[U^"K289BXEJ.(0:dhݸ !bRn!aKyk0G1n;撖y5 1,h"f ɕ2qSxVMg>̬uVT\0(2ԡ2W=FH¶L6^L[{a"a)y{`^߁as%Xɴr%?3-I9cH7_Pt%By$Ã{B&]ljqQXv>aFR$^Ix= 6o! (b}XjVQсcŞ .C{iDƔyZ. ȭoK blsF^*96cf8!&ZA50e@ rqb^0=-+MKd5FP6:6Ǹe{)FGF5UE2zhɧ;ќ ŰYOQEN{ >ڐbܘԬ.1pOv> ܶp"ۘw%3+P+{r,YJhq}<|yo7keD4R5?M%dۿe 6GP]Kf| (ٌJ.R9\s@t-Q1DWYƣqh990*vPbѨ.5SsnX="̰ g,^f^ąKl$17ܢ$\K(w$|Af;K G?2m.wr,P28c]^%) 'pnɑ܁(C cWk̲[&fwhr.bՒu =bbk+K^bS4m ] 9P%[ (xhdCA6D%0`*D5`@aY\n0LYJ@r!b}`yjU]X+?adF=1 !3fLyCy`)´R6 3PIYe+p=X-0f@+w.r SonPfdBGJ˗~ Ċt f`(rS!HcU#D&@sTʡ˹ I@wn1_̷d/h;[!9GxQ$4!{=h-.[A VO<@gR@1WL:"C F]8FX#M>fLXF OBb̲W<ɖ;fl@f^+ej"8'd0^3JlL=AJavIr  'T{}H;yT;7܀Re#m$h>ߙR{dFIL%ex1M=@flŸ7 TbK r3h1evc9zYJ`hs(0%tdDsĄXTV6en̙xoTkRU7pĞ@w_cT+̤c2P+sM:\" -L{OcFu $1l>@ATKZe-o'K|>yXhkoǘ]Ce)Bj㕻I_knOo33sXŇ%U˱-*acZJ7A,DoSquܳfDS`ˊׂ;h L70',Bܑg$iPw*7俈 /QJE&X1P؜jPkm0 4DkfȆ1Rc13j,_FcD;vo͘f.2;3(=I1m6ɼL4$zd= X{o#.ӨLQŹ,V<{ӘgZԜGmIwkSrQొ븰økG-! sL=߸$zX.90SMO>GJ/piAI"A?BA/;pT8Vz\w2?s2R5[d;Q`͛*@XȂXE 9 u3e68@*n\RdjXu60З ёGxh$iCܫ x0^' ,Un%9-w,u2"1A О((M93)a4K%߉{U8X] jو-@ajff QCdЁq-^\Pr8{,jk<(WRj}\,gS0oՈ(.Đ-W"\kV( hH]TnDaTFڱyON[kU8)}ЖMSEcH܀ S@Y8YZɌm5z!9Wic͓.OfǟR{xڀ5b+RěaX>$RKJS(wU-G'{]仲9`m\7 [P)Evamr`I2( #Yںn F㮣S7*v#q<G.EHk̼J 3B-rS H|E"qnx&i do1$[Zva*QF'3Z8R% iBf4(ةVlN\F`ǽ'Urؚ6P nKc+gfixDp b P^:{'S\~LYʬH"+*h~%1lH$CmܞؐS\NGW2f$,O> )6?[^6&CAG$1"ԒdG%G"ѿq!H/-X 4M Ј(W #RĖDc\n(qRh^lh`[)5@cWj kF#їo|K[kKW%WBԣ7Gj%/]Y)&ɐɸK DS#s&@IJ*Rc.% *YzU~bXTh)+Qg( +A)UFȺΊ E3U-!i 9 \,sm=ͤ\ јrW_} <@Vڕ.,(/A v%ur@Extw  $ٶr  9'DW̰ n-7. ~#qXd,=N#KL#4@ǧmVe>ԁ!՝.Ľ?ssͰKZn?oS͌bԋ u_[vOηYcKsLj") C@^k|KjU@EOF) o̚ӌ"Z>L<6Y`ve om;NLk I`@3 nr zj*䡻m$ -m|C0dʥGe qL (MqNTD#ƣ_>v%eEBr[V@GEv%v;J@rn…"KɐlJ |c m #{ 7wP.~c0_bS&\hJs c cQlIbg9D(73 p!P,^Or҉nZ@&[qxv2w0&F ep4cr%>';j4iu ,}g3ND3Yd֬01DE,,MgQ0(TW, FBmPUB[E QЂsQ-G=KfB R%̂M8RhGPbnVi,j.$-nn -%E#\G+_гE"aJ9LOƐXfa4#ƭ0۸`{;hMYE#(C1)nݲ,3q2Bm _Q9y.% *DRM1ecA3p 17Y k?h"ğkpenLQ[!0r¬" !͡ YWk bCm0J[& y{(qM5XTc2e3:B$NUuЩ/w3f3*{z[k}"Z-Gq܉Pޡq"byKasN%O"4L7 h/%X*טD3$"m%XxprK'vnzE!M 1qrlk+2'Oju I<@g>п53zO?b4Ռe8᪓ЕE QDP2A̕$3᜞Rx*"J{fp9}1] Ʌ{r8쉥dR3 KBZ^{<*M! =|(v-fLbweP2A |FUr.`T*⶘r"#UqRR?qO2 W4!)B-&V,,&u| J v%=i=CUGN=GB,-EhP94ZZ,S&m*7UIܵTTBw<@^Sh<|rрĬ`Q4x F⡅D4&YR hŌZYX`Beu`+$"? ET4"3 &7r̄Urӯ̪tOđ8ҎؒIZfX{2I3Y/'rI'?b4u$`?1de)?S6?IzI$b$d$+I&آ`?$JuO}̒KHՋ4I~$_BOI&+p^a$)è2IKxI <$ƏI%  $;p7I"-A))#I"H O$+/$Y$O/$*>$+A7RI0~~$s$~'H EeG'$URvc?$c}I5A?)dH,_2Iؾ$ 3$haI;ISgEHXjɓI,KK-{IZ:I$@Dd D  3 A"R~q{l~F|~q{lJFIFC    $ &%# #"(-90(*6+"#2D26;=@@@&0FKE>J9?@=C  =)#)=================================================="8!1A"Qa2qB#3Rb$Crs"!1AQ"a2 ?cC3VϨD&D&c'Led3 I}3Zc|U^pC5G1chx^2F*K*$w tFQ[8*abs(hq-@f$t%kK$^cv*7(I{f5c_UB&b96#T:;dhxl;HR"Xt#~o@V}".߾9 L"Z;nqQq`E9B%\ao(5)bWeDTO$W172-xFNY8>cqCXm'ndoMFf,h8 b/p0r@~|KGY*\*̢g%K@z/|5Pژ!/"X̢Л,0Bl {۩ ĝE$aGeRj  ąCX >%/nGq.# 2̓;>baV_I^^Tf6yXU@S%L+%5?<;z0E܄؃;dX½9ʲF VdGB553vv1陬\i yf'qukiɡi @'Blá؅ٚN&(c|ȼ$F%\+HampIi@uZjd SR 5r((BSIJLQ PUC\AE:$c9ASn; L$@_Q2 D{D ki "؋RZM{JaFP8$  h0=gJH$YԽގD=$ c;zi@yn}#ļj%8lnEC]@ /̱J%BϘQ[grqT (C<1p$zPBi P@Y $/5'C,s.t/Ͷ= 2&K8oh 0~ۡ,0QJG&h;2U~bHI /ɸT(bg'p`)]b  +;a]iV&.lUԽ}w^a/VFܼ( n Ġyzxfn4nČls.s,@e%$O؂- FA$zQs5^nL7^AB*}r,MgDoq̣5뱌W0NQ,[5p/uxۢ /pW1p1G5PN0?&2behS+n@B3w{hӘ١Д*,<&ja {ß`g(bXSVYK껕ky&U-԰G.J5P@ נDZD1>+ xg48'&C{2#pl*lYC Qv+!wMX,0)Cf@@mR;&@&Hs'< }DL$lK0ܗ]35 $‰%ۏrE -8+$jC-yel If#% k.BOA>?BOr%j0m(GpPh^yg`Yq\dvLRbLɰ~"QyWh- kČh"<5=K.P~`;#DM~935n53dE u2^ D2<ɉOw&Bs+!d2}ra b S~+vD׋7VjRA~SaFL/lT?sך139HU-^b]BRc̼OQ1fƽ?SgaofbuV_\kLorLx0~݋LOS\`e i:|.=+gjt62lyyVϹr& y=7b2j&*~ 鵟hY3yjtXhy1+DQ|NW %lچnHpvL:1f0B=H1w͘KXD-ileZ (e |?z`ORmOWejU;bURFg[3qaCdQ:Nl %:tNB;IJl]c[WˆKPwdʠ%?Os^rcgӻdje6V 왿 :뚼ù6ܞ3VCflSk_f5ڧyo(NvW4ؙ}ӲfwبOQmɏPq}ӵT{̏Ȅfl:x3VC3Sϖ7i\}y>(Vr@3I koug#OFcNW+Y:CMNqr7E0Nda`ĽsǃĬ.b 2WOɖA^^Nnn0j*U&a L qr&34yB 繢qþkPn"RZ;nQ̴qkGa'7>w`f-v4q}E9K5x\$t>eq' Ϲ!s d{ݿ lMš4 (l1G_&C߈_I|s\xsAR{[22_x15'Ks!Jh6r˝Q0H1pZM_&G>bϥ}Bk/-ɩbd|Hx"CN0@m=U\_R 6m>4P2P_3LlOV:uy6B r鱲KwU N O@Eڣbh?TtLt zG Ҽ67Yc9 p'_66@ Q{6=3ysF"T٪8b;)(v3&L9$n=_gw@i0j[3/s"r=x2*ь3vQV{A&:[1ŤɔsXJ&@z0 $"q7]IY)}& `O&W:4f`O+{>V} ;#7uͱ3d|&?4&=N^m:mMl\f-|@W 2cos:yb<}ֿFF-Ηe7Ҿs>E<nՄ/ÐuZvJ+Y?ū<E߅cR}#:kӧazP뱼jy.KȾzf?OawQJwn#<tO >S02 ~d>gm 2DSDe8σ؄BBU0њӰ]B_O\LLދθ6=C\zq&. ,cc ?@ڇ]BqG ~10d0l}#1l˧8VX1P›"-tʎr>)MeQ3bMGa"?* 0e:ʄ\ >Ñ,i9?f?I\9El. f38]~v9͓ lwMC3izfC1?m ݈lrM;o\f6:s^MΔGFKi67;ckY\pcGbKZun&W9UH=+48=N~ NQԵ3c:.*/1!*/ BA̷m+ȕ#V =X!T̘ V_RU!D#6AVw ykQI&E;ś0etEv `w c N;bCeT(`2dwtCpw|B QLh|l9Gץ|&#}ԭ}ɞOؑ JPO͝~ۨNTb݅j1˪ TI?b8|+W)U2L._3w?&r}C(c("V gOSQ}vcI?|ŋK*iO>L!zɐ9'[?Sږ0ٌx 5#t"iϨNOKrd |i\|3ju9} |(6j k:d/;dݟh= ve y;˘2cL36 ׺}ʏo.&rx'S41>xѮ,G+ B|XEi}xY#dȴĴc clVcǼnR:MeP{]>mˆZpI!D;:}3YH9+tN Bt\ g s3lj1(%c& Au:_ѧ-  Xj4DUU׼')E %"!Ke]6MG34[/*\"U?J_YdeRZBz,|PzIǍ6^ʏ7gӒtzl\xsNXe//3̬%Tj4xEs8"t\sRI=.TQ Oi33 '.ugo dܲ0㎥+3eN@3e0P_6e Tq5*&$!؂ `dBЈN[jLBlܮ;9rFϴ3jFEhh3Q0#KwN3mnĿmp~![@؝,~| \+a#:X/ NZ"`ќL>ص3AeCUɎV ?]$h؛jOG8͎c69/㨵@ZNOl(8{{EѸ۱Woe7m(.#+u Hm<|Mjr@X?](Ř4ES;),?ux|sg4 س{=(F98k|ζ96"zܿ>v(?GLI\R3oZv,0no]9~XWFJ(ht!oV2(iLG6Ҧ\$/}/8şMΧGXr&&4U(84궷}+ø)'Ux3O@hVOsmº!tć*`nǃ,QHHvWnG m S2s/`1Ѓ"#Y1Sj#rLCe[&MɃp k>B<_K+LlۊR62V8^k6\[4(MT邽(-4b#bӋ rZp [_1lzc_lϦިxU y~v*_s XͭQDb XqnoL}˲R%ffgM&054&=8my9YHt5#7=$c]*l0v>!0L$%\Ձ67wC4XqјYUEŌG?KlaR٨foU!b\{ycgɩڟn:edi 1|uxhaz_!CCbLrGYڽV5m7737&zq(.}26"yźLVs}6VCOKaR,|{.3j4n\r" mc.<ɥUoQ1[1 t^C]Nߴ׺y_8JYeyӭL%o(b +m;2U& E(!/ ϙ\m OX7zy3Z#YbSk3]fU'-t{8]LtXME҃G肨$|8 4߃~ 쎦>|Mn8,frfd@ٜv+otKJR+&Q:[ ;.%%cI!k e4']Zˑ]r SeoJVQ{p@e?̿r2Ƃܗ+qk~dluĦQ>&j4-⏧d<qwg=Ƿ%ipt7Vr=@9XS7S1ecǼnc r10kwc!d͑Knc=ΰڎ^2mLǟJp11ʬ1r!UD'c@i1y7Kʃbj)+4 d|3a: [y5 PrdwAh ֓>Q қ1 lZbL䞡#='}7gkuds1u\Q@uWBLZQ\bG! ;n$5~F@1]"*bBS1K#Wr+ ##~6߈7;8db6;?jr:3QvR3c#6@?k9 }JI&ji(KC>"Ǩ 0ɦ?#Q·w-2]m?SZk#5Q[OLg|#OrW5EʫfzQi\EX 9Qy]?rǏ?vf~hV윟?Bif~O_4l׼cBmSM%QDzV?i]= yWGbq:_ 9WM02Ղ(HXQ7!]'rBQ*e=]ܧm ݕԕx?(,ȆY;z!MzP@* A"_" CG0 +L ~{]5Ѩ&SKY@n"̚yEaT4ܮ]rz@xG+ e:9͌50 1jyN6`&^Ɉq殥F0 W]| O hXj7 IT͔7ST0X ?@sȦm4~l N+IiZ\=\iF. 5raFxDm=IpcSuǘIoȫCi<I"yQJ%K=ג*g?;Lۍ1;~2q0^ TWy)Qf.&2`oqobt>{1dm»5y7tE'RjdeߍHr>H1C#muQ\n3K!'ij-qnbBY»i&Z ƞv4I7, B5,hLWm 0Kx<--Xv8""n4`+yh,)f2?! mgJ,8! ]EqWR@.Zhƶ{Ep6Zw}ͫ@Ujn1=(]F9^뿙DPX/L,"[U] :1O>byVguy7Sߙ3yfˉH89~'yӚk6b<RSBV 6W7fǞzcɹ!VezIZNnGI =Cv)oI[d>#Kro1r=}{-SQE9j;0[eZtZeƢ36P[`GW z-'e@ :L1Z11Xp{Xb/P<Ѐ]Gf.'= dKv;ؖ 9~_rه2}^Ȃ@&İhfw$ t N0 P֢)WMɧenF@B?SF@c1xە_5a㹜kyaQS>ebõ5)}G#j\Im;S7 9}/9CtH-W&z0R VPyRz0) KwRARxuRʏT13v؍מĴc`7Ի1 TbqxmT{L {1DlV_sW@}FQ(10 X>O)AELtb"햇z#K}EbcT` [+0[B=xj$F1U"2Q`zJ/`ܕ5;EL}McH~&mj,3U{B"Ȣ$ ,n 7ݐ}]kц> ^꤂r8B1@_I\gAH I?&[;t,+Tr$԰|ICLYn, Q7Kfݞ!Vf'3-$y|Y$ (J ]Qɾ}}?R@7>6w, y- O,=TwzH1kC0ǷϼS:]ݷrd%U Z T\|ȩb~S;ʵ-ʕO1{/F[@iNuRq$`G0Ic"PT̺ok{Lc.&停ёA'{*8Υ2'no+K-Nf׌\͞Y[Xc ZĀz:9%$i$ )W̧7Aw91Pf:s1ˣAN3Ş.:YSWsj*!ie72DߘS B-c520"wߴٲd}"gӠ^C@3&?v0;a]b~ >&SPąi[cD.O xaƓʋ>`nTS{_xAKQ{4aR=VGqEHQ]iNw n7UJ#Z۱ÝvD^lYA oC]KخO?rɎp&/2Q fP]BMS\ =b.lḁb!IY-=<wR>P _rnju\,BǐW3)TJ=)㸳nUƁ@+K B bz#㸧Gr@L5-lX<@'m(%+4',MJqRۖP%DRϓea >AتMQ `4d>ҙYXSPsBVJaw3ZZ`l X`DH$ٕz[1f 7|B(n,āMz9Ɩ8e- &X"p & )0l~D`9@@ٗث= !Y kq" ep{bS" Hoh lJپɩ%XC@r{1&X-83=)giS&eR}B(w4yK)Ӯ0Zҷ`%.@`w]¿cX9SCd6ixVRLsqq&Lk5S}F7y0Te1%g T[4y33^ONPV<s;R9wFNqIGr [fxi*#" {qW [ƞԵ 7_}AhOب,ƸS14p77iTYK !ರ<C_ J`o Ѻg<ـ /w~bwTύ^0w2T*#Z/1/6 n|ɏ1SD3f-tܛQ ^JPwIJƨ''Frk::3[Slj[5mR'=rܚ++Eԥzz=3 !+$bf}SVc452# Q3ALk (ePW L :XGjҤ/׶ q0QP}M7g]МFsP7A*"z ƣLMFlw)&k@e$pѓ]dam״#B+"оA$Ge0 7F2F.G+sgŬ9j8#zaP4oAknj4*^|'Gf!qhH,:}fJrA]yoF-&<["qC־ZɏR;214-ѩ+]'ǁp6~k~1! =u4a҄2|Mo1þ߃̚msu~ZEKx3vO/Ļ}XqP5vVW,m#h,KJP+c>7辣º|{6CI*/D:P!6(_S6GYZn-SNGpH3V@!HnhvlQVl>t\#3wӣx4)=t u4 φb59/1*Y9yrc% DT_yܰlF-xBW1 DF栒Q*|u~O94ǹ^@嬞g!UpL6=WiKΦPu)D* lt91-oׁ6{7{O&FqGZgZ}/\-EYOf-ƼP[MIm[MO;R3($p>CxCg"5`xT$$W0&<[ gzj_/6(n``qu}\G.+prc}D2_GGQdBQbYl>2 RH؊r/+~U4&bo3dkphMAF ~Y1"\` X&q4_Q k3vv=qӞjۃ r S)X饰7ļyvD[ 71yZݏ1SWq<_Ƅ=^rʲlg>eM3~ɘSO+F /:R=` :GSmI~d-ŷ/^*#/E\ Nq~Ptqfi.fmձ9WR485-VMQ*|˘ne!Bt5q""O2.j-VP8cNV8cɹ%@Iuվa񿙥v \evoz8=jUP:cy% CNltNh8}lE>رz3lm=S#urq1="ďzq :q'뉣nMݰfPaiOP6.o̭}32x_&-['#Zy~fMrGO\+M&k pf=f1):pV/1I9'/>.'O%sRYF ,yF]qRAĝUW5IQ01 ӄYkCXσ2^@yu:s#3sr"b QAs-N4҆?u3⹯0IB ᔳ1)^q1LBH,n DU@3mQ,ޣ례WQuύK2ؚ9Xsy@zx6 9 Sebj0\L{lr' 0^T*/pˆE^bY &FUe0->:JO@vPI3lSPK|;8>oQ26VkĿ}~pT/so9%iQ3x?i=6]2 h1pWc''>Лpi4qgp*\ׄm:RgN|Glؓ.T~9W6DeV8?k#. ĵr)j>cekE+& J8l#uja?}I7ѝ {eLZ'p\N35 6!D q*AFLlmg&M,oCKo·sifc|x\9àk18y#TdnG9oƼ窃zoLEq5bkac\bd^L-m1֣3M }Qϋ݋f<؄pyDe$$ af hĚrssFMooLc?E&rLb gĈ ЛSn-+h'Yr74/^XY㩗_l\*R~d?ɉbseDz"a9q@QocƧ# &s>eE= q\q-vlōiDg_3̽WHAl%}b_!L&u .Ԏx:O*M>9מσ7i!ҶClSL@N~0KuN4_J}7aa] FsWR-\7c0`Ԩ ]F&o]ns_@,C{Ӊ< )*p^%0+3?)JV苣ϔrAc:d4-yZЙdv5\U9AM0hia2!O2!W7n7@bBn-iff\vBjevF?3&FMVtu&݊/̄y=+zMȼ|"9,Q2=5gk#f}|^ЫC!}B(%ŗYvoG<^BmFP63^H0͑#ۈ "n>MT}/T]O 20Aq :%,<}/.2`i>~UB`U_qԚ7 }gT>^FNm~><)M秗}1gRP3ze:e@y\x1jL>\"*Vчy1`0R>gwv >Rly1dFܠb1# <1'.ֿ.lAdd>hk:׿Zw܅P'ӛzfns5J:glNأ;ř6 ^/ĭz^OQV=f;E ` u8ͅqe,W!qOP0y9X\cv>sN'p]"fl[]9-n$ry1*s67xGRļUb}=|#ӱ2f^fr\F18cQk\+qdjj8!R#f)BY{B 3`ͺӉlz}6i-[}};GgNe ,?{ F$|qS0BI"y12n==C03+21#\f|p>sugrl%Ǚ,e e4oj݉x{ӹ3[kih:V9q#K6a[Ac6Vbyddq Fh5L vB Xo. ec&w)y/(!`gypltjVjw:QxV x'p336nO]Ł@Tx6?$J@_|Y(z-mq6ݺ/dftf{A;nxc"e#-%wײ5~[꿉ZuXm0υ .G=kߗ>Gg#}N S€" 7f:?OY\Ta36L]:ktLv gV뮇9 `|#O=\30jrRcNJ݋U8C0']"r>}|ͅI /mL]7g=.ѻ^}G| /2v2F\M^';QdkgK7 d 3.[Ǵzn,,%o|^~ 5CId/Nf 9Ms+APsSNy︞fe^yB9$g"A5sc|`0Ա@? a҇dp|Jdl Y1Q&{G9#fѪ4c;H\d%WӣDُK܂|G˼OM,\7Nl|t<,a(殦YvNQ:urc+C[Mf͛&o2ug2Għ3z3Oc?W10>B(N锠l͚}NiQ#=:s}1%dlxz3CǼϑ)jq<նҵq)W0 (XDԲs !S.@qQWFFeB@=Gi3gIǫp.UΛI'ϜjBxE>2D[SLާ0 `8U&Fr7S{b @JLz}!$鴕G N=]y{Ze ש1bI(M?Q1-?p٭wY5 uqWbJ1Lr S;Q"w(kn)OɊiN5LR*ߘ)>a@n;xH*eh̙9s$5q&ďHɨ`} kgr=I )7߉*6M3U 9y-pF6_&tO8x?30AU#F\My_.]#s ߯lm39j>RRmfhcpTFŌn5-NL>f2o>yC%c^оI/=?O6GrpS\E\=?gM_W;2Yu{Vm5ah_ }bLBg90Jovd0m]*UX9sQ~lŦE| CFSXxqc"tվ]'ә3Vg\o&]3u>9~uܽ<\{&wm>Ffqsk{N:{yT[|(5ţlЎM!1-j'GK+~Xu7t'^?UmXjr uGt%♔̤*fW3yA/keȼVVA{'<ɗrsmchm/T_ӾxNP7ׄ>q:}%fVNE@*SfNuas Jܲ(2$E .a7" a|Eƕ]m2<Ě6ǹj:qΩ@eˏ"&{(Ee}<ﮞͨ#3\,G ;& ɠb!ou’qG Pqz: j8$S~Kv1=8ٴ&c8ڍ #Jo$ϼǓn+yyߴ~%u`|Y0oǫ01IT!#7_FntF]́rm uԧY}z?jtz\}(V½_DbU9wSR)[3^R2G{yW2:::t|!I阵_I1G㘽>(P]AXP5s} k3|zc;;d:QsOk#['Ĭm-WTFEqV|sP%-9I\ehkuF<: y'wj~nVQ\{h2fِnT Bn<d~f'-w7qY L,u*;DS[˺Ӧ#y1˧N蕶|͏pjsg#!8`'ѩ눐Z~&7Āԇ 6%Kj64^ v#R(܈kh5nmA~&bA"ȈCc&eˋ:;bl,[DŽN @>[n#?[]j?&ٔ#}f.Tf]@pnG> jMlxc-kwlxdEAD~7|;Fjd3P.˜o3;+|sf-}uxy}wenB7P28GQC 5SV 3fxVj #w#11nSI:V{[S&CaclO 0Lv@vUT ǒ<^9 Dbx*Zm?ił33LH"ie"Hj1ob'%gJql3C Ė 5-Q 5hmϼKw5|sf$1؛5bZ}?3271XZ1Oª*S5PZ")ɗ^Kbe!d c/fgXab<؃u̴Bҽq2MX!$>cv4p;+33E%E8lٳПőq9 xMk K>V G:FxЫX:σ"7!e>3ic1<ͿeD۴2{֕Ԗf\l=d|NFC=Y.ˉV5sY}5t#2fQ2[A7A*ơX'nv, HX1_:{kڪ#UvrJ499z}3n7 ۻx&Lu]DV\\% $CO2|G2$ Ew,b/#mPw z E*SN1!Ѿ xOH:|7 &3Gpx7l} 1w߉A=\q6'Ǘ^7o{i%^t\x1)tg@ڋr Gd18݀9ls#lU;W#0+[|ͪ a`7a "K-uYWMhOЂrۯaw 9#}]|K/i)Y򌪤 xUbU<śbX*4} r3\?RaެǥcbP[X_c@n;oY#PF̎rJcC0|̬1uӕ 4}cB!"gj;!3d4 0FUsfnDrcPTJ7)?cǐǫSx('S{7!4d_  2K%IM)Nv8[~'Ѩd"VglX:l? *UMi*Tw5j9dT qg9>6J]ē5:릆ӭzf V*W.#7|3CK9jpb2 n̮r.3?Y\Nzz݉2JۻKk& u W$GcKYϹQ, ?-Ү)K> 窌pt:w,he92 3z̴ǻI? ݍo,~r@QK$ZN73HZ5]cC ɌэiC0`ڊU>; J6_y̭bJK M&_H'a2' 9t@pˆZū14[X }.">dɍʞ}gM%|!t` ߙ!ϒsB 8?"сy/&jARyYUGy kvQq41'< B" nI!iԈ)<+(Tj RȣP[ h̐+Q_hFrr}@\ѓ@H,ƨcQhs$ZZ"*e+,(̝u,@BUZI.V$#$ ԽV auPbL+"ZMg%p$ pxڲ!ja`+i"5TwR’WJb b%4I=mP%igE$< Ȭ1F5p"ulfȫ#q3m B(ܚX&F}V`%N1RoԇQ8_y@'ykˑF/ s7uy<= scmk0@ok8"ĈS/1%@^ ҘqlZ1}|@,u UZ+\Ӑno76ykNVmĶfDtC}'2Yv߷!Xθͧ)ٝl@&3,7x=N}}k48uhĥ󹫯Ha` i #qUFy^e5ȎaɄ1&gYJ42hEl 'ԡ12 B +f J+|k"Zp}-eZp=B&_s-E+/\2БpIՌ'V -1 k )MХQi% 5\n5|$m lFڃKR]ُb㩖k( 7(7R5<\"u,5,~%y9YBVq.dѡ# `QIn @``F~Xq5__0fN M]j`m+.F'dOB f+}@9lG":?̿2MA"& KbKՓ(LQI0yڔ9_7~BY._F*;F@=H@NN`!jKY$54.?~`^l (qIGF_0vYOYko1 d;Ƹ1!)nw "<&XШĉf\GmB`c#&D'[M牤g#OiK _7$؏ı[+qvǏTxu bnS gm渉$DM.- "W=X%6U@8 P jU}MsWG#^]p+7"#kr#8"#ZDZ>9ɧ 23#`dCM &-ܕ>a},>*EqMVޚ`yQfō`d{)0LXK#A dh,(rh7*Ǵ^#r A<ŐXo-b˓]KV+#3JH*pa0A-`] 7Gqh kVp!X}qn?ċqf%yY(q c-HOKcjE8Y &/&-Bb2e)AIccA%&,ƯIOYH•G+ٳ(y1 nB a  ,n㪕w$PPXtR*/x2,ı`6 6RpC\ِr ?&jȢge;, ̛u$XF=e F6!Q#Tw7i2nPoܰ;+=`TNܷ?ʔ,G y1k@&דbM ȑ}ܼn7sHJSX"5=.77HN=D{Cˆ0 -Hˈ^;@ǕFOq֭rKQyXYƸ D|ב(d/!vfN(R,GE-$VA}07![2϶A?]WfƵ Bbe3mKYF/A| ,:+ܕ)Ef]q`ŎG}FalA6pDQp k̪Pl%lK ŎL2 X#qQMYSq+q$W1EiPh c$1G=88rU$L(*kqY@X Ru@~T5p{=A1o~&G4N=B DP*yi%mB]є2Iۈd2HoCÈ,Ê"* lb㊇U Q8&TDÕ(Ξa0L8NPzĞGuQ u[P9MjPb\ L rr[ Hu[EA T`*W>a \\Ԭט!ehj/)c@ؙ5{!HXjԲ (=JDeX&ZA VXe܅A@Ɩ e`;l&nj&<,O?}}}0*Z*"Ȓ >_tmT"A!{kȁqEOY,P'J*F0 v%*4jcws|C#15}(eYV{G.Eq׼19udCnáqV@1)7|7H+ CcdC~=$ r4MEh7"<=() Iu!,ܚDvbۈȮL 6j[HWioA9Ҹ*f0&I hȋMw$-4(͙$^A+$q$5F̒GuqRɾIw] $4 4I#̃6-_Qӂ S$9jhD$`Z?G7$,EM 8I&V.n>I5f$$]aϕ6уhk7I$ulv^GÓĒN݌$>0-q +$j<ܒ@BY$1N ͐ $^¾$;wk$( dQB_u$kqܞ$Ś I4B fatG0AH*!R(,A$|@T9_5ԒBNlu ㊒I 4xƅ$~bI"J"e(*j3Tؔ$԰z$Al=1Eh\H%v$4I$Q$$If!vh#v :V 45 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4aN$$If!vh#v :V 5 / 4a\$$If!vh#v:V 5/ / 4aN$$If!vh#v:V 5/ 4a$$Ifb!vh#v #vH#:V F t065M5;ayt,$$$Ifb!vh#v #vH#:V Fh t065M5;ayt,$$$Ifb!vh#v #vH#:V F t065M5;ayt,$$$Ifb!vh#v #vH#:V F t065M5;ayt,$N$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aQ$$If!vh#v:V 45/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4aN$$If!vh#v:V 5/ 4a}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q}$$If!vh#v:V F t065ayt1Q^DdB  A?04Immagine 1L:\Dept\PAPACONSTANDINOU\Manuscripts, Reviews, etc\Fatourechi\Fatourechi_images\Set 1_03-01-02\04.jpgR]B(+aܙ@f\rF\B(+aܙ@fJFIFxx fPhotoshop 3.08BIMxHH(FG(HH(d'`8BIMxx8BIM x8BIM8BIM 8BIM' 8BIMH/fflff/ff2Z5-8BIMp8BIM@@8BIM8BIM RKpc 6JFIFHH&File written by Adobe Photoshop 5.0Adobed            pK"?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?1s{Nz{ASjXK]N/\'77ѽڎ,T g\Kײev }1yыUc暅Ye!~v6{vjak-m{WPwf6A(Xc[@=[#fn9|*cZ$F:p]5U[x{ˏ=b_/[Oʕ_ G r չkx 90GeRV-8ޅw'EH*-OxCauc FGY\`I0*Ycs)mL MR}{y 8X;@z6xi^@FV@?K^/S7kUWm-qqC7× O~3F|2R |ܡ,Oγ2PgBA{oCP=gLYak^ H<#ɼvy~k>wgʿ~q= Ѿt+cCL̬oZ7#2i,~gQsq2HqЁFfQkZKڞNW&`3#fd6IGߒVufNE3P;,wQ52Gqf,׀8~"/Y|xQf"uT+x1" Ab{c7c'/ɉW:a" gV:/_Fk 1}~2*y Ξ O(fnO$ `#Tkg_Kװc[fX~!1b}z CSj@~ON?Nٮl;\].aiۺ]ao<ZֺGkzXcSasdmнm!Æl`[~Q7= xElU3Xiԕ}]sf7{[?CX?$ߴslc5L~gyO'/8GYxO$!BRȾC۷9p&'n呚۲ZQS`FvqO*euy6[K7gD mb1k\)g#wgcb !! tk.NVp1`F7\7OaOlw*6>k: Jk_/yʏ o殝_8BIM XICC_PROFILE HLinomntrRGB XYZ  1acspMSFTIEC sRGB-HP cprtP3desclwtptbkptrXYZgXYZ,bXYZ@dmndTpdmddvuedLview$lumimeas $tech0 rTRC< gTRC< bTRC< textCopyright (c) 1998 Hewlett-Packard CompanydescsRGB IEC61966-2.1sRGB IEC61966-2.1XYZ QXYZ XYZ o8XYZ bXYZ $descIEC http://www.iec.chIEC http://www.iec.chdesc.IEC 61966-2.1 Default RGB colour space - sRGB.IEC 61966-2.1 Default RGB colour space - sRGBdesc,Reference Viewing Condition in IEC61966-2.1,Reference Viewing Condition in IEC61966-2.1view_. \XYZ L VPWmeassig CRT curv #(-27;@EJOTY^chmrw| %+28>ELRY`gnu| &/8AKT]gqz !-8COZfr~ -;HUcq~ +:IXgw'7HYj{+=Oat 2FZn  % : O d y  ' = T j " 9 Q i  * C \ u & @ Z t .Id %A^z &Ca~1Om&Ed#Cc'Ij4Vx&IlAe@e Ek*Qw;c*R{Gp@j>i  A l !!H!u!!!"'"U"""# #8#f###$$M$|$$% %8%h%%%&'&W&&&''I'z''( (?(q(())8)k))**5*h**++6+i++,,9,n,,- -A-v--..L.../$/Z///050l0011J1112*2c223 3F3334+4e4455M555676r667$7`7788P8899B999:6:t::;-;k;;<' >`>>?!?a??@#@d@@A)AjAAB0BrBBC:C}CDDGDDEEUEEF"FgFFG5G{GHHKHHIIcIIJ7J}JK KSKKL*LrLMMJMMN%NnNOOIOOP'PqPQQPQQR1R|RSS_SSTBTTU(UuUVV\VVWDWWX/X}XYYiYZZVZZ[E[[\5\\]']x]^^l^__a_``W``aOaabIbbcCccd@dde=eef=ffg=ggh?hhiCiijHjjkOkklWlmm`mnnknooxop+ppq:qqrKrss]sttptu(uuv>vvwVwxxnxy*yyzFz{{c{|!||}A}~~b~#G k͂0WGrׇ;iΉ3dʋ0cʍ1fΏ6n֑?zM _ɖ4 uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)Km&File written by Adobe Photoshop 5.0Adobed@      w6  s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjzm!1AQa"q2#BRbr3$4CS%cs5DT &6E'dtU7()󄔤euFVfvGWgw8HXhx9IYiy*:JZjz ?URAîڕ`' chPȲ⎛YaybP& G$Y{etCr/=ױz W ;/FU|3ro<6֤==[dJy$@jGzۑP + IcӯN o &I9!?~;3RO 8@Mm@V{n!S1d`:$w1,~j~~pJ [vNo+)&hRA+B:W| 2HI*ODRՀ =\*K&+zaZӾLy0":Aysefٚ[z2Ӯ!;uI%+!$O^̍tGX ܡ ב.؆%ܲJ-<0-&Vy$Q7Ѱ1_5[c Klb -6i-8 8SYA\KڡvTwn;s쨐HSݲE&{u}>q,XչH #~+ItrLsRn)^ǯʸ<)ewvc "H j I), EeUQVXWUn<A uN0O#d1ıř`04@]  !qUF({at妎 nj^DD* zB-ujxtC^T@ EgT5ۏˮj%cpC{dD+I czzn `vLSp* tUMrc`nJƬ9O.k+&NdQG.C)_N$bed3QF|ec2z1}^+[ NOۻ+mͷf95lH]1c_Pk˛ؙ&vGߑ4F1DB=|WYrJR( =BÓ_k-ïU(_ſ` oSGCҿ~}(A/NG_;xp^]Zj{cD4@m)ZC^gEoY7P6¼াݹ[F^:n=ebX,IH$ lG CM1gI(R#A2>`6Hjx0<,ŎU>(iot%MC Jo?i`tU}\@Ɔ?"S>`7;mLUBFC~Gތ J !&KRGӌ`*zҝD V-ga-w'Gٗ4k]&3qd&9(, tep*+"S8 J‚(>Y:GIlĴ5r\$s@Hٵ9PPo_8ΑـP֪( Iimݕ%1 W|!o'Q9Q#vJ#&6S$0'3W e =i%,a%x'|{~x ؈F70IʊmdMM*+ˉ*ƃUPdN4su4)QޔY Wqnx.ǦY,A.i\{ _ce'5b>&pII]ZJYJH8Y:aLI)6i?%H+R`H = g5C#LI.drOj>udl1(!EMkHJe?XoMYO'; Dt&t$65J|} CdbB72UҔۨݕS3n==UWcY.2=O>~PQɈiMsk#|WV}2>hr8#s}>?B.Q5a4$&!Ϋ_8;/#q̦F?FfEIS϶|xFroӺ9h[0rHaA)z@s7 UMO D6Giir*,H!91b _ՌU*|jQM-TF$ Qp eIvĵfR c 11:)^%´ujM2YP~w^EXG;vrl }7N~odhڹ:!U䤎\kWSz54peSH(hPc>ʨyQy<\\1?Z%D*}@֝;b4m%SXP¡k֧3}:}G$r˒r]F{g/S@Q=ߘrA*;!bƬxFi$ `(Dc~Jkڻ8oe8^5,XʤH蚴K'&|=J+3/"jb'|S$%JȍGmOj蘖?yg5BJ%{n-4=/̓Bzmdo5hؔPS*Jk"gJ) uKH< zg 1I$A&y! ,hFk"QIDߓ6=OLDg'?.<y {;c}8ߙAjBBoڽ_AiE1Ѭ"j 9"@30G~_Z +k==;A鲜k8`.>>Od{@jt7@{tai$!eQa\ky*ޞ88@_r.7ABi_>j)fAR҆$A=2EbFvs HkulH=q>RvɎ`7*ȴ7H]$ 12A6%q, AP5>=H'0P-v / (6B+$sb}V7Z=>b"d,rNKntI]A/3n\Nbwr*2C\F*& NݏKn*,j*zPVd? _<ښ$zFvޝ=ҡ^l _΂9?.x,A4<+~r\*$YWڤo˯LʉDB⼗Fƫ_ɷvuY!kmFpЃ_P+VeXl,xSqyAc#~cj"+ObNl[5I,:NShY__O=K!H1lS+F@y'Y 2'p>&x9IFE8!dzt ()/߻ A\EkC3s=$Sl`(Y0U*x/[/TX]eezT#[:%&zt#dXWcd,& KPH^T2bbj@AA#w=2'1]Thf%k^fq em"cڔLFn?4;0 7YQլ'B_i -|:2Uzqq6<Ruߟ=:F7Bz(\댯Ds? $}[["-*7L#3x};g<'?iyrkN\sŲ3̑XJb[2`N8~ʉ:Y2@n T\y^fwF1dvq@n½k`#}RRǶLQkL/*fQ@2\0( ӭzW y%Y3 J$0! qR#QcD 19^CA+\I)$K<<>chiK܆$fnGdmiDqFUMvXbz1%BhFdцB%iD%5eRP &4@Ɂ4Y >3Q!U$HUt/]9Ac2+=Ƨk"&Uɀqe+e%V*?LEeM^3=v1eLN=vt% Y~%'\ؑkEQ!((CTu;$mu M뱫r%(iϥ|$"RԜi(c|Mt?CLJ+}`:~彬),-W/Par#^xѢaHam.022&ErJ[jIw?e$Knpʪe1)cHsuM: 8HYݤn>KJҞ ׂ0eҢv26ľVjS* ^uPYR.0-" PlN^|&!{~?)c!F$mKNGcŅd?h$q oeb֝p$ROKYҠW>>(E*AbvdT7Zd Uz_ ,LOr_/M8;ja'RVV8>NxF"2 wxԄZj(W $CHYj~&z, ܎hkۊ=\oLT{ H]IM| {׊ J۩*ۑ^2Y0.?`NXiQ6ebsmᕉ @[Ȥ$Go- 䃼!M$tPJbHҼ.$M5*^+䀆vZЍrlM Y҉-G!~8>r3ɉs;nASp|~TP=PiyrcqƛӦJ1a6_Tۘ=3Uߍ[p槝Yb tͿgWy ZDLK~Ii_G/IM]M KAcT[?/?z7N.p~{X-| ce#FqoٓmG|dO6OJ5}BE2osIA!e(3 WH)[ƑۓC=6:1I6^P|\G Rhe<,%BBH֝<:MtS5:vL0bvj7\p@TR'qʁ|,ڒMsj*I5@ry6U K*cD)Jl)4f*k܇5D2x%Ӓ$ OT 4c\ڴ3 ntLLmYKX=GiL$l8JU>ҵH'H +C29P?mDD(^^bWpkNy0^`/O7Q=krb|)tO9ezј#ʃ:#2O2JeZ|qp>5 [x_NcN׭%Zxm?]h ",҇#$ԅiqnuzQVr$݅ zᙌs&Gn&4zvS8Dr!/ (6Cgsr!tO/NQ8[nhFUL+FΕȐV%@cA-{0V0E =rgV@UR5Go{(P{,$Lj]G]L<#T$ cVJPW1HBO4.Y)^li Kyi逥k@ k2Qi!+ za#"2> PIׯ㔒JGy{ mjqBW$E'.gx=! n,1ų,Pho@В6dcO*וɏiJ׍0m7>cWSxȯ$ͷgͫ] ~AR?*.5 }+dž$u?)kpz,UO6Z^qm E4"]~ţ5TO~ɓ>+t@>>F0-vg5EeR5anA(m9nt6Ďpe>DP b%ѕ,BAGW," =2z~#Ӧ*a.on>135B]i~~8pךA(HqroOV|%/#5IڿA)Vԇ*5 E;/Ӓ2dl\BQw裥 ۾ =c-OQ@;5ޔ$moBNJ gX$DWn`=;A^&oF;Ss}fx(U9uӾqcNeQ ,}ֹ7"&k D\ 2 rGwKf\ 7Z%l-\Xݞ>JVIGrQ8(!?^F %D\UN)$j2Nndo:(n4nJMVGֹoHgY"U=]H"I)*v+ w ~90Q$Iwl'&6!_U-l>LzLg!s|>++‰6cN[oQq'/q}=Cg5SEoR4YD NY^=@,NۏcCKufHEv {iMAOxc 1V JsHHѓBCXJ}f`MiҔAJ߻0T,qaZ(Zay3NGZEkZkz rE#"H#5BA ceyMcr1eOPrPĶl&' ùU>Ey3DٖF$X[^Ps=?329$zӥk֞8 nV50v7 lXP*,0öq;]dnUXW=B%:~ l:݈U )Z톐wW>T*deT&uwy:A/J?_bwK1{RHL^UoB ;˅~-yTq>_\{;LPCo(\^< rC#f~I[<>eVB)>u$f!fo"A/Wyfr5P{%3i#mT FY- !}H$f@J)V1-}5&b 7$z/]$<0Hj© @v^(IB1 >h ]8"OrxCI02FIMvi,{IXbǥ\ IesJS}k]6[#J]4OӄA-Iˁ iޣ'%2hx,9UX;VB~%߶_)xG`J4xz^e {XWn$î{(@Hy HO2mPѭb};"Q*|r-Qy!>qljJx- >"+U>; hpRH[T xDKJɖyjvKb-9_qiM'^j u&~HǏ25sƳضx:W`9|$~?vT]jrA" VȖW.;nNB'aDGi&%Yc?6(ym?Cho-j΄Wj9n/ajG%~_6lYF+BAdw%hȠ=f4d.^h⒍=Ȳ?µh灐]b[t<ߒcJ+aBkPʀvYˌQذ5r)1$!$E0ĊE*Tu9Q"\(R nz"H HKZ{p5 Df'W0I3miXlݘᖜE-{eV.@t`|}pʼn456GZ24AF%x`j|x*@\uX]:C3t iH ƖPcUOHp@ XS,nݨKIP z~n^O;/4:M] OWL C/kqfGk``Ң3oe~JT(9TH[?Tt‰1!?8]lJ@A&0+Y5%"%)\7!vث>4aJS呫Њx̞: v2 cRKPc=7% }ڂ~a|*^ `P]HPԫrO}%BF-܎*S8K Ř$ m YGS?DLvC\HW qN%e`]he<I=u <&Ր%*E۶dm6k(B\~&5Aޠ6Hqu'~IAT3ҔlN}f}ꃝi#N;n wH ΅Ixvԓ-汀+^b$ Bպ!ۉ) <%xB#i;֕Ҿd%]c{ zBC{e&ZUbu<GTJ3UccYluj}5*FI'EpV7pQFWA'~HxC_ Y5M*P:Sa\"$5Ԅ$/1JP6BEZGWOEۑF@}<&e"ٸ|65C{|!>u4JUhĞV\>]q䐸\YĄMǦvYeU w$nx#/X!FU,DsZ[+vM@!hAJ 7J}UŎn6"4 D\G:ըU tLŴ'vv鼈{<Xb2DR۹啑|xAB~(T{$ܿ. j˦H)KFyN @lmjj[fjoHnP5+P;2G\XeFRff+smݑT|#mrTz(FI#hO{S$2pbZЭM=jd)4dՌԃRdl afR5)`ֈ=W 'u49geWqsm :8Z$YHP3z7 ^U;sG&3AGM\%g^Y(k_EUTU;o֘/eTGCZ}ݐD[HǃN2'x.f\9|hH[j4dT~YY28_:( Tjjv\݌,BPUMX3ϚOsY\J*5~ yB |&|r YZsc,vJWDPYipB&X~qɲ!4[G 3R:RJS44ʄ3JB*ר4߀?NgeRFrL աc I.ѝ6<~cMo3FPStʖEK~xG8YOX/H#%HCHҢb5 e¼¨<(wE4o4Jb~{Ȁx~7U5Β8~/OpUy%\|?PGM=+MgM벑ˊVx+AyZ|7>PNcJ5ݣMwď^ş.2!*.2;%E~|ӛxOM=_tA2wz|w杶f,rhYD @H m۲dUwjzo$f,}^Me7 CkʼY樨G ]6(10O9di1zê] b|kqte`X|RnJ{x@MP' | 2mKvԆ6VGڴ鐈DK.5ʴr0)%T޵c\yyWzu%з/LCI $$Z6閁`^!l; TkkFnek ;oڋPUO= EUnȤG#o&i_w7D%r6s? )ouSxf梈TL_exz ~{1NA-tf@P ;ӏ7>HaTwWkN*wK;UO^)d"oE} aN #>VAS>G񟉟VQ;$ U BÈ*+M-'|&z @TRLI7 W0Cv۲F#SA؎=\yA>N=4%.LH=9U$()^vcNAn- A?k >ґ<N+㑘ز'e8ؒQéa1$M2RRJP*Ikn5HUڹ ΛKi,_P>]ҟ<ǑV2H$m*Jlao%5?q2LzshPWzxGJnpJ\HMČll!/ҷ'Ռ+߾ XT}׿рZ":1wY%7цy[apC5!O{;\3ݙS2pĞ]fv vkǗ Wm3w;=7?$[(1 3~}+e?k=8ՅAvœ"[7T.,GC9{4HF\K.M*ץ6#Ϛ{N:_4S2Ѧtn*sSethb‰%_A˚:Ɩ#;`-/3/}]J:T+Jnizh Vz[AF`vOlg(El+8Cb %/&b܌BoR F$fBUGZ Hl2LriUTC }L$)Rfj'2"Rc+H 1~2E)_dB%Ɣ'~m.ܫP^ vi'"#z'F/LyoY!=y1 유!C@4Wx٘$*W ڈIv$$NYqu=gi43xg/+i԰y(x9D(Ddjo^J|2ۡ &$Є/̢GxıcN>tŭ+w^2qa!HIT);[<1դBR%?9Ʈl͗ obRqaLDVpcMJjr]USNEX!9rl/YnS|vBӨoz(6$tnlA#,,2VޤΈ>"K H6liTq549KM$SJ"?ـ& U¼qyt]@74:Ē (4ll'f-*#'Pz{L` dsKw]Ɩ8Pv M+ VY.M'Xm#dwzu2oX`wRo֝3cO|<2 K9e-5A2aǸ ')qC%6S_8Phx߮H\$q0`I y)QRd㈲^V+OekLe$B A!)c}$*]#V Vª 6\6ԊlF'4C{v.xLu~}g8!(XF:L+ջD^[4,Ѻ$| 2ƍb$Tc3֭P? ›$ݛ[iFSR:T&qݝh9ު&uTucUT|1FۢXM" ~ M2-cOzeBsҤ/,y2-ň4 fJ\[p!O5pM ?!|@I6L+ ɧp*=arErDsl ,kQ"eJDRFȊJm5G-YL.OZֻu@ coz#}we >%4b I3>_+iVKF]iZj+LXs! &rG{ r~p[e[N#5=VrIn9uScFI5K;jCEqSҴ_">veB' RԎNp^/'e""!yQد A<@Ҿ WFiB]#{v2PLq_QP땋/&+4J-Ԋ:zoA˛3@xq|rDY`JCI:@!QD|2HyVb/CR ۥ: E Lwq1;5zңUY~=̄wp@FDdl -[#gxRFJQb|0[Oqn#>iQ_oL6{V*kRí&#j^ w 9מ|1o}}8 9Ha=7>D} 'N^o@LLĒOT|b"k, & a t!@Gc1cg Hu{iHEp4Nn5?O hA ?/=FXIU-pTC Z=iA3Ȏ=B-H$T.+QJTf!G+`z\v/#0T^؉dA x d#0P"ڊjI#zlr0<Ԡhh;Ipڻ䌻0-IX?ԟQ2FiNlSJh|9F?h2ȘˬubH(JJ֔(Cɔcj(˘@JI47cA#xn^9Q>tP[q|*ֽNʉJ: ˛մLvڟJeћ]͇ɧ]46 rQզxiQ ӹd2Xl͒ V]xff+qrDŽ_G~daBרS}>Rr}',Q[}#=P&|GӀr~XisSȍZ Vc=\z%JQH%U7$GFq ZxEma) @$=sy @@$CsCAbB%`[9=;W$3pbx>yFO+!L6@}rl| ]BRM~BLLYk ;\ǐHEmuox:q,IJ`cLCtoi,Ɉ=;m%X)5('v^ EtH#0U,?j)+v5<+LgwR L}=;7|{ߑq5S⿗ZA]-Juӈ|T?3fbҌkAڿ5T+ħ{S„  28A!kJU!c4٫ZWۮjzGW s Scڭ!h&*} :؋=4O~! `6>y~0H6Gj\ IZ| Se'Vfъ畐[c0ZDP11QNWh+ʄ=7azAElѬFlj; (MFC$^(>=OL xAb!zW#PI|ZEؚqsy>g"mZ5E>Vkv{mVHi%_ޗUȊ㍲&Nֺ*՜vkNBa:dPBA KHfI]P1G4+)} [[U\IMr} G,SI̬r#p+t$pV$_z8b0J]Ie[s?㬴InjMwC@Ʈ%eP 8 Q\¶D4nCuoZdo>BBkMmiMCko1O^FHm"V_H1H@'É;|WO)ִB94rxYY K m#,RR*/ɞ^%@ZI,I\:|1ڃ?hk%<{%ՕVt9m\$9n+CdT!эs1IA}1up,}H.of< L'[/ e8{Щ5hi\~&(iX&Vħjci;S!A^K+"p<gʎ̠x((W8V<!)FBn_#^mW,3\IHJP7b|2X~tX&FGS\g~Tԉeʽl$P@-L e?ur@Т4 ƮF;+~yl"C;N4e#oh2=4n䌀LK +PnuFͿAcGt+0gG#{y&_~W݀)SBTgSHDž $:T2@Z~B.{q6TĞ^ v[$IHRzF#`d7@TĞ]+9L-(K}fg&B8]% |.q gDmCֱEe7?Y> :m0Ry(ڧtb1wۗnULi[I `H_uO7OIn[7ݚr⦅}j>x(rvTƁY:>G sܔWfH%-ڙ>o@›"K5H գT]/݂1!ɁIj&^p[~@w'-WÕ)ŸE.v蘂>hPHۇdֽ2ÄFp5K1C@Gŕj>d!rVMItE#6DZ *woǮU#L*XV1`z}97E[\QDO&1;(:խKTd> GnO Yc}<p$hfh3>S6(2KE\u2Lkq,K ~0yI^裋N2u_|9gMO4O@ \aߛθAM*#`فRWlVf-MVmS}q>yT>'Dȓ##fp,q]G: G>uirB^xh*}-e-n!i2tL2~M딒:C^4-)nv$ [Ԯ"eAme}j{cRA&j~쳆H,zPd=(|(;H _PXce(}*GZ9 )Bl'uobMqڛ qi KX-Ȕ g$֜>;*S\8ݩbOj=-, ZΧhʎ `s?K@!#E>ʃ`-l+QےTK1+ңî"ʭ+4H.oZ~qUHJzga;\zeȂۆf0CtV p|shKHbj`݇A3,q#x[zzG.շ㘳X},[kgUt$=OJrh:倰JɹI*Yk(RSscjΪ©,z/ c lL#vcMrzou+(B`;e&<4$vn{x]Uq*OXYl@&',LԍJuOԖKy%aNv{l Ak(@UIRE:g쑒qy;M/.JnaI${oN 񿨊IWХZI)mxNL^$}5кOZlF!(Ty2Fȃf7gH2+/`}1A4/^ٯ>r<6 x>3K )S}`vr`c׎H.> YևrO&yvCbJ6Hsg9 yu;PZUZ)/ZD8qqXGc(L6:3dVZ4.~ʰ=uj,?"1Mu< ewRZ r#{B ygatd ud t?r2B9c& ֠LcJ@w+["2ob. M{/(kiXU4=3]8ɩE?'S^-d՗b<"kXj?Sbj 1CJ"b7ZWyw!F js[>M(o=REAi#ó޹F䣡zRY\*f,* Ҹ02)">T .7yZ4۶Tc ?sj ؐSZʂ6ROa'y{xt9JWF0V3"y5U1<*cj$)$B;@ɒP(-ʒE;Ӵh 9OX̀f0ƈaQKTS{nUYn"bF8"a f R:w#`Ȃ?zrMjҾ>_c>53%q Z;Q>OLf?kڟ[%SrE%,ħ_E1A~`1f({r#ޙ9e맏%Q ۠ݾ2 Oޕ j KTƭQ@|EuhĞ_nD-5̠Q}PyKinc?o,IJFvsP;'"ùtm [$D;o^A$mc:='r{<%#wj:R4[V'# yVdF@zbM$ʚ ,kӃbR;v40 +ç$x#Bzxe3i>bЪ-:Z{ȉ2.Vg2Pc%a_4J>k^+J䂘"r^":aI&41p:^Hlm(YId,zLdG>y#_<9Ucl:2/BX884}j_ ;-" C!<4 f!<\ƭCB$uVBd~AʛX<܂#VG)5ՕTyH  nMvJb*$p3@R>c%qyV ?$6hrBE+O%d+weLp luY ":uA VSC\bcw7g9mi3 Dl5/CԐp23uo2a:f߇̘tA.*GG?;bspv|i-{*8gB2 oP.Lz{_%\2 dxn|)vȥR)އ $@M)P,)g?ߩn+Ok×%Z& RYH)D)G&RWo@) ;O bX0J0V.69JoQI= zM62=̈́M.俨Cb,G3!x nH)3jc.)D*1\(@>9d$C̵HKf= '`\nV#@F4#NHViH;}p @Kom@j?ş`o+ 1zDv>@\UyF)鷁Q! t⌆I$cܦ$dx@@$Ptˎ v @5rgO/y7zj^"5G) I2PfF1 y<ȟymOPO^)Q|?";׮POӞvr7>I(V^ +(iǗSVl*b_\y*8jS+lO4BAckڜC'g{/bx})LE7gAnd,ѩ֠јoYC+X]$- T^F 2(ZI>N,āhZ!Bk~NBqB0HDWn`A)R1jExGփ-\PI,eb'!ח~d䎊piJׯZ`:DGvc*>%$+) ]0 g4/P5$r`y˦[^cʡ#`xSCrw{yoc2i:?O;OcB~ nQSM>i%Tw$mdhnjIJ(L HaEZ%&97QdJzccV3rbB45>%@s(r*04Hl7d|O2AmO]p8߉_kvR{,Lm6fy4>tSB_J[hIZy?x&X'}q9ZlxvREG긜OO*0-ѐKkbT 2*O|)ݬW,nR~ymJ`ztǨ4ek ,MI#ZI4#+$"ޣ` )" %5A,bGs'TU"Lf^* %PuLP Uu)u~T nT ]JD&xJu.OVٓRm\yo98 ־^z?>E C,fHzE&4A\60'aW3sQN} đjܡ逍z;SPı՚'ݝx5K{Ɣ©>rϹl W4ѤT(o!o*P_PxbAMI:1PIqAn&sRhz 2JE9Ɓz}6QKu3z5GjuNcSdw@IL ^\#0vR貁2> ;сA`˜ؤEBŸahO2(7~\$fe%UĵSchy&(yC^nƭӧ/at Ss8xk h'~OaB t/ϛRiNկဵ.ykC^z@OH%rè$m'7KjO›(> ^3 4cSӮX `|r!c#&;-e1$ACSAo1d9e}D3 8x4<}ã#gz#ҿKmY g1ALzN9Su|"0=c!lwY2Z0g$mP$ ocKrN3בZoXn}S3^o+N>=@ Qץsݹl$5v1֧^!@)$d!BUiZL$iMwD1٦C#44Q^kPOx! B{W*yu&夓VJ? ?L.]LV%&VA%KqJRu p#EA I!sfBjk(a ,\י>}T!6 FU;;8@Z&[8yxRXcE@y?]h0e=5y&l%Gx@| {c:܏J[nd؜h"." ԮHUzу1C~V}҃ZX O6nNluFYHj6*s_cO?qv}3x{,Uco|߬3]C=96U]Yv<ԏ'2%8HV>\#ޫ*α|2Iś ]:wA)%s*)ߑK bs uQ&[F4D}>+QCnb !OA'%rWA UaOqi,KFG$NȺccÇ!A jѨOح[ƴMZO0n.?g@;ѕi(Y#HєƹdDBvmߖ cFrV;tV+^(@zRȼ/Pgl &;!AkOc-Ŝ^ԎY&z(?O|/n2p?aZiԏ2ńD$ Ak!8:j 1=.$Pz W7WљBCڹTfٌޫ7 @y-~줆czVT쯀rݘJRH'1JA""Rmj;H19K'c"{uƕs7fJuzƲO~ UsaB"^/wn,4έU\!f;}91}X#C5Aj_n M#Ŋ ze,OחaQ)}iO՞H~4/&e#331JxM36|U*}d Ҁ2ڣE_ T2TӮAT̵=sUC`xZ yu\כt]emqKJRl/~|&s6eZV]TC^=4[d| +-GV Xuu.]G#$Kt=LUdQ3SR1Z_2=d"Q#(QP6-$-f$QTWr~C|(ygQw14&rG03ghbz$6 XaZ XA⦵V6~d@X΃~\yO8o0dVMAy(HZϓdƓPgMuGdy©f5hgN$ME)[v `́Ho:-Mɍ$̹" J OP8]~CM*?W?ﲐvC}!žt*;,JtX@ğ4Hg5meEy=L*ʄ\d !E Y̒3+lvv,tF*qFm5?,!gpfxr;Gl dg ,#jgcd8oS=$9>+&^-L# ejPѫs|rE:k%@n­xjM>ƕ i!-9DWPy3 Wٔ|'3T?u+is>_T > [8j#d:<7 g !H)x b)T!;1'\T (SFQM3 0K ꇑuP_TF oک;ąUcCXhE9á$EY`YAw#~@BGiVHfqvɘ@\]]x:;QDUϣzCYD)q$g>t{92 uU(!#߷\p 23Ӈc\ꊫ Rv>ژ{áǤ:nlR}lJ5R  R`EwM%"IqJLJ 㐥6#{{DJA;g` k@:d8A6M7lf?W898GP| FH49mw`G^v)FJ)ҵ w(Uu_d@Q ͷn!Ns_ ͐\lNW%;4.hM|sl$M/PXR {79K}܋B\E$b'" F=9q!PѲ] 25);{TR@L)Nl0^5Gߠ(N.Ą~JEf6feܷՆPJDI*fUiҽW˒PUSȎjHeF-/Ӑ'}zczuhHa6>dw2U+|3xQV I wZ$j۰AAiVqLUqV;Q1? m~>ߐ6:VzΚdȍ "6~,d.YYKŶ:̘/gي9 ;oZd{:+q%C#Q|ɭnDGzuYey7"Gb3ٵF3O|K $@9MGp~w#̱(MM9OzNr~*:fz[rTbFQb >!v/*(^" O#eT0> %/;qɸ$E<Jп܊؎|Q*la ;SId2H%q,S727Iʰ-#eF*zҀW2 N>C>N_O:x;,O~3^;mo{K)[(YAm+*~*H h7p)žxf,w1V椩zPFNjo~={ [pŹԏ+^r d{{U$nN|ڑQ=('T~*FyaUxeϦs ʳZaܥdєInLiyG=A2 J,Jw鐐6a,74m)Ɋ-kn\T @C1! O}xݑj11e U"$ܪ6L&;%ۆ)$HҙGz {{eRLMw_&OFe ~ʧk`!(XaHSߑ=X~HJu#j6ɂŠKcZoaSrL%I+,FvIS JUO|i_;Un÷Xtf,$Znl@Hq3Uګ$]4CokϋY2ِ|C-YG5rsw#AJ,_}]%* !P+)Pk@wiuyqM 2 "oM%~>Cԯ`ؘ<GB@聤Fooc;v8uy#_{"bzhʃ1o>͞n yNޤ@CY=UAeɒa266! y Ƃ*6铕жVe+T,v?f' Xƪ@V GP)9ڔ'I+HLgxu& K/CVǀvw3?ʄnHWl1"o]J {=A_mcDs?=ȞX5#w]%bVnX6fP xZӓ8c/LJMDl 6mrMVYtƷvqR=&jm1H3!D󄼺#Ny}ˈ'IOw|v%5JsaՆ@=W;uj2$w_RNܫHŜl bؤ7 )lm;/˘S"Kly(?"֣]@DĠ%iZBе~:J?;i*;ԊW$'VgʼUwFB*^w8naxM@qGߥ ^|H<)ϫMCwqc&:T|N\wAL ĺuRXb*r"A*ֵsP=YĄP0^N炏 ֐ E-PWrNbL* tFioM7l  HJ꼛Jq+$a3UA4dimZ Z0~+O s)CbǠdD4> mJS784f щlheyb:_ˆTYE-!_LiÊ~fDϚ8|L@ ܎ 5+,HA㊇41N V*S̻%^Lj$20n6|) sRz$6;U,%#c< ڬ^#dc,vVhC!0zz+b n=\̑J2J=2LsM2OF ɊH$z2GGr1TFː|G߀沍+Hȴf`͈@pH(U:dA`ZK/J7Cd,< V-U(?'z#q~}vw"9/; =p tv`$'OL4_'60pv;r(܍@K=^BO ޴ +U B:qyS?Fga&'`)*|o"sHl#J֯PI}lys~?MCҿ[.@z=9põ;)!&'l &F;S"Gs]N¥?!" {rw&ѺE009 L6/E)SgҔ%pZ,za5 (6+YZZ+yUx:}8ڐYH)^@11Bƍb#ռӾDEw%V;.SQAMx3F*va :ۦV!͇U1f*B|HrQh;/$ BO6>3kŇ RԲZƤA+Ϧ(GUG4YkZ@;%x;~U29XJAS ?eÿTha6QjjHOZyXcFdG׶%'uF;w22 *ǹ>N]2j_n1k%p7',(biQўzy=@w,#ޫR#J`7*SLT J-UzFhx(iM L|׳ SJ~.\p@s1!14d7hO%S2&I2VA3cO⿁a9zv?(ş㶊^::Rx;> 5y&ډvr JOjf܀ W7?WB(š1;FXkƜM/R,ў1Hy4NKm5^F2Hɘv·IC 8s?q,* OSCY?೮Ze %@WsLt"A/ycيRXFUx-*rx P6Z@\sIiBvQ2 haž$|+NG CLVʭi@L k;5p̥Xn{9IWtb" aڔ= -"6pndJl|m cj: SZ$xx r#@1r,f~:KTz$T;}M U*7"Oچ$[pxӧH#bp5r~0TӦ9{MΞ,e esU.Mj4a5(s Q^PdiASfo4KArBzAt,|j=h&ГJ"P"{''ZKĀ;|.!CPZu.WMY!۶J<$DC\H l? S 9KJfQ˒z 2,R)U hW`以4^MKWA)A_'@وy(>>ی#~'LH YyMGFPPEMACH cQ'ƃ[ c/| 2yRh<8)P" @>?˜8bxt(OZeIb V#W<G'e8sE}ȲX4tː}: Mjt˄diMS"UJњ.(=pVj>&\I͙Օ_nۥ+XUg5P;rFN{aCe.Rǯ^#]:" ON7]F{=[wPN4Cz;}bewPT_ r3}󝵋cq *v8$#6΀H:pA "L%wWn _&; mrFJ>d.f#ncʃ^,1j60"@,& @^Y E6nT1Ei^qPmTVc 71Q*Tvk{W`s{QYvɡPu)>Yژ"B_pNsBEITjP.2g\^ #~gϽo4Kޓrz]YϲJB+ڱ4;4 xYYH |sLw|@]Q]zly-߆[3 S]ŜR9y= 6k1"0 FOOג뛫'MgJx˄䟳`>`(w-$Qwp+i~Kj +Fx|>> >aªH's5</њ@ U_O :K1eĚA@j9I8 kΔ[Z+Cu4_®n#zU8P[."S|w*Qh›`kfc^MSi'>!zS+1 M8#IJ'bzu[vq(84$- ҟ#H_$4< $m-DLaT+n$t\"%Pf;Y;"i쮓>;(!HʕU1F@HEFzצZ,O4]FM?ir)vmZl#.(K9HluϪ]9PI&fg@;|Ceb8}r.(l"RfY%=yB_?,ZTwŞym%z$h4R*aݷ1nvZn&,IݢP'JٜFfUi^;Oc1kx?mri9԰~g1P8lU$ֵ0t B҃ nWP~i aܘ *-)앨ߩM?>) w~ݡSaARWV_M3ozP yڙR"UP(` ݷ߭U15=}p=;7$J=6R)QaOEUv1S S-^0QP[žqI/OCj}JHpEbZw26APW%j{ֵ9W2T c`}R~0H0"FܳHB˱kCf4TRcS(f/%H(suq2,CIE#e).ߋ)q]nM#0S &rIFFhc.LWR-$~̣7~$< US?03PϨ^򺁪kJAQe ʽ);~m[}ĒkOp꫺*6e銪Wq>8 T.ZlTG﹯7\w',k+~9{$ p<3²tnS9͎CnhqqIUp{"o$KP{u*QE!%72Z3p o_& V90^L=]$|ʉHf%yG|0:S@31 +"&\S) >!qz` dluc/ȳCZ,& ;;wf1 ESseD''>.2m,.V`A둾QR `jz?^)_ۉ5Sj!T< E%W;9kaŠ{>||me 񁴙຀ckFG6;Rz֞zڵOĥP9VSx('S@o||SQ'_TpU9iևNG$ ԤDw*AI#cb+3dϯL՜X\K@ބr_'l \Ior :tĞ>9F< =PfLEU`%fg$=>.`IzSNݚGO|bmƕ$%e'pE5=8 @YcfkKPpU;=#L'.@kBQ3ASq'̥~降8qZ֙+L:[Ӑ߯2I&GCZQ*Q+)2}87,Xkm8JmPJ9~}+$ሂhro Cu6l"%~*e6.q2Q4cT%܂|kَF@Eø<X'=xQ $h3ϲ/FIQ~ү'u8I#H,”QJ(ؒM:ƹ-P٩&PMS2N4 brdw ]9 qE*2F([LL{ yFTHXP0X&!;v欰NeoQ\/_ zn]֖dfEkY!jul_5$"Em'bz־HĉID"biڝ)䐖8gxV{aaPbe ߦ\#u9C͸ C$U TRI;pMI7OvV\%pII'qJ in _JiDq>R`\r)N$nM֞ԇq$nqP v" eMzb{aBP +Z|Q۸M$<7 ,ҫ%0xT}O*iB% (CCAO0$ H\wqbOL%Uv"zZeݒU:6¹:Mcp"UeS&U\^rޢgd?I\"x $jI!s4~ f$ڂb9)(~];T)?WӌHuBV$d?biS_zd".E Hw )3:Wڹyë֋}q|v:4KtϢqϯj'+5~dpµ9 m\#B7ݫUUFvjU~XmOkLIVh 8*HGk(Ë.wgK4HafG*Tv>v|:Y~/W mE<~5.@AvOIBwhMo4H@y}eq)]bML-_V."j|])Wj(ڣa+\"?' UY@n $`YYaE3<sxU@<$F, lIzuȔW5ӳQ#P`@5>5eX#oJx0'ceD0[̨a TcM%L.3ޝ7/6DRP3w]ދ8GhdJ}bZ5Q '?5gdFb*BN٤=pP(*ݺ $NWS ZG>+V%Bu&Q,A;߫dwn1gE #&c_ JW hNAw7h Y[2![ htj%g A*JA F2EerTrF?zcYT%¡Fnyl|>n>wnjHu_0X҅"1cza^($(pP K/#GֵvAPʿQ~7jYEC%hVszS+5a! q3\*S+2/;l$zrͦ%w0ʍr z%J~b-nR~RI醁~)]@A325$7IJy$m4tRk܊ 'Kޠ8o ͮ?nz=jҟV /T}B'~g0{ʡ^2=LbQΆT; Ў")Uh׮&A]5(S\ZVp~ɧ#_^@WcfFeUhU񻤬WF2 ʋ~2EoF+|8uY_;'<ɏW9yٓElOVHbU&@=hYbiU"G&Ev<J!EěUԅ!Ձ"ɀ`'#\jS%DݶbwݚBy"e&d%+ɨ X)|*DfS rRFd֘~I}Kx ^$S|pդkSA V xeGcm}'R?f\bHj[4QI7`MD#]m彦xZ=y*YT|"GT> >{r_'-Ž!LQO%wݶPB`8ԞéĶcH<^TP{6ywo=TlځI Z0jy0MOK+OR~r3fR`FbKIjX~H=LQCJHTE1#+R  $H>zrHRku1Agao%()4tr]@D{RK#fF? ;GȠ98,Ew܄Z[QjJrXޤRLb*)]" Aç,ibFϢ41?3c;C27 Z`{ dEͩiQ_*rhÕ-"#26$eR<T!z$x(G*wn&hXӊH'AnxdO--"T J '`D{=KI`y$6=zn8%RQ &$(, * l{<@u4K/~ĺzbH Z׮J1u'2B̡(p"CUAQtF09 ԉf 7> 8yMMH\}2SaS5ōM"GW'S/$#dy#YVR;wB2dn&wY$Hicaϓ ?2b"r,Lk1DQ<**~gAnsZ;z̅Cn&zgFɧxX͹^dd$.K5v#ȓH2pSRF +}niB\}arJYXmזJe@-z~eOj7%E>_D$2NLM}A#u>5t4ָoa5P R~Yt`!CM:;E @zehX6seE떢KYH8ojp䌻)buzNЏ}H1e9Hs/ jYےc;0+;9@)’a=#[TYXAR]"ZeR*c,SׯLFN`Ǡ9Mnsiyb6rdXMOՑ4W,?|,XkO+(KO%HOL&\YΪG=L(S {m8?Ϣ1y-5m }FU Kiӑ0\eE72z_E[t$|6$=kzSQ@R7'J*9tj6&Ahdf^@y"W+AZ7\i%XȂPZ?hЀ 5CzofTFȌj+~|@ n!veC'jZz vz/8IJO'@o 4#z'xP,sF1IJH케'̦

dcoQrB]F %w7erҙS'{nͅy mf,aֻxd#en`)@^~\z.@ R ^D*D>yѷkJ+\ȥLVb}FcOƢhuqŗ5ȇQvuS$EJg/|duOeNJ@"vzs/UsI%׏.[6t!9H/nZFZdy4Ů`C)K K W wĆ6SONJ6FDjūM@6_'a.=V{,>!qd~!ZoZ־(b L'(]DZ7Vw'*c B|;̯dRM8R'\lG&j)$n| :XV!Wz彨!m>>Zcsg 5P*EiN9>D][V{{Ȑ]6ncTWR3& iXbP$kOb3YHU⤰ zDBkdXDI)<0,\ʫ䟌ʹA"^,I7 >z}xA*ڠyAy}Awe}gzQ!y7>|rz=MCBI:eYӫG AWIga @L"xWa*/[NZl =zyDJ8ٍj2)Tm]ERzS~Jq|r"uh@QG;1ɓH-E~brun㯾DQӧA'y" sZCv/*qujզ=s=}%=ib}OS=vOor\=Xl i2)' |A,&.V3ba f)fxy?qSl6H>#K 0}Zo[Aѭfk9IZ7(~Ʃ@wV%đ*)] ɀ @e3U'Hɤʘ S+!"6;5/0n]t;ueT1[J'6vRzl^=&c|"Ji%y'Ï랳#-5_7M"g ˇN:ʰ&wR)OLfcJ w eِc܁OQjI#儳zֿ,-'%DA*Il QX]k{> B0Sl!}BFzr6킩y^J91 \1?TmU>WqC[᢯'*v;F$ 4w7nȽ5'A ZRfgyCr@ҠT BȐE#@ZI(e}ͼ@-Y]#*FaӰ!()skkqR_N(Ɲ+צFmIŽqFCPLx@$MW1ƵnWFǽZˋ2C%xNrn&SH$vd? ,n}Sirqٰa:`oZ co [ƍ$$~Ydl%ݐՉpHYc}X+MWN֠#Al70xR 7,R-I$x`ٌ U9rH" JucSY0udFRq*fuOUЅ*;`4Vl&(cVH ;y8_[=by ( 蒎{2ܲBSJzrv|7Bي),/#rA>9m$+k.XjП--RۚSy4FxC_ZiVP(wc٫aZHdx]W:Úv*;mHV3sZQ#uJ*WƟw<ؗI 8q6F?g,趁mݕnZ>jۮQ21ײ>"\׿#.a8 DU p0$K0<,ǓMv|mإ&cyq,Rq:dgW>1ƪR[)=F-rXd}(HUuuM69\s (Ic"U M{+TcGӮtb5Y5pb3Q5|P~$rLNж_O?k.ĒBVE45΋ǖAvpՖӎ7&wG|xaɨY0:Ƅ{ƚJ+TpuBX>*6wBec>T@T͖9w3GXUm@KZV+Rof;JUwjÈNe :iF7yBMXb&DOR \ e m-MơtoDGb:-^C<ӑR{R96YɇRpa^C۶J[2yr: z a@IŠqOՂCqL&p"{66CT Vh]ҟhr^JE 3ߌ_+Un'(ZZƝگ^#u@M_LFw6`E:ua,n݉ᠢĜ[^GJqnLPw2s'-QNZ6;gDt'!*;Azge"@&!zlnd$dnP*ڣ)3M%w6W- 3BbnFؐG4rEˑ=wJS-q-Ǎ#hmZn95V9@ Pz\` ۯ(h\”< v Xxv4팅N=. rP2a}I`{1:*%O֣gYXMN8@?}0N}wZjqo''Rb 2dlÒBG^QUJƼD.T>, *,I #_`> `-T>ڪJy#`-@5tHHE#@BOb?GWi Z38?lrϽbE"h=NEܲF?RhUdq,δRYKI >#eP Acp\b@'zeEHDecoRM'_ D 1+]EC ƒ:TQl!+0Yc/H-֕iᖂd"M"GFH|#LU{,TX G+(kz\nwrUJcHׯ|ȄK 1FkDRU4qc0fNzL@#^`5Ío==9S&VO;,SP#amE\؝ٝkL2e&0%c \z05LF9Fg' 9ke'E.<ߣ 4usCC'xmfNmٚI('g_Gq !E2Mlb !v;;VV [UY1#ڸ"em`y%Q JVwNTs\!7 > X;( /iA̿Lz0NGSz*N^dpf?>ۡ[4n> K$Et='`r1eQQKT܄±SqJp5-X'&̾-B Hi/oJ2o@}rPy$62z7)n b)rpk8S,ueB<1a؊n 80'i-#(ۥ#,yVL*zqs&(cOMzgc=dMrf8sWR7%ڻmL1|B6XenA kL91 JZ!(@o^+ [ӧ/EuL#э_t!M&!SE~LJxR8%Jx`Q_s((sNAms'KjÐQ[8a|q qAAG?k24daOf( "ם8$W#rCAZhŢ?PO*+pl V#WX.Z(:*܊Yn L +zS|.@BKeI@Yx&AQHKp*s5jwr;Av W veu3)P)ᑕs]ϦH|dv MMAV~p&Fx>,2çΒaCN2DrvnTԶ=/( 3D1^*?=8H|h?b쎇-Ii UbtĄq$,Ij#N!$QSZXhJ]ȸdP)^C m1f5[;2\MRߞ HvO'e}pHV !x  ȵhGx $i=cq4rUmF%[NLYiZkB6H_9C,j@lǥw/ ӕ䤬02\BkƵ`lnH a2r# HN MJoh$ahĐ#̨1nu>L# #^6DZ/Ե;:,3TƜiqRV^9EMo܃\R4"ʙ>`K'A_nscؗU"6`y)ߧ"3b\!cQ][ ݷ!Բgh&h«7Qg| jnuLG!=(tMv @h:;QƔ#Jl7鿆}M2BWEx=S*=| 8R҇%KĻ~%0paZmow4ǀ&M& (-$-N)-8$ڃoJlpN;ԌJd*͡\s 𞄾zSu2 B_W5Ӗ; M"vZ}9Ird[v. *)ؖd#dA$̭ZUX{wQe&ڤ=ͤp,e I=vV £ )l+$ 3F,+[ȱ7`rihrBY T9V$#Jۏ%ڻfnd[[ȓkwG\! QJiPiI>>|g 9̥{z9Пo;=2$s\u5H1&*50&#N)7mj*n0H855LmHezlv>\Wj?V QU׮Uk |cMZW*w)hy>FbrƎDؐKmg=oy$ّ Dж{VOVB%tXrN|Ac){e>>Dw'%o@[I ;[V PH&gf5HAbLEy+Px}nj$8U^ʿ/ /m픤o'@C%xPصqe !#2٤ȱ[rL PRpa9w]eᕇ#;mfFODB9mCUZ^9~0yg1c7ET+l:GI j'1)ox璢y2uRY@ZȳKLUf 7M3]cw4f$R$IZP|>}P ~8"- pyV>"Pd$/"6ۮO&0|z LT)-xkd|F}j .hjAJB^")-7&0 l[k MrdF{׮ cf,wSCRs4,Y=dq/=_uhjNjA9;fү)hIIBZu0֡l^B ݲ^ (0.D*_l 97+0(ۊ܎h6$H;Tt2c)NźݲV5(wy&&K#;rq+c5 v@NڔɉJ0YɸF*ƠFݺf^@\YF/)Fc<>)YZ|+3_8l^w)v}Bj5~B-sCmUz- ?, J` PMj'~˜6)uUEvtbԥilIPL|a8W5>7(7͖ ؐgHA)VXUP7=*{f`tZ|'ScXoLvyYX|) 3i== S,Z[EMſ>b'> 30ۇ^N`mW% M!dN!N+L*?4+qB ~ Ҧ4[%d[yB|5`FkZ{H)z!txT˹X Q";Qƕޱ 뒡Ũ`HZq,T %>%Ͷh, !ʈ u@= e'~Zl~$Tf">HY>wOu5"ȭ2HNTwJd.GS<6z#S0ȽGZ cěN1;(^|98FCӠz2".9T$mFq]-1;tNTr/= Nm8UvsWL+ MS# =7)L q3ѿxLtZKuRN"\ľ?׉t#'7 5%o |A榒qR?h=M'` KcL`EV QDX'JTҹ׬VzA)1j>ąoT/^$| { LlRAS xՈzo/q}8ކ OW ԀIfd.a ;6F*"ç1uM<<XW|&@0e ֻXH$|bEP(փnݳ"kyo1s+ ٟQ 3%\Xl :~ƀϨF~GmLn7~21ʃF\cW1Yj{I%fzq6]񎡎T_S`vj+]]7z e`jԠ_|8ȧ6ھ$" ΆJ/!( #H7nϧn pz`U"f#秸"H[q}imi թ]Z l Hyk)6g q  Tl#VB ڪ' @cdm~e,B}k3 nPygI ^+ $.'4*JO}-zces5X@ڹ@rn+4 6˿W1|E2[y(Rh!aJ0Ι " [@+7CA&P zM@/]Q+jU &H[JU8jш&G #駍AZ5/Uu(/ꪳxL1`V՞ =ddVoTYn;J^&4DXWS`ܚlo߮zME X $8M+(4o)!YUGkx JUEvS UV2uU7G c$O r*MǮ1H!rNP@E8־8$ySdhnyrJF< -guG/d4gOND $$G<0X t !QR| ݬ&JF45pz֟)LnTY2TI@mh*AqdBFL4hZ- HeX\*/72! a4d4LM'Y,j(+i^~ٙ$=,<Z%UmU;c%xkFU;ك0ת}5|nCJ'uqjV3yO T6P4WR CP z ܏ mCIF TbZH\JdczS$vĦPć;>5ąUppi,h{ėn EyAWBO|N8 !gf!Ny*j) U w*ʼG)>PLm2%m\xJQ5M{CtרJ՟.{X)1;2kHU||^H󁿲lVrh8/J,l~% 7sg<2} Of`%C[sZQځ׾bLqtaW|ŖS&;N~&b00 ZRT]L$\HaVB瑦ݲi<@m:+\~B;19 ŤXE6ȁ ud8B|#M PnY %#GC B {jA@xn#&ɮPŴ#P M(H|1f́Jn,Tl+|F;E1qܠ~mK/z0"NUָixzqI#$-zבJt퀋[EۿW&aA%h0fSEc"C+]DL |zed^'(!:<@q(m4{I#~xpi`:Pg)#C*suFbIp#^W7`%ۯѫJ6_eȤ+R#&&+ݞ5fxeߧO1O&8d)[S*xS߶eY .f ֜#ΣdD4uRg(s/uc0į/_R@W,~2Ƣ̨ѐj<P2~pU2FoŨ>-̀SũR=%f̌}8Aieg&* JUU;qȝ oUK mJAAq% ֔Z]ey !ދ.lo:S<_X28c%KV3Wj+:LϓXB֝8gp0UȚfGn"-/NBYy)#v)&1X;~WƒU}Ĭ/i06nFc~ ո\؆퐔4@q)HA%"FGz hqM% >h ̘&D<^@x{S_+Ÿ]!h厼)_f_9ì1H|oLQˤȄ[1-^Tđ_}%=HzQ{GAb0ڕD ?l:,y*-+*1O>)QNP"6cR!#+ƥwUfcFçe=.V}Z]N}v>U!Vɔx9͚R&ߪt,qP2HR *'ֻ\5M$B/ԉ#z}ُ9Sl{QLMFwV̬SĜ+*W"1 ᐌ#81,b*ѺYR r0z2K(-^@0"@Jmj[D@-Ƽ[ *~(5ePDG|ߜ(V2 yS޽2&4OPrS:Ur'dBG*֦4W5c$ON8C9qaWI߉A5t:$73~C02Z-@ Q+}F8kӃm٧_I <82<z-c:EY_u1Mn_`}_\ԇhJ^72݀'l9!Ά>N<רYj=AƙN\y%V+c->FI%ti) ܈=;c%5LSTPr,lrMw"`e 7M$5a6H&cojv_7mȕ2/*w8 i g NN\j9dgj0OƤq5MrIuwh} A;S2ft0 v68Cb KOuPv^jG}kBtzoJqH!dŵzoYS#Lj"B@xՉݎe|pVeٔ^ĀT)#r ,eXSW OIXr>-{` UOibFr wϚD|ߢ pO8Ss4DcJu6[(r\[#5L !7޽)y 4`jӧZW"#{*JW<И$G>^w02 |Wp@cAZuc8~^yOPL%TNl}#t$`y![^ ZÚq#fKVrnHZIހGӣ0VOR+̀B>O_Q)w&f 39 f]ah>XAFJQ%W+r썈ڸbQX-Pv¤۲+JMpjDx_,TLR4۾A{AzI  .T;[հF jqӐ~xvw^jR)<QzDiQfv߀#9wJ-ԂWK"i@*BVԎ |#f =0]]_[3һ8 >zW*wt$~ԋsYeC M2٧agjHG:O=S(' Ks$ bGH$L $Uǁ -2IU&yHcOU8rlщ}ihR{ZFTWƝrBQ$Je)CC* l!U\-Jҕ#BQ$wIMO269lc\ 㵖%yLA PIۮY^y,eXAklpOsjȤs=?}M,(|# X }|C8Z 4#?,.9F91^Go䁷5a)8JxԎ&#j8bĂQe;cwt!Q['*G|%[l^[E .Jեe)\&QOӳ-9!U}`#u'p6xtL7K˖55wZs,뛓3ɨOn{x{$ۓGDGjZ"@xM3rPdBfYW€ Hɉ{HAГ72TFDO%uVwHo( )5AZv3N&`yG$x8 ;wN>5@_.j?VLzSϡtxQl򑼠CT.Z3sMAs`ōv+IJү'VAoL5&9B+QR }0 V¡ڝ;YMc!HM؍AD @&w˩Za>)ĀbJ77)p#YuߟWu]9 C*qbNí7ȍgOm ȵ96.H94weJvE[awDD* #QOseBw 4~wtn E ">R@G>q9N^HOLm+|a)ֿd*+mJЎ#.-O|6t`d0vEG2G٧\,KPz"C8$cǑlA/|:\**ű޽>YWj;G!OG`hUaTNgnU2 Rޛ d94? c2DV$\tJ3L0*)#,$[O?5gi-v}/NŌZx}+*bjl1Jj\ݵݽŒZCB{6xˇ[08\[k}cSۑv$} s4PSc^cӛcUmDZɆ4mE؃Br[2 qZ> R$$ i\2- ߀D L1[}]Z/0 {@sUHxZP{ 'L `B:2 ZgKฯЈzrr,VureܑWER3bG=ܵ O-2 ҈Tu$|p)ʩrN<]Er1b׭+L$1/}YH48"{cJJ\&A1DEu͋@fl@/*}g+E-U/H"|})~qqzHbAS͇|lElA0-ӎQqpCrJ<ΦCG!o 1NdPWZ1*Cqcf Ր/F/}4|^jv?::~~?,}I'G j;o][FrȬ9~j֙#H%{)Qz~dBdD ߴ;d^)7U8jV /Sa$D!kbcB߸혺.˳x0;E mR URHgʺ>y̿Uh!E|:rMSk2z 2J!)Gji ]צr@^Mg%XI 6 1NH݈XݡuߦPpC\lz}>-T=z$<8l⾗^0Î2ыbktngErQʴdK(S"ZN1K+ U"hOl.)!UFPɰ0T@8V;`< !n$%h#~ |9ݖjx6H:ƪeUܖ:u8&RNf?!ʚ|=տ\]OMOl/kF:\~?CvoqHda UZgzƂ̲*rX]4G4!!&p)3Ԑ7biZ26hCλʦ 6 fF>954KW!H,wb$yB#_Pқ^DȞ^jT䦡dVl mB;$]h{HVoݟ7 㱳HLCR xJTw" _?ŢyHg,! 4o=,>?u'_k&QRA/R AsU U ZL(bkԞ`4U{F߷1+kZ={H葷6p@7| 46C<Qf&c/Iby{3({pޔwϗ&ofߨ"xjPMPҤF)6fߩqqn=&OTK?_ g55[ܚ뜮 @Tʂ[dfk; ?ђ%_f2FLooI7tӑۛ 4N@;dfdM ˆhxwπ0Aҍq ~\)UgjA=TSHqnU@|(@84-Ӌ܆J+n*n£`+]܈bȀ#OS[ka& --X իmUp ߲R8*%'##VO]<}Rߗ'p$GzCK"MKw3`926LYch`9yvA&oM"!df3AS8EдHȠ~+22nNj=0h-",f1V 5m}W[j rbdO $(ޝ2&) j|,aҔ @?ĻtWт=m~/ӊn#b=}RE?96]z>J#BT~ƙM ߷n+ \X⻰?L$ m  WXwTrw 싍,jIBkeb$W6B$/ld#qƫ۵ayǵ@;yrc}+QYچ+\qi]:gg3Dxc_DLRr"*ucǮَ =nKQyOq5A z,HjU7DFX~9T@ܷAiV6&\V˥v>ց$QBZKj*{ȏQc˓fV@FNQAxY-W54Z1)%H'do/cûY&l%6mקlgXV-YA97NFlpLjmg$9y{wTUU.9T7}ؙDt8y~wErJ&m3.g@Zrz~ZO%ԅH=z$pW4x4-xT>8_ZJ>}3HBA_lE>Q7 ij;>z䄊}r^ʧcSH'ëi (qOj@M$a'}]C.+BnkЏ9F%4#DMcjHGޞs '7n~87OI?}zj+waѲэY㴂4(I}Ud(.^ N2干a*i! w;O|@ ܤ#w'*>tL[@AFf|*;xK >?V-Y=D2;M@`wxޔ >nnetHnq.kĨ5 J cpį>W}bnǹÝwCl䀩q_ 6nlҐ$gnm#gs*o%dI}"=zvFWƶ[@)D?|gg#s~,bliZLFwjj2=LmxP[=Kf? #u\q (J1Eu{slN5$23p `{6ğJk[ O?4|?.Q@K*[Gro7,._st0X\uR~링Ŋ1ǒR,i/,'%irۧZw4gujFFpXX,rC)A"ĭ);o4#U8)ٲ:%қqxR6]RcUd2Zeg%,+;q ^cuURM}21 T+CI41TTLjC|IeYH2ٔ}zZX5Κ.#"H }8vLX)kbE*L͸(cY#>`~uKZ;XۊTOo%" "YREBCJvlm<шkc5ɞ9XŕOZ  Fծ]J]*=GFb ڙXү4ۏYMZ -&@i ڻhRǔzccŶ Ө9<9DlmSRyڔH ]J`hc7Eכ[+q%fR;|0MFw׷i,o VAP|aWiMe XQ߭i_I^E}2W5_B<)f㐐Qa\=mo&xenI~ v@DO ͏>IeR[UFE]o3@o;KRq1|kTߜNzakziqއj]̅`idK|>!j>9;͊qzz "UVN!2X!w+ȝlsG-zܽ8Rwa17Tדb@, A4N8$u}A}7FlֶB?h }]@{{ZdzSo6Zz+4%T20$!NxxsZquVꚉ7I:Ym`k >|:4$}3]A :eWQ2|7xG5[/<^>{%vi$H@j#)Cu7BxǓ0H QJ ")' sYLޡ"( ~*P- X8JsYDZN}Q:=J'OO9+>I3غ+Soѝ$tbAAB3 ^y6|h>2':g}ytiߐھ ,gS=},m'Tz|Tx@mKJ^5;QXlUEw5|1 ~BI$V^O'ƕ21-䠓ӜOYŴ]QivvS_1yH"ɣ6>J Q1i5XL5F-V:M&.1@gLaxm4]65ZU>IQi0uNSW5jd{LS5sQ">l0B9(xWp&WnfN3C/gԵŵ5Sof-ڜFzfv4b|B)< <{+8PJZ:}fd=NS8(=۪ă?o7:͖QoҕePuhב{䮹)Jx屘`BakB˴O^a'fgaٯcC!wS2 ѓQ|YhdS6$8yuULJkhpК~9ghsfz>pn+ P級hzdK:)l_6o0.LD>x?j%(Ql8"kԤ#:E8Fi"rU"n>aR۩.lDLyx=1Bj2#-c突-qu4Ƥxr s"@l/#Tҥ>^ Zm=2@}F|ѫy@H\]s"d)#<ҋ2s-(BjCN2(ѼK~oF,@Qz(y}UJDF8 }ז-$۟p 2:|M--X6@[+6c%X$IЅw|2:#zk>zٟX!+TERw:qWlQ?$~Z)B Up{Nfηy`>Qe6I*+CcO=ng { Zl$NhR-S)Nm!WV^^{tL;H 2Q%?G~%-^C3)ΕogY)iE B !<^aȥ)N!L.]U=$Q_Q1;ڦ@sQJYRU:xn drfNk*3$04[4$@nL|`*W<;ۭOړ@'L'fĎZӡNpLnd&Ts9=?T[КBB2ԥ}eQ@y_.Th݈QN+Hm΄ģ@'ζIxF UV'ڹh0%Byz4u$E ۦ} 8?L۪pL␩Dܘpӌppۣ$U*+~*AP PxW\y=#OUh"?q2Ip=@6ĢD( $ 7j0$H߿ MňQq ԩV-Hy/ 4'-Z:Sy$[lcZd g`W7dRQ5˛d=V.t `V{so uUy/6P>׾ACq]X_gbBQj밮+FBڻq :I;u2 L2S{ksE$##oGgf|u'v NhJrc ni Y'ߖmC%Ow뙘S?Y'пL+QYIl;e-Im̍"B"R~J8,9 JnRWY$iɧ90 Xf,^v&)x=.<ZӮN@Xl^S~ SN N4䋦3"rSB~¢v ;83P{JK#%%å cw.?hx{&Ե_5Q$vѱ6$oNFz?`8z܏lԳ柢Gm'0QSNΧe6[\2 JIѶ:W!f72٩Ws^$0u#eC3[2J\1qRɬ|i0itCs&yJ IP.0~KX =)`&iT+PQJSDT6sxYpˆs;C_J=&BF<>̘Ԍҽt?7}^'xO[ ݢ)v> 4^.ԒӧNX7i1 CIzH~ك!Qy qwC u,EC l(]ykK$M-G+SOSuD]_By{Z֮'9g XUG{-ry"`}=alfxhPy}퓌OVe*4dXdW dj:0FF{>n[ݭrbirX Gy!28)ru̼DnVlC$.V$fHӞs7҃ ˣ3(b{^~T{y): o̬q YetDX}N2T5*Q$fE[LFR )Rtp~vDg A/yLKӢt=E ?VLMrEoE0/#/Ztùpd2dknW;S-էBQAUOP] 61EFjW>|Z2Z6J Tt;dUB̞@_ xGTa_yedI!YK3RsqeK[R"@E#W)uwړX\ykϾe;| ̞k^ v Tx ;6R6s^kj aT}%ߘ0q,rh!XWphF|{iO|;[Ѯn4lxv`Sz"=9r&/hSɑivlfY dgIghf' 0hXp%$WA`"e{3%|izX9,@ R1:ڰO;#<9iy%p”#@G6mSrk֐x8yQOWM6;)J!` p PRԞ\j;W"Fm1uK9Еx[ʊv5N)sdk'2 m<}f y>/ ZZ%ăMHnjr#UcpV_G^j+=;UJrNoO& DE,FvZiڄa^l mʺ2b-k-#Ml)8uey&xui罼-GH'ܷ*h Tև9昮+1?n4jO˺rqظwPV3?ILF?[ ˘ _Ό/7 YasHYf(G_?5?󬜼ar%>)ߝn쾣KPr2qrZ9B4mqcF1>qI:/e6O>N[=oIo%JF qpVFܝ^M~\(:YQg=s@qS`17Qӧ,"4q˪%#$g?k X%Aҧ1ųZԨS%(F#j*r톐ӕ6ZZEH*h\YnQC" rB4nwފ;`{@]sYN,<~+dd%(+BqOא2 6*81Cs_ċ"7ˣ+ܣvW/\@aIو9h&:FB>uws"e5~\Mhp3T|ӣɉ9:`Ǩ3CMYRBj5Q_"?0t@"~Аt>##=9lp QCj O2#w>pa :u pqrf}-yswez>C=1j67m $5:` rjk ۭ +.@Ek3! uoDH'⦻ӣj::1ZLP#@7fBmQ)~dAKJ-'յ$ٕ< Ko>yCYZ&qu.(^D֋fQ*%žº3}!4/UbgT"MM(vLlz<_U&J&rti@]tޞ9OdM[x?Mm??+)@V6Gud(xtVaֹf!ݻu邩 -84ĂUtc V k|SfSs1FAmR*y:9 oC!jBA-Zy51ǰ'dQ],ȡ'ݰ vߨr X TV2(!G㍪85+rH$rK.4;?L͜fG67}Wt(yWsxarЉ)B VڙG90ýy^/8iN4WӶ);W9[O<@z.X'̶_8dkFɭ)Oݚ '1/ie?qrv#u"< C.Tb#!NyR& ^#_WExk2=ۏqFqu_ʿQZtQ&B$P~eGadMn--ϵf _\z Fn4+z6 C)vQ_7M4-Pr^xP'm\kU!ď`k_.>פ+CRAz~,~|]m04dK3ٿ-?9|Ž4Yxr3s|ΏS%b'?5X[YDH72NGztZOg0iZjtOʏ(|^-2;GAZ=뛼x1#gͪ˔ّz)pcUQ<8Ds6.<.\lхx>58Ke6L{ DžLƠ 䐰CZp>el?T G힔#lk$;`[DUy/*[\S!ݑ!*-P@mIM.↿vD2Z6>DJUyiliބSw@]A=4/VPԡ|D bveQm4ؚ}(Mʼn7^T#]>% QmޙQQn<#VN߁jNWe_ݯ:vLK`M@,ݼ>)ZքdV swycL$Y=[$XoI78~7=LQoP N8 pj3QzҀtƖf-J>0ߢ>"/ HYJn }-2]ێ#F`"경4QSk#ΤR˫( AX ]rȞ[1GZW.ߗ9]2p'CmS꧵{Q~IoԴ5EͫجQN+?x !X]Ϧ2Ý ǞߵnRF`E#GAޠy=c8 [&^eR_&WE P 􌔉5l!qkRE6hp)֝I +7nCȶc Q"x|@P".MƄvLs_Jֿ*]dOpHɱ_~LHXH-RzHw=$S;d؎m9BS˜J;aODd8"  A"?"2-973-943_5-6-93Immagine 32-973-943_5-6-93RwޱKKSSFKޱKKSJFIF`` Photoshop 3.08BIMxHH(FG(HH(d'`8BIM``8BIM x8BIM8BIM 8BIM 8BIM' 8BIMH/fflff/ff2Z5-8BIMp8BIM@@8BIM8BIMH2-973-943_5-6-93H8BIM8BIM8BIM hKpcLJFIFHHAdobed            pK"?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?Ou@t?[?? 2U~`zTyU\Ϣvo:Bb;1xJzkwcWP̏e3>kSZy MnZLIjĩݸ J1z6 4\ϬF>՝OcY'v*_pX-Φxq6.k@G%ss{t-!WL#{D =T<3Q|o\j^;xuUqyl~g(֑t8u,wSqް`9?zvPą*Uvcq<h赟տKԟ[ZϘVvW+5M/ngb\tbwZ~[}@]J(jˇI"JZ^iM䏃_ϓdiP9C1QDYY)g}yp7|mټBw B};LH0]L4HC2 @V-icq8DΌ «v-'ō?xUws8+m7Ygf-V2@ |?/0AN6ƵpiO*k4ih,an`vBP2q,xЃp1jdb45ͩ;lmX&='v7zo.궐r)U^Y,;6}^a6cG.vk~sڋ{$>[xf3 q: FV6~kC[=VUòk)luD񹺁}SjG'R8nm{k?I;0r66A{Z;]Ig^ܧ[Cv)xAxvߜǶkg=AXu8Xۙ}{('cBܗ"x ? l{Z;OrځF-MFqOwܬʵx8z4xW8BIM!UAdobe PhotoshopAdobe Photoshop 6.08BIMAdobed@       H1!1AQa"q2B#Rrb3$Cc%S4D!1AQaq"2#3Br$4 ?bg)R{PirGjv/ E-fk蝻;$ll,u*.+`IkP&۠\eЭj2 TM؉#ll2'"x\(½ g-յ*|[F,6&IJnN3L*F:OHev$kW2-(ݘxc|/ /TH&h P%n='y6~qg3 cW*a@#8["MUaOp%t͠~E6"H?: ikPǜPیXG@?iVIY0+tA6pmzx2$H(3H0˝ˬ֕|lbRAЃcޮ2L' e4`gJioÌ\$+>I7_:6"SrK<R`30SU,Td;B=6ƛj#WFL1HO‰9&?zU0 zVo4b4$RăȓL$K W_z^kqgLPdMc8h)Sdiʈ:Pl fkb"  t廽k?I#;AojV?)u $ԎLaIЙ A&F*F7XRD"ƏBq0utZ *qGh HbfGg*SpRZ TӓlW#(ԃ"җU,1$|n:Dꅝ fcO^ gbY5f!DS]pI ,o2fsVB:\ 2F¾F6 ʲkg}ǁbXv-v<>k| b/R PA$Ң6^JѴ XL潏Lio^ޒ)/ڽ;FRA"&bQ|`CSa:Oz^nLp Wݏ3F,. a\v"lCZ fb A~bhfYZ]nQzO􎂄[wIVk~P["l߽S*L6W+fț_YTCϻa1=5GSd'zns+mr[zk^0>'SؚT2!BF~8G;QYMvֽ7dqqI@OW*'?Iopf:[ o0tlٍ#t_ޥUMwܑ1!ƪ7(@F LE8Tb@f c>DR$A:Ұ"gtmT !jA(*1UjrHl@U\(T;u,]+-74Ɍ<rJm>Ɯ'Bc|`ν6k]|:2+ 5T~~TYa?Ed 8 1ڟoe8,h:޸o8|Iۆ+>zN`[SDH$_)1LF?5=UϷlP-? SpBq>5;LrS!"Km 5Fc-mݼ(?uMvi)KsȸK%F#@?ʝm##j1ݽ!K&~A1i1U$NQz' n J jD4,1$Aί.OV~'u峗t3]瘣c?6ҥSaԭjp WٓZgOG^S?z/?qbLZZێ.SEGcQN,nY" 3-&$:P2ޚ3B^GJrzC!؟ ōڤlNmNgm>^({in:ґYyB?=)h4L\R?fD>U\pF>SHf]eաt~;0Em\@AbO^<.}B iL-fl{F@a QФ@ 䀤z*EpplhZpX youx;oqg=I(t%t0GAa?S}5ǵoN e˿Sa1c;;s~_z^hk^Tt1pNL)2z?hnC)]E*_eyaIj+_C.{zչ `:֝э36A=*gKIj bH~4L1ۈsO.ތ}lnvTAfg g ;@&jU$A7)Rmy y)p2f UI‚-,#O*0HQ}i^ʬlwEnSJtT/u2F3FZv}Yq×X*!|o]jK@AoPj54jk&]g$GL_w:Jf@w=kCn}ϘARWaPRn oEmqYAw Ɵ e=Mڥxh vL 蜀*jnI joA/<%D&>4sFU">yhqQ h w,Iim0t?*' ~2փMclzvbgӧ#Qs: 5ҮC=u6~|yq"048}3I~fmkuSxJ]Z*#н@^k{{:߳༃CwGgV7SO&m1֌MsyK,z:BROۂex&l1FMHĊ@&:@发A E;-paf*e305467ԧS(ewRUR/'X;QJ/1&t.Zu|X"$+xe׫oD[it/߿}+Ęv5Q֝2Jrڢ*bEOzUnh鍗P$&01'ڊev%UVG ֥r HI""3JXImaʧg@qEЏzbER" )q<*e]uj[L bB7=ʥxwXTbUGez}]wv)r%9$TɏYE+Rdl}cUbTOZYTN6&02EQ$ǘ\+Qaj 2]XA$=)lMeFp['OŽ%1[%)ɗ#&9v2sq>^Ͻy5yրg3hoOʾ4Jn a&[\>clm՟J|\?\zF̛V?UYY.&>Վ(/ޟ-kGVYAMU&U6& B4Œr9 /,XCz!4bfTBYD~4%v*RL(C&:ҿcH X́7Ns՞:P)h8Gw)$R\jJB:ZJJ/.KqE ^Zkת1ܡfj4 pƧ ޿mx繬7TX*uw}7GLTgAq~&oCUAcoc]6L $19}"{eI.ɸـ!_"@VEKX#o4p@;N楒.2 "/, vfnoN+n +@%ZAD6_Li"*1YȸAedyIנRFU tR"@'VeӠd_Y~~.Wukyϗ~^vyPFq} 4+/k:%D{rja]G̃\׍k&_öU`$I'W6\]AK:0٠FBdx(+,nvY*s_32M@s >XTƩ*x2^>zQO\@fƌULPf-}8(M,I*jOL EGB'$IAۃ uJy,dhcZx[#9V>IReBUgOE9xEǍ偿Vnw';U/yN pQj?]g~׈R#vxד./2l7:q*L~4Y}0Iؠ >X@*'aޱd6=OB5l?*V[,q(Ƿq'z.^/cަ T6?ZH&K1,e4k$>'v?eRU DUOV0#"vvKoCk=6uxK)>&Xm1 \N26!*ݩer=đv7bBi#*9y׶2Wuj4lrئ4:JTe6%MԜ«w]#5FzPIa&B=CTh:N <ԑok2S&[@(P *o; nD^T{#Vm:~#9z>}?+, ,ҿM/.5wIHSm}dbH㡵GL!Ԗ֔U*A3 1.jQSv - wp'jVFT*X$̏+UJJ< GʖUW|m0n 3aX \?:IM=J,3)`lumVTݐ! Q`(Y$t.9/QO>w~Ȉ9gἽݯ܆5ԆJT iHc a·H_J"/z@qW_H#zc/n|g^Ge2PMy 6Ooov`Ab9Ƀ} D=cVʦgL1!5;%W'.bXXh, ]9nS#5}{{:Hu_|kC.X`9)ljdr7#ڙTT B4QpW\lf"[ )+0I, fb(EU$gMMUD\ 3n6xwݱXzE&X\0v26cqqSfī)vtfWk#YAp@"baNA*[Ba5¨'i륻ιV#7' Y槹8y`G#I7m /Zr}mX998#/*O}F8BI yM~,7*3u=hb'ttU7 ţD,Ji8:^df#]gƈxHg z#<}sFUI ~$]o*IDͨw!){ЬEw!Bn4FS^I4'Im>R EV)U џ=e2uZ 7o{B|Î5f "Tm)`H|*prŕTA_)0bLXhՎcž3nO4.l푀W0ANY2[qco3g1)Ia> O3jP:R^%YymR Xՙ`K`4=b ?e,\_ Z=ޏ=`#OFcHAr1`V3ۮ_},My=}Ѿ"/QQ ܽC𡃥\H)rWhF$1:K+pʋX4^2 o<:,QЋ$Tu9~6BrHo.;S;s’N`5,h91VY& (xQRDh, ? GSSxSl>R荩HUؽנxсvԬX'ƜVp̻5ܠ _V1~̃\1WG=|_#BJlkH)R/K+ڏ)J:V̮D>EY1@"G 6'a#߳{ֶL@u*S#Zlh_2Ӡ+nFnGP:;m荪+]؁jWly(Ȗ#!k„F@yKh]UPal&r$R(K gX+egPycJNr^K.%GH< I" pBV"6]y+lIm%>2}v:XhW?!j$):!,fCمknxo=;١]uy/un|Zfݴ*`ܫD3JXp NXRܩDPw887I^Joi\T"kJ}nD9_,j&!ldF07}׆ 8K*FQ7fx`Pц;2cWed`͈ԯTcX+,T籵]X3&ƜV8Oq򟂀cƚ6 ]ǚaBoH,2X򍃵l98OH) 'ka-&krfXu_{n#\N{닇lh GZƸ\1(³>6|L`7|)J=p!ls-aƒqȻB.Tý4g™7 ҽNPRZv;Ӫ A0%MBʼnS*=frt "׽2M%#"em:ќBM;cCkUY8ܠ̛K% Tu<4"* 6~&;l]Ύ ?z_GԌSzsRH\i 5εظ_}1Xa^G~}.ttTś=D6p=-ȧf[udU0=AJuNŋl;@n1_"d:ʼn "-֗ztYBoJ).2Ⴀ] WhPO[hjt{7CvO 81+kJE ʑ 0>t,ÍIrFOm u"76Oj@ V'UQyC醙' ͉ckk|A]'DI@&HiW C𥕿oFur\>H(: GzNNjJG}8MS+:{<]ݩ[XQV[8` ZPFN3r 􃭩ps0,2k7Qzk%ld J0zl^߫#&O7,Z$veɳ+#R>&5Vs`"Mr"<'ӊGmnI9Ia?v?undKLkc'"{u,JŽiS\(PZv,GOK3+k 4R!NڎUKƞdcC% K1=|*Q=B1z`.U,\)ѓNU(%ȟE8r<ĜwX6:w+&BP2EΗzADZZ@;DAxSY/G/č;[Dnrܼ9XPFG1༾{V| 3Jaqzt~ɒ1y~x=~CtpڕPuIð GAS0'ˡ) zXAҦ*ˁJ#NWiPǚP'$1tvc]n.=rvpMVK l.Gʒ!DxЍ[ 0Y%{UK9ASu1Uc0&z񪜪=2q\4 , 6;Hvo³/LzxxYHA(EH:'AMF?!T?V]pR1xT*؆F@G y ڹ}t@t |x㹏0LwG>C˴*ܪ-6'EOJ džIpcv6SH~BKT@ Ζ8]Pr;cq4P?Q9'ʦxA@0zR(EP ȂdiRQ`@*z2rG0fft7~4!:`&{܏e33 Vil½oǃҚ+Ya`ʐIIMC"6=4CֶXz1л#!oMntŐ:b,=YK0hb6*hP@'Mߴ-:`.Eɪ=zgiӅ\E`+)km1^s ׂojg*!0pHGj=$@wE0e&H[f>ύqb^i}&1r2AiPtrm'/2rS1;JR7;OOAp\[D)Քzd[M6MqR,X_N$W-Qsz*'`E!m:6m#]UJIQ3ksm{ ~W^c0a;(6zt1gLi\.~aۆ͍Iͽ;:xȞ)g9j8A֕/ d?GRx)Cle` $ UlEZGJG,I*l*z} ȫ -H>1ug٤2]~.b%ʮI@_w!p&1hzcY=oږ1_[  n,"fI+&2܍QqɪŮU]P$1֖!WP7I3Vˉ@Wϛ#B?Q_כ\I8y@Ȇǎ-AOCСO{TxQT KڧzTM]Dzf >uLʸFquVx5V,ӈRU&PiIdVSm6Qz$1rR&y ay29@0zcY=)Xr nERISyq6?Sa"SlycI"BDBEgp;Dn͌ #P _eխS-w Ӝ+ȫ$tJѭW)đWӤx^YXSFYTycz=GWߗerL:ʩhLS垐MF (JaRӘ!o-7SIfG" 'J9/dϐtiIiάQ #R) Se mtE>bcI+  ״g<-t 6yeF J9 *x+$rnv3`B ty޼_ex>{g!{G8+}qg:LcY</A8O/ʟ  XqRT)Qajs(+Nx\/^vFF&5ͮe5&'tK zfp!zVfd8[hk=Y0Na1UW9cy3(&{4]FE, 1.nODˁW$ ïUJ@*N0dԪm|s 0MZ'Ό3$ 䝤@*ֻd>2t_E0ЍT^ƶ;}c[q8_1W߭aW z=zSjAѓ r޲^,t<2@$k\neb .,0Se1ɔ@wiLMؓAЊfEF&SrE|& 4H/Bh8)oEKS ig  TPezۭ,IK;XoE'|dQm&e6} cg.Z#^N^Xu6eZ &pd`"zOJK0,gJ ){'G`~U3H~Wkc4dQR\SK 1L``҅?Gb8jS2A{S#^ӓ+_F牿yv˭̼@kz;`<1?N3QFMx5˃20awbV:Z?~nR.DLgXʭEe ԖVh֨$^.FeѠGz"1wV|5RDlxj͢I;QK9!82AD1GPĀFɵh$hb>e8 #jO~mk JW\#y rm$N?*u>[axݧ+Oƒ=3H:Ɉ$'gn6txa/\|71R"EDMw lX9!ZR]Oi! p`ўC#mwb&gڀYEɑ]uRQfbuJQahǦv2ʰMdlQ2cO Vs$0.ufs7imU^9r&2H `%11s2L}:uSNA<:^Mݎ70*(2HߠđGD8HCґYfS/XŷQՐ̈ Bg<2@9#sBD^ǥY5w0.y>'HO?V[&\`T9UƷ۪Ew0/2Xc8 F[[ .;zyQ\Kҷ@bmΠٍTl~ e+ieXf"ŻxTƮᏙO:*n,Oȫm uSr*"7֝Ilj˳rvOA͟e;=<0C;! ؉#UcNKyF)6"mjL9z~ՔdʇLup!`n<0ިA(Qi0zRm¤TH ? NzVfBF@/ɆL{M|}FAOomm?uw|->*4 yõiRD}BOZ[jdj/Vj 6}X)^`3l6x}n*辶"˹\oLR⋏ U? x)LC#F3kME ''NC,eUi6mҥRrX(~1=K jXZ|*dѬ uQޜ_VqPLb~xҷˊ»9ya RS2j'l:Vq݃peƤF\ L7t /X[\Esi߅(*/SnXJ= n Y0[~^Kf$TddE}YbF Q)g&DoOAU8k MIɸ0Ɵ^On8LFpyrw ř@Zy~9UKQG f㥐iqZqڑ 1Oho a]%VJ.%E2➔eȑBp'Lqx֧uoxwնƤ2v|4r&S8)T\5"\̳dꀙ$@']4,,1FMqT<3PW$.鿅M1LNIr&E%33_!޶s!@ebrOd/$7XSTKP3Z1oule$Gœ?m'4r) ޮ2\i b441WQEH,1 A; rż}[=7x%lhu^7c7 $Nyb-1`ɼV2jT+E|M+r$·h8A[m4De1cuʄ &3 D#tw8TTF܀Ťg>}T07uMܻN5 UÎr7{3*T"١ _Y1.+LlcU_ϋ4r<ݳ>Jc[)g^"xH&9Pc^ 1yMSVR&?:`u.K&[&:O.3IAf+[,&o\Mz-vl_c01t[fe@z+C 2؈/@wwˏ 2{q%1eBK1S1[ ΐ5RF+²gպE.UE2|ֵd)8)/&i eO\^',Hwr`JU`/1#JctvAWXbQO jO f8r/u#;N4^8muy/Y/ o[j}IL5'lu+ya>cTO< tk4ҥB HHޚ;S>]AqRd;aʼn6ҦbZvW`@6"`AnH:tӌ ΞX6.,x61yƮpǵY \Ee1޿36N>ݩdp{W]ElIP^|?E{陝SZQ"]hk{U d"@jdGyU!>r; UYuq6nZe@IE} N!z%(1t$UQq%2>3[|k׬󬮃h;6`5$$tJeUv$ҎzSVVbJqEljuDMI 2f Qp}1~Ojx\0*ǭ>*qOaTccIF c ve;r3'fb+cv]ˍrJiݎ:s9ch<LT/#c!JRLgGJY +Le)Tҙ/M2n#6U? 1kbֵnڶ$OIS&@0AGe, 0$1U:0\S?Px.CE?Kzp!ȶ L& S!W dc]`dcSbM, Tcqd-=zkO9H]#[.-_*G0Ŏ֒O Xѐe1ROOLDS\\mz -1"m|?eafrmM&&w~]+{y!"|PH|EH03B rە\AL zz1](p+c@e\<*,3z{ c-g(A+Ίԋ:mfO,K;E;Ƅ]oOAuIpv/R0MMI7{- צM֫gy0W 2Y{Աcŏ+&&m?PmxFR):NzZ7$Tނ֥q;9 #wi:+ jGOkl]:B/bgq3ӬR/WmSw,؁YЁތqFwnLL\T06Bl yZ-L.T n&ecg `-7;U'rs`qP,IԚ>EX6Yђe*q'r؃ 6s_g"c[?º;yףD UJaqNA P/ nQ\'=a+ۃk´+~CAIRRbfn򡋨C!o34'򡓯*dU7PeoBm?J.iyNGɖ*Y@OQ.,ɺ vS@Y\l S÷=D|V& \W%w`` 8iՋ@~55q<ĕ֐0J PdZ(\2cErc*\t*F|s[6ظW9ۀaGJpiV,zBk?V*_3(dNcW46?^Cdw}@iqPF򆟌SceP+Kmj] ^}S\|FL$}JHƧ0qWZaYA͢6l qmTcYkXf*;QfKS rxx@O?g0.F{Pkrur7'Jƾ,W*qWGꢕ8ԕܲL4-ޒ,huXB̤9#nِ{Q#7=Ù]viϻa1-W% &A8a|aY6FY1i*,#frǾ0ٛ'rMv;ܹڏe*b mRc֙DESjH1 ,*iȖ5+DbfJQjb ʸz-,ARvqk2@J$}{x6irlMp2r jQPqa1l{]S,d2&ܟ9EUR@ ZK! J!U1խp 95ApIW^ uRb7IL~?Gw׭8tI/TYgFTdswW/ʜJbbXG\t'/רp ")1}٠ٵ04TDԃg2N6'w5_b}a&`0=YJ۷6p4ȚXgƯY\YI_δȸ iTmLLVc\?t[pZ;&đTp4LFGQLNSP Aeh -#ENS&:2O6: D7">u덝| ,TʾgD)UÔ2ݙJܚ#D*Obj'gX A`"OdW:j=j\n\v*%9B"d5X\$dcQqQaD@j83Jps^Kd.R"gUdжLYz1i=V,®/9,4X^4uKLs5H\rC~Uy!X0"ƖX͢TuZBY^(&E5P 0NԆCdhT4ZY'(Y,*L!`Mhy:Kѯ͓eIP b{%č 0X)[%1K JsH%Ћpb2bNƩIӌ[Z3BHGKU~OuL\lx 0,5&9ݏnô-7)gWXG4ugs H0ϫr1! ɧT$n?J2^则݁~x/O؅n9414eM9LPJ0o+_%?jϘZGgn6G,o]q/W;eĀ.GZ*!T6SM>DiQs=6dr  7SA!lȡR``V YVχeiE!$ #hb&-U`X!-Yfkݏcʁ uW lG+{=^{6FVیaHD3SYSԎ1HItKM(``"_biXV #6cJm?IlZLˌTJC.=b,h=`XuwΤrG:ЮRA U,5u&XQ@"b/FS.$'jxcʩWu1"אFLSliUt$HSI_"oC7^6ۛoԫϏ^c&+ܱ ߎ%6#"ҹZE%Ǒdۗq~EsgrT"bۊt˥@Ae n9́IBfS.2˥i9xn-昊t؋y$~`WWƯ7+p)b6QX9%Ge?_gӇ+ {d¸1xq6f&&[TrWNy r kyKY jf SwV>ւHm5R.th$V9Q @Bh@Ğrr1wrBm#iW+\Ns0G_βeiqot&L};ުVwp〠 tCsҲF68zu6ƚUHo:;M*ӑBSmX-THZ @NlSaZ( ))%!&#e,PJBY M+ \DޡRYq,7`r/"~uuWhZYJDV {T@cNՀm1Mua0zK4dd?*sU:SLHIi<}rf&Y=Fe+&j˼<lXd)\6~^5ǘR-4jxbIZ0u xqv,߾OZkĤ\mD`{~7md#uk9O@:Z`fNX#x\y`qq~y$²Mjqp0-zz,UqqBUZhl8 9JY]qב)YdM$;NcMHTiJ m,@62 |h, ՠ ;hf2LHS G)laR9kmkWq7~εڸ8=Rr:Z"#"퀣qR9AtC,ڡr%H67 r)`{Ԟ$f,S{TT <kі֙s>6%Dٟmqy]yȌ+[R*v|B3aǐiUpGۃӥTadBPȑzoT";F:ScN +@:icW"Im7n͟rbBŭULB@6q'Wmyz`aUm?Zm9S  tuZehvґeiP͗e8c4ڹ[a ( mʹ`,)FYŒ S`/-Ir͌kKh+UG1|o;X2n+av!|<1X/s ~T ȹ֑rHPuu3 r*>RuHTdyTeQȒ #>Y[7Y#FՉܓ{oUHz9F>۞˙lL,O wx(q"5$H?_Bpo b[f7q֛ոmt);HUnX\v6>ҫLֶ;\2yWpc[)6N1mMX:$Eep'i+€ T-SM;M,+zuD (3a )([TMhc3X6^^N6UA.G+!E~UQQL*a$}Zw6 6Njciuj$]*%nIpDw=R 2HѫMpw׵mW8I9g'1Yzx?.c^dԜ4v6BVh"V%Ǘ}ה &F+/#|Kz@+oxtt D/yӒ5v9h. +6,Vۖ>YÏ- ~"ok {ǺTyGBDڲr.FʼnU/-=ͼn( nNڸ;ʞ/X1]v•L[ĕF*etjltaJRe0( "d(ZQh.S%⒙6XdR44¥iP%cF{F?=ΕǏz, -cֵ.J)1c!WpH o*Yo# E EA J;JOrɚ-g /;kc"Z8?~m? w쟠<[>_gnv@'DVE\džq8V\iE8lSiLt!?kY;s;HPr2w匚FٯH_gK yZsq>%PU;SrkWdW]yi9c)ek9)۬I[c**LUccXM^mCxH.,OM_V;(9.CU&:|+$i/\3DV].f^3=XbJEVXGE H22(:l ɆM@( m"3m͆(eOjPE%A'XL'j8ҶY*2,W޽ƱWv.O°illiCT{l y,~nTq)ښU"ong tO S!ǚdcO_U[&; 3~ \5ܑnSk>{).~uKʷBlp<^%S\nl"p[MZVe7+Np#!Qk_qlx=/~HÌ AEyW{NP$ ;ѽC:tiU٤"!Ncm@'KO?oE LxovՎ'3yq 9-T]9sy8 JYʯ\}XwOaǸf/f5~־NPIDZ|R,eZ ^SuԾǴab-#]l~|I[9ƵLTˆ%4( & P@ ɖS ERh$hZ I#ll)O#**2ڃszy=E_+Kox=^6m} y{vƋ$Cծ%/ TKȶ)ˆ]ds/@MTa%I/k E \JQeڄ$ C~N"du{ Ј՞?.lxrfSMz/g+j@":^ܧ鿾mLX&dSof{|OS*$^gy}q}!`5en`aiSjH=/ЊVXrY oOGq-yzɒ2i#"QpϮɛ+E0 Qr4TŃ)eD,{֖2@2@ӌYE]mULw/rL?F6nAS"LhOݪ;Pv˕q Wr ~sx#OI8!süǘqpy q4]NqT=u?<|ttx8G?Gyrb ֬s-MªPՎYnC1kuEO-g v_!$*Y1,H v<>C T@`k{N70)V 7uʯ^~d%>giKz$]ҭ$Dž0mIdAR/@dPxtWh*(JS@eP@e?P}-tLvyP7c)u* lP6&4k~qd I=*-dY]ntqтdƂɍ>)e$S45n=(Jùظ%aoAT*mixd3~8\2ǝJNjTX $ZyN)&e& J]B`gz_EG fehDu&߭+V"SՈ#^Qvgq|u x<ݏ!LTKP+A0"@i6RʣƂep5YB:PkAa`A LAe0 ۃe`/_۱o~vidEjs^'s/+0-MadAAڝdҬk8+iӈ#q*+7IڧAF*ذe\{1六v[Y?PVH&<®C\nfUNoMpta2(z }7vȦ*[Pq~pg{YJ]>b:V߉qH~>'2h'DWs$P {Z0EDU6p, b cm֐H*ʦEb 9O!%&VcJN]yA> ho7A,jlʹ'z9BSU c4Jxs?Ew5xhiVI J)^-5 L[u^ZkF@S Tw,2XOJ' -SO9) 5' u >5;a\҉%kx %ܜg6B둷: >UlqAjz2Owdb6m Ȓ<*X!Qe̬RCc1hh$qqc k(FA͍USz>Gtlf?Fl?G}6 p),`?9CqLWf ^g߶sXa7 F2i|m61̚n|Uv$7,Ei+Fj㟹pun%[? =&A1SfjQ"DR7uVHaGYbʻI$H3Kԭʹq".[S9}g"+* wn^1w;#Zǔ$ɦ&i"ɠ*MY? "`)$H )B EdAi6ryfx \#V5ëgk~9ФxWg/]~q}o@ME,'J&Yszhԫ&\p8&6kz!SfӜ߇#' ^m5+]rڏq`55yb_Ec=:bXY H`"/msӺ#c+I;RT/}JPi]b<ϻٽ[S[N5mPdQG1nH>q|}{(Oy@+Cəz_{nyOW2܈E& Ɖ};!v"H /O [(.h|4r~V!-]y;_ndz rIPq>kl޾I~C ևw;Ol0 #N;wtlde60n/ [Giʣ!/y[izY= &BZ LS;  {όUIm 6ā֬!; RL`fB LR&4,x@%MjYxm=/r Ouz"*.Mz].f^/ySȄPL$Tnid&)f`LCU t-`,PX@ZAZ L(רÐϟVë۳͹7 dv=V)/ aA"C1 Fu^J#| zn=>YcB**lV>V1U%reCDcL˜."U\dl ؔNhFvr 56GJ}Sɒ/f݉^Wʹڽ7 َ},a(Ec~9y9SИ^.߇mRH$cuz-/0#OY`vѦ'-=3*&w Z&e]IpZyT*A,j=ʒHGz0Fš=0n]|D3iJʊAmz 㑉4\5=3NPx2sWwky_7?WC2"6S$m( EL\)U(N٠,fvԄ h"y|\>>NFcFMfk&ݶy79ϟ!tykxf4oI|+Bxʸn ŶzTc"z#l Ogpr` ^i9 䜊MoU, h_$.'¦13d׸QdWʄLr$ª] ƪBG+ ڹҋtgFIuګYL{fL;wN{5X(5EMM-Scľ(<@OeBz^ҵ9˅x`[`zDVY8vf\`N~wϏf`q0cܤ2nߣ{~βK-rmciEaCߵ.W8wp?+FJ̏}=V`=,ASbaU*[{0~Z q]TD_v!<6 CmwPpg(Q3ҫU]YN2$cHVzXgyƫp1Y;swvƖ:O{]ʭ3Qh("'8?"0EF⼽8K¢dfZ7?g/pqa@JjawK#/F6lk;G4R/)ΌyE,;edU܇"Y+]3\")[om}o] 8H̤LV\3Ǭ[/i/U+b~#ƨMcl!aF#V.Ih)ae +|~55Q >>z2I $\kP O5+Diӭ1c^V(z*b,24:URs ͌< Vbg |T^»y`%h$l)6d,R\Gq?Ѓ5c549 @g]ѩ\rqx\w^;.? n~q0wS65 no?E)Ur&Sj^{톰%EXx9ymޮub(p:d x?tWHD|6ɫ叨 ~xhꇌwԑU%#RӖrixѺ\_;wM`Q !mj uI 0PMh H8Hol4agQLŒ5~ ~8]ikkgrjFG9r\o^uLAU7ӭ,É|&t{ST֞X)(? F@ "k*6Od&c)(!` D2WSV 2U 9 /N4<[v{|7 u}N Vm+FB<(<_ޢsO|4ՄBQZ߽r-v1UP'S֭FB1&$iu3^JldF~ybP n^yXtts2ȸ:dc1[?y]ʀzWF#ea!ІF_V΃z~땈:wwy+[ѷ"ZP(3HLT\qLj4cV=֖FA|QT^2 `.GoKCa\:#zOvWb Xkn#&[5\Iho¢R.g^#o0L=T,RW=DIrpaqiTJ-?n @3e:|(1z65)^9C\7uZ5Y GSpvq9KYW'qdvT;z꽅Oo w{;{XڅI4l>F\ݸ=IP:]_sފEfVHi$R<|vnٙQO^Hɸfi͕3,ES>b "8WT:&f{F|I77"uY#Rb#*Q22:iN\߸c#)+[Z7U}O-?e.tpJ?WB[9I4`&Ze8]6B~J?δ4=t?ifѲ xq~KoO8ȭ+*LU@7ejw+VI1&qĴ~q\>_ks<3<+z݆h-YxIW?Ʀqwyre_nu~lybW!S3i6` Ivy@Ҕ(l~6SP>eCX&EqWgܤ]>WV kN_m:> XwN@dw&3.gs7k['mɕGJ3aDѓh>圾9-/ȥ5lyS;.?ek&,^OZ қR "I/Z0("%~i TZ R8?o^P6X \/̲ǤMwp&Veh_ iwMlׅlv?o _rl~Li ɽ' xY^x8^[^nn*'l?ύJ2@v<ܚZs9}XCFF?^ria񩳖ֽَ~ T#c“vݛ"fo'{ lX}(U[YsRTakJqw:QӡKrǐuSL7c=xgs{Mx^PXR<&4k v+&'$Miq4E^k w},rpБO9bpmryFЧ9o\j=Y;&hܻSKAYs_7Pp=ƥ(16t.gOx2E"z\0}n,ǵc-+͋/rI^/13[G&旟W_]ݎz> oFi5VWzʍ vcUˡ;ͦI\kXW |`W;EV4pd|` @^˓=x=$ZOg4x7}^?? g2!3b+c;[kio}ezeKN&3\99[ɷb;b%b^ k}O  7"LAo1M-z5|[!'țdE/VmߨyMF<+{6;ے{7P@Lj:e<{w&BQBA֕s]}_7*:'wKxneƲoI=ؚλ\y\f?j㝛?-K?'1@LVs|ܶbb#># U ,Vf?k9l\}^PG¶Oղrg*Oƌ0Ɏ+%gWcŸ^{Ϲa>*G*™qOJx@ن3 0T@[mOx)>'j7m1Y4۴oλ2boMynq^O/$ XAX:6uׁq9yt력V`aXZ{g7//S6UbE*]Kl4bσe?T1u*iI`Ȱ;w{u3wY15n]}2eM5cݰ}UݝFl>u|ꮶܗٲc@ ڼg;~,z+n~4~lY\Lb=ˇȄuErvk{6h{n~!Ɓ6M/QڎeQSTkTitNGXkXD%pR%$iBf+aNSj^.PUd>q4>oͅ1/Svsջ7^/' ﷹ-|E_ XywM{a;i9qۍ1]G?q]OsvgdË.l=Lccy65mcKmےmwu;|+.I9yfִw88899DoSkxl:w{Vs/$ [Aڶu}јF-xGv42/O$i8 :PEMHZ2h4ڑ~ˇIljUR\>'w۶=+PNvdWWW1ЌXQc4 }ה=UXt1r+ 0<޼wٽޱFJ&:ZvWy6/C*[]s~+sM_m{6gl2DLR:Tk_/ز]Z{N?9x }*;uMӅLI[W~$C=' ?"SxK1pw=?l\or lmuffr?uz?rs88ir6LcSK{O'ظ)㉏άi#wڶIY9QhiT "M[GVI9iHR e qrƚ⫃jj_#ؤ%J{cụ,.>\Tmi2mηN8e>2f-Z]_m& y>׉q "[kH6\lwg^ˋ$"5}Dži۞}lyg(1jWPjS>F@q-1Lܸ}#mR<8A۟yˋbpnCkgkKw=u=3p(it;~ھor6q1A6vg?ˈ^qLqde+ʟʯ[uh9k1nQ&+w48/ lj/EDnugu^S̬p9$2xMiz_[=/-ۘ=Òh2o*,ƞkkyinp?{rYx»W۾}` ѧx2,)-c )$I1":"ViP*EI 2zPqЛЬ$ѓyp+"NVjqʬ}2#r>vvn[}y1 |Tڵ{6v! ּ=183/ing[UFҰ-\]ޛ}>GqÉ]#O ů;$mm}w{KcDnj]~7˞#wϸyHBe,D?ֳmۗI_Kq3ɈAX~ux3ž #mNO/.<8ղk"zuĜ;t_SuP?v=:.:>. PYnq"Ґ'NT%K]+Mɡ"HK38"S~c兌yߗ#:cqtYY@ 2xwoCl,G a>uF9]iטtڲ16cm(y1hR ?]ӷn[s?~^/i-Zwm3k'w/^oZ=쟊rs\Bkg#:F.?eQPN&SԨޯ}f>_'rq}eŃW K ~;3^dzuO7Ç2(I7 ~~sq35kewk=yhCo*?4ƺ]׻<^> ۸Z *oۚ7sr\k#,*1eP2 APRMK[)Sz" NƐ'AP*wƔqRHGU̇+0<}˹|)ٸ>r>B0ܜo+~η2 $(f ;HK~8 ŋ Xk:{'^)3cclR@R:A\on6z{3p9s&B:®Emގ", [qg;fuzg~{tGp"~u=\{H0`BcP( ܑɻQ{SFO@5ma9`z m`")`(XȪ'H5KUi.@#fwP"e]C42F E5{eFHon)+E@)Pv2`@LYH0(&nP).jP֪P#UKX{89FTVє\Vi?kn[$}H7OkGozWwIkߦ>ȏS)&!؟OpX~__Hoپf佲˙ݑcƝGspUфY,js~rrYOlEʍH;Hv3o!LlN,JXɬxr^k_;m1^ۇx\C%TWC]fwsN3l9mx=5HlF )L-@ftA;w^ٷ/Dd    A ?16_9-11-1958Immagine 416_9-11-1958R.6_Ts1z t+.2F.6_Ts1z t+JFIFC      C  K" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?K9*Y0CckNBH۽OFATȦ-&0Fu&wFC )JzxO{O`ѻmV"G2ݰQmlU #C^F%>-R`Pʮ 9cڸ+0wK b8<کov`هf  {Xݜm),I0H#kC|*&klV>S>]*J`W~a~֖HwPۧ5J\3Y̪TSԷ~aQȷF&HjN \ڟ!^(/Bt6vE)i.3(-LH=+Е%yl ̧̪)׊q:^ǧ"jx+›b6t׸|5g#$|gb0A{7gB_UU"`mv58+>rg: fq)+<5r^21`p ykcmc7 ƤeG]یy`6qGBrѦ .rFkax,~>$JƟ<6yEp1`9韥tZ\dFѢ(I gְm2ØkGbO~yr<Ē&)vbGqɹN>o®Cx$ wf-0?Zɱy2?b2W$c"H#ޜ}lbmOXVts. L0z~T`R6Z8䴐}NIۍD6H)sJ)ym"Tw*8¼Sɫe^9Q#6ѹ@A$UJ㥶 \ qȨ{_$4)=[$K[?Q3 .:*eP?"_iJ+B2G9Ǚ$!aIrx 励r"F8־'#KhmQdgl$V~s]6fO9zkKhUb6|#^kȩ>Tb6QvM!%cF_ʳt%:şclأt 99$K D-@w"hV,Ff 7!SǥUapbRCc. 3I ύ<i۹:jGj$P  ٩c9}8XZ6rDp}˓HIrr\lksJ6/I IK ᳌vU$0K꼀=+Rj;cD&8Aq#ZSJ;Δ/b A"% dG%1{WE[R2';@+Pv U]{^0Ktdkr[De; e@o'{Y#w9BH%!hto@v)2L>+th /~YZ9aOQ\׈ӧH*%`M7o#$%&9 =_dSS%QZ?B'j!ȋoʸ FF$Pزz8%%V9 "ADr@ɓʈ*rx_*ipo2*Bw?g[֛\2HVX:Wi NV>%"X@U3&<_JxJZ(!PYocޭxÙ??{$xCFEY4Q2,5830Nv8 M$ 1rhHvYٔ6@4(_^ƎRQ 4,,A\sXW2VG*HSbVPm$oh;f'\s'Rj$+ZHYS}*hNUOWT );]J5UYi%N*9эǦ>pzciQb뱑*>\J܌ԫ1zs]ʘ3Jɷs? 8[r-wϥI&X<ZKK$$ |uR@s jUwK9RIV=kHax|ySc\GS* ރAF۝#\'P6 VN{W]7tʿL;,e;<_eK$;NS_rCyrڥArG g>:գh:br}4="2 Cʹ ۊFNs}k)tx?Ķ4i9aʑכWنh.'۰O{O]$Lȣk6 cݐAy^Re0#GOF_;jz^Y['H޽+=䎇^ePrOz-2O C00ٯXݤzK VXrO\ֿȌbO*1+jl>`,;VR8q( 6峵΋I/Мڡ7 -h@T)+oOHtcz ]-75"RK`Z7P%Ea<+2ՖUI⤶Vd 0:f,4[$*$hi ^w.́b]2l5izrP7ːVymIj|{in 1BC0eg*$J̕IJFkuM茥NJ-,ndW9VdVJ]ZHn =ϥfx bPzLPrݬFLynG X5ʣGҶ_Ik8b?^c:I+)U?w9\\ҿdfj,rLȥoƼѾ[gY'`G]Ih^Itkw(`ek»xصkssDrc>uvbS޺@8 =}t/> xJLG !]drs6Tm$Τvp[K HMUO܁DǩfbiMDQArr[6t>M0YWRǩF*0ݳGYE,(ҙ< ^rvQGm;HN9!xj:ӊ-r-UK1pEᛃ|P.ASXm~^>³;j%?tWfBa[HK2z}֯`^[*wzY ro :-% :ik#x%g޺] RB;xGCfbX!9h3KJ";ye qY+jP }obR rp=ipw4I{u *P|!}1TWqc4cg-]lXdggBEXnѪ$WL3w^e}>4f{\mvBi.OnV ՋOzVS} :/E' @PTts[vT|&·u+=k"%eC&0I Lz hEK vjw慑qsZҲ#XAZZJ)/ R ;Op@Ju˘Q|vB;5mnI!!c$m^Oe"DBLIrFT)ꢜL-OKoH*~j+Ś!`[BQ]uYVT`vqבyϊ,^өc^)q|g+f8Gݎk/ُS:N ]Ͼu]a!O8x潻JԒRWlmy~)4VH S,1_IxOL+1 vtpRx^'9ξ(xc#*@~c 68ʸK)i];Pۤq#="H+t0/:sRT20ҡuHͱ56@I>\DI;M\K.!ᑼϔZi ؐ@*x瓚6PE7 kC8|uXr,KnDnOR8Iiw;sSA"=,R#Z{+3OҴ%)I1& NHϷNkmyUKgj$2@ sV1mQǷ_z앎;$9*ןh%z]i]i~[`{4@"1HMVcJۮjPZD&Uz N\w<3  J&*#=\FJ>P- T>_ҿ5?kT-5=7ҿNh6$9K+n$P~\8GwP.$z~QuDtJ8uxF}Z\dH=ܤcy'cW5OYH ,s^tGR `?WhZۣ1^3yֽWgPA1_)$в9A6 Q]u 2DE9Ojm!`#iO|so%ĪI GV8,Fr97wsxEYtZ|ϨFiGnBg+_NL0# TCU1V ?ZB31Ѧi\ ~gUS G~_2E8V PL΢[#qLrJiF`LbI^ڞb[)9&:EmGPh m_Q_H$7Ue%aTEdي;QYj-6LK|F“X:ݳŦKƜ=uŅ$qQ+=dSԶU 53$O s(X+I+mQriEMۈGJɌ(`'$i.Ih ӚqXp ‚0F=jGVf\j6'Б7?-@&=Q/O ,C WI,o(Rx!|93\q &V p?|fi;U]kCqzzl)@Li#r~H䈲8e^ ^ip Wާsh5GrrѷUF@_capUk43ٶtW^#)N*餒Z,^;TeEW2I/n)Oҳj2xTm^b>BO]w^f2ڪλcO8#2Ú2'#r/[PbBǭ +\ū;2dNd¨yGSivZ8 d$S"evϥLODhZ:P*1ERG y&UyV5[ÕTVDS,BL,>+IZ)-=11yk `TO-HJ#(H۽xR5G'|J<6jM]լv6z\$ޕYtR2[+ĺ%VrN[ ;,`oW`NG<~^٦ ܅;5 *g3K買gC@!zcDfEfveV_oJX^拚E\ӱi;))VH ǕT#z{H_*c%$8A$2KUg |5-zuV2Ҥr0FZ 9cPYbUd®AyXp b=8r[L%2oesj/81"veYhbx0 >ʎUi5Kd$iB$ZJy;)>`s޹OjFUpf`/v̫zXXGiSmv?w~t2En@ZpP6yֱ|fm+8{x I g9׼̒h+br1CIR~>fJg48lL̳eqGEEḏRqi$c4@ ?ZBCHA j7s$tu$m\3HʮÂzz5OS13W.4)ێrHPJd~A?~l/xطPX ;9ǭ|No/ONy+֍lPm~uOz˥S+omCIt5i!Cی^5>5$tc<@m5@<2P++JD,$ 98h4%WqԘdfW33m#^X*$R6-5 ާ4:QqMO]Kiks*d G#@!p+?J̐B 7SN]l#hQ}k.3!\F8%dhT?ZID'qRcpffB98Xs>FgjS_"($(ߓr6W#YȒA.mltk6,*wd#s\ڶ9d-dI[zӊUKdU A'ߊ+i4dDJ0F݅v*Rưb 2rsEVԬLZ%KeK+\o2\c?6k!Xػn^y⻸#N '97mS#T s''>p[*9)%ҏ2%S 'l 僫<2f?{uέَٜcY^9%3pAR8׹ 0H򯛿iJMOd;Uu\Kmnc`1'Z1m}υ~~ϲFVP?LW> fOJs~]B #3,9ǷҺR=44H%sڽ&%TSaR7@$sVS׮N+%fZ\ˏz8Xq:Ewn2*(l1ɷ 0NFx'YTqIB8-+&SdUKdʦ'c1P?N˞qf0l. uWqF"V WMt(铲ж##_7ԕΪFp< 8Bх 0Gֹ6$QTc#;}h 攎҈aP16AtW}L:Wy[,[uRFuRx<#\;Y2`nִ^巙\a~r~d,RA fK:~rT=zWcgi1QlpwhE>ӈ⹂61^Yj{€2Ă+MuOC$c;:+saDƸ_̷~.墸Y:~=w2Hh9ǰx9.yփha;XWJ*KmU{wĞa+|HЄiR+yAE'k2=W5^gє}Nög988 IAAX>2ƃ|K=PlVز*灁W8NWK[uڅ^O`u[KpJ֨YRFp <jqqVm$|74teS%svk"UX|FHYLH$g9UXLJOj2Bca6UG5"k0JO]Ȕٕ`y#ޢ56*9z8kE}B@.2=rۍǐ==dK~T`R֚[`Y^Lh"0p9^pp٣ IGxE /2n]W 7u+>Ŏ =Nk&Mk-m 0U9O֔d/ke.TT_+Vdv1'  \p1kq~>#wtYq|5e]O_-%ٟ:B^j=#dlv8GNզm'w4N)g9`V1ƺ,v ,1A^y4TRq[/1G8)~-RH#RitƨxZ\բ2"|i"dz IY O>$㞎HI ӻ[<v/_Ke|Eķ&5([?RF? 千3Ǔ|N{\KKho] ǂɮMRa,eٹH}+/5NH<=xzOj]nxM>|^ RIoJ9uFùA*25,w(|nE[5{fK6dzӤ6xw)SLȠ ?: GʻmkYK]nCuT :O9r1Hn&BȪ *6apX8e\'be ̥@=I>¨(#s e߭_Fhާ(ED vy=@jjЕ ^! NӏCQӳPe>eVauIsn pr ,JXW Zڄ}}zSXYu=YW(? >bgFVg$OSk pyJydKk@Lc kp4kGczj7o*A?U_vQ vWB=+`}~vŤ( J]6~| م#i.+g|>88Lcd _Wx A@r?l٬QٱXT@=弢9WqIS,-y⤂Sy YlTe#v۳>!6$ ^՛t @HexRIc'I(ji+!Z( JрIPH݂}@qI^Q a [v )&$1tQ@ ;GJmRB\u9$8* ґYsM#9QDcKp3ݛK6(1]\"c0?)kZIa0]'-nzffs+c=8j*VqGb++&JVIqu!2MyV\ƽ͓-i,AQF:׍na$+j攦t Ԯ%s?h2Al *0v;sptؒ~Y>if(FG'80{DߴGxQR;Lo!,kؼ9vrBԞ Ǧ+|39*(aֽ{(j>?D5ɫ=o.B"F0p͓ řj^G\OYr?p9kܑ0 *TcoIqy*6'-8ɝH7u4(s4)MNNח# @mWڵ3\\GOZ%e#F;);))s]ϖΪFlܡTs2rǞ?gJ q[&菂yni~\@P PwC V̔4&5Q37vyD94٤hapRG*I;ha1[߇ P0ǡɩ`K ~U5j-/R*@bۑ]¡,GgDz,V"U@48ԕ+oV!=u(8C˚MkJ > xъkwpNw#Oaܦ@WR'XNzRg}vP aW[%Iڿq+ O>i7t6U 2q_,em϶u~2z$VP\+dzWߴ7ABÀ:s]>m#!̄t ǩf/(]\.1V-o0dTF)HgǞ+I]; ɭ[2H{R 1ԟjdTp|y9z^ Rv- 4%!rszO0-$c0#*mrլ"A" 8FjS4cI,r39Q+pG;}Wx P#rH3W5H^,ddi?xtbG\KT Vc ɜ~ }& J۟ս>mN)X&]ד־Al<6rvn;-Ԁ06kՊksBf=矽_SK($s>BD6 }3_S 6Z*3Qu5]N2̱=[YnqQ[FbC`YUlDco] iRLs81!hE-#$Vu6OL\:Jw6s\I (1تxݯr,I$@JM"{Ecv1֤>_֘YQ 885Y|-#Z%}jnT*G@+;C6AevCNshܪ(999u4xGJ6h\қݟ¥ W}k&d;)Y5$#tv@$c#e>v1낸AX~!9 $GJۓ j?0U:SNڄw#M2B$6Z\]1*: 꿼t[UW-zWjANzC'U$` m/mf$g5-T67J!LZ%!!My vmZ"94{f%ng `YY+<-"j H7.Ҿ?u+$~m6zφHto7CmqhS#G)a0;W 2_4̄63d+ԑFŖw`t >=##k'EW$cEmGx0J}Am=Xx5-}q]\vb9޾&Sjn8A~ꆺ[YkH\Y0%1]6jTaqD[k(5rM/`[129U-^nOzзX+8iH6=;V4F'>b[:Ze]sUm9x̬vImJ*=3T쎎8GFV A ە^Z_]\#1* |]lZ !\<+?[تƬ6ݝw_jˡw,ZJs*1-Һ9-Q"f |G+՛\)-ԒiV+g4}O&2IIz-z4 bw=$wdp l,+Dpp~ﱬ=6 ?OIOzΣ{ HSzP@my.7N‚b5V'zTB22riI)v"JMH5췷Y 3pI5SPlNW=M7E]C,Sd0'־8tfaN}KP*)n8Gd\ stA?1h{DQ7cNw!HFwӚӌWw==5߉- 7S8|}sE;g~Sw09 Ҹ6#X3]Y;wR`TLW\؛rILR5yZjrjywdt#ɩmHSz,q+мy-[vǀدƤ?G$úhZ5R#@;}+WMԚI ʲf29U7Mf[)dH$du?v-ά q$yZn>; RW0\]UL9뷕_C\vwMt-BGSnb=[+gz$ Q16ѰpO9$9fF0'H|JKFG +5kMK@LAB0j`TO|䕛v$Icg!x E3Zhe6ˁ?:]Q1 @e 9s4`e U.[5̱HV`d8 JHad wOגp?U)=*S-^)!`#ߧrd4'uǗtrvO\W'#lp?Ҫ 5(SCE-puǑ _&jaV#1F3{J8Y|##d[BYH$kr[Rg]rp:}t0z|FsTCJJVM1l nGjA5"FۊthmˇٳWBAfuڛw`!;=J9QK!p۽zD-Be5$VǙ׎ . _3 lßʜ'|:}J7,] ωs%H"RiN<$Vr1唁a}񞕵6a4|gWSLeFF{uEF#8ԩ9{p2ʻ{rs^~kjw9qI:.\4K>A+Ap:<8‒9x9·Rmڭϧ|>.6XIM-1R<#DSӦk2"K' 7]WuŘA>q-V!gƈJ ef*yGsR4Qx⣸22;#}صԶu ^O/r#E\ GB >ͣu`< f͐y$vU#+Vb{p|blqT m ]zn,6$MZ$QH>!*G9B;Y)t8_ Kd@&hjg=T;Z˘݂$(c[2z=_,*HY"9T٥RBF+uu[~O?mR#bG&Apz%1KA9vR~=IwQj@u~?!0/ĀtW]ٞF2D}ۙ*Oӥ|enW}4qtЩ[(1|[ʾ :. . Xw:u1{/쇦O|O_1pH_~-x7_7m5%sv( ӭ}-ˈF#(,\(׏|#d0aJKJBgMmnc8<'nةau.h'O6%bcozW-,Mgn̯r3Jճ |KJ$g.';ջU+c'Hb0 0kN5#i5{g$xl{mkjpr$f!@=F3Nd`q%9 sUȮ\7ðjaCvǥl(qPx,{VRcY6)Ws߭L Aǵ*BԊ2BF`TJW;a9>K1`@"#YABXbBX%KrߏJleT i$b8H 'ws_(A|*Am}s)#yKQP{1h)PZW!Mv~g~viT6_2H6 ;c5F̪@Z߰PK$e7>ՓmxGXx=u 0$ʉq&Hzztn E: *IkW~uMO ܪs]n!dp U~x?69kn~QWTզ϶= Bq*,H$20H5i;\략i&ew p@!Z n85cI'rfbfV'iAc"z}k:cLԮdmf'.ecu.Ԅ8hdsQpH8d5BeKPO+*{b'28 b'[\Pst`@sz/d*&GrjQ5ď\HpUm9ȧ}mshUEY{Ygj:10xִ..Jl*9"m BG1cz^[yi >_VB#kuWE6eUZV$\`Wz ┑ZC9YQA98==/e]RA4 O<091rFtq1wv^ ۹*Gݭ дv& n xtYfq'GB3_ R_;@"`Iշ΍#0!BrR 8F=9cWǨ͙qU,Ur(-܎:zFgrxXHR&P?4zM)0 Oʋ 'W*>z,!Bؤ63wjv˿FYn k"PO[i#UL9?|Q`a| Ġ$׎:TFTH ǰjFM[SXM̛ >"(q 9y]SDK:Ru^4du'Qz}I7\XG9 \ߊbȱm_ǧ=wT5DdwJǖeq?xkQң  ^zz(6Rbz3KGnWxic-C;F{k<_i #zA_MI+>"Df\g ZPm!؟I U%u9ٝi- JCm!h!w cS ß `Ux㿻PX) M|m#ܔ@O]zYGS1z 5nuv8<_n;Nh`G|8B]f2`O'_ގ~n{+3NE~s6l-a6H:W|'pe7N2H^ḌVh ~>:>0nYRP(!OSl-wny~O2Nɬd n ,WY I>Ch p@Ubo~$KENG" PMč"D c=kV uB iXqU@=8w#m$q0Pй+\?JѰy#2}nT:8DJrH^ҞTР Eks PThRӥ9\ZA #BC2 *jgj2BϷaW$%#V %j%# TsZh|}j[K;h ,]\!.Wz`}MXMS$q 5`*pN7I$~jZB[ Vb$)mk7as<ת8a]JmҬNJߧcϳɫ8x>}3aRUAr ^Yc7w7~"oQcEt@ykq{k~kLcpg|"Kz~ǠvdU(es4[m9#28CO dJ]#-+QI{Gcn2>XkF[Fbo/'Ʋmrpcִ%T61K]I$1x èAih>ti,h*.I).nZyf>Q- q3E6ޤ4Fe zm'kNy"4@KqiS%$*J2q+7Tdݳ&CצMoPe +pLo,Q8b.;viS'UpJu9Qh->w9#q\W$ܰ,>)MU,dtHM~~f6:I=qߋз,rq$0{rD}EjE{=#q&$IAk$͌q$895_n}+qJW?VxByrTz-ni]"w\JL;dz[ggŽ~UW(+$lAp6:@̬He>KOҤF0 [xZt!0`)>Zжؒ{;)qc//;}"vccօB60hjIi)ȂC2*pI眎x]Ik(Xa#db⠷Ui$,qcFiu;IDp|zE8N:XV+$4 uEeC3VJܐq-}-R%?NAŝ[v ,}+*_<41aKNK;2Xcǭ`G-ځa,)p墌INzֺ SPRd+qֹmvG-Ĉe@F#ڒM{Cu[y5@mlFm5ߊ'h6JxH촙uHu ݓk3 6M[Z8ctP8u8;jϚI$Y$p[@ٸ Lq^b `+?l?RWkHA$(Zq~d8<G'>Z)#Yl7]PխPT7^:,4wKxdp+ڿ??dM(O4y*l~Q2h߸SVs(yY+6yP0׊ YXx#a_vzf:3 ִMQmjQɼ8\FKh>ň*To"HduO&vwuU_2#(֫[!4>G~(pܞT %k1$bI5n؁eᚱ T]l 427H6O'EZT+䪀@u(HQX(>L*V@F8;jKV,Q6?{qthdrGIU /dgi"J2V gz I ]+4`I(V '(`s\OhA ws:e47lL#oЛ#Yznk,+Hʣ9 }aY"*Ac^9Rͼ!-U¨.G7(*#=Wt+T,N2H ~~ZTrȋ_ƾ Ӥme`>R^O"s&hdH$i)sUi9Ǵ28νCñ)钷agd#2 >%=]\n)T\gtlbخdFM#2dcW* % ;KgvBzMčI&FʑCo/y_NKRֺ}bǘC_r<4Pł Wk鈪ʼg8xRVgNv]͍&F/ ?jEvBVTVmOZв20R8<ԦrW\RIJ7z)<ȟ8995Je0]d'= T ۶ C33ybK|J-JpWxRF6:ZM~6}̭`qz?~2[42fbUgu1JH|bU H_?"m'H_Xg>*$e] NOEz,UmĎŗ ߾+~ld$I\yc}̢EI?S[i?CI1:Vޖ!(Ie<9 >2qWIMx*j*][ QI5[M"F^Zõ"=oiQ,ːA5Фbi^IyUU到VFktV -| s֝5T?*)m.ԕkygGpUU[t;V[,sLo`C@;V%cSxX(q ;F,jv/ p" vO^k 6YwXdBYg@ek _+)Z `Pyoc]IŨTӾ=--\q$f\\|I#)Ҭ^#G"wD\;z{/ty3p&r ҵRt8q|QWPg} +A㷷s['$)c,j#JWkp<^>\H`([0ֽ Jw]O6>,p&y$Jܻv9p[Qh sY\J\ǯ,5޴yÁ0>+h왡<J\q ky㰂MA=CX$>[ҥ;>yƖ:>oQɯA8!rkd F}+N%1k?CvW/"0|2͌}Q%(50"V' 8s]QzȰ[ EXF+뚊Ֆv%SvzF9,n38K\djժ2=+v U4d즟Xq<8j΁@'J-'es75)zUUrF ZbHc+Z2zDXY`Lm6PKsH\8+QpOZ7"1kovӻwhHCP%r}B7Ep*)rR‰$I $$H0pv1ـG3K ;)B9m*q$s׏U,s0iJhň W|DLs 9q^ëTXCg{֡x:CG ZGI>t^dn1N-nggB sk&YP5|ܥcd4JWI3ZZ!g[,fWVxU7Gֽo7 F?ѯٮ!}iR:$ҶAn>@$5Ii5mpҏ)-*pk,8V_u'cfNA3b>R3M𚩲Ѩ:}yeXcN"B!+#璧u]x~ClePteYa(K7a "Pw+єR$2د0墱;n`ŶG{]5bqTY^7҉<8$WM kkp&gޤkIiO*E%i֤ͤvS@[ kQY LFwn'\{U=M΂7:G(OJGMud(hYˀE(fTH$Fp$PA;nu)ZL"1XW5^i7+@_~{TfYAgE'E6<~b6n l812B޺# YVH) uQ前P*dbC\`1<ڹbkp]CGJ jN!b=*$v>յr)&pJw3!PzQg*Tpzz՘kG`=I}P[U 9ntPrN{OeW,`w+;lP2T1֠ػɎ\W+!4$ C9R0JOi>A բc^g_>& iO%*ݒ+㦈&fKS#?p)RH:YhݟNP63`Ilm@?5v#f H#>mܧ*l5v"U19qҽGgmo2+˓ך9/B75 ekC#,{9عW6&+ 8V=g߆MդW[>ٖ EWF*H +NsYm3+gqk<ZMk\D{l UH035Fs I*ϴ| =cDգ((t*yeeVkZu⺲sţ#p@EԦ< ~b'.SQ9:wd4kr>Tk'q>VբU2goh5"2R7CwaBmGȧmhh6;"e|/m-%;:ÃVQdH~ldsT%grXxcXI;3ZMRYNXN9JnL$lʥzHՃ9;$+2㎕Wۭكֳ5{bвd|հ`#'<''ja+^HM Wr$J&v!we\ƣ<v* P QR7m\&wh{5NIM4p׺W<;WYWS5S숫0~s|".zLz!ҏZYh,5Y[y#^߫=D;gs2ݹt6"8ڱUܥ;pq[Y JVG&V*dIRenj3"TܼCaF5-lQ%v|+8qvպ{r'8SakC )Ryg{VA*(qvcs4+\pВ=W!h|L( M;<|d X6 B&IiSӮ?;ROhZFW{W:K57e 9#Hoq_Z׾)7jƒy[`ױ,Rg88hѕcqo=E{٢M> WiA%*x19s\u(A~NJWC$w'+?ZrPʨ_)~Z,V'8ӽ}͡cBn VSh+HP[ GS]=N +'AybWmBDhFSri8daXd T K: !mˑROj;A$G_z#犉IŢ5āz}~{ͅ@=,#+&D@AG+56ԳF޸gڠpAu+\[C{x,#P䞙6x'!WIj#gޥ] ?\gg',myb6ڨ*XeIuݴ<ԉ IU ORSD)0AueO:4kn z2Ic=iB 拌λ+qӞrO!f85\B 3[f$I}hn:t3A#Jg4wj>MN:W+Vqノ|YIhvT3]a,f5'^kv9 ``Ut2Wx[ڼ~ KqzX{tbK!s]FS 9hY⹱l7 ԜozmkqoАw'nko ZiDW^6G\{~0Դi!D& & N:}1^ HνokI2#>{lZmNvn'?CBjPxF4?I_K 28f9Vτ:^"G 3}֋w}b$l~~Pg=?JeW#j$ 8d\U9]4WḞmZ}ёDPqE*kw4WDUqHΠ:HijΔmFKy"O=-VN\iIN:)UN[n-. I hOŃߥMKk SU̞UF0%{+Y_R̦;1qcQ՟AsL6J yV-R,(Kp;Pb2,U`Hne8$V%QjEޮ6ʃ[%܎pk2f3'#ZRZyYkL9UQz},%m/EuExH;<1osמWmanUQU>`PpK*ݼ&U=}y5ec/xSwj"9BAANQYymR<3!r;dp;WsX΍[Hk$KVLJ\9T(\t}9䝧NW:S8h 79TN0m!.=8XI5J"1 /j1<#g5e1{TiC{OmP$~5J]$@lUA@=Bxm0HJV QB2?9"c!}hk`ľ}sRr;%ǠzQ QUQ8_i$-⧈dT;4e"ȥyc3ڰC H1*,WY$ *rNk+SYGe˶^\jtö`r 9>F1O'^Uznd>>H\m\s^(<}t?59"s䵨$ɐ޴)c-ՙ"^}j"prY\/*ܞ*.n&7K:ܪ87!#|zu,r]s2:W7..vR[h~`: $]ڃmytfr T""8b*TxVgJ" 9 qyFC tQכ8fU8F o𪚥І 嬇zUnS20EX-B@&7Js~V'dD%G?)XygHBqWI騨I-By W7aW =ǮO]?-e?h.RV$TrT;[~#i!J1/Mov['~oNWm!;j(8V4z&<*?Ş C pqY1.bO^?h',zWιydDiKe۞&W;z7 45$ h'9pqڟ0a=)Vٰ@A9=Ɔ29 @—1ܷtX pj7;( IhC"IJxҲubc%!+a yR-+W`(qjwzpӜnpNy7M:}ON{svm>/X|GiROev !'t]*vW{**<FJF%]w r^,?E F>wͥZM?Aȥ/c#ΠA&'$q]6PN \ ui% )úk[Y&b2{טuϦ ꨤ`݁ci$Lb gqX^5TTmJ4t&x8QI+VbIV#5"A  OZ]3:MokȥB(A ңđ!d< ʱ#gqһb㑥 v{Xy7HXrޣt,pԛg{ Yb$.y׏t%\D,1 cz^d:8p+Mr^\\2OȄ}(ԾkA&x5-`זܲdc3;]kd+BggG~#C0P5BCDTZ*o{ԗj^r>[v tc{I8 }kg% f(> C0S-.H 0kr}D6!c<>ҙbF ۇy/ki;`@;׷^Tb@LJʬS7,fT t5{&=J8cҬK )'QRbKU 0ڧ'W*Ũ O ]4ұLqf #bԌ@7`~j2Ic\qNs}A8r# alO###8V*F?jӆ#uj)^#n$x$%X$4 Đ+-D|#l)rMlXZCMc +R$r>46̨\rkU4IXFZEl'Y2& pO'TFc|fN2>*eVO6cG0GTVnV\cmc8?ʇbb8[+hROz9Lׁq#K UYI";+0 HRաI,T.9P$*;@ ӸS6UWj㮈M8!=pkو9d c+>5i)!⮙Z]_ti@)oQ_&x;5/ hadVmw־=gR^%b SFIo2+ 0^kc]u$1oǵehY 8'ikrjWG2^JK"1o3O3hmr }/>׫=s9d%ی)ڼ࿇ Ӯ̍yd|3nN!wMB<zW\>4: =JKb [ KG^pXy&bGxšs6DAiRvlWy,Ycf#gF99j&K>ZgS9U#ٮmbfrwt%qSqlimxUP)K[]" na OUIչn3ִ͚ͨ3 X r\!)'fQr>"Dou׶klfBJsz hܴX~rڝ𷹅Ǹn}r(7Q)34Т$n&]i%wX@{׸fIw <}PXiƸ sҕ5fhx,`_;ϡ;T/q%oA4ֶIFNt%KD!i``s:́^4f ;ߥw 3fʩ2QVGB3<'iݓg?t]Ms m 8=}'OY<'ßλ {LXvd9sm(kNZa]:""9Ik4!iePb]x9U],)3tVvyW<Z褡L*Ti MkVIZE 3ӥeOyF>Rm6Zȩҩ}EYHqsJN/K0fU唋&{Uv;, ~j"Y@pr95fi %rl{W))˕s'9?j%s޻8Z<Ʋ:.ϖzcp%wbRR%uگ.zs⫋h4yLʸ-ecC$H9>յ J-UgxK+ #4-,d(=3|Ѱu @j?QO:;h)OEMa㘎e,Trx8w +A3qϔOٟJKȜ!FUG98i T{ Um$8s_?ѭJct8}?(Xac^m)wy<,(# 0y^$T2 V5hE(pzZ~0=yFHKvZt6CHà#нE DVO&00gT[1T Q@c Z%&+ I^4Xg4veeH[M3A @ m1ܖvqW@Xm ,1J) :$q*Fb IǸb#9[`Yw=kJYֲE Fx #_IYbHAAs$pI*.A"1`!`}v`R WXdbp*?N*XHV 茬~T.q}MT89&܆l=˅-O?>94I]Xv9²F,˕ 0O5?.'Vҵ%`x B\XH\gi!̤(8=0HH}ێ!H1)~5`!RGnmYk[xΧnm1ncٸdJrUFVGgOh r?b 1V;{Wxy2匀z~$~"S,l0]w :GuHO'\CTu:JIey%ZM: pJ9㰬"&3Qr`J#}Y)o8ԊKKxkf^uu-:Wa)py95i{ :@ir8=)]-"- 0'g8Żz%֑%T;`r8\-"y#xmm|t9^եviym >$pry+j'MhB\[+ A *2JBXCH䑉Fa]a5ؖs DdO5e$xg)r+ym,w#$dW);̳fo*XO2(JlcAlmQ_4.#'gd㎿Nc2',LGˍOaZFVL9z?(TdSO&~l &$K çzW|jawޣtSZ&D[]FVv3hOЖhY `;*QkODb&EoMUJF7=m+oN"¶<DZC 9$k<7X\#XȜhL^I<##ozi T |*׍U;ms'<7m I1X`g>i2D #6X#q GCT2(k֗o5k !8Oγ\hV+vh%\]iB9$c׵c^ie$N%Pr3}B[8IX:A^(;Y~"~4{idaab2W~y 4RѐeW Aධm& [aݞտ)c  7ekXJVG/~sj4Ȧyex362+׮[͵D08''-6FObOך͊^MlEvPf8n yoVg'c>WxVVF H74#蚯8fX>o_q_8±8ĥA֔j ےF:v *H 9T/bJ+hh5(Qnuny^:cqQ^sn#$s=Y:_)$AV9ա{$=xЌn '{Iq d\H1DESs?]m&uBqcV&$۸QKJo1X `{̛XKP\Eln89Hl1VhTwۏ+gFr$0Pq~+B$gL/*>l {W]!ٔ+GֱM: *n w,lF/" onJNk_'F|̓C} p=}Z^G昙Um$?VYxRjB@'w GP`jojrzh'"(!/\Xv3J W1492|#=9$q8݄ +<{&\Hɤ- l)ϽXbgn$9[!KAoja +\S1L3 :<س#12H Hk\.ckmd,Z񟋱4Uv8ZmRSaIth<0}+eG;(t*ďq\m#$|@7yף~voqi p~φDa,6G_9%џSNsм/nкFB+(l ak|9X @nIÖKu*29ʼY~T4#ingB[HU2KKb=HaR ăk&(c&@VVP?khr,aAmlzB< );-Έ,IJ¡jA!3H)]Sw k.*JۑRW#=xMouK`Һizt3M3قn $euge aA#gh^p!,.qڍ䶙8JF;V/j,-xF1JHќPO3ȱGX,H2Hڳu-w n|(:Oz}l7Rd*Hq^Y2ZeL̟8ݿ+׮|dew@AyFiI|ב#^JڌZW%#9'"e$*`WTF+mHwP]Hbxck%AF?)xmxvWZ圶Ј7ݜWC]܆c@\pWiyfH5bs*k(,乑D=j.Hke.^fTYK wxtBRX@y&00>jq["n݃??^@+\#9~tլ祝_wxk"|@~`Z}4A-VS  meWeG+!nU2bNУ ׯۖ,lO\ȯӕmG#GWEɟM'.vT5TcpmO$j,'cּs4@ 2{WrViUdP=x=ۡZ],FҠAϽib䜣6pڹk-dk*psW(X lƲ^^,)8ϙ>IAX~S $'%ͬڬnvjYmÒ' ^.fհ>8j#9^1EwJI| 6x`.Jߎkм?ǪAp-rtSԹ^ǏϢ?gE #>ۓeC5w, w!یk꿇\p$A]6:;#BO{b Xg#mRʸ 8Z'*v*B-aQ(T֣%$^Ytt&$/&G5 ~U@X'>ꂣ6EE ddu%FA1N &U <Ք&=p T"A#5`1[B6Ve3 ci%.TdF! 5@E(#SӍi' >H" ,4ǻrCc8VZt .)&B[qPAp@\g4j)wV9 s>[orzcS,##╎ĂWVA6Xzw Y x5KQ: 2j?,ĺc;F28i]$JHsWھ9M2k?;FW}Upp=jLo6&Y aX7vҰfiIWrr61k:?n$Us#)ܚ^- (qn"1n=N7)6+&KM'54Ws<伱0 9p9QXܜ+~1tMbyM%9ZJfzo$Rw=M~%iodcf\͸k[_ľDpۺ;@`}x_be<%(? j[6 2EɵU=}[o:{YŴT4#'H=zԷR $"ǍZ‡[g,x@ϐTmN}kjauY ;*Tܖ嶡c6%'sJGas3BLXji#9}dFz3('ݙpm%c5kHdFC/)>}kVJ$Dv]]u+ʲ? wfQj>}XO:8bvsM=I̟[ZST O,fRpZO߹9\w55:@w`>n3ßzmKb\W҇Qt2vmGI?oZk"o -ilcBWzTڨRֳn#( @=}L* 0qIl~ sAG`uhK+./%7uݚi|">aK5bF[[8#󷱨|`|qm05 k+FI$rW$Ȳ {הJSkk*]NM~H&r!G<ׂxRY Q#8}`=x[-%~3eN|w#5sMES=E^4*Q:Ͽw^ TP#+oμub@OyV]k4 xVgiwQ pN2HOAZzm6&$r5hyX"?;GOҺ .(s3;k p}jpQe񥶋d#=o 0xVF$chP H8GLRQѹwj^icOPG5tv8k׌~x/5 n" xq1AhummFK`Q gw֖U {d tV[2bYJ#WO*Yʰ6ʦC틅E$cLJ%k;P"b0xo5]P̢kcf>pt㜊lثuX8_Lx. xУ~ikY\k/hOREwxJ)PH 1Gr*I"20*+F^pT#"ib\mV8PIգqX0 zYKy6y e 6{=y|c\`֞2I 1W!\  $޵OKSCzԲNLkIoyw%q5ۅ}ź{ i.4n NVURkE]u5?u]NncSF_$rZHҋu8^k> 弽YN km^:wdK(74G bG% L4?vk9SP@dOח'o7z9}$<ZSK w>> 6t&0 mR}}8I\X_E0h2UMt]h2S\u)^M)$`̗% m\c~N 2JxYdi`:ƺ#Qnވ$p7>&Y.X2\m9c#G֦t\5썤؃SB>;dY8>}w݊pyFpQUԖ |AܡvuIBkQJG``9g',;LP1UFU־qҾp3Ao3냏ϚGBDAު>nX}U({ZIɳnlYF犼-|\pKأqB`կ, >1+%0FHXV3qH]v M 7LSߙB$)$VcjTN3M37\-8N$*^*pҕRxvm?J܄t҈VF GOygż=3޽oPMM!s;g5b0-g¿>]~Wk]>:3UxS_]~7BePB8=kkke`Be\םA^nVh.wz_C[!TQ ZǞY0̂6v^+c1 20 N*W]4utC"ns)3[GtD-,%U8JXOȮ~Oiڄچ s$g$ƴzNiTw9۽OZ0!,HptZ[VBpb$5im Gh.NGDJIFx Aqֆ6κHI-GX64aVm;=юEE,X]_8Jjʠ:Q2*ڟU-W<-opaY\ɱℷɞF{pp)5پuɒv8A=Zn u,ѡ`]bG==[3ylw[[[kcqsm6I'D] 'w:jS޻Ɔ&s{b4}KE7eaϴs5 -̀8rH"uƒ^U\ݧ,r[+?~n&_ֺĺn-zc'rŀ<>CLJ]"(8RѣSk .Y;zԱd+qNPa!yc>>c,? ꔺ%qǹHH }G_ʀT851eT•>kn9UcfڌZKpAGPjʤ]þ[H,L- lT}Xd)2NriA$ 1gҤ8dSP\J 1Wml 0pH?'ğ_kSOݲxPw5Z}^VIQzyi3kgi7_ !#8pv̸fwzg6 oZi=Yg|-{(۴7f`;c2g=*4֌i()?)=*DdaXk)09Qpm 1j#;pS#q[x6b>I.6얧I`A#SBvd|q2A1'pf.{l=8.DJs:9*Tg'֡j1\=PY^OR(U_$Ƈ`[3[ƿ@CO__~կ4;?OѵCH SVkZ? 2^jRܜ4V'?M[a3g=?*xrAz\J-95%^nihB ~{g!;T"gaJ ^X&|V?JcJ%crI0szEG{zYJ6:watmd1$TWwM#Bmv'Rww9'}iPuy5(xN}=+NMzjqiv=c{[mu_:T’0#§op~]ʠZ[c<ɷ#rkTe:v{S^ZAD$NVxTr`K,6MjvWֹr2 㥱ЭCb +3ܲT=+/-lAn:<_ l\ W”ZIuk`VUv~N?,?~^WyFF Nc"ӅwY 'FTOMP1kwdSx=UlǍعZ-|uc185}ởZ_JUTp1֊d#>8wBp94Gx+]JL\gP1Sߞ{@_7V?=*5DC#z I1Zm i+\/H+#ry?F9 .C$יFf} 2{ִ5b\m^ik !]TOj273iB#n+RuPJ`};͞3.c{Fiv! ~ǘAIENWUFW=w)̙6{J-aa!YT#/5ju]%P .ݍ'Iя5\n#Z>ԲG]m:Uvg 嚵c'| TYs+\I S۞EC) ͽpqJMֶh4J%t?qhsG$Qk0q·3!TPcךxik:[:FyةWn$ֻ>sm+L-N+Xèu8 聃c?yցV1q 2}5K_]bL RNd\1q׵iw{"k[ɓN;&X :y?Ju}Ad+#;|1]Ǹz'oFY<ݏ\qVVB gsm=wq{0_Sqi7cF:=L)G8aXP&MUXڮGqZ?xĩ q[V%ݩQPyYJ+szՕ7>8銫h_PWOV+՞;tNH,NzWbC]'6w;{Cc|``( 8\rߣIwV$H$<lћ#_>G r}MI7LP +KE #Mk:Ly>ղ4bxʒ5b/Ɉ}땂Bۆq)kh:<:jh$!HaWxSľ"4Ǹo 8݅ ?@*w\w smPz420A'X`N? ɵ˰*xCs4I] !})k)***OΖYY `E$-D{h3պsҩ qҚe1 Ү7ܕW[X#`A1*vҠv>Ңw"#5d9>㌮0$$f%B#}Вey8ڹ?V 9b;{`rvNC=W2-],P޾;m {Le&V,m@:zs~12 4EHb/>^}AWi ^N7- SesmMroxSӮQN0G9wzOC_lc@PnY>ԥd20VvY^I$9rU|lJZE}~.q^[y%`6e>vioY{{~U6MuoՏ]*扩^hrGx/mՌ*(+טFU}ɭoM-Rw6@]",PL鵶K 5.WҬ+ g<4[YP24I~XZMh^0%*NqޱTZho)&ٛkwNDB7Wuxe$c۹9PMtmfhɍF1IjxniaeD%M${8.u{T>%F *YُWTS/!b2VL4C##=oUKXQ"嗮BUQqvoTsM.+&IZY-0_j|_@(֭ {`f.YN77yn*8'}zJܦOГR3#aq: O `Fֻ%ƾmJI=I"z7I)$}a,y TzWh !k>ۗ8a~Z*%h 'ھd|x__ 5a"]ds: kx#E#]\G+}MUX@EAo6\,ZUPw{ϕqF)H*srM$39 }cF{#I=n@Ժ@Tpު);E;9P{{դQI*9' EP8OȁA!i$bK.j Q[PPESǑ\/`7$(5Z88,c=k=0q=I_Ij|C2IUNWɓcpb##_jњS2#8gUԕu|^όp.ZKcJ/+iMZ#fv>\`\;Ŗ;(Oc5SlJg-՚hCk[g6q V.=`mhʖ= ~.%t+}S-=  ~W8byU\p|6o1el/ӵ6mo,%+Fs¹[%#(1>5rnA_f /=cek+ٛΛE,٠9'{k['MȄa_"Q] ?fOڶZiמmƋ6Aps׷Cv>O1})|Yo]0Ѵ8ҵwTSk,/V6xCҸӺZ\\fu|.ځJo1xKJbNȔ"\1늭>[Ɨ)wM@˓{W㱮^vGe4c*Ҵ5\$X78-Zrb!  Gn¯޼~01ųV^1Z6aq}岃N(ЯFWBT9 {UuHf@*wIOjl5x`P ;ӭp]20`v OT ֳљ5Fd,ɴ@Tcr:WeZGl~Kq zg^)?t-J%AҤE.jyDg 1֔eR8tf魭j\^i׆9defsi_-0I"2NxjR1q4 _z`NjH!5idy5p.nN#YNbcO.3]H-u 7!{zs޼8H υPF<'ǷIdV‡9=3ZAҵ\rU䐷u߭kM%Uجej~k$4cɇ 'uQgog/cg=UJDVZ>--I.gu@yަ5!q&."EzY%&d/9~j]Zg"%g(UCΫE, m{KfҚ(Mg fr$6ޗ:M[P* WvyB+֛͞W7cld d>j| 6cÎT!k;DZNn.fZD.GZV\6:x>xC8VGa^ݴR6?(f=Wδ>sOBV}OV@1802܎q aƌzcw@ }:osV-,c*\H *"y'Mgӭ#1eA#}3Wi] ^%Ln21S$m*ɦDѲB+GVR'u2G]P5456 |ީcT6Kr EV%HP8M9#S3aPnA<'R;w/=\6;pI #XfBJ<㞿jR 7ԂА.NpK5fV x4xu"mrm={Wo_*0&'Y/ՊNmP aEomŪCVI8 M4؉b,ү%t&U0?v0 Y r3_LIhW`$玝}u.e^llE$匌0C(‘4NM+8.Wx1/r{dWӼ?^s ;]R( yqZIjΘEԏv?]LOiQi$H$=9_~kN~G[H# _P O~"e$ F1GM#3vI)B꧄w/F$v7#FzTfK 3$r.촃Ҵbuӯ?z[V9"aʍW'RNH{woqntv6rGtU`^&%q ,G}w#ͬ-#S,4vQs*)հ=:MZz1/u)8珛?+m*l(<\n @s(s5Cև) SH컬!'g_ph\OHVS1k?úuLc+}Ҿ?ho1S"ɝdƾS/䛚>$d@d IZvڱ *Yvwi/%H#3B";uPqRi?6,E+I(j!@ IUDlT0S6J]TަN[(TV q1 xOQp@r<tE >e~ ׌_yvחw[ >9 Ay<+2LN'*˴Z@!FjD1ʂWޮ%:߰#2l $sIHs<{P1dbPXԺТKږe 7eP{wPGQkX2#6/{9. Ga m1`t=;ק~xg%˦i~*拻fF&f#s 16_w$̻ %kĆa2F9vZ>"c!Nz/Nv88Wwgai="|7ql<"!^lxS'M!%gA^/`@}֡$loPrJm1Awd~+pN2^9*y#8/L\]FnU;q{;N:֟pf!#_95z>HRV\twGW(uZ9 \砪 gP߼֬6m9.G`3UeATm foS ӲIV1)OJ\%m ;kbhЗ`f݌fP(ֶQև] J:#%_'M{gxDW) J1J~xWJ{XFpk6ufŶUbs+:{ _35bjdNЪB,5=P sIkPHM"#SgA8QIl" iI=_:c cBYeB*J<4Św.mלq\iA!9}gM9QG\^Kt& /w3}P:˜)ukyrFF'U;=jK+7|&62q]6 %b)E3aJqG~kCȎ0yixg5h amh|}S֮4RN@Fǭy5fԻABms/ ;H2)5ClYE9ՀX =1QI\F`g_a5:X-N{v^BK(h!r<heu8cu޻6)FA=벎 $ˈ9^йfܒJ}օ`t[x7PwER$~l{ Ox'sʼnیIu%9krGkc-ESzTegDx`z~'iY?wi},gvGFLJHʀ0>ƢE5SlY?orPij\<r+i[u#5I nZoclP³fXVf ۚOYWh4 tgd5י$<TNVJhe8ؤ@kG Q@zjV{Xr0kkfPD*ry1d~_~2 $ uv0G#ֽR Pd6_r:WAxĵDM>hcS?~|5 Uug_S^ \g>|67+N#m]$ S1Y 2qʩՈ/ۇҬǐ9ky.K啀Qq5ܤ7+2Vs|#@7ydf}wZ6qrSHܤ ZʅrvPU!ިiUYAmֵ[ 吪8^֬aFbrX5ch tɨ-!`S ~שgg$*F\6m +腹ɓtWm xfZB"~翵wRм+vm/q6S޽:?|[ipj~!_ٽ#5ʻg$kf:}7}&_TiU_w>!s;ܞ76rۻm#XYH^|U/5xn-^~O$ֽ;3Ð\w2bs^$ϫB4u=F 0ǿ,dUg(5xY!YZnY{ NҿGrגaJ63)idqZVdFFWVi6wP'\c6eX^Qek8$t-m,895DF$cj;+/`K=B)PQ*aڽDLkGJv<0VRm&7) -sN.tFr wkL׋aʞVkr@BpH nue/b9q6-nTvs]Gt@ewdQ'Z5G ;ȽWlMMTl]*z V Յ;JդÂ_jwuy2q! :Kc*%YHBְqsKVt$rp=2zE7ӈRBӵy~;xr9?Muz#o ]xY(=Yco',*k Nrus"_ץ%ss׶&}:m?tԫED5弗ZB˂01Tת#P1J5'OReT_Ayy(U=oJsǫ7:[#Gr0nxc]P c*pzh[( xW-rƕE^)PoPzi4B#亸UNOY\./$39\#y*f].C]vC:p?zMz8J%f5.} Ē[Q$` WO1cl!`\Z$lU$9-n8 Kop|ge*/Gi}[4PE) ITP=h`85*z~7HtF$'JWoFhRTیRl6NG+:wZl-mSʥI!bNI9⤉ $`)Z<**I5iR@$M?kOQ9{GzA#YTXxWv<>GXC.;rHox Fn4fm)=}~=Úm5k+H4+"&N`׍]BPIMيVʷʤ[&eA܊,1ָ|D³?[w D"f=p8aTߎz}@ʫem+u%g|5V<&>nSQ{Q}UA8)svSCE[1}1I}ɧ۱ ۻqJOFٝ*RJGsQ_[ d1k0UpVhSv{`V\z2(x1^cGįgtʷ3BEQ|WGd09cv8*(T#;6Yy\z=JMjS5oW}`i1R6;@6J &FûqwV]J`0c FI5B/FuW^0mM `3##Fhz;PWa4 &Sy#$'WW2gD–H.6U,gxA[{fD[2189#ڲu[Kᵊb$|! ^+ߌi{-Vvв}z~UyW'i ,z Ԩa%t_Z2?뵫?\!Hc8j~.Eq Tѭ.d߁֦f]I9ҽe/`'p'FҴqItk⬦g_-#wL溋A+LonG_x'W^b೨WV~[x\L>F.K=XІ*>ZWc':Een*Hw&Giz:ĤW@цٯlLIԌt k/,aI0\iOmR}emqq3]G5++x4sjt|vS?_39N: z-7DWT򭐫sZɾ] ~|QZEeR(0l51I'q?᷆E>wxtdoڒ:Zz]V)nnpCk]*o|^i?RZ>UUWҸ/|kEC"2qVϰr$6OPa^oF/t|oh FQ!p^:2$d0OCM"BHU5W~x>yH;Pr*%%6MJ[>1i_.\jE{£W??k={ݭİsV8ռ#ЁX?.>#h,vg*k',Fc; cWd}UFT+xZ;$ =-lt{t[@]ֺkH 4z1+u6M-L|܏¸T=a8ϊ ͎qsehzk^ൖwB"c -Z% w5nI,0$+Å\ҫ8:;ZKbci%*ܾ\< m*X7NΒ1Ss0xKI0Yo2q8Z9ea[GJ Nk-".ww`v۱ Te0:kϾ$xQ4b-캛[NEEv$ $0#A(eI+;n)?{Vy'kwvS&y'ҽ)|EfTi#p'O¼zWt4K!*`VrA5,FkM#ۅ8ssMi6ݨD$Tt"i6a(˸W2=^m0<~潺~A geݯ:I5k"_KKI`kͼakVuM;ypr1ʱǭUT[gmO'5i\FȊI#d(08tX:bT;?R>B8,)ShSھ=y(=9&YU'$[ P1S{aSb@NE4n9uSHqm 7H4Iw`|2YdOPFBdW_!˱$z0?wmi|W񖧠L2tQ<N:Q<.oi|Qpjz-7(d| 4Rik OUW{csUo_?,t]U{yvM$WY*Q0rp+YGy⤵.-&h o^MsXE , 2#9aG H  VT)<;Uсs^*1V׫)6˴ Da#,c؊zN#ۊ!5N yDY [FUInJFwipcFnTm3*! ߠ$s1Œ0:Sd2|x$j&?>ߕ ’9cy(r:sM?|M Ch<=i>ڰŋ9\ڥ؄e$1G+b3@lԴA\&y'x~%wSGr~=~ߟCo!xQc7yx{zxdɌqjo gYաN"oGR͟.k/ÏKjvw>h*Uq_TV8E&)2V(5x1_^kG CAa{xv|C ,QG~]:o)k=# B]Q4mLo$ 3Ê53,m##_홮>2Qk J؟?u:x@mNԢKg dxןRN| eknw6*8wZ@UW㌜zS J# 5mpF;9sj}QV%|"_?kg"ZK14PG !À`3kFky+MS1+,L>e+$m[C)I0J#Ҿ|,O<0W_z):\IFxم=vT,x|Ku>nojfik2 `",Xw mý1*hPb[8OʭdWw>ܽOZYXyH~NkӮ5B7 I[cWei6,oZ$}58;ƭTtg<~NYՆ&m >j۴ɰrLYy8 {mKhуpRHɭ ֬+0#zjMUJDӃ>x#fY&QzW'SZ*b9^| ľLaI gH!,1%\"0V3W~Gޝ~Es< oa}C>Q``e-'۵Xׇl n6NxcAyoitH2)R3NЧb>5;34R<2 ӵ${x̿yzGOQZ|:Ŷ I%Ίr?jþ]<\i&v?NkQ6ض!+:⿀(Zq|sRxR]faPs^։;bg:##ko]+^!LmݔCZ-Nzi]JVI/_Oa5F K;aUGR}||\[o/hvv#$Ƀ'b;#ѡյ7c.2ߝ|3/n%Iv") [;4ĸڒzn"mג8oR4X+.ۙ"|6. Q2I5 F&|[{aX?Oځ4 V$hoƼ USwoxǷ0R&aT#/?{B<9V~{g Ld =ľYI| gZ[s-~йkhu`g[j%kQ<`g5x4嵝 -ÒR9߅<+mKi47oo2}5;J#zQx1mnG=%[ִd5P"'X}曺xg$mq"#IG<2EtT8s dݮ_ =% rV^]𕌌acdPqչ$2+-ƙ `w)+_z,$LMWbEvrjς&mddp2P}+M#ŹI͜LWMm.@YH8SJ8ͫltJ 3o;&'# =[G."Nfb1R9~ՈS1GJ:Ķ|1&Y:獪: з@$: u+BǂrjղUV!qp96@TH2h,\LUB@$NX S`6Afyju9 wqץwGh7jd3ԧ3DᏥfx{-̑bE0eO~>؋5-;dq7)qjbO*TmQ*$IyJ6tx;`^n薖OeR21j|W2:pÞ٫Ы,~Y.^:5OF^)K:Wmo1FGO lF`kNV U`9_(nqjhxj67eE D$br@$--?`[WOO7.5bUx|Z-V4F~g'<=(N|.G~4SLhpSwSZYGRJ^O4E.po]2j6;,y78<!oj@y7 $};WSGFEŭ ʿ9OJ㵟 #Qw{iwνDaikp22Ysg' 8sR?NW-6{{}bskqp9}AfZP~t/Q7д[c"dW4=Dy|K_O;Q{\:jW+ayoģHθE9J⮍q6~!kKLO)z`knڙhHӔMߣ ۲_:~ʞ55G.X\] #8rfmWt-/ uGmُbP>@i;NG_z~P4鵭JmB|<1ycNY{10g rםkLW#+ K C٭4>;KB0ˎT[)ifߥRn<8]} 钊V_Ec>kƄFzrG0^A% |!0MixWO3A%paYکfmv=3J3O 3ddrwXqI}jX ]ϋ<'<eYHn1RGᕶDTI#;X΄'Z0^@K@bzܺZUH8皻igIYV[t`G>RRM_Yy"i]$ uϯBMnqUIJԧ>ܡ`a_!Nj ~|8_SQ6(3nkvv\3^TV_qoMA[GQҠg(uO0l#Ե m}xbvyPW]v&u:M7_'N#o?l=nwv[0y5 KܓnIbu?fOOOCH_:M͸l}nף-aT,pā1zsZ1J$B:WF.VOD^+MPF:犝TPbZ̛YbGWF!CFð=Gk3fť!W=Aҭl܂p>l"b3Z&f+r 8SA+ps!Aa z k GOaZ#'~F .( bYgw$ٞefl2Uڀd։.L)BnCqi'4q10EXmc$S`)=@>r3QOq,@-N1ԁ8n 4G Wڄex$`OS3 2H`l!<h2r=SK4 FJՄHdT$Ny sj\ղ=1Uw\W sJ.;K6OOj@ʕMaѐ1`Vv^I%rv<ӑтUxnBfgz{Ro9K1@,Wӭ$"BXP"ܖYc8F)sӞ")8DQv!@c>yU'_3$mARf@'=HC +—4&7VtHeV$2~5RCН/6dQ GdX'k῵g¿ީ2Ӕk,ʣD=+2{{Tw=0xv5].x.d¶'eđpF Q߈ߙi] 9Zk(8̑]ZOzeј5+;L "uS'VP-E3ʝDJJKK0ex=kѠHԣ/,x́w2C溕b\Ry +}*WgTfХBqҩ]"GA?A{H2'y(,:rT3w:մvԡ&kTHjh%_`h/A *&" VԌcW75OX5ŭwyDLp~uӈRtUV,~"\*5͕ |#>|դƏ@ (q__׋#״ck'o9 _KE6Pk1^+&moV<)U'q_ei-uNUѯQAI>7fa{~mV'é[ݒxHǵw?!A{c_|>>|Oѵb"ggyG'[8Px^LݤᅰM:ir)~gޓs ë28I 6nԷd(#g9ӭb4|c:2R-Lи&l }kU}HR=HL`|-*cIX!\d6[Г (Vs62={Ҝyoz;s7uuT xPj+gTB5x^ |BфL4-.k9\O՚\kzf?{VeٜFykN ᭍ſiQ}rr*uH]Ӣ;h̸OzZ׏5xWʟ;x=Zi/-/ᶋPf"CroH&timgvшOc?t*T|LJ pwo6|7(to xOM=r<I4QDprzʶ p@::c0+؀jt હtzEF*'_:s} h0#[ D?-倻YMǥ>0v KvF׹RM X GSԷ++T*9\F/F%AZ m#1Me/qֆܒBvjQVgrcUWlrA )Gl )l$95hf%@"ʸxtQ3J቏xjI[!,vFJkB)p{v-a f2 $ƤI)ɏB@fb˰1a%PcfZ6Sk\X\ytTjuzO͟_E;;)|5V"Ԅzc'#5!j/oۇ>L%ѝe$lH^]LqA}7'Z2ʣc*;61WkW큡ͣ!сMVΤΒCF>)&~s\/-չ޿-}~ w^!U~ 5࿴w=/_Yi37r]TP2z׬x c|Hg-{Ol_(qF]ߝ`xc JFO3/-CfЊچKROߴWo|gaK}i|E'Oc|DMU' x54hLv8W>u|@𽝴{UkxXgN+ThZ>"jIVxm##b!i a8JKI%~?U2Q%D_G2 w?~9Z6KmAO,JA%zo''?ڢ^Yu)?׹X0[(@c-ʝsw;CG,B-OL(۬dƸ_~?~"ͮ*N+crJ_4}zYQbv|޾c~*~/̏*5(~lVn;AcMCƾ$ __YK&d'͏0kQ둝3wQx7~6|9?M^.EtWKUeasmK)_o_LN"K܂%?S?Jg%|?_inʞ / }3wx~׊oQrc'g_j5I2#1RCBpF =kءҥ _Va/Toe+#uBocGlQ0--1 |M1Qb+`Rʶf0 1F;y,}bm#!]*8g Tbi>C'4*IO9v1X(!IxXjwsHdF6fl$e2Hh_o=*ds=c$tMx8Up`#"܇P4BHi[,ʼXXp}>PU"=# h2 TRDaĈ*أ٢\GqN©+9DA#4N0z9@+ FyjHQ|Yq#}#ޯGhiXdzj7ܥl0 )֛1$Xt M ]Fv|Җ!*gJbfabl >63I>ӼXf#W&rsW"7dd&CM A⮦ohm$pR0P$F9=br1qMXr> 7=1Ҝ 2F(I ;k$2HQ:_4Dub=6#2F_,@&3@Iܼ-TQſ*5%Er[q?BL+EGa+ N y*QoPRn+Ċc [`DCx/RD`sWUr09ƊkPL v \9=[l GlacWU#LҧB+tZ3$]d@Q, _Ү]Rcb)I#;y8xuյc,pv \s֬FnۥGoC zUQCd*AP=AKʱ+-8۞M0#l`fW?δlabrꄰ7g 2k/`to '#@f@QY0}9h/sV[]*{u*HjATI62Ry SMҜ]bgX3 LZh*@ 8 gJő5 d*4X X`kUH0&:b];Fi4i#Ұ49E=+_ID`! Vsw4NDb7G$2#cMK,T~>2)2 M!Ĺv4~ ]l 55cتPH˫1\;z P!RDL&2HUMn0JG52m( wT#MIOpyD0HaցR6̧QM4IF@E>%X:$ 0  HFpGB J#SǺ$THřTS*e*62J<;[Si4CBAF(O9U :ƃ ǜs%Fp27c?]xw8` FĮ,?(&`@Du~1 iTX=[Ii lcV K[eVCq  ۽) r? sT*$93Һ*Ck'ʏ!@r^B /gU ˸okTW'ߚS",ةGr1簯k-kz4F/\"d},NzͷyTQ0E|3c12Z(ݏوODd3'   A 0?04-350-324_num-5_4-15-93Immagine 54-350-324_num-5_4-15-93 RdNqsҦO@NF8NqsҦOJFIF`` PPhotoshop 3.08BIMxHH(FG(HH(d'`8BIM``8BIM x8BIM8BIM 8BIM 8BIM' 8BIMH/fflff/ff2Z5-8BIMp8BIM@@8BIM8BIMp4-350-324_num-5_4-15-93p8BIM8BIM 8BIM  pVPpJFIFHHAdobed            Vp"?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?qI!IH$ttIJI$RvsX\4 $ִ}'.ۺ_Wla5-w $ xZ9 |R/g0)ώZ!kj,iЇ4rWFHKGJ}-ܛ KLGvB\p c"qN|R!I%atΡ@Ʋt ITIu8_7e[^0]m=j.pCK}?gx)E3:۬0%yda5m`7Z\khO;;Ӕ G ;V_I_{ơ .϶]M. Ƿx@t΁X}*OwG6K) э;r~md} *Y9:xnXK)WBw4A\O>+ XvNI0I?5@) 9 tib]7cN~ ސ~>yK6!zuxu5Mm ۠ԑ5{(R:6)ka̼K[oQt֍FG&cFx#w&N몶Y5 H;hQtxITz[a|\KT;M$|tAu:'" :<]i[k$f/Z'_Q$jK/-!ƙ跻Kg$o{c\yOU"*\I2OtԭR靛cߟ U]BlW44n3r79@Hߢ[gkrI:8ˌ3&yD 䔷۲I$V):I"$ddRI$Գz 3S7Y=Hk#MӸ;Ώ^ncn;7ʒJfܷRTE I)RI%7*I$JI)8BIM!UAdobe PhotoshopAdobe Photoshop 6.08BIMAdobed@       pn !1"2ABRQabqr#3C$Sc4s%&!1"2ABRbQarq#3 ?C__“[Eׇ^F@2 h4Ch?|&P8*fH҂ G'__ i%B2i`, X@u,8).񕘋L)Quc1a'2 2^Qe H'@5xFHu-M Y)`At,!kyJ @i[a;BH  Eo-mp j[*mWRmJ@<jVgp S j (!xl aI:,iĠa‘M?(`) FiH-*. \A!p F2W(m0 jj /3*xÊ6.,)\ oS,IvN3a0Qn$)`xR1+.m!XG!H9x~6YP eN A;`aRpnhFV"򃤛d x<x)f#RtBA)T_ XJ#S8&rT0V!NH Z,fF LT*Nc&]u$E@ѧ~W-%0ZP\8I v $`E 5@ 4"brBӄ5cXŘ pp B%#" 4 AIE7K"iI4dyz FA|b)JNq"h*~1"CkIB+$F#Pd J_ rL#3]TajBa2 AE@%:BRS^1x jbr|#Su !$BA r@`|!fT;DE("OMTq~F),K4&O4ұ WT{x&gʽp2V Zň&A ii?(L(BN6_8A Z\(KLH x XTGc$4nܔChÚPBX#XqXe#ҳS!(!V%r FVR {B򂴤0V ]bNeuPd*&EE'NgMX$)h aT%+N9p&N YIO/#(t'! i fVC]$)<~i@5RTSQ?#< yOLSC*P O T "pY)1?(0$A(B@1E O|VMX~K"qCPI 0'AA^PcnGٓ2 P4bH"`Q >4B,*a8C  tx.M`$:VUPj)" 4iA  bJ⨤)HʱpH>Z G1P!kX2jVc4"< G%9D3 x )A''PiiiM\HmNhIGXBp*M.o-(O1z+ч9I< (04 ZBC :խY(Y8% tDRR!`(#h 8GRPRMQZCE1Y0L-*j$*$(q `Jy,NL@Ĝ"c̃1Z֟6'HO&D$K0ЍD@(ÆA5y2֕y +ZpuBL1h/7s`-9Y/40fLP cK SjNSO&fAc_ ק C-b Mb`K x=@ CBt_38~QD.cMHhDֿ#%ixu B&+(T1MNM>b)Amg^#:ZU@ 24YM5+(!E5  UYEi (M%' S4M͠ !o PՒ*X!pkԨb jb-҆^x)r *+\@ұC80YVi D|RL(Bo>qK(7 Ro ґKEP5c<)C T5Mm%M,c iVbN'(OŌ1RaJRmR)rxxI2HxGvI@)A:CU4((Ґ ><ya/ 8C00A  R]`@AtJP A`i~~1*G1B6vA[82nAf% 3h(Pei'Fj. @cjEx@LjI Jhk$,-VBZE+ k&H!794 AHzh O)1ϳ8򋥛3Eۑh%)X+M"XC{tSu"YJ+hD;SM(O! i0xڞ")~+wk l9QH|@R2(G PIm\Cj-Z0pAbreoθT拍EO$ݡñk> vͷh}B@SGm[[p_c2w/)pbЩ}&}kv?o{kc;}LŒEio_q}ڱ{xƶ/-wk5tLXcQL] E5zv*7mPv}>r[OT֩g5fnE2;&<64/T<#컵Q"ΫkmU^xn6lrsM~ݦ̷u|j;&lR >[O7,so ;fK[VZ2UYZϳWD P@N]y[0dErijKq.<'fmaZ~Z(H4.yOj [܌o$XCp.%YdES&S |fԫ $?C#_pv Y@0 (l!iVS%J"2ֲof RPkX` B$+x)@ӗ,A\JMi$`|fx_i r-xi1"W5`O‘p1TV1R`@57RC8>B XVR2aE T`Cl| y%i;`XEbqrvu:v" +JPZSܼa* ee4M0< `b e/ZB V!1IZʸ>Q ,BXM($Qҧ0B p ew vuimQg5evko}e^ٵܷYnO1#a5^srML;&n׃TAmS"ʤcZ5N]9!r^nUkuB'LfUʢ## 3m£h)ɣm헚Ι>ZkKʿL}}oWo r2׫ 2v) I!BaS3cAµ:$Y/d0VU^zdf}Or09 @PNFk'aJ5&~X`2v!p}cT`IcIEa 92cp#S TZҼ?G:fr@!`.h6&X FdK?)ZbNPPaSHi i1$I ( *XRܿ kisI,-ׄY3iM8ð)ʕFЊ@ |b4׊RQ!p"!& rBHd Tɥ[LmN,v@0W~<8E@T|#CCD _֔ѳŤWoe8Buc0$VP wp|%",f_g)ѫ⧙y+)tŭkr\d3LKhۗ.ؖV^΍~.gϴCҼT6c\]iŒ)Wg}ǰؕ(%oyW}[cǗ&4M̖xG۬` v%fJ V.`'49VbR-wP0#Y`X5pea8*Abqկux D t0/@>PL4t51P @"IFpA +B+Ȃh`CC`JJ p9d #C +WE)H|ahͥ$(HEZ _WDtAJx T`u, ‰CMp#HkPZPZYBJGex=`i5)dg&ZḲ& %K?vUZ$f m"p$VYZa,IT(5V"R #*Ay"'fQ(K!a)S + P)H\`Є#^1f"l/džHpr=O_dw_] t:"ҵ3iv~3YÏs2)\+cg-޽-4>XL0vV7RjKU3gCQFYt6*mm0ZCY,ȃHޫ/Ӗ<2s߳.MT^YiG_#򬳾54hG~"g͍a?.6UvM9p8Z1HTGl /Oq﷫eYq =T+&j3te/6,ww1saڦ-]k5ref| fif~\Dk^#xʗ,= r'=mPoo)Apׄ9W.baY+-WU''??&Bj(44)W_W QH*F(|8 F.J@52r |)JFRNӌ$a<)G B#"Mt()S<` iJ+xCp'Tbh]C+0a~\A (VJQ-„M3`U:* "BORJ%ABuӄWefJYV m#Xk"XP2$N hum ka9$j0T5ɘm%eT,YxBA<"D)uXZD dXN",Pc3-ׄ| -)Eki''[4t !Ao&]S_w0n>ɉ+ oE0L/M{?N}jmL2󷳪MskLJ6FRfzn߷Hk,ejчndvb򱔗C/儌6"ֳF/ iEEJ/7<Ψi 9_V=E`o4FL/[D2aThWfAVᛕG4S\ ]IF ]2c^h7Lj|9-mGu/\exMdsUpɓM9~_SMy`ۭ;ynѷUwo!gUN<:iZl BKJWXWO-M8C 45>%T$ A06KZSW nB8l) E‘iA-ZPk@y)1\)ֆ,E+AdZh(F\Ƿ|[LrnrLhOA?&{5_o_n_\;12YjcKΕ:Ommӷ}}eٻeõ|~_q]ۮf:{o>c˃.wb+qߗ|]cvӻl8&#Q][in>6;1}/rW؁X|G6z>k?OoM*dVKYW,omܘ?Frle}`_7(hL!>>iFr(ZQgyyO,wpSKni1 TصOQiYtIFV ݕW{X͛^,JȭXr(cΞ<6(_cf;v(#j^_l[aNlXΛvo;_Gg]ss= Ď̵Mz=m-:?j.B]=?/&/U_f*JX2~QdL S%AI5KjK| A:爏 S d' @#u_i&)+Vx*bP@ Lt)iH$Vذ. %K0O K SP-+tCA P[rw83P6(HZKWHJk<%VO(IYX9RRnB$*E?)M xGu u1bL"2(E$RSM|"TJ(EM*LY!E*6h֢9bXF 2Pn1 Qh$5V(X(^}dmh dRZ-Fmuu_Gg_vp[[s2uN+?~o;N>p Ywd\Gsse^\k>ν[}:\G\XV{W>٣6eN<>Stug5gݻdǑÍGOmf}Zş\߮O-~MZlYpޙuՕP_mնT;4jxcx۫U|Mcg١p "Fb~ $E)DrMIEkYxY7S"7EZEO@&VJVm2 fY5-CiZ(ѴhCe0}m)v+s6F*rcvr]zmv8?r|yNm}u}w}.]GtY}_^ٵs팹 m6uavdw'6?mJOʭ4ׇ6;6LA&\Hq#5 (q`e BHy@AX\(+ETJX1 DHE4bħ-x"_k5}c=lY0{0:}Wov66|a@lfݮxjX5BCl>훆wM*Qi/]=7_WN{+cܳ)uM:gOm}l{L˗2v;ލ6~Csc湽SIvſӍY=+[La`ŠUqkNzN.\nuʼꄬ}ρJˍrtIՅV=ZCV&c;i餈^E*ɷWG~qM4͂J~K#rL%8ٴb:]t17fjYKIٶp>X,}@ Vg6ܲʭ~ljk흺|~ś19Ou(mL~m ~mooʲ }u뫾o˷**+*pV{ #5ʭs4_1g dw廩[}]Vο/OW ;5ʼn:θ It*X9R&Sek9I*5^RMJז)}:g`UYm_]kiqwVa(e~IQcA6*[YevꞮ/گ7wLk?]I^M ͍擌J,R+%l92vIٴny92`U\!z+L]5ՅYݘR^/[Zϙ436"|'^/еin[ͅEj:c]].Ś=vac=n`&ཀྵ@}f'wvn{;]}FtĭgOEDカ_׷MLckU]19rnyxM5ps7/wjߌnXlzm>+.ZX<>aݕSƫ-9u.p:ćRe~ )OP +e$CJ,),H52MP52qGν&#?V<4i0 PJ(dTtFP^RS't#J@&_>ڊI 4ij@A!cw#`6RNB< Vqf'SD;,X*qS;/SA+νR{oqNh~fʪDlޡFT{`ʉhN1n6|hP~_,iv1jJLΘpӌ2_~}ʑ/垿YoxcʫwUҥtP wKMf1~=&ƙmVdukge&Ml9N6k3d,̭:Vn[6gRyk'oW-oŷR>l\4ЫCoX>K p814s[ƺyI&>̭f^n7c~FMbȸTom_sqvxF?7GrQݹw>M6XJ:1$rg|ɕZoyoq7UG˗"]d3GZv|:@Ԭ|߹WV_,vxGP*5FfXn0Q&L}2Ԋ6%EmA:3\㬤R<׌655ևɃ( Lp%@*Z   h 14>2_f'J@TV)%d) (Ea! Z K8 5kS[n&Ba2&IRрVaZ' y<Z?M ׌\8%"QCfVU5R@)R˒*< bGT\A'ưTE tS )]xI@H<&eMDR``B%&՝in,XTa« [Љʢy=k/6h7ح=]-aPHQVpiך,^' K(ܿOQnYƋ<çQlbd|$XaerDzBJ K ss|t{Oaҍ^gWf۲uȞly:ZSm=W\ y4~ͺ1lEJǸ͐\yۦسcmtyV񖹖܊Vjǃdl̬O}u/|ܹvWcVscwdlvm==Ko[~kO'nۊ -=zM5Toy7caۛM]=r?vzתݿc%q+&{v1m}:u׫ume>J1ȹ:8fayxVFpF;[d{1[ݚXkYWξn[FҾ^eӣW߅yD4N6)mi #2BX`5 SP1N"fMwRNALcIէ,y>PjbO $ i(@d(0P Z@R,6"0G*Ǖe(8QڇCI*xRhx |!0,F0Zb* `IOd`.Ґ Mtc$Y<$™ 5 +#kM#rP"0:k & :R@9N+XD`Һ0"k/IL|a$ pTG,/NaQ YhF AEq]>0Ģ!aB!pQ>0,[OU>CE8.G۝=}>ðPT ou_Uw>;L{mUSpm۽N4h-}mUVlwbQcDeCŖHÿ8.wٝ7hkq73QQO,A,y\1xy02XEM3Kndžzs+p-^adӔ?Fjl8Qm||$zߪi>,f½ExNU7݃&#xZeab><μ2œj,4O܌)B܏?_enE_l%&:kz|% Яs-SIܝ]2s\+%m]lc}k[kRo2/5?=3fNf{ܯ_W21[F7kԾV#݉ /坟OTux+9FP+JyH@)jI]C?K5K5ahCYPZT.E Mk+9)aT+R9OI`5@D<2`@3 HHAf4)DV(Vpp@g)V;j"c%:3RZ9 X@?Tx$8*eE8,R0Ji)H9ySOJG!M$\/b uȐHAEm!*^J@Iಌ![M"0SH"‚ -&+H"? ҲVD mJŶ2SȄV^fǷ&\jcQV$M_?_nɳ}۳t T_C8߳I&j}`ǶmvKفUVg%3]gQ4M0mvyd(kGJ6{_;Seui<c\/Gկ损.IddEz/40Y?Ts][lM9? mh`wlߨLoߪ `eyNl R-Vkn`uψ3'Y$aj;O}W7FuVݻu3m͙r5ɉUzݏ]\.hvر^3]' ˞^,yAzf*nZ.LMǧ7d̈́Vq]wmxFU ac&u+Ydr):ǹ{Fh~.vOusjc\jZ2-o\9{<'yܰX4[n9]!kyVQ;><.:O p\M%Ik啔Px e. L1a* Cu @GH@1"ZƓss3dŷcLPwo=i鄂OՕkVoVǦLu, #ZJmM)E+2.5QͧYt[xindkՍne"Zp^^eM_xDc6Mb6R+hG)vrůŢx\P Odʭ\aZ9М3گm5qck(UVmrﳯN,lO24{1{ӕ|M?ۦL8_{[ZVs7omnqe[4徽{- >|ekdyUU|NQɃ66ɶ/LokMsܘ#5RgvivǴie]Mfg8U{rr^fY_EYwKmr\<3̹-`-UZ/M٦lJڲNjssU.B&\̫֩Mub}[47+ZTUt]?5̷Q usK_-~"ߦ&-unV"~97TgN<qK]o从l&y;昝Vk|ܳ]uyn؏*Wm93ʢՋ$H(ґHD?)YQ "R22Pu 54*q WN큗G+:t3X |% ( `*DR|',bNN"PQᚁtTIUPh^ R>΄ahSvْ2+M(4yP1Z|S0ښOl RPaBm^J+%Ea qhʶ(Rd͡mSZG0+R@drÌx  9R1aFGX!1VbQWTL` }1p&0)3BXXb$}+TYJb\O'[jTNa sxheui7lcZ)Ʀ;bտ?x-6Hr=5-\;~35/amkvaC*|'.]Ra};&y6{\iL[y1{ɾݝ8YyFc亴_D[i#g㴎=tvSm#U7I+mxhZ.2f/mV0B?f7Om#WҰ/J[|ZkWې!6;̞ZG,0Xз-+uceh:G "~eiW?n Qe yye6ڜWgȻlzumwos;uˊos'R8MLqU*-*]Z,؛bsn?ys'ol/]r]`rtNi[]:>?fA+-VŽr#yl|lS`%;3*s[ꭺ3*<[8g~LʵeG_,<5Q2Z cuf/{fh{Šx*˗9vyN }řu}1oÈ:~>3ep4! $̲*xEBGR*-VTCrSAйKeI)<3[VFB`yB~Pa.D%xMi$@~T_5Gf\+,V1`P1! @[XↁN+!"Fҕ@)Y>(4SYCȚ))H"9TSX Drґ`) p2b*Rz%pX+b ?쓜0eiP \+ SaqOɔd{w;>ӹ;q@'M6Gb>l÷\CW.?{an;͑*:k~?ZzWo oş'ue ʢ 27|_ ȧE1/e~ۏcnɟeFMHHOYSfTb{ne_pnOvٯ>Uv; W1s\3*5P]}뷫KgƝg^wc6H^u0]DL]j. n=rrjfoղmP2l}?m;_ڟjm0g\p\/&i S 8*1La"&$*iɴs&-t2.㕛*۲6\Zϫ鑮{hQ2fՖoXn}T}i՞卿/1ilՃ Vuշ|Z=WqҪh+eǗ;ڽOakn-&fv_:뮮I\ *oZ͇oǟsnٟ՗yLLˁؤ}[]]15*z7mMl7?Ұ޺[#.6˶ŏ^ *,G^on\mu)'+V6eLۥőe]KazfVlX۟q7UVgmnx3lgWۻ闽ឺ8//չ9W&zr0nycodm5uQhZ_weaMr>,sзyb)FLmYq7{dŢhϊM9L)3債^RַU+"?SI]rEn_,Xte;+jTvs [BϞ+]>(#綣g{;=9[3}z5eר[tLw٭g,y'ZuenfUnYܴ|3]'r}bZ|Gi(t1ʤ6(񏄅>Q PeF,ked y$RQaHZP\VLm<"ZbiCO(! iH! N e&[zf1.o~lN WC1gx1دs ΅TǜTt~cOo^ٽyq˺| P*jkIvWaɓs˲=9KNux@9_uzkCmg-oWSgmInjiڷb@<NOaGcșv(֧gWdʹڭ26`RssrM^]efvjr2jd؜ P~Yy~6kUu>mDzُUl8cڱ͍[ʭoVLf*Ǫ©iyd<:|k_4&pO4-oUjZP['kMIeOdKgkK1W?\6lbe|YyO՞e(䵹yٯVRKduZNl_/ؼ utvx˗%V_i]5찇oƼߚ^䏳oݪƿSl>[wyD_`kr2U~]}{3.mc_Jf^Zv&(Tzo_6VH꭭=SsEN=+g.¹e#yo N`/\jߕk6f™růW&[ݷmEUǑo*3-VYO\|u6>xv̹3|z>K/ӳ~UdfeʢMѤeWU믚fn[17ҫ=Y3oabMܸ]{z՟7.k[nަsLqvЫl--u¿#<<*|4[w̮Xm-C!vȅKzV!nBZ?t&wVKޮV,|j;Ȕg u#dWee7T3\ Ukoi{^wnYzϛur͵gi 'kja!2@kB\b@BL|)0v|>dlgǖ"OxTx,?}v¹vyg Qco?ɿenNj}ŹܶfjN72*ߖ-j0Л*dT[y] }vSvٶ*O2.ڳ`T =_L[lYW>673/Oʖ&.V bvlfXim2cb15=㾖-n\,ٕJ[ EweEV1iV[*__ \JVrθ YrZ~וLxri2B0hʪִֵ4W5V p[xŐ 0##XvFeŵ0ͳ'wUetnj[/1f4 -@Nfz͇^e_cUl| Ǘ#7^YFg̪yYzXffۑ.r4fd՗x6ɗ^ok2iFNj=DgNjڸ1n0cɷv[~tsb {vߨ&޽ZWW߷f93-|or}_sfʪUCziɚÈ鑭^VEc[cVoO77 uӶݶYG\ *h(n: 27զɻ}v"7W>Ͳow86 28uNlLɃa[VnZfsL,N_g^Wg.O;]fc.,3pʫU~[|N3b %f͓+;n޵̫^J.U[6鍝Bmbgϸۣ@oiꋷVf'3nitek]?݌ xr-ǷKټsfzpɍqUǷRd|Ƭ36W,ێm/J]Fd9WkW3f铂U(9k10 αe8fvKqڽ>k}.6]fɑ6n쾽ufތYlmn^ĥsw{\>k|bdy~Be֚ǐ=xCUWd&K.F[_gn4Ǘl iOQN/k!RaN *Z–9@tЉER:G1RVWE~_FW RPɡRQCC`cN) V@T cX+y)C9 )GRV_$/)ZJe M(@a9@0nK~r0$F$;8]>s1*IN 22J ,Ɵ!&!@ُoѷ[;cM+'>_n,N~.j0npָ_+7bvrU>4w}s oi4R2SAT/(VV>o;4S 6[.9.Wt6n\>^DܱFl'7e-}C{L>=Nwe'' mZ2STVlydeLKrXL!D(U±eÍGL~1*c<_+Ay'9'²m[%iun]Zu]k}0ܭ=^Y*ۆZ+yj} <ӑyf8ncnS<̯oi#kmC̓ i\ʹKbvoX v&n{bmYnbԿ.΅݇^>V=#F|Lyd uuEwqc<2~iU;*c!n-4ڹZlb|iW5XNuv]ڛ|_ ms_afܙ;v38؛m\z׶{1m&lufg&oVݛc>eZ9oqNQsdkUͲClKɶ{3;vȶݧ*sٶr# fnr.$Ӭ^ѣ..ޙvϕK:z^;j3:^[;AJќi:E}|?,z7{颷9rW]sU}ʱkPe $\ȝdi7nU^;5ьzڶ}gɷϼΘխuٲ}2Z> cʸ5èZ#ܷq宬ۋP q/LתیS2ܹ^8~,e^\xTw*ށn}1.2jŨҾiZyr7ʘsޘtigqMW(gʊmˉ;W緛ÅnffUu>/훼7d{5-]dU}MwL2ѝGUf۫)R~o;4sqj i+ƓJX@d $bQ_V[|bRP18HXڴ<3ɗۯ{D;Ѹm !jh drQllٮ zs)-=TUFY$[k??nrbvM=|O3c//yͷWTzo[tqejj_Ma']suLٳRvߧ}6^{ڮL>>*VLvib罒xzdMhѓL\nvد.ڥ%Uh\H,ezYr-_@Äj`l{]KXg:5uVLeCjTMW&8Y8GNPRg>fƊTU5GeIԶǃnr_g?˲)OJ|:{vo?lZKsdֳr}MmlUvmJ D=1՗٠fN]ߦWVmk'*Q[ _,c]29XJk/D_/搩T"(6_4꽶LAu >s/WVwaޯ)>Y]?SN6MDw*z﮻:]"33ZnW6u՗}o{Y6_mYq0l\Ou}MzZ)ƽ:}yp0DfMi/m\mufmswvɟ)$mm[l tfu mrݽonYvsgUoUs/7ҫc_Uo|3ݺ"쳦W/koU5p}lZ_g{lN#_/o* m1c!͎Nz|(0q1w+_mWf\ʼnI @kұ|6UIZs|d;*RddƖco~+ǛQWT`ɟleύ L\vbs/pmx5٦Sp6V={뮿T>?7VF [VO:}oCmTG/{lX#Ik&.ldܼ6ůwyxxI9V/+[kwk(ԭr5Q2o'۫ݷ8Aǥ?;zN&K;꿙7u sQpV3L'ȵ Z֦`^y1";0:ǀk eZGrKN8*s+(")FeGJ]Zx*'ZtHXaQ2 EX 2HX@P£u qX R#X >1[m͹ʛ}6ϝbR1}_IkylovNۆU6Z$mjOmC|q/eősR>nwsa[&5TDI_ُ⹟Խ3\*W4x=cVEhLh7gMToٯ©]#שm9QR֓n>9U9OL>AK|jTogFZ%x`Ò(Wbk\"n,*Vepغ2q(镔np6MYm2ti^-MֹE_4};zvvc1l\S/N_fiY<.?wsUci׫۳ _o2\;z_mn٧~Xc)I[[$L·9Ώ~f7U&Qbs7L6 _ Q16G2)vL[oL_*ʻu;;j9=ˉֵʱu'ťw.輺賯2Cn3&MVecԶuĘU:JlYƨmGw5Fȭu3]uۯb#l,U+]{3f}\kYZk"?zܾXKȏzڿKJua7ŤƪٙGj3,P O'U͸ٗ%TT1!uEl+ǸK^c"kr4sxڗlK[~q ;h99rOQf0/724ojU0 }.<21P:-\.,KsFQzҁP i[GԐϫ{ֶ j!7[r]+^jl͸-Qz[V3-.D_pk!x3~-۪C]ҷKG|ܛ 3If{+̓muB>}Sm&=˖I#+۰-&M~ͽ-ﯷ6V2 \cn3t__ fKN616ll>i:dsMLٷ *XxuoVEbx/Jə,7ʫ_W,m:˹6rnMusܗz#\b:c>j ?ۄvw cqmۖJ׫Fc˒l/t|X;xJeIļԻSW,[ >Lm[5>\T+oV]ʱ47(my}{oL]Zp`II%E!REah c5j~QU-!(#ŕF@x^KZ#)!]udrշdUU,RIمa_lE';n\{TPÌ|>cUVs}פ}ǥf_1d n4YgY5XX1ohlt{NP% Ṣ-aomUh5ZןooYCakCd*Jp|#\Hz_ǛU@;B*Jǔ-ņܔ9s֙/s[ ]& \1-~J0 uJ{4iTj?ɪPr^oX5UO2R  Sؿ$;J潼KJT'#8ҫҶ[.J".V_nKؿ®麹^ܵKZ֯,W^WֿRY$Grl/C6,Xx[w儌ـlK_~T*z,panUh,TDŽ.wQM#j+anczV?$3lqlms3}^kg;}#mN[gmܫ(umצ\՞׷ţm*7(^gǟs 1>0L{te6O\w xWM)46{2_VRvS^?h˹e͓ÍVF3UE\?Fٝr?ދHWxGfvkoR~,9Wm?E 7SQEvFڮl̋DYDŽa!W7!on Nf@Vrd^e]qW6{ wLFQJz6dVzf{.\GT`k5s]YrEKe{P-"~Ų\ IӎSw,UZך9Ǒ1ܾ_Akj]nMsZo.Fvk1 TL;' 9[5j4;Sfͣo}Sϫsnxm6CYS@mPxZ}ky0awnlk &4RJ G=f1l.M[q܊LRQ'79Ǹ=ϸVUKuEG"đJ̛եr&"$áʼmiuEѫL# Y2ΩM/_ZW/~S Ut^-.W=[-m^dwtb٤ռnjl+PuG-mpeuظ=5ѳ&\|-|ʱ1UVy%86S^OMU#b#Zz5rXm{j T{Ku_Qƶ/Un8Iu& FV&ߟ"Va&Q Q~;qU_fanly[է_e[u8dEz =Kfm]Og]*i. X\yTZoer\ˍ.Qk\jD!\^XQP/9ͫ' <ҵXl2زީmT-tƖYa y[dӲ>fZbYl[jLYu̍SUٝQ&׃bːr 5j^75VY%vAVdOlѶdQUU_=9Fn&?8)>XݶgVl,gϕ(?U jfuя*gq#"L+|C}r27I[X6mB쫷_$kf<6UYuCʽdaʫqfK`e|ʲW OSGuTeH4:Y?͠*luj-ivġkUQte˒QM1#ڈ[[MKAo/~3dSKdsV z*3ds^IV#.GƋizL8բ}9Nzao_6]N卜w˕_G<:$y̹nA!POc3+}Gc/74'r33pN2䵘7k;q;m*~sMpw#MxM\+- G-a`n1Q0+1hD6<#^ GʌuM+I'U8NɴJFV,ZsmS1 WeMrTrhFH řO~>6n26QUG&m;Lx/rLtpnʟs 3h0,< %'j߱ZdWnqFM(=1c_H2s73d1ZXMj٭N,8ݟ9 %|̲v׳o8c]׊ =s%*)6V0U^Gt2& ]9wꬴN^o29DTr]0+]5W//,Zb*x;pӅJ9GQs1cP톰lq6j>3r^jWd[,~o|S4뷪dLvUJZNO622|/`nEUF nOU`mWJ^mbFӱ*V^EVPbw {usnhiz-e@VoSD:u֡oP5(z}R/":&nfW zeNƺikpVb-ȶHY]RKyc6TvYlݔo7^vS;4vUyWʲy\ٕ7[JGu5l$ZUTo]jx)ߵiy4]TmzX Ĺ9W17922lN- qZɕc-]L/'u>#.chU4P+Um(1f禊iuF^j*oUܫ75*Ze^oov̫6Ʊ{ ʱ+ZL7)|ʬʾX;2U1)3nVO6UL5̸2/+3tϱf\ֳ۷c^NzٟUNsj M)lĽ*&2@ޭ%zOp+UC¯q=x7+[0喎XORew}QDQV ʺ7G-XN_TFE4f,&fꙷ <)A;p/,9rB(kO7\c;zHJ xZ4IΝ>?ٻz=jf? Xa 0e$ e44NMnja1xȡFHDxք)2쳖rG65#ˀ%E{A d˻L{m;U%N;̱k۬`(S4vmOkܼecs"[ekS4&.ܹjڳʊq6*d]j ~wEęݯį̷C]nΝר~n6~UĶ56$ߣ]uuVTbSM.]tgݹT~K<-yGNm;O۱ZMz}θ|5ұɶq^dni}O]Yq|ܶȵէ~^n4yXt}xcnkQdՑsV~i:E*niR}}YV[zcω-geyLu ť,Bɧe$ʚFefIٖVb|IŶK SP]ŊquIqc%Um꥘v3#rOŗfy2#Z3+ri\lnǔ6I{mFAoc̵v[ٽIU&3%+IYߝ*ɏ9dL$1>9:ܪg5G7ǵeWpG*ȍ6N[Z3\g&>F72keosb׍Ys(5ߗM}mόKiu&!//5# u[=}}fv%Y:Zn^7TaW]Mc;qUHg$WGY7Mlg>*ّ_[]d%&lK|E1{+3W!K~YX29/1oLW2NyezՌf.$oiunhǫ]{9Y?lg%d_49)^fu7*r᫇poWgoX*iˎV pFcMt2e+ i Hqr& )1V& ) 0m>eJ+]aob<4ۂĀ.i lW VS4N. n; ?ov((v>{=ft. +Zi7ɖsev/]e 2׶ۥ|XuG n%Soc#]ކ̌=Vyotz' 7k[oW>5v ^Suov eXe\5[e*Ȝt9"_LpXҭU".ل|mC9z9o&_߫nE*|6աg5{qSH/~f4:^Ga.]UayVsrʲv 3U{E)l9͡o (Ǘ6!X/VTj\; dƹQmZ3G̻{-%Fnf^^e]磡`0ӄ!|.Pcќ&Eb<(*Ïts~XIىབྷԪ5?&l35!+NVlo57_?3掠2r=aZ7l;B? 6+Td+fNgnhj3<ԊO;mꘃ'*5-*۬h|<-5~MeDwZE^^r]PҞڳιYQFV[Zfڔg;T2s/+}Q_S(rz%r_"|W|ly츏OSDub}K[ݷՍ|/?'igژo2?=۪2G{l@.^_ݵce.VvE{.ƈFeRUKz2]zl`( sh=.tl6i~nip~i4ƷӅ}-k̾kn+ӌmEΌvqj'LΦY-Fuf)ZRj_dtcG}RrwN;+u,q8ZZ"'nod+h-%m]1rL~OaZ1LxozZio^Gf?.ei;뷪N;j*ڬLyϯ]YspʞUi2+m:g>]6˛'rwRfjڹ w'6\͍^v׳'w/6Lf+L'm\.fMvtl՝l UoujSd?=6EșE]U>5zkc. >L]u~^q.kxB3T!$G!f{|$Z_7L֊uadM.+H*QRw[幾,VSe9ՔGNwqݶXZz0O!d- =ܶ0;77G Ԁֳ-yezy>ǔeGBq}v_w߱lX)JOt}\EjmLYejJ2B4񤆉t 0p#Q u>>1ghX*بy]evR"aXjE4&䩯'RpF:HfC ZX[}A}Uw PxO~ܽmx6=RoeXQr,LQl7[vO=-$YFeV~׺N.}1٭sX6;|2]}?u+ouú3OośRKZ5W˱)\ZFq7VZa]lM,2.Zrnfc׍Fms,lLn0 !!"i  Y)@i%fR)*a((L'+Q.$.E> 5'%X }+o%`1Z~L͆- wiuҐX7؛|#ѳ;} a_d< g^\^{Bs-&[rQP+l!F_V&;T%.ִKfՃXJmhk~l\inS%23+chW}J6H͕-ұuW]NSuqo#;:[os;VZurp5C3볣mܘeĂc.% Sa™ڶb$cQ {73'9-yͱսBv(26DY7ZjE6tVۃ6=e1%bVdm~+WK?p;;qڶ_TՖ_Rn}sm0\1:6۲sUܞYimW~e}[vݯo#O]v_l?X *wY=*3]uGٷ]Z=r_m9rNjSG3/rb1mنU[Foդ2mM.cΘٕ|7L'fٓ|et\d^c6,o&Uq~[ցhOO^^iI9.m@]UXm͏Fۺo,֞Vި'<,nUdf͙ڶsٴ;bel{}?SGۛn:]/Lz6enqo?zj cʲ.߲C:Un[k]5Rו!Vjܻ"46`͍TcaU%l36%Uv[n  ܻ33tXnSqbNoiq |h*Ffz{-W.; sn5οY,\ U'ۉó1VpqDv6%ݏ jyiQdިJ[j{hnr\3n醆ߪ*z]3ff¾6Xׇ8s֓ӯ:#"ק]n;|+=1ʲ"ԵqQm.u2V*%ÅX|l'x,O}]VY͖LܵU?MzZF4N8+LYʿ-dFW)nL|dj]Zso(U[UU{jlYrlJLW4ll޳օmrrӛmok굳*7/(ݗx{Lm͛կiYkg/s%Z/ٕӮ.LimB sijuof}YpTk)kW$[U\s%:Xrۮû̶ҾYD3K_-"ܧ/.voem=%rc6?fˢtdѪݾߦܸS :kػvPwyw c;#9۪j˜F͚<~fi]zF\ֲ*b>-K 9zI>=~-kqir#&`.p-Ŧ=( Ve/yryL)VӦ|){E_T'c{p+ʯ5+;-S&λ4QQQ'Z/:e,l:0hDdKnoW*qYef,s}7zY*]=VoM>E%lVOlǓ9؀J3]<1ًrEoMiQ"ڧ+eq敵WW#}y+]Zi۷}y.fO^4>/E9F&ƋֽMlҸu]\龿#8ez}Rf:Vq=fğj_}k[}^{ksq?UW7uǏ=ԼvH80a"[[m+m{LۮİvkUic6.`VNOm{|Y[[$=UQ|6j}_7MЧnn{xm kuo3ɻ'251խ^Uլ`ɼ!{N\=i5ߖU|Pqb2\՟ٶ|y~.M:ƏE)lWjwr~dn EǍTUDRof|;l'Z×-%/ p+@bGLyk#pD: FI@WS)6f-!u<"`%1Z,4aP%09T2E5~0XTxK)#`Mop)*(^"b;))Iy*lDo xanǛq~#]T:./u ˍ[HFt| 3tIO}LnܶWD7G_nͅ&$L}|N#|_iSml^&NGI<ȼ/[VlyfƾTWOU1YfiIۗg>6U+sJׂ͎|ܿLKKW>ۗ\9.7XѸݾ?k(>弭%[SYL/?JB^JݟkyQZcٓs܆U=6{lf2Lg?gV ؜Ȟ1Trwooo_V\y*skoK/W;s4Z{Ӿopk£pef魿=ucwv>L}>&޸imVnjn,]Y#cœQ4l<{ &lיuяvL>QҾYu6#{!uF oLHo9/XQOnSjY+$902ş+| H"ȘO3vT_C*Eˈ٩q-E~ZJǯey3z ɿ3rHH(@ÙZF~,7>7w仚o2ew- ֧:W,r&l},\й:+cOodyRM Zih~sʿLu}ֵWذnF(Iѣ^ŬvJÃzpV¼z.n8]W&fVU?L:5经q5*dzt˾S#ͯ4[lHm~YxrQ6\o\j]2ut1dԵڰsv,N^oJ6ƹUqid=*#+1;]3gSsa `sdH݆eo(һEf w=gWn͐FnZyiN~եO%ܾۓ1N@:͵yg ˑŏōf sUkYQnjY@N Rk8ґ%[I%(`2PRSJ, G0tBC$qF Jk/< >;ab#-u%92cp $fpS4%-v]X b|>m)+")>[1ٝg m&UEɅXV: ǎ/aW2GN5LM.j}®q{nXjZj>o֪JW_ZcLbs FugŻn8sceoajǛ NIRnHkB9a'lpː}1klwnؕQXIo`U%V:8nV2q64Ii"'y[ܼ-c]eۆz7_*?uW{y3cINr"~[cDQG`jteYTs0Q+!XVUhr_r}W_Tm-?SnVuF_m1ћLjÛ"%M_RNr)t4;܎v{ wwSM9{zq7qYQoVjmf\YW/r8m*ֵŤ͹kӶp9mgpݫ??J5 ؗVa̮%dy_Jj_zZkffWO*jJFVag>nU-I ^olW7?zõb}J`[6XهnrK]Ys{wMq?GeIo-NO8~a;1|]3i<ݶO XDb]N1S(a 9 +JLeKWCS_1MQH+-fxD )' j8G0W]fȣFf&EkkKE8Gd4xLyJTpbQ BZ#CiuD[O *9 C)SHf*pn#ɜ1kfZR1GpxW7#_qCS[['f~5vڻk3m-nFǻ*[BⰙIԨ4l 2ڷcǺg<VG/ U[3fl"&Ǎrť뷱V_4 J5dvdVVuSm;ŏ 6ELͦX'-²̫cV{c'ms5cV}ƭkUi\ӷWwk1Zu,vk×\kzoTsV̸qڦELf7mrEz_s_keK}_n62c^4{Xu͝ݑ܋ʣ&1!QlU^f_L*5׳n8yRf]rGdcm[Z=X؏Pde]N3S*dnQO0[ŋhțs.,l?-[aYŹ^V'jEBh_Epە}1gת _S^i2[mQżʫ旆} ȷ6NƾQr$ҳ+m.Y݊X2ј2\k-镲bTިyXf[y^Il2Y-哶g,8|ٱZi__r]aeϷFۼ;s깷9ٷ?|keuRV__b\ G5{)8y,ky]+{zsݻ;uyp|ܽ\;4ǩ[7ueiᕜ91z̲pyZPy~owjٽU9>߻{J~%kSiwًwC%TV_K>|afLJĆO/ g4>w{e1_}?]\}}r "AO_Is}ܙ!X×mS*K0;JI?x+@qкBdRIPx! ~qi @1 )IiM V&D9cCE PR8iAZ 5Ã2Қ0 h& Ms1Ba *XKH'Ii~B rWmxxQqwLUgE}O>UWFʩw3_1u==Qm MYsLuqٶW2[yV+o5旝TKlx*2:{z5:Un[Fvϸ#/NWZ.&e}8|Mq[sW+.{,kHoaVݱdM;zk]!VȻWl߸[=\2U﮽]Ae2.L5[:uf dz9͹N_{ѹc>5ʙOKI&^ec_.hoUz]q.$[Aof" a^ϹT̾e+yV|Ucږ|ŊR^Ui5=ftvYzr}*:S{:|}ij?Thco S;rwg6%FNdClZڭ۟ re~]{s ųg-ξ[Ů\vꊬ给}1 ]eˉ?/ťL6o/K"ݓʯ-?p(kݞ6l[t6߫H;mPsݮ%cα+w&ۯqݟgowE͗:|Y[6 ro}2ZhM_VwP[VlkOn홮3ڗL9 *دUčCP/ԭ^9qgU_dgWkNT_Lz!˷ɁY^[e؁h,nkscd+};0gwWꏪ2&CqnK|u}+4ϼH1Տ65sye~ 옰v)}p;rLj*cM}Cwܞ%}3'n7;}.&MþQ|uU͇Z^00v{l^4,lq|&2?mFȌCs%}ysMvO#ۭC+П*׀},-#r$~&jK –8YJ-XTׄ<$i$D c,#5RFy C c  % )!|`!Ih#<+ML\)k+1>F1,R5"µ𑙞 j  KKnZpbJiFL-Z0*Ir92"*@,[W)6[>G}ut\Ŏm$DL<)Fo2.,2J$x;]WFn4Uhúd.""murpcȸdtz#?ܽ@.&,5M?;{iKzέxrnvin^e^XٯT]3v;lxSfܪF6~)]'.Ff~MfHV9a 9ybkSI;g66N\|'jzj3=(yn}Vh⽙UyUec\vO.ftLV9V"}mR몦˅Uncy+ SW;7FUPcQu U-wMSw5U%Ynw:Ek}u>lVYuxcʿn(n6ym띘B\Y[B=Sf<ж;\h1Nvip;xf [#h/J]ydjz,.Z7+Z-,+Yޮ^v;yrd8[5^׫_(vT=M]L~y??}0LD&VnyYx,"kXB|#)Z`k%[ɅCƱ ȥ e$(cK hLV1MQ]$)pSJ,9AJ,T iVOsrJd)  Ji)JCY(CPDxE# ĴjekYIX(XY0hBD-1C_Oٹg}a="Zys$œ!Ƥz/ZMN o,Kcr&eTmWaR3 ׹p]Q8rq5n?ۼc;@.hrG)*-b^6mjyӪ62e\] 26dr[VS>&\#ZyevE۵*nO^K#d1zV)Zmqȹ7Ƌf ~5׫Q?Il7#~eO-:ɑ[9<4Z؉+Fl=Fܯ ʰVVƌn4-vxUoy5ΩfJYbLggd ˏ %]nTub XTse;8l?ݴCo/vU,5]}S˹kfp«2|Œ̤cFcwKV{n3b͗۹ɏBlo55 kz?Kt|-2ˋ6EUnlwsJvفrV-kosb<}3yŶ/@$'%0fǏ.ZU9{lϳ!͵Ê՟27C3oYnUKYTXmW|=W[qyW^Smp3(UNE9d͉q_4^ɑϹD[^ֹ\KgU1Uv]W[k8Lw37ui}f|~Z< 6Xiř=O\L560ӫV{K?dXF|\-E>8=V,&Ce}UEaV,9enjƕKT smU'k򲞊gD7U4WmFsok͕Ul4bȭmr5v٧yM~2h~e-u`lY6#θW=MJTJ+d;Ϸm+qfsoYǸmne哭ll͓rۮ_=gOקP_M{~F%_d?5l>-ӄV/]lZr;0>^i+];9߫sgƽlXџ/$}]6]ur7[,M]=VJf?Ɏśsn=ܙ:7L ^g73<`=y4g5pfPW ʼi.pvdۨeɽ.eҜީec^]oP{z7'~^p̭!Z|{ɗy][ަ}2ScvmkY-;l+ˑS>LK$.믫's.k+VVd\onqU[ز[Ӛ['df73}2j]O}ܾ=鑖 m"6,krn25hbuVvQq&Q}{jC937M~ѻZT`ղ{˶~ W q)̓ o졻&1Ë9S],˿G#*V͙^[`Wnyؿg]MҾX=tr7<9^lKy:kþ6j-r\T7GnM>[<s}Q{;qE4:韗zrĒj~3i$y4R(E( ~rWJ0M" ~pQj8J 9aB` b ipVAT UCJ9gHaZPł~L-:J! 7 *ebc'8-ftdZVV%O(m#Xby>F@5*yJ)]![ A&xtfaY(m1Y*iX`Ac @)R&.mԱ_ ӄE+l}쏳MS rW\e}ZJSrZZ+}×j5UuBpW̲8?e;.?m[̫攭uW/TOTSan3gv߬ʿL*V{܊c33uLEٛ6KyZOGRcFWU>'+- bd ZFn{45 oU{wxzkX֯㲪^lҦn m;dy W?rܮƋÒ]Nvr[GܫUmp_s>EN=v,͗ՎNP}°t\+*R1Ȫ6͘E>mlmen<+^koYx싹}S.5LjJ^{7]/4NRpdV0{ :ZV͞vgθ|\~v"|7FUw*fof{YJ,a=-]$lKYnKGR>Gψ-c7T5sdnݐk6*lPCj5ifae?;?RuŸˉqzh\=Y[1έma¼14q5nf]TJoTz0/B15ߚ1= VZv6P.ASW]#}l=ۖ|{/ڝHFϯ\o< ZʑRm"ɠ>50!L1 e i'9 bh 2eU _+Aֲe6cgȬL.~*3dJ"'SGy'=Ҥ*jWv @t7׬L۶*mOcNoooܹ*r- m=JӛVսmq<^#{t' U2_ʾ0{ .bL/y~F[Q}udoQ}Wþɺ\{;fejfvDw;>ߕo^Ni3䯯]QϙGN3ZgǵF[Y}W7N - .epb]kvls[){l}|;L_[=}Q`nfCKnXm}{9ztڽ-ym>TZ9=ýB_ǩuw?M_w6;Uk]tr7[۲̙/Ksu,XiF>hYdPpV}K_sm4и`ͦ3dC}~5u{E\)RC $oseŲ1c&'ݼhfZ(B$f0w>0D %0$K†"dMk-Hif| %|"P"OARdX7` `Ō3JZ# TtP4 P [R r(cFҧ< '#ObTGtS 8BE8BcoqWH p-bZrZf]Sɛ&\#T0[jDr7ˋ,EV~fm0w45YuSurZmz7rɛrnYݿd몼֭jf재;ܳmL%\1lrY}P]usՕs,-o/͓UMUuf^oGsݲk_޻aLŴ't%ys:/T]vb=6.OM&9v֚4oiHT'.}|r՘$r]UZM .0(qNpS('G9 OBb kXG#ET4|"(SWRaHh?Jk x0R>22J#@H5KP 4YXdH6Sƒ$)ZC4H㬕^2!Zj? Tx0@ `@i׃T㬁(0ku?)RJ zpupdtdPS%5Htp$f w/)1 0Ay0T:ʚT)k'e?gfLmvlS)bG5󬹯sI'.,W 9=#Mukꭶ͉εo.6}=n;Xnd>[/c/*ka.ĭ&4de7#ɮe} ):eBjzc^}X7#3sEu-ß&rvʭ m,\rz9ꋝcɎqZu.[}ʮ=O;y]9c^nnXRwmqt=oV}v\LMשvk[MoY]^[6<Ɨ)˱Ij۵T^3:.#wiϮq3tUeb9nVkڥb6ǎOVɘO2w]6P{se2LY[[m/7e6>|X7VzmYplޫY>]z셯m/I[om e;E9Uzه]edsrV1E7}uٶ* mof:wŏǿl5|K_^^1~vM6;Up*~,_Nf{*G73]+{ ]ie4_V&Q܆#Z\ǚ٦ԬV͙n_ol'=̭pƹ.DW y+6崙5W#urUf 1[nh5Z9<ǻ}Eه7qNJ% eɳ=>Nv7R}Ab*5e8>Lpg(P4“]tÃ[iY@I@+Y&RrTĈi&S!aJ(4>0i_N uP SJ3kI495HR|*"򜈤' :>fZ/$ aCi,|ѾP)ONZJVE@lfΪ˅^˾n{ ߗ'/״cgߌocu?T7xɳ˓ 2FzO}Kqwƪr?7N&e N,ݻ~'۱wT:{~V{q%37:m}Wl22b9Mw}u=2;݆љYk}gP̫Czgwbl0 /T׶ͺ{6ecmg%mv{w3o2Qj3οm~Ŵ90c:Y:/&}}Kocm{{Μ~qnޫɗɝ-TqZusgsts5(&R',3wWkU5;&V@߇L:2o ,oR7L:ٟ&¹[PꋿVL U&iֹ~i>V$~c}fgٍ:qm1ɓ#)Z DM iP|BɌT F)]5WYJ4ZT\t 1&~@AH J@~O fp+ e*+)f#@`Mi h^18, ;Ffj% U'f$P)JW@eLQ2['Q+ҼLkd'X G %&,+)SB!-[!CEfK#}y! G adXR!-a3=[q+-1".j},wQj|dݜe7,CvmrZٙ.U_lVotW *cLe[ߖEg8~#Q,][kqد#P=yb[3Snϟ-"5hݜq+eY^ˍXB5NW ϝh ݷp{{xo*ou]r>%Ƀ64;2TtسJrZjϷ,csrj[m?c^'= vǩ~*{6[7ڶ?;i[F^߳Ξ)l8m0Ƿk[#yZ,xpn{%E'X99Y?)UHq_o^ڧ=Xrw{H=\^ڼf&EXjok3)}?=RE͓I4J21fyr ()4Ij ɕ؟\]LӌaYNA!*a&8i,FR8B,%O 0#A@Z@iIu$4 Jԥe Zҟ9)Y#J(L,YK'bhHX6bd@*xe4Hk#hO 7DB敗 jԃ'YO)a'CWN+k_1XMrPRm(5CdR(DxiAA"1U㬹4$d`B &/kH0V,gCZ`0 ۬SڛۯC!%1}ڕnȟj\찧n11;>ižfg\vlϔpv. º;\Ymꍶ ~(S 3)[uaۄbw-vK<|2oWV{_LlZnn,r}<͗v03cV>Emᥑ7feYs碪h{ usnnS[m"zMԪN l]nΝ.9ZWm;՛ckW^7\-啄kl-e^nd6uxwbzfG5&"cHwQTdeJ]YW{o,)~L5]}2kYȷMqvM w]v՗&U^yok^n3bn7 1xLw75Lk)mGOj-ʵɝ 2hFRjG2v5Lړ6MWi5˷6ubL1d+XVap*E&k,0 O! TB(K ibT-Kt&a  f]b D RKBL1#Wc-Uy{7dV"4G3& ÿ'0N+~ۅ?/X>e_ZDFֻ \Wo46%^΋g"?S4t>bL/n>{[#LکpSj5XQz=Q*1Q hٕz `ǃWlL9bVbWgkoخlFiC«_ڨ2>7nʪkF.#ik%W;qė{h4wAcwtijݓˎMukezf𷮉͏e%G7fLjo4ru,NɶײGp1ڋvO\jŗu֪ss4jm U&V^/mK>?2+:[n^Yz쫳N\ZK\_}Ry՜mU[Wwݕ$闎3bЅ/[r-gc3]~3L_-M.֥@fĊ_z\06gmFncWV}<330W (Ԯ.A`UT0 $|5)< iM Y0HC(Dj "e )ClYT9i 35u$++$X"tk( ʑ$U$Qj@NAjMJ5cʪµW S:@H4*Fen1SZknj%PHDQJR7-9WRᤙ34XDPZ d`@kN:fɊ5L 9dTQ1ZDŽr~h(EE:51B)_XT @2ňLV2Y.Q %aB@/*%Xq-T}%)F,<|euP-~BV)@ C PQZId T|A"YHZX0<$AFPZxJ'"iH401LB$ɡ(IG*CQ,HX@1% yBuH4ЧͫKz.[EռY]zNҭ5ekJoTWdd׮[]FX7+n]k/2/J bͺ,5wVaܞ5÷ᅲCtbGe:fpK*Ne G )P e?A@!yk QZBj`"+ACTB^&<OҭSP$B,)_(Y@Pk& A'TH?x"a4DGPB " Q)1.djfu&F T֢?R &49.E41uId<%-֠h ?j6Ub*|<"<1CcBNJ"4:Ǽ b,+S&̫ZU(F,rXgȕu\jA1E3[QXg!!&BFA2O-+ֱMk-DŽth?X,h j}=a:xڭӌ^澺GZ1|ޙY)ͺՄ{`zbƎ7%N׵^U9lƽFucިƋh+6&U_F}-*ZW_a b/2ts/T}Tgߛ/,Y2m]++y%k:sf.t˝Lo4bt}ܭwTUX1l{|[^~"ae%o0bm|i~Fe:3w2nXpϑ~Y53yיZ; J#>WruJ_\.ܹ̏Ms{kFv+(7ǯV];mevF(][SUrB|zyRd"jU(mi4qox`|Ƴy$-5KFFN@0d.5B łK֦F",CC` K(M!'`dBSSreia4 RT$,ZR&&Y`H&'H@$@ 0,#`kґ&= :B %!& V +iV@aJBR RѤ1e+C+9,8G8+RP:0-+<-icT!t$2ѣZsTˠ r i_E"EN EyBOQZG̶֗P") h)-p^8zIXg8}v<=[ok,Mlrw;j͑G)ϕto74ѝ݃6v/,n̹w.YX"?[J۳+$u_z"w (C4[oqrn_5ro)M\]aB@a($ʐF e3 BMD2)xYI%K kiQ 0CMe& SC P(k d kXxG X(k i:aB<#AX0943L|f.f]a71no,}IL{>oo-ludvO7ʾio՟f\93%nrkՅ2fĮ},efϾJ9ԝE[Q&}wKY<÷v򪤝bPj~Q !) hH`"*($k0CS  ʴ%u @(hcTM6BC8 BxR=%d $'M"ѫ9 4!%ҲmECIG8`)ST Rh\ӄbSCHd-V2y18f t,rIL(YE(#<E| RjbZHJHH 0GG&AVLx%mNyJTk* 2 ȕ`k+$qRI&RFB5̡yƞ.'Ma% 1S%yVe89?IKMuy%q@j!Cq(8@ H_#i2!e-_8?(*~q /}~͙_/dغ^_ļus[..])j+vW5&];UO[~a9V[|kv\lrmϷ!cÉ+[g3.&w#\QEtAǰƙ.;K}]SIwhløl-z~8}r?mp-M㷷qW {7Q uel93%-g/͜_amG9dĮґ^mڵ֭Lno Ŀ/IU\2mw+40owM{6GbmҸʕo.B1ֶ5n!fWhՆS;QUiv6lK4և˒g'?>EGm5ygvQZ~E"4Mh>q`jƤiB<+*5*05p $@_0\58)X*cCRXp#u@e`IQ4'ʓZ䔬Eb+L Ab0KR($(X, ?)0JIM+*(}b҄UkX)CfH SKJ!&)[˼p5mSt%EQ&%J &FM$B\QQ%A"]`<L;) NhG5W"poswڸ86@j@kzI]7Xs7B}Q6ٮ[m{y7qQ#iٟs,ٲPr*WYջon[Mїaͼ.Mduqffhў;L8sdeTEO6muoeSB^{v;q37SGWRo[#AfnP4gT3afǸ!2,*#L~nn7Ny7ߒFXɟݍF>Qc W[dV}n7S;덻=kdo*s4\ۚ+\ͬϜ7+-JyݗՕ嘨ޯtfZt- 7;M' ?[9s}oN#I/o8501"Xp/#>1COAaXeBu0hEFmFD Fե4)[4# 'XXֺp c(bRqJ 80]aS :Sm2eU['G%lܭڜurx[mroRȵӦn-΀6CoSJ\4^:bNfUcV%~z@86-ޟ*^v_sKSR*oXnEo3I_٫yeW'[v~[n5_&>kQɶ|"}[ٚjVyr󞛤몍Msv=-LۅX0d܆#;t\t?w=;Ku-$rwMW29B+=+r6>]Y6976F07SMY߱טw5O7eﲳ(WBilK1Rױ-0lc|˓mM9v]LMf}}8geɒh`^OXJ|L2YV(c+Jh dQ*`+ N+]'%"HA)G83)@U!I41*GSXKq9.r֐PVE&jH>0|(S(kM AMx u#M4@uT& XJ' +0Y!51`D0,XyScBANB`@X %1`!r W &(Xi`Si^#(Ow'XXnR1MVRkHf @ _DA Rk'*#X'Hc 84GlR[k%Ɯ#5Rccԯl+}zn>scۇn6Jfxoiv?Lx.8Y^ d7eU3V#wW ܾMu߫=#M]n[|e6[oq]sҿT&nw)>Ū|NNRk-jv">WBU~_kbϲ3wKJNp5L+.Lįr-Af*3G7UR x˱QsNfm1bd- Ok5~\X]/}5S|DP kD9BJ" F'HE`X5$@˜*KPH" PbDsh(ZV@UG`+AP,iRpr NIRMe4YZA!PTEab(0)Z(8 h)N0@ʖ*%G9IEk '_.B@8_EJ K ,ZSXxXdPuO%"EjxcQm 7R%u "B)%SXJ,xC5C1 Q;B4LRJ¸ `4*!VY)18FdiQX bJ8F<8A4~5 5F7SHe8:Eh)GSf R/({F փ I)՟mcLeS#v}c/\ia._hٲd[ܼRf(wt\wio敷e}U2z]f?eckR69vo5G ύsTw>߶*Nakj *u/3@lY]yLF5psn^xRǓq_}2ݰnXϪ/ء#8Ͽ}._/4.ɯ1e+2+!`Ϻ&hMx/F=?9qZVd(Xs@t1Xjk:U)L ,IZ(RXD~EB(;L N 4RXAHk,NCxJ|!t%0--(YVH27$r(HFKd_aGJԉ2pOP?W(Hx1)]uYĹV-5zԝV^UXm=ۍ+j\ Q[0Kc.=oz muxT>ʗˉʷ0B,II8aIM>qeU.?)@M?I Fxf$'ZH$M _ xR)#ɘ(QT%b5:XiQNVp?&@1@hF1d3aX/ AO80jG"M)XN0"00hFa k" $D9Rp5` S )SPz嘺I{v}mwr^z/=p?]2({VO"8D(xJY'Jg*% G$,Е@>0"`vDj |>2s|'#Jk%kk%4X C#?)' J%Zm!F%%!\E&x-$|~R,@ AXBJEF@h4 րd'YYWRdkN04r3OiaʊkTq!u^[XsvTZ(M X`٢s嗆}'".RgG^B^c#ceQ_cÛĮnhSg s{=K)wb/xN\ ZXF6u>+waonVϲɖz^?[oUݪȳ h=)Z,.0SE|d)C %'fm񒜠P~1t%4`OE? I"K VO 59 J~1Wpk  04RrxMѭ$R5#<Qa@ ""H%%Zp 5(PV ֒jPTV嘯+$ȁJxyyY$ux@A&oC4#R8@ p1,%8EQ(F$p4F{|c n0Q$dWXYb>2AƱ+M)7RI(k'"(TMaEh22xi`/` 3R. B-k?Ǐ? v͎5Dre lݷ4mn;d!Q6fܴodzTF4iXr#眨ļ擖Yr"//F1go4)kX$[K |7;qP rw?9O&Gί6D0Bh +$ 10iMf+IaxRW[d +m2)40 V IH5AuPCV. JC2P3TM-M8VQ&J0R|b !gZGH)(ҰU89 xGdxC M$R"*J)@"8J* +S4`m?FKC%`S?) hc!52E~PԈfkm+G1< x@($FH`R"<]  ҺGM!jp 5"3F^P cX@E ?K PuY WI cXpAti|Fq✮lO&53{lfu5jW!:eHl,aȶr63VzU,! 4 pIaeD.*ՉfVdzKLy_a3fw.ܼsͲ5O:enj5K j >+PRi0@1JkZ'0DY(uESPe\ Q-;COE xIHch#lyXhL2+"S5! 4eEֲhN5i5 $ IJY P 0?(l:Ex%jt+YG2+MLJ` k<%u YHH>rv^")A.f+gFMRijxhr"N%dDRi $xWV p2|3*8x6Ʋ-BG kҧ}CSTeӄ8Hh`8qB5Q"IJI"&Va&NJJIG$0`4`)HX+P %}Oi|gܺ:徾 aNv*3NOXbdE<|'--D0k2Rb}RXI|ueX`&BtFu{19V4ϑivxdbH6"+#KWλ[ަ >f!F Ny|kUHkNQ_@fp_ +E?TTRĠ0 ~0f0'85!&4'N0`E"" 2bi M IAN1 "RPJQn E?Kj"F) k4M 0 +t<~X *k1D" @x "2e1LXL %a EPNuҧYNhR uP9+0"NխcS'Y0B3EMC7 b#")ɪ)o < j`n22XT?&5(Wf'J VÈSSP`A GTSq@1ЀaiAR:$Wy1bj$Tv,y?h$لn PߧoXm0=W+tQr豹lyulcEꗯ\nUjè.dNkʓ2< ܁/ W0z|Ҳ+ʸ&_eO&6n7s,[vcغ[-;6qX⪶:][쎶*kkLkϔwX~ FJpo]~}+xέ+θ<&q o R|!Je j`Pb G$)CS+ *) c,?*N,""?S)_!0I_"!b,$Qth|!1yB|QxJ f#D"&cZi HL.R;`8I j"Ѡ^x)@~@ %~J!H5Laf'QR߄xCI8 m#!Ag04Ge8PFc&A 6Ǜ VL8Bq4 A4% E)?'#Zy4&L)A~bWTxxIV@Ao 4xX)Q*DMiI62 Y23@<$X0H Z_t @P/8<&KҐ%E+GJ `M}'cp^مT} -W=(AlYflZ,ۍCF=Mnr:kYmaVvM)w([__flS,1sɀHP  B%kA<G kbAZ",m"la 28M8ojH$GbRr[#TES(^IjCӉ+ಎ4$-|#NLq&!H(eaH R(kX[|b\2k ah!:KAyW7G.N OM'jG @ֵMXNEC5"8/S1dt2| `%K?"S@407Hd eq 8MЉ0֐K]cgCF&I5+YO"e( ! V,1ABRXM4 g"I*_eg UNLۗwd)j5%WaiQоY:Y1+r՗>KV,u-7Ebj]~JWZfbV#kgosFgT\|;U˸Q4ە; Sm][Vkÿ;Wyˏe,ؕy>\17)NWe_5[" 㦑^'Z<4 Ooe, 4kxM?^ʜT>A,>R"aV:S W SR| O -8`i 4x#QrXքilP>1(AV8k@d% a(@p H d!M`"54'H hcHɜE%, ҇I<5OR2<7C HI 1\$)\Hȩ%PְXZ e֭B1 *#nŘV+DS󉠖&I<80_xG"F(>&#pCBɧFJ)*aH@)r5PxI 2VJ0WAdc}Oo~e9ar4(.-VyًY>DQ`WV뾘;*ϐ<ҮE=Pr;[3t4jуg˗u?Vꆗ{5unݚk }H1X=6[8FVT蓇.׏c%nw+{,ϸeE䷚F=seu*̩ukQd:_~r*P 1a+iJJ>Th>pf RCx$QYACnj`>09P50/"Td D ~>FdVr 0/V&4?CT# rraS p$?J1 6sې9-p]|zgu q "4mqkYxĦ3&Q]-#+;W Ϻ߄M^owckMYguǍ7'*]꯷m,rT>هa|Xq[5 hMǩ[6]vgq]ӪȾ6s ޘuk7 ˊȫ#U!3dC3y7nI ֠R8M5sp,jgV}5:|M1M)tha&+'QXMe(kH&^&!?@?TP<31J("8)!MA+]DIi :R 1"d@4#TH< epQy JAea,,t2p<-u0RiL&FO#VxQJ%(H/P5ب iTӀbH2sh@VJ"J +&g*~A,[!3T[D5@Za)+c8+cX$1Ì1m3NXGKO,d!).bA `@k"#Pk* (fQM"T櫷YQ>EBRX?b@|c5 xht+k3Ben(÷Sթ[zzF +\'8*ھh\X՚뺚U5yYm_V+s,ܷ.#+Hwg_WO|UT]=ϻA yg^0ٳfE :1km{.c۷O_WʡSWn|dj#ܻUq#{yW^UC2Wb|Fy juk?mͨ?/#.\SCH` ӌa pG $㜄ֵ!e 0srX R H#F`!njrB 0H4riEa#<51 E,Zk MO3QLYsEj{D351: TOLP䅔U@edQ!i`hc*n:@m5 1Y'XHV-MOIFm g"Pj pi0 (#/7P akn2QKL5TJz9{6Yk(_Sg}TRmݦ>ݗ3gͦMsMޫm_AжMY7vAnKz^TNF(@-w:5yPN<*y?Z]YխUѦۉ ^ W&%2W]De ]^ۿ?)ѫʤ׌C SJ̤KT k%E!@4h!Btht„JMO? P )If?8ׄ}Kk/8ZT'Զ ERqO 0"|>ri|$ c&IN ZɪH6VD3 V$tPLFTŔh$PG&2jJI+X(>2 Ny, 0:]~M$ R85I(b0X 4@AHҵ"!k<>m 5Q`OjQD4L?(b(Ajԃi0Vb mN,%- !N1pt:by+D0x6HT_A0<+i9C)bp:E%Mr^ROn/_|Iwhɸjr2F9_ 34g>O&?( Eic" E)T- HGL('28E0թ`>rAgM򆲠X0i>ZV^~P4h8p-ZȂ+< !!3|ֿ)J,~D(Q:os2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH @`@ NormalCJ_HaJmH sH tH >@>  Heading 11$7$8$@&H$>@>  Heading 21$7$8$@&H$>@>  Heading 31$7$8$@&H$>>  Heading 41$7$8$@&H$>>  Heading 51$7$8$@&H$>>  Heading 61$7$8$@&H$>>  Heading 71$7$8$@&H$>>  Heading 81$7$8$@&H$> >  Heading 9 1$7$8$@&H$DA`D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List jj Pus Table Grid7:V0*O* 'G firstname&O& 'Gsurname6U`!6 'G Hyperlink >*B*phD2D `\ Balloon TextCJOJQJaJZ/AZ `\Balloon Text Char CJOJQJ^JaJmH sH tH  OQ Om'jrnlPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VvnB`2ǃ,!"E3p#9GQd; H xuv 0F[,F᚜K sO'3w #vfSVbsؠyX p5veuw 1z@ l,i!b I jZ2|9L$Z15xl.(zm${d:\@'23œln$^-@^i?D&|#td!6lġB"&63yy@t!HjpU*yeXry3~{s:FXI O5Y[Y!}S˪.7bd|n]671. tn/w/+[t6}PsںsL. J;̊iN $AI)t2 Lmx:(}\-i*xQCJuWl'QyI@ھ m2DBAR4 w¢naQ`ԲɁ W=0#xBdT/.3-F>bYL%׭˓KK 6HhfPQ=h)GBms]_Ԡ'CZѨys v@c])h7Jهic?FS.NP$ e&\Ӏ+I "'%QÕ@c![paAV.9Hd<ӮHVX*%A{Yr Aբ pxSL9":3U5U NC(p%u@;[d`4)]t#9M4W=P5*f̰lk<_X-C wT%Ժ}B% Y,] A̠&oʰŨ; \lc`|,bUvPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!R%theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] $ :hmrv{~n U &-)6G9%=BIiMVc^cf~j6osouwn}cݨ%-9ƸǿR# 0[G  y!(18>IFbMWbt>3{ .9<=>ADHIJTWcefghijklnopqrstuvxyz{|~&t(*)XEnss_ttluuvb؋Ќی\nЍۍ(h ByKʔj?W+a:fC7@DQ[^3C?VjX+af{     !"#$%&'()*+,-/012345678:;?@BCEFGKLMNOPQRSUVXYZ[\]^_`abdmw} :YJh`CDDvxxxyyz{{|}}cdX4XCCCCCCCC8@0(  B S  ?VeT\9DVdyLV  aCDvxxyz{|}vJ\c413C3G3P3q3u333333344(4.42474M5Q5v5|555556667q7x7777777777777778888W9`9d9l9p9x9999::6:8:A:B:Q:::::; ; ;;;;\<f<x<}<<<<<<<========>>>>>>>>>>>>>>>>z????????????(@.@>@D@A AAA)A/AAAAAAAB#B'B,B8B=BABJBBBBBBBBB CCCCACJCOCUCZC^CbCjCwCCCCCCCCCCCCCCtD~DDDDDDDDDDDEEEEEEpFwFFFFFFFFFFFFFFGGyGzGGGGGGGGGGGGGGHH HHH!HHHHH4I;I@IIIIIIIIIIJJ&J*J2J6J>JuJxJJJJJJJJJJJJJJJJJ.K:KKKKKLL(L,L8L=LILNLtLzLLLLLLL MMMMMMM*N,NNNONVNWNfN'O-O?OHOMOVOjOsOOO~PPPPPP5Q;QdQuQ R*RBRGRRR|SSSSSSSSSSSSgTjTTTTTTTTTTTTTTTTT_UkUuUxUVVVVVVVVWWWWWW/X3X4X9XcXhXXXmYqYYYYY$Z(Z-Z3ZSZ[ZaZhZZZZZZ[[[[$[([.[[[[[[[[[[[[[\\\\]]]]]]^^E_I_U_Z_h_q___` `%`+`/`6`:`D`H`T`Y`_`````````aaa%aIaMaaaaabbbbbbbcccccsdzdddddddNeReWe]ejepete{eeeeeee7gKgPgVggggg hhhh&h+h9h@hEhNhShZh_hhhlhthhhhhhhiii&i+i4i8i@iLiPiiiijNjTj_jhjtj~jjjjjjjCkGkSkXkhkqkuk|kkkkkkkkk$l(lLlTlXl_lcljlnlslxllllllllllll3m7mTm]mimqmmmmmmmmmmmmmmmmn[nfn~nnnnnnToXoYocoeohooooo#p-pDpMpQpYp]pdphpqpupzp~ppq q2q8qFqMqQq[q_qdqiqrqrrr#r3rʇӇׇ߇ˆ̈ %]c~‰"19=CHOT]biv{Ɋ͊׊ۊ BMQUltx΋ً݋ "&+0:EKOW͌ӌ+/0:;@NSW]jtˍٍߍ &/7FSaswxŎΎҎ؎܎ %uΏ܏)*/CHMRWbhoxŐА  &,08<DIRV^bj ).29GNƒʒԒYdp{ГՓ(TbwϔҔՔߔ %)15=JOS[_gktyɕ̕I[ÖǖϖӖږߖ0?RZėҗؗ(,6X_cmnxݘ '+37?CHLVЙՙڙ#.267ABGW]bhnrv| .7<Dm{ 7Ecjov  '0@P[ioBLQW\f"'-29>GKRkt  $(15;?EIPT\`eiosz #16:EJRcjox $(-19=GKTX`Ģ %)26=GMQVZbʣ *?EIUakotǤդ  &-29>FJR[^_cgpt}ťӥץۥ-8<KRVWacfuz~ɦԦئܦݦ 8FZ^|Чԧ*.23=>CRW[dhmqvz¨˨ -12<=BQZɩ -.5itvz{ڪFQ׫ݫ 0;?Ihpv}.4lxǭ˭ԭܭ3>BLaj#'+05>BKOTry}ȯ̯ү֯ۯ "6GJNW (27>Zhuɱбڱ"'-25@KѲڲ߲;A\dhqu}ӳ o}#)-48@DINTX_fmr{3:>DHPTZ^cglpy}ʶ!%)*45:QY]einrw{ٷLPQ[\aouyɸ%-޹ bmquvº˺%fp!2<AJQV[_`jkp~ļ˼ܼ!FPT[`glsнڽ&;DEMeijtuzϾؾ۾!/JRx¿Ͽпٿڿ .KOPXemy :>?IJP]bgot|uFT "(-5ci{ HLMWX]y%&1hns|!2@\d~+6[a  Y_`eorw~KTX^MS`gt}  9@DGKPejnuy~  /7;BZ` &&'())*+-.01di2B7 = aj@M+Kdp9P5NEWGZ!!2"A"a"p")#5#$$$$j%%%%&&'''(\**,,556E78::-::;<===?.AaCDNFFHH!K2KKKMMJOXOSSVVXX-Z9ZZZ \4\\\k]x]__a+addfggg nnlowop#pprrrttuuvxxyz{|})8̐#ГS[f}]~*~:Gv^d_jWs#EQ nhdlAN_foc,    A    [kj!$9(U^  3#D#X#g#%%-&>&&&''((d)o))+-%...[/j///e1q111223$366&7,7;;x<<BmDnDDDDEELFFFyGMON|OO&V*VVVx\y\3rssuvv:x"z8};}/~D~ ʍ?Boz|25HM$Xn`d?J2:&()+,./1233333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333!+!..m//aCDnjjbkskkk"llllvxxyz{|}\؂^vՄل(,flF{KOHš6WVl۷%ӽx߾&4jwտ'cf&313m33334445I5_5w6666I7h7r88;9W999:::;;;S<x<==>>z??@>@A)AAABBBBnDDxEE+FLFFFGG\H}HI4IwIIIJKK&LILLMaMMMM'O?OO PwPPQ5QRBRRR[S|SgTTuUU V+VdVVWXmYY$ZIZZ[[[\\]]^^C_h__```aabbSctcccHdjdddNejeefjff"g7ghiii2jAjAkhk1mJm|nnTowo!pDpq"q r3rssuuvvXwowx:x#zBz]{{|||~~:W}XuI]r ʇ1Olۋ )N&q?&Ȓ}ϔ*KЙ0W Gc  ĝ۝?&եRu֦H,R+Q֩v=^$@a˱#3#JJo%od#:˽cpFe:]x"c{FlwShB\Yo-K5M( / %&()+,./12^bd aCDvxxyz{|}c4@%&&()+,./12S7e((^(`OJPJQJ^J. ^`hH.  L^ `LhH.  ^ `hH. h^h`hH. 8L^8`LhH. ^`hH. ^`hH. L^`LhH.S7e*}}ifDN|?Z:W3544ez::b(K@awHJ I y { { # 5 99 H A 9 w=B!`\Q!7Rq0Ime,/n{[ ?& bO!~!ME#cY#Iq#,$%iS%{w%L=&{ ' 'Om'(2c)P*h*E+yF+e+b-2.X.^|.4/>0eU01"62(34#4+5t5)688)8WN8]89M9^9e^;j; =-=6=w=>j!?-1?-@W@%AuB-C,FTF&|F$G'G'ZG "H NHUHpH/I0I\I6J4fK\L+MN=YP3Q/ZqzC85y'49y18CA+P2DK8&m6\a#TvI ?_41.Jc4%?rNcg)5swLK=UXeEz?o18CWX8Qs-sm!-h~ -^Py0IdFe)uQ|W @6C$IttGI9O<s~ybD4`hW:2k%'<8ZlPPdfz|8)cK tj{'Q+,^4K 53D\SiEOndaRX:[eHjl=}>F@&(@....LRSZZ(@Z@t@8@UnknownG.Cx Times New Roman5Symbol3. *Cx ArialS PalatinoBook Antiqua5. .[`)Tahoma7.@CalibriA$BCambria Math#hťbGťbGQ blE*LlE*L!xx992Q?c2!xx  Chapter 12vcanoPereira, Dario Oh+'0?  4 @ L Xdlt| Chapter 12vcano Normal.dotmPereira, Dario2Microsoft Office Word@Ik@Rg@j$ɪ@j$ɪ*lEGD>VT$m    !1.@Times New Roman---  2 @00    2 @H0    2 @`0    0''@Book Antiqua------  2 00    2 H0   --- 0 2 Y1'---  2 `0    0''@Times New Roman--- 2 p 0 Published in     82 p20 http://www.thyroidmanager.org/            2 p 0   2 p)0  201   2 pW0 8   2 p`0  @Times New Roman---- @ !r2- @"Arial---  2 00     2 00   @"Arial------ 2 00 Chapter    2 i0 12  2 y0 ---- 52 ~0 GRAVES'DISEASE:COMPLICATIONS        2 0   ---  2 00   @"Arial---@"Arial---@"Arial- - - --- 2 00 Luigi    2 R0   2 V 0 Bartalena,      2 0   2 0 MD --- 2 0 , - - -  42 0 Professor of Endocrinology,    2 f0   ,2 l0 University of Insubria  2 0 ,  M2 ,0 Ospedale di Circolo, Viale Borri, 57, 21100      2 0 0 Varese, Italy  2 z 0   12 0 luigi.bartalena@uninsubri  2 .0 a.it  2 @0  @ Arial- - - - @ ! -  ---  2 00    2 )00 Revised  2 )i 0 February 2018   2 )0   --- 2 F00 ABSTRACT   2 F0   --- >2 [0"0 Thyroid storm is an acute and life    2 [0 - j2 [ ?0 threatening worsening of hyperthyroidism, characterized by an e    2 [0 x 2 [ 0 acerbation   2 n0a0 of symptoms and signs of hyperthyroidism, with high fever, dehydration, marked tachycardia or tac      2 n0 h-  2 0 0 yarrhytmia  2 tf0 s, heart failure, hepatomegaly, respiratory distress, abdominal pain, delirium, possibly seizures. It      2 0m0 may occur in patients submitted to thyroidectomy or radioactive iodine treatment while hyperthyroid, or as a       O2 0-0 consequence of infections in unteated hyperth m2 ZA0 yroid patients. Treatment consists of antithyroid drug treatmnt,      a2 090 rest, sedation, fluid and electrolyte replacement, cardio   2 0 - Y2 40 supportive therapy, oxygen therapy, antibiotics, coo 2 0 l-  52 00 ing. Mortality is about 10%.    2 0    X2 030 Graves orbitopathy (GO) is the main extrathyroidal     2 y0   _2 80 manifestation of Graves disease, found in about 25% of     J2 0*0 patients at diagnosis, often mild and self   2 50 - Y2 :40 remitting. Removal of risk factors (refrain from smo       2 0 k (2 0 ing, correction of   U2 010 thyroid dysfunction, oral steroid prophylaxis aft  2 ]0 e >2 e"0 r radioactive iodine therapy, anti 22 50 oxidant therapy with selen  2 0 i-  w2 0H0 omethionine) are fundamental to prevent progression of mild GO to more s       2 0 e .2 0 vere forms. In moderate    2 0 - 2 0 to  2 0 - 2 0 severe   _2 0080 and active GO, intravenous glucocorticoids are the first   2 00 - X2 030 line treatment, second line treatments include cycl   2 00 o-  2 C0 0 sporine, orbi 2 C^0 tal radiotherapy, rituximab (controversial). Novel biologicals, such as teprotumumab and tocil     2 C0 i-  2 W0q0 zumab are under investigation. Rehabilitative surgery (orbital decompression, squint surgery, eyelid surgery) is      S2 j000 often required. Thyroid dermopathy (pretibial my    d2 jj;0 xedema) is a rare complication of Graves disease, usually      2 ~0h0 observed in patients who also have severe GO. Topical glucocorticoids are usually effective. Thyroid acr     2 ~0 o-  2 0 0 pachy (clu  2 s0 b 2 {Q0 bing of fingers and toes, with swelling of hands and feet) is an extremely rare c    +2 y0 onditions, for which    2 00 no trea  2 ]0 t &2 a0 ment is available.   2 0    2 0^0 Hypertyroidism may be complicated by severe cardiovascular manifestations, such as tachyarrhyt       2 0 h 2  0 mias (most    2 0f0 commonly atrial fibrillation), congestive heart failure, angina, particularly in the elderly or in pat  "2 0 ients with pree  2 0 x-  2 0a0 isting heart abnormalities. Prompt restoration of euthyroidism is, therefore, warranted, as well        2 0 as  2  0 specific   22 00 treatments for the heart.    2 0   ---  2 00     2 00   ---  2 700 T  2 7: 0 HYROID STORM     2 70   --- R2 Qp/0 Thyroid (or thyrotoxic) storm is an acute, life    2 Q0 - G2 Q(0 threatening syndrome due to an exacerbat  2 Q0 ion of   2 bpa0 thyrotoxicosis. It is now an infrequent condition, because of earlier diagnosis and treatment of     22 sp0 thyrotoxicosis, better pre  2 s0 -  2 s0   s2 sE0 and postoperative medical management. However, acute exacerbation of        ^2 p70 thyrotoxicosis caused by intercurrent illness, especial U2 10 ly infections, may still occur. Thyroid storm in      2 pf0 the past most frequently occurred after surgery, but now it is usually a complication of untreated or      |2 pK0 partially treated thyrotoxicosis, rather than a postoperative complication.   2 C0   "SystemU- -   00//..՜.+,D՜.+,t0 hp   CleversafeL9  Chapter 12QChapter12-GRAVES'DISEASE:COMPLICATIONS Luigi Bartalena, MD, Professor of Endocr ABSTRACT THYROID STORM Clinical pattern Incidence Cause Diagnosis Therapy GRAVES ORBITOPATHY Epidemiology Pathogenesis Clinical Features Diagnosis Management% THYROID DERMOPATHY AND ACROPACHY( CLINICAL ABNORMALITIES OF THE HEART References Chapter 12 Title HeadingsTitolo@ 8@ _PID_HLINKSA .E%mailto:luigi.bartalena@uninsubria.it=;http://www.thyroidmanager.org/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~  Root Entry FT;ɪData -1TablefWordDocument D$SummaryInformation(@DocumentSummaryInformation8MsoDataStoreЊR;ɪT;ɪUPPDMF0QPY==2ЊR;ɪT;ɪItem  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q